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Abstract
Clinical effectiveness and cost-effectiveness of surgical
options for the management of anterior and/or posterior
vaginal wall prolapse: two randomised controlled trials
within a comprehensive cohort study – results from the
PROSPECT Study
Cathryn Glazener,1* Suzanne Breeman,1 Andrew Elders,2
Christine Hemming,3 Kevin Cooper,3 Robert Freeman,4
Anthony Smith,5 Suzanne Hagen,2 Isobel Montgomery,6
Mary Kilonzo,7 Dwayne Boyers,1,7 Alison McDonald,1
Gladys McPherson,1 Graeme MacLennan1 and John Norrie1
1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Nursing, Midwifery and Allied Health Professionals Research Unit, Glasgow Caledonian
University, Glasgow, UK
3Aberdeen Royal Infirmary, Aberdeen, UK
4Derriford Hospital, Plymouth, UK
5St Mary’s Hospital, Manchester, UK
6Patient representative, Aberdeen, UK
7Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
*Corresponding author c.glazener@abdn.ac.uk
Background: The use of mesh in prolapse surgery is controversial, leading to a number of enquiries into
its safety and efficacy.
Objective: To compare synthetic non-absorbable mesh inlay, biological graft and mesh kit with a standard
repair in terms of clinical effectiveness, adverse effects, quality of life (QoL), costs and cost-effectiveness.
Design: Two randomised controlled trials within a comprehensive cohort (CC) study. Allocation was by a
remote web-based randomisation system in a 1 :1 : 1 ratio (Primary trial) or 1 : 1 : 2 ratio (Secondary trial),
and was minimised on age, type of prolapse repair planned, need for a concomitant continence
procedure, need for a concomitant upper vaginal prolapse procedure and surgeon. Participants and
outcome assessors were blinded to randomisation; participants were unblinded if they requested the
information. Surgeons were not blinded to allocated procedure.
Setting: Thirty-five UK hospitals.
Participants: Primary study: 2474 women in the analysis (including 1348 randomised) having primary
anterior or posterior prolapse surgery. Secondary study: 398 in the analysis (including 154 randomised)
having repeat anterior or posterior prolapse surgery. CC3: 215 women having either uterine or vault
prolapse repair.
Interventions: Anterior or posterior repair alone, or with mesh inlay, biological graft or mesh kit.
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Main outcome measures: Prolapse symptoms [Pelvic Organ Prolapse Symptom Score (POP-SS)];
prolapse-specific QoL; cost-effectiveness [incremental cost per quality-adjusted life-year (QALY)].
Results: Primary trials: adjusting for baseline and minimisation covariates, mean POP-SS was similar for
each comparison {standard 5.4 [standard deviation (SD) 5.5] vs. mesh 5.5 (SD 5.1), mean difference (MD)
0.00, 95% confidence interval (CI) –0.70 to 0.71; standard 5.5 (SD 5.6) vs. graft 5.6 (SD 5.6), MD –0.15,
95% CI –0.93 to 0.63}. Serious non-mesh adverse effects rates were similar between the groups in year 1
[standard 7.2% vs. mesh 7.8%, risk ratio (RR) 1.08, 95% CI 0.68 to 1.72; standard 6.3% vs. graft 9.8%,
RR 1.57, 95% CI 0.95 to 2.59]. There were no statistically significant differences between groups in any
other outcome measure. The cumulative mesh complication rates over 2 years were 2 of 430 (0.5%) for
standard repair (trial 1), 46 of 435 (10.6%) for mesh inlay and 2 of 368 (0.5%) for biological graft. The CC
findings were comparable. Incremental costs were £363 (95% CI –£32 to £758) and £565 (95% CI £180
to £950) for mesh and graft vs. standard, respectively. Incremental QALYs were 0.071 (95% CI –0.004 to
0.145) and 0.039 (95% CI –0.041 to 0.120) for mesh and graft vs. standard, respectively. A Markov
decision model extrapolating trial results over 5 years showed standard repair had the highest probability
of cost-effectiveness, but results were surrounded by considerable uncertainty. Secondary trials: there were
no statistically significant differences between the randomised groups in any outcome measure, but the
sample size was too small to be conclusive. The cumulative mesh complication rates over 2 years were 7 of
52 (13.5%) for mesh inlay and 4 of 46 (8.7%) for mesh kit, with no mesh exposures for standard repair.
Conclusions: In women who were having primary repairs, there was evidence of no benefit from the use
of mesh inlay or biological graft compared with standard repair in terms of efficacy, QoL or adverse effects
(other than mesh complications) in the short term. The Secondary trials were too small to provide
conclusive results.
Limitations: Women in the Primary trials included some with a previous repair in another compartment.
Follow-up is vital to identify any long-term potential benefits and serious adverse effects.
Future work: Long-term follow-up to at least 6 years after surgery is ongoing to identify recurrence rates,
need for further prolapse surgery, adverse effects and cost-effectiveness.
TriaI registration: Current Controlled Trials ISRCTN60695184.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 95.
See the NIHR Journals Library website for further project information.
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Glossary
General
Effect size
For all negative continuous outcomes For example, the Pelvic Organ Prolapse Symptom Score.
A positive effect size (mean difference) of > 0 favours standard repair.
For all positive continuous outcomes For example, the EuroQol-5 Dimensions. A positive effect size
(mean difference) of > 0 favours synthetic/biological/mesh kit.
For all negative dichotomous outcomes An effect size (risk ratio) of > 1 favours standard repair.
For all positive dichotomous outcomes An effect size (risk ratio) of > 1 favours synthetic/biological/
mesh kit.
Readmission Related to prolapse surgery (for complications). Readmission for new prolapse, incontinence
or mesh complications surgery presented separately.
Serious Causing death, requiring hospitalisation or prolongation of existing hospital admission,
threatening life, resulting in significant incapacity or disability, or otherwise considered important by
the investigator.
Satisfaction with surgery
How is prolapse compared with before surgery? Very much better = cured (1); much or a little better
(or very much better) = improved or cured (< 4); no change or worse = failed (> 3).
Satisfied with results of operation? Completely satisfied = cured (1); fairly satisfied = improved or cured
(1 or 2); fairly or very dissatisfied = failed (3 or 4); not sure = separate category (5).
Symptoms
Prolapse
‘Any’ symptom Pelvic Organ Prolapse Symptom Score Symptom reported as ‘occasionally or
more often’.
‘Frequent’ symptom Pelvic Organ Prolapse Symptom Score Symptom reported as ‘most or all of
the time’.
Pelvic Organ Prolapse Symptom Score Range 0–28, where 0 = no symptoms and 28 = all seven
symptoms all of the time. Primary clinical outcome.
Prolapse-related quality of life ‘Overall, how much do prolapse symptoms interfere with everyday life?’
Using a visual analogue scale, score range from 0 (not at all) to 10 (a great deal). Primary quality-of-life
outcome.
Symptomatic prolapse At least one prolapse symptom (Pelvic Organ Prolapse Symptom Score of > 0).
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Individual prolapse symptoms
Abdo. any ‘A heaviness or dragging feeling in your lower abdomen (tummy)?’ Any = occasionally or more.
Abdo. freq. Frequent =most or all of the time.
Back any ‘A heaviness or dragging feeling in your lower back?’ Any = occasionally or more.
Back freq. Frequent =most or all of the time.
Blad. not empty any ‘A feeling that your bladder has not emptied completely?’ Any = occasionally
or more.
Blad. not empty freq. Frequent =most or all of the time.
Bowel not empty any ‘A feeling that your bowel has not emptied completely?’ Any = occasionally
or more.
Bowel not empty freq. Frequent =most or all of the time.
Pain any ‘An uncomfortable feeling or pain in your vagina which is worse when standing?’
(any = occasionally or more).
Pain freq. Frequent =most or all of the time.
SCD any ‘A feeling of something coming down from or in your vagina?’ (any = occasionally or more).
SCD freq. Frequent =most or all of the time.
Strain blad. any ‘A need to strain (push) to empty your bladder?’ (any = occasionally or more).
Strain blad. freq. Frequent =most or all of the time.
Actions necessitated by prolapse symptoms
Digital evacuation of bowel Do you have to insert a finger into your back passage to help empty stool
(faeces, motion) from your bowel? (most or all of the time).
Extra hygiene measures Do you have to take extra measures to ensure the prolapse does not cause
personal hygiene problems? (most or all of the time).
Fingers to ease discomfort Do you have to insert a finger into your vagina to push up the prolapse to
ease discomfort or pain? (most or all of the time).
Fingers to help empty bladder Do you have to use your fingers to push up the prolapse to help empty
your bladder (pass water)? (most or all of the time).
Fingers to help empty bowel Do you have to insert a finger into your vagina to help empty your
bowels? (most or all of the time).
Objective prolapse (on examination) Stage 2b, 3 or 4, defined as leading edge beyond the hymen
(> 0 cm) when POP-Q data are available.
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Urinary
Any incontinence Defined as ‘How often do you leak urine?’ (any frequency) and/or ‘How much urine
do you usually leak?’ (whether you wear protection or not) (any amount).
Incontinence-related quality-of-life score ‘Overall, how much does leaking urine interfere with your
everyday life?’ Using a visual analogue scale, score range from 0 (not at all) to 10 (a great deal).
International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form
score Sum of responses to above three questions. Range 0 (no incontinence symptoms) to 21 (leaking all
the time, a large amount and affecting quality of life = 10).
Overactive bladder Nocturia twice or more; and urinary urgency ‘most or all of the time’; and urinary
frequency nine or more times per day.
Severe urinary incontinence International Consultation on Incontinence Questionnaire-Urinary
Incontinence Short Form score of 13–21.
Stress urinary incontinence ‘Does urine leak when you are physically active, exert yourself, cough or
sneeze?’ (most or all of the time).
Urgency urinary incontinence ‘Does urine leak before you can get to the toilet?’ (most or all of
the time).
Bowel
Active faecal incontinence Any faecal incontinence when bowel urgency ‘most or all of the time’ is
also reported.
Bowel symptoms QoL score ’Overall, how much do bowel symptoms interfere with your everyday life?’
Measured using a visual analogue scale: score range from 0 (not at all) to 10 (a great deal). This could be
due to any one or a combination of the above bowel symptoms.
Bowel urgency ’Do you have to rush to the toilet when you need to open (move) your bowels?’ (most or
all of the time).
Constipation (ROME criteria, adapted) Any two of the following: stool passing once a week or less;
straining most or all of the time; hard stools; bowel not feeling empty most or all of the time; manual
manoeuvre to empty bowel most or all of the time.
Faecal incontinence (any/severe) Faecal incontinence of solid or liquid stool: ‘Do stools (faeces, motion)
leak at inappropriate time or place, or before you can get to the toilet?’ (any = occasionally or more often;
severe = sometimes, most or all of the time).
Passive faecal incontinence Any faecal incontinence not accompanied by bowel urgency ‘most or all of
the time’.
Vaginal and sexual
Dyspareunia (any, severe) Pain during sexual intercourse (any = a little or somewhat; severe = a lot).
Dyspareunia at baseline Denominator includes number of women who were sexually active and those
who did not have a sex life because of prolapse symptoms.
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International Consultation on Incontinence Questionnaire-Vaginal Symptoms score Combination
of responses to vaginal symptom questions.
Sex life quality of life ’Overall, how much do you feel that your sex life has been spoilt by vaginal
symptoms?’ Measured using a visual analogue scale: score range from 0 (not at all) to 10 (a great deal).
Vagina too tight ‘Do you feel that your vagina is too tight?’ (most or all of the time).
Vaginal symptoms QoL score ’Overall, how much do your vaginal symptoms interfere with your
everyday life?’ Measured using a visual analogue scale; score range from 0 (not at all) to 10 (a great deal).
GLOSSARY
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Plain English summary
About 10% of women have pelvic organ prolapse surgery, and one-third require a further operation.To improve prolapse repair results, surgeons used synthetic mesh and graft materials to reinforce the
repair because this had worked well for hernia repairs. This study aimed to provide evidence on whether or
not the use of these materials are more effective than a standard/traditional repair.
We compared a standard repair with a standard repair supported with a synthetic non-absorbable mesh
inlay or mesh inserted using a kit, or a semi-absorbable biological graft inlay. We asked women about their
prolapse and other symptoms, assessed their prolapse measurements and compared the results between
the different procedures.
Most women reported that their prolapse symptoms and quality of life improved after surgery. We found
that all of the surgical options worked equally well, but mesh or graft surgery was more expensive.
Adverse effects were similar in all groups, but some women who had synthetic mesh (around 1 in 20)
needed extra surgery, typically to remove a small portion of the mesh. The need for further prolapse
surgery was similar for all groups. Results in non-randomised women were similar to randomised women,
suggesting that the overall results would apply to most UK women who are having prolapse surgery.
Overall, we found no benefit to women who were having mesh or graft material in the first 2 years, and
the costs were higher. Some women did require additional minor surgery for synthetic mesh exposure.
Participants will be followed up for at least 6 years after surgery to determine longer-term costs and
consequences.
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Scientific summary
Background
The treatment of women with pelvic organ prolapse is a considerable burden to the UK NHS. Prolapse
is a progressive condition, often caused by childbirth, but symptoms appear many years later. Conservative
treatment with pelvic floor exercises, oestrogens and pessaries might help in the earlier stages but 10%
of women will require surgery, which has a high failure rate: 3 out of 10 women require further surgery.
Surgeons and researchers have suggested that mesh or graft reinforcement of the repair might provide a
better chance of cure and prevent the need for more surgery. This is important because if the failure rate
is reduced, women will be exposed to less risk and the costs may be less to the NHS. However, there is
growing concern about the long-term consequences of augmentation with foreign material.
Aims and objectives
The PROlapse Surgery: Pragmatic Evaluation and randomised Controlled Trials (PROSPECT) study comprises
a panel of pragmatic, parallel-group randomised controlled trials (RCTs) set within a comprehensive cohort
(CC) design. The aim was primarily to compare the clinical effectiveness and cost-effectiveness of three
treatment modalities [(1) synthetic non-absorbable mesh inlay; (2) biological graft; and (3) mesh kit using
similar material] compared with a standard repair in women with pelvic organ prolapse of the anterior or
posterior vaginal walls.
Primary outcome measures were women’s symptoms measured using the Pelvic Organ Prolapse Symptom
Score (POP-SS) and prolapse-specific quality-of-life (QoL) visual analogue scale. Cost-effectiveness was
assessed as cost per quality-adjusted life-year (QALY) gained, based on the EuroQol-5 Dimensions
(3-level version).
Secondary objectives were to compare the three treatments in terms of bladder, bowel and sexual
function, adverse effects, objective measurement of anatomical prolapse stage [using the Pelvic Organ
Prolapse Quantification (POP-Q) system], further treatment, cost to the health service and patients, and
satisfaction with treatment. Longer-term implications for cost-effectiveness were explored using a Markov
probabilistic decision-analytic model from the perspective of the NHS.
Methods
A total of 3087 women who were having prolapse surgery in 35 UK centres were consented between
January 2010 and August 2013. Women who had anterior and/or posterior prolapse, and who were
willing to be randomised, were eligible for one of two trials: the Primary trial (RCT1) for women who had
de novo prolapse in one or both compartments, and the Secondary trial (RCT2) for those who had had at
least one previous repair in the prolapsed compartment. Women who did not wish to be randomised, or
who were advised by their surgeons to avoid randomisation, were followed up in matching observational
CCs: primary women in CC1, secondary in CC2 and those with a uterine or vault prolapse alone in CC3.
Research ethics approval and fully informed consent were obtained. We included women who were
deemed to require surgery based on symptoms and/or anatomical findings. We excluded women who
were unable or unwilling to consent or unable to complete study questionnaires.
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Study set-up
Women in RCT1 were randomised within three strata: stratum 1A included women who were randomised
to one of all of the three treatment options – standard repair, mesh inlay and biological graft; stratum 1B
compared standard repair with mesh inlay; and stratum 1C standard repair with biological graft inlay. In
RCT2, women were randomised to one of three treatment options: stratum 2A (standard repair, mesh
inlay and mesh kit); stratum 2B, comparing standard repair with mesh inlay; and stratum 2D, comparing
standard repair with mesh kit.
Randomisation
Randomisation involved a computer-generated randomisation system managed by the Centre for
Healthcare Randomised Trials (CHaRT) at the University of Aberdeen. Participants were randomly allocated
1 : 1 : 1 to one of the arms in the stratum for which they were eligible in the Primary trial, and 1 : 1 : 2 in
the Secondary trial. The minimisation algorithm included surgeon, age (< 60 years or ≥ 60 years), type of
planned prolapse repair (anterior, posterior or both), planned concomitant continence surgery and planned
concomitant upper compartment prolapse repair. Women in the CCs received the surgery that they and
their gynaecologist thought was most acceptable and suitable.
Study interventions
Surgeons were asked to use the surgical techniques with which they were most familiar. They informed us
of their normal use of mesh and graft materials and details of their surgical techniques, but, as this was a
pragmatic trial, deviation could occur both from the randomised allocation and their normal practice for
clinical reasons. We recorded details of concomitant surgery for uterine or vault prolapse, continence
surgery and the use of mesh.
Statistical analysis
An intention-to-treat analysis was performed. Primary and secondary outcomes were compared using
generalised linear mixed models, adjusting for baseline covariates. Trial-based cost-effectiveness
analysis assessed mean differences (MDs) in costs and QALYs at 1 year and 2 years. Estimates of
cost-effectiveness were extrapolated to 5 years using a probabilistic Markov decision-analytic model.
Estimates of cost-effectiveness were expressed as incremental costs per QALY gained, and the net
monetary benefit approach was used to identify the optimal treatment modality on grounds of
cost-effectiveness, based on a ceiling willingness to pay of £30,000 per QALY gained.
Results
In total, 3744 women waiting for prolapse surgery were screened for eligibility, of whom 3089 (83%)
consented to participate in PROSPECT. Five of the 1507 (0.3%) who agreed to be randomised were
excluded after randomisation. Of those included, 1348 were randomised in RCT1, with 1126 enrolled in
CC1. Another 154 having a repeat repair were randomised in RCT2, with 244 in CC2. Finally, 215 women
who were having either uterine or vault prolapse repair enrolled in CC3. The main reason for declining
randomisation was the woman’s or the surgeon’s preference for a specific treatment. The majority (1264,
84%) of those randomised received their allocated treatment, 218 (15%) received a study treatment other
than that randomised and 25 (2%) did not receive any of the study treatments. The 12-month follow-up
appointment was well attended (1299, 86% of those randomised attended) and 1368 randomised
participants (91%) completed the 12-month questionnaires (primary outcome).
Primary trials
Prolapse symptoms reported by women
The primary outcome was women’s report of prolapse symptoms on the Pelvic Organ Prolapse Symptom
Scale (score range 0–28) at 12 months after surgery. Adjusting for baseline scores and minimisation
covariates, the mean POP-SS was similar for each comparison [trial 1: standard 5.4 vs. mesh 5.5; MD 0.00,
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95% confidence interval (CI) –0.70 to 0.71; trial 2: standard 5.5 vs. graft 5.6; MD –0.15, 95% CI –0.93 to
0.63]. There was also no statistically significant difference in the prolapse-related QoL score (range 0–10)
measured as the interference of prolapse symptoms with everyday life (trial 1: standard 2.0 vs. mesh 2.2;
MD 0.13, 95% CI –0.25 to 0.51; trial 2: standard 2.2 vs. graft 2.4; MD 0.13, 95% CI –0.30 to 0.56).
Adverse effects
The number of women with serious non-mesh adverse effects, such as infection, pain, urinary retention
and dyspareunia, was similar between the groups in the first year [standard 7.2% vs. mesh 7.8%; risk
ratio (RR) 1.08, 95% CI 0.68 to 1.72; standard 6.3% vs. graft 9.8%; RR 1.57, 95% CI 0.95 to 2.59].
There were no statistically significant differences between the randomised groups for any adverse effect
measure at any time period. The cumulative mesh complication rates over 2 years were 2 of 430 (0.5%)
for standard repair (trial 1), 46 of 435 (10.6%) for mesh inlay and 2 of 368 (0.5%) for biological graft.
The findings from CC1 were comparable.
Mesh complications in the Primary trials
In the first year, 2 of 430 women in the standard group and 32 of 435 in the mesh inlay group had mesh
complications, with a further 2 out 368 mesh complications in the biological group. One woman in the
standard group received mesh for her prolapse repair and had subsequent mesh exposure; the other had
mesh exposure resulting from a concomitant procedure. Both women in the standard group, and 23 in the
mesh inlay group, had surgery to remove or overlay the mesh [of whom 18 (72%) were asymptomatic and
16 (64%) had exposures of < 1 cm2]. In the second year, 1 of 430 in the standard group and 25 of 435 in
the mesh inlay group had a mesh complication (a repeat occurrence in 1 and 11 women, respectively). Of
these, 17 in the mesh inlay group required surgical correction of the exposure [of whom 13 (76%) were
asymptomatic and 10 (59%) had exposures of < 1 cm2]. The remaining women received conservative
treatment (such as mesh trimming in outpatients, oestrogen treatment or cautery with silver nitrate) or
no treatment.
Economic outcomes
Both mesh repairs were more costly to perform, driven by the material cost of mesh. There was no
evidence of differences in follow-up use of health services at 2 years. Synthetic mesh inlay was £363 more
costly (95% CI –£32 to £758). Biological graft was significantly more costly (+£565) than standard repair
(95% CI £180 to £950). The participant and wider societal costs added 40% to the total NHS costs
across the treatment groups for all women, although there were no differences across treatment groups.
Synthetic mesh had, on average, 0.071 additional QALYs (95% CI –0.004 to 0.145) relative to standard
repair, whereas biological graft had, on average, 0.039 (95% CI –0.041 to 0.120). There was substantial
uncertainty regarding the most cost-effective treatment strategy. None of the treatment strategies
demonstrated a probability of being the most cost-effective strategy of > 84% (if society was willing to pay
£30,000 for a QALY gained). Uncertainty remained across the range of sensitivity analyses undertaken.
A decision-analytic model to extrapolate results of RCT1 over a longer time shows that at 5 years there is
no evidence that either mesh strategy would be a cost-effective use of NHS resources. Standard repair
was, on average, the most cost-effective because of lower intervention costs, lower costs of treating
mesh-related complications and similar rates of surgical failure at 2 years. However, further long-term
follow-up is required to validate the extrapolation models used.
Secondary and clinical outcomes in the Primary trials
There were no statistically significant differences in any of the measures of bladder, bowel or sexual
function in any of the randomised groups. There were no statistically significant differences in the number
of women with residual prolapse beyond the hymen (objective measurement of anatomical cure of
prolapse using the POP-Q system) (trial 1: standard 13.9% vs. mesh inlay 16.1%; RR 1.12, 95% CI 0.79 to
1.60; trial 2: standard 15.5% vs. graft 18.1%; RR 1.14, 95% CI 0.80 to 1.62).
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Secondary trials
Prolapse symptoms reported by women
The primary outcome was prolapse symptoms (POP-SS, range 0–28) at 12 months after surgery. Adjusting
for baseline scores and minimisation covariates, the mean POP-SS was similar for each comparison {trial 3:
standard 6.6 [standard deviation (SD) 6.0] vs. mesh 6.1 (SD 6.4); MD –0.41, 95% CI –2.92 to 2.11; trial 4:
standard 6.6 (SD 5.5) vs. mesh kit 5.9 (SD 5.3); MD –1.21, 95% CI –4.13 to 1.72}. There was also no
statistically significant difference in the prolapse-related QoL score (range 0–10) measured as the interference
of prolapse symptoms with everyday life (trial 3: standard 2.5 vs. mesh inlay 3.0; MD 0.43, 95% CI–0.90 to
1.75; trial 4: standard 2.0 vs. mesh kit 2.3; MD –0.31, 95% CI –1.99 to 1.36).
Adverse effects
The number of women with serious non-mesh adverse effects was similar between the groups in the first
year (trial 3: standard 7/55, 12.7% vs. mesh inlay 5/52, 9.6%; RR 1.05, 95% CI 0.66 to 1.68; trial 4:
standard 3/25, 12.0% vs. mesh kit 3/46, 6.5%; RR 0.49, 95% CI 0.11 to 2.16). The cumulative mesh
complication rates over 2 years were 7 of 52 (13.5%) for mesh inlay and 4 of 46 (8.7%) for mesh kit, with
no mesh exposures after standard repair. There were no statistically significant differences between the
randomised groups in any other outcome measure at any time. The findings from CC2 were comparable.
Mesh complications in the Secondary trials
In the first year, none of the women in the standard group, 6 of 52 in the mesh inlay group and 3 of
46 in the mesh kit group had a mesh complication. Three women in the mesh inlay group and one in the
mesh kit group had surgery to remove or overlay the mesh. In the second year, none of the women
in the standard group, 2 of 52 in the mesh inlay group and 2 of 46 in the mesh kit group had a mesh
complication. Of these, one woman in the mesh inlay and one in the mesh kit group required surgical
correction. In total, six women required mesh surgery in the 2 years of follow-up. A further six women
received conservative treatment and the rest required no treatment.
Economic outcomes
The additional cost of providing mesh inlay and mesh kits for women who were having a secondary
prolapse repair were £398 (95% CI –£197 to £993) and £914 (95% CI £349 to £1478), respectively.
At 2 years, synthetic mesh inlay was, on average, £238 more costly than standard repair (95% CI –£929 to
£1405) and mesh kits were £873 more costly (95% CI –£27 to £1774). Incremental QALYs relative to
standard repair were 0.018 (95% CI –0.149 to 0.185 QALYs) and 0.096 (95% CI –0.081 to 0.274 QALYs)
for synthetic mesh and mesh kits, respectively. Owing to small sample sizes for the Secondary trial, there
was not enough evidence to determine the most cost-effective treatment strategy.
Secondary and clinical outcomes in the Secondary trials
There were no statistically significant differences in the number of women with residual prolapse beyond
the hymen (standard 14.0% vs. mesh inlay 14.0%; RR 0.59, 95% CI 0.18 to 1.92; standard 16.7% vs.
mesh kit 0%). There were also no statistically significant differences in any of the measures of bladder,
bowel or sexual function, but the sample size was too small to be conclusive.
Conclusions
There was evidence of no benefit from the use of mesh inlay or biological graft compared with standard
repair in terms of efficacy, QoL, adverse effects (other than mesh complications) or any other outcome
in women who were having a primary repair in the first 2 years. In those randomised to synthetic mesh in
the Primary trial, the cumulative incidence of mesh complications was 10.6% over 2 years. Some women
required surgery for mesh exposure but the majority were asymptomatic or had small exposures.
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Unless there is a significant decrease in reoperation rates for failure in the medium or long term, it is
unlikely that any type of mesh or graft would be cost-effective, given the excess cost over standard repair
and the excess cost of treatments for mesh complications.
The sample size in the Secondary trial comparisons was too small to be conclusive.
Recommendations for future research
Long-term follow-up to at least 6 years after surgery is ongoing to identify the recurrence rates, need for
further prolapse surgery and adverse effects.
Trial registration
This trial is registered as ISRCTN60695184.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The PROSPECT Study (PROlapse Surgery: Pragmatic Evaluation
and randomised Controlled Trials)
In 2009, the UK government National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) programme funded the PROSPECT Study. This monograph describes the research.
PROSPECT was a major multicentre UK randomised controlled trial (RCT) investigating the effectiveness
(including safety) and cost-effectiveness of surgical treatment, primarily in terms of improvement in
prolapse symptoms, in women who were having a primary or a secondary prolapse repair.
Description of the underlying health problem
Pelvic organ prolapse is the descent from its normal anatomical position of one or more of the female
genital organs. Pelvic organ prolapse is caused by herniation through deficient pelvic fascia or due to
weaknesses or deficiencies in the ligaments or muscles that should support the pelvic organs. There is little
epidemiological research into this condition because it has a variety of presentations and they do not all
cause symptoms, particularly in the early stages.1 Commonly reported symptoms include a feeling of
dragging or heaviness in the vagina, uncomfortable bulge distending the introitus, urinary symptoms
(urgency and voiding difficulty), bowel symptoms, such as incomplete emptying, and sexual dysfunction.
Prevalence and natural history
Estimates of the prevalence of prolapse vary from 41% to 50% of women aged > 40 years.2,3
It has been estimated that women have a lifetime risk of 11% of undergoing surgery for urinary
incontinence (UI) or prolapse and 7% for prolapse alone.4 The annual incidence of surgery for pelvic organ
prolapse is within the range of 15–49 cases per 10,000 women-years, and it is likely to double in the next
30 years.1,5 Little is known about the prevalence and effectiveness of different types of operations but they
are notoriously prone to failure: around 30% of women undergo further operations; the mean time
interval between the first and a subsequent procedure is about 12 years, and the time interval between
subsequent procedures decreases with each successive repair.4
Gynaecologists have recognised for some time that both anatomical failure of supporting pelvic structures
and recurrence of prolapse after surgery are common. More recently, it has also been recognised that
surgery can be followed by a greater impairment of quality of life (QoL) than the original prolapse itself
(e.g. new UI after surgery). In addition, repair of one type of prolapse may predispose the women to the
development of a different type of prolapse (a new or de novo prolapse) in another compartment of the
vagina due to alteration in the dynamic forces within the pelvis.4
Significance in terms of ill health and use of NHS resources
Surgery is common. In England and Wales in 2004–5, 26,947 women were admitted to hospital with a
main diagnosis of female genital prolapse, and 28,297 operations were performed (some women had
more than one type of prolapse operation).6 The majority of the operations (93%) were undertaken in
women who were having anterior repair (n = 8560), posterior repair (n = 5406) or both operations
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(n = 5654), or with a concomitant uterine prolapse (n = 6837). Only 7% were in women with vault prolapse
(n = 1840). Assuming a population of about 20 million women in the age group at risk for prolapse surgery
(50–85 years), the UK operation rate is currently around 14–16 women who were having prolapse
operations per 10,000 per year.6,7
The need is likely to increase because of the rising number of elderly women. It has been projected that
the number of women in the age group 50–85 years (those most likely to need prolapse surgery) will
increase by 1.44 million between 2012 and 2020.6
Description of standard management
Women with prolapse may be managed conservatively with pelvic floor muscle training (PFMT) and
pessaries, or with surgery. In addition they require management of associated conditions, for example
lower urinary tract symptoms, such as UI or overactive bladder syndrome; bowel problems, such as
constipation or faecal incontinence (FI), sexual dysfunction and oestrogen deficiency if postmenopausal.
Conservative management for women with prolapse
Although there is only one RCT to inform the use of mechanical devices (pessaries or rings), these are
often used for women who are unfit for surgery or who wish to avoid surgery. They can be very
efficacious, but questions remain about the best type of device, the long-term adverse effects and the use
of supplementary treatment such as oestrogen. Further research is required.8
Conservative physical treatments such as PFMT are also often recommended as first-line management.
A recent update of the relevant Cochrane review9 has found some evidence supporting the use of PFMT to
reduce prolapse symptoms and severity, as well as benefits for urinary and bowel symptoms.
In addition, vaginal oestrogen treatment can be used to reduce symptoms for postmenopausal women,
before or after surgery. The evidence supporting its use is limited and inconclusive.10
Surgical management for women with anterior or posterior vaginal
wall prolapse
The PROSPECT Study compared surgical operations for vaginal wall pelvic organ prolapse:
l anterior vaginal wall prolapse (urethrocele, cystocele, paravaginal defect)
l posterior vaginal wall prolapse (enterocele, rectocele, perineal deficiency).
A woman may present with prolapse of one or both of these sites, and she may be having a primary or a
secondary procedure. She may also have a concomitant uterine or vault prolapse or stress UI that requires
a continence procedure. For each of these sites there are several alternative traditional surgical techniques,
none of which has been properly evaluated in adequately powered multicentre RCTs. Major potential
adverse effects include infection, bleeding, mesh exposure and dyspareunia, as well as failure of repair and
failure to cure symptoms.
The techniques for performing anterior or posterior repair or implanting mesh or graft can vary widely
between gynaecologists. These include the following.
Standard anterior and/or posterior repair
In the standard approach, the vaginal skin is opened in the midline, the fascia is separated from the skin
and the fascial defect is plicated (sutured or buttressed). Any redundant vaginal skin is excised and the
skin is closed.
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Standard repair with mesh inlay
Over the last 10 years, gynaecologists have begun to include small pieces of mesh inlays as an extra
support to the fascial defects through which the pelvic organs prolapse, analogous to the use of mesh in
hernia surgery.11 If mesh is used, it can be positioned over or under the fascial defect as a ‘mesh inlay’ and
sutured in place to reinforce the tissues.
The proposed advantage of using mesh is that it will optimise surgical outcome without compromising
vaginal capacity or sexual function.12 The rationale is that it may help to reduce failure rates from
breakdown of weakened tissue or failure to identify all fascial defects.13 Although the mesh materials used
may be stronger than the woman’s own fascial tissue, the indications for use and choice of materials
remain controversial.13 The extent to which mesh inlays are currently used is unknown, but recent surveys
suggest that many gynaecologists are already incorporating mesh into their practice both in the UK and in
the USA.14,15 The decision to use mesh is complicated by the different types available:
l absorbable synthetic (e.g. polyglactin)
l absorbable biological (e.g. fascia lata, porcine dermis)
l combined or semi-absorbable (e.g. polyglactin and polypropylene) and
l non-absorbable (e.g. polypropylene).
There are theoretical pros and cons to each, but there is not enough evidence available to allow
rigorous comparison.
Mesh insertion using a trocar (introducer device): mesh kits
Some commercial manufacturers of mesh have introduced large mesh systems, analogous to the
tension-free vaginal tape (TVT) slings used in incontinence surgery.16 These commercial devices (‘mesh kits’)
are available for anterior or posterior compartments, or can be used together for both. The mesh is
inserted using a trocar (introducer device). This involves blind penetration of pelvic spaces by trocars in
order to thread mesh tails into positions from which they support a central mesh layer or hammock, which
supports and corrects the prolapse defect. Currently available devices use non-absorbable synthetic mesh,
but kits using other types of mesh (combined) have also been used.
These have been actively promoted and introduced to clinical practice without first being evaluated in
rigorous independently managed RCTs. These meshes are inserted blindly using introducer devices or
trocars that may damage surrounding organs or blood vessels.17 Prospective studies have suggested that
the mesh devices have been used worldwide, but it is not clear whether this is driven by gynaecological
preference or commercial marketing pressure. However, clearly some women have been willing to
undergo this new technology despite lack of evidence for safety or efficacy.
Evidence for the use of mesh or graft in prolapse surgery
The most recent update of the Cochrane review of surgery18 for lower compartment prolapse concludes:
The use of mesh or graft inlays at the time of anterior vaginal wall repair reduces the risk of recurrent
anterior wall prolapse on examination.
The authors further add:
Anterior vaginal polypropylene mesh also reduces awareness of prolapse; however these benefits must
be weighed against increased operating time, blood loss, rate of apical or posterior compartment
prolapse, de novo stress urinary incontinence, and reoperation rate for mesh exposures associated with
the use of polypropylene mesh.
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For posterior wall repairs, the Cochrane review18 concludes:
The evidence is not supportive of any grafts at the time of posterior vaginal repair.
Repeat surgery for recurrent prolapse
There were no data on the differential effects in women who were having primary as opposed to repeat
(secondary) surgery: all of the trials reported both groups of women together despite their potentially
different prognoses. There is, therefore, no evidence to suggest whether or not the use of mesh
(particularly non-absorbable synthetic mesh, which has the strongest mechanical strength and remains in
situ indefinitely) should be reserved for more complex or recurrent prolapse. Although gynaecologists have
stated that this is their belief and practice, evidence suggests that the majority (70%) of the current
recipients of mesh are having their first prolapse operation.14
An Interventional Procedures (IP) review of 503 women and a further recent case series of 289 women
drew attention to the high incidence of serious adverse effects (e.g. 2.8% with damage to surrounding
organs) in women who were having mesh inserted with blind introducer devices (‘mesh kits’).17,19 Our
opinion was that until benefits and risks have been properly evaluated, mesh kits using non-absorbable
synthetic mesh should be reserved for more complex cases of prolapse. Therefore, in PROSPECT we limited
this option to women being treated for a recurrence of prolapse in the site where previous surgery
had occurred.
Current recommendations from the National Institute for
Health and Care Excellence
An IP review, conducted for the National Institute for Health and Care Excellence (NICE) in 2008,
investigated the use of mesh for women who were having anterior and/or posterior vaginal wall prolapse
repair.19,20 The total number of women receiving mesh in this review was 4569: mesh was inserted using
an introducer device, trocar or kit in 503 of these women.19 The IP review also included additional data
from non-randomised comparative studies and case series. Using these extra data, non-absorbable
synthetic mesh had the lowest failure rate compared with:
l absorbable synthetic mesh [odds ratio (OR) adjusted for bias from study design 0.23, 95% confidence
interval (CI) 0.12 to 0.44]19
l absorbable biological mesh (OR adjusted for bias from study design 0.37, 95% CI 0.23 to 0.59).19
On the other hand, the mesh erosion (now termed ‘exposure’) rates increased from 1% (95% CI 0.1% to
4.0%) with synthetic absorbable mesh to 6% with absorbable biological mesh to 10% with non-absorbable
synthetic mesh.19 The data were too sparse, however, for other reliable statistical analysis. There were
insufficient data on women’s subjective prolapse symptoms or complications, such as infection, blood loss or
dyspareunia, and none on long-term outcomes. Particular safety worries were related to the use of introducer
devices (trocars) that were used for the blind insertion of mesh into intrapelvic spaces.17
These and other findings were presented to the Interventional Procedures Advisory Committee (IPAC) in
January 2008 and their guidance has now been published.21 The committee recommended that mesh
should be used only under special arrangements for clinical governance, consent and audit or research:
hence the PROSPECT Study was funded to fill the evidence gap.
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Decision to test alternative forms of surgery
There is not enough evidence from RCTs to guide management for women with prolapse. Additionally, the
Cochrane and the IP reviews conclude that there is insufficient information about any of the surgical options
to guide management of any type of pelvic organ prolapse in any population of women with prolapse.
We identified that the largest group of women are those with anterior and/or posterior prolapse, who
constitute around 90% of those having prolapse surgery (including those having a concomitant
hysterectomy). The evidence underlying surgery for these women was clearly inadequate, with very little
evidence regarding subjective prolapse symptoms, effect on QoL and safety.
Both the Cochrane and the IP reviews18,19 identified a need for adequately powered RCTs of the use of
mesh in prolapse surgery. PROSPECT comprises the largest, adequately powered and independent RCT
comparing traditional prolapse operations with new methods incorporating mesh as an inlay or mesh
inserted using an introducer system (mesh kit).
Questions addressed by this study
Principal objectives
To determine the effectiveness (including safety) and cost-effectiveness of surgical treatment, primarily in
terms of improvement in prolapse symptoms, in women who were having anterior and/or posterior vaginal
wall pelvic organ prolapse surgery, separately in two trials:
1. In women who were having a primary prolapse repair, the effects of:
i. a standard repair versus a standard repair using a non-absorbable or combined mesh inlay and
ii. a standard repair versus a standard repair using a biological graft inlay.
2. In women who were having a repeat prolapse repair, the effects of:
i. a standard repair versus a standard repair using a non-absorbable or combined mesh inlay and
ii. a standard repair versus a mesh kit procedure.
The two groups are being considered independently because different surgical options are considered to
be appropriate for clinical reasons.
Secondary objectives
1. To determine the differential effects on other outcomes, such as urinary, sexual and bowel function,
QoL, general health, need for secondary surgery and adverse effects.
2. To identify possible effect modifiers (e.g. different types of mesh, concomitant procedures, age,
complex prolapse types).
3. To establish if the findings of the research, including implications for service delivery, training and
introduction of mesh, are generalisable to the UK NHS.
This study assessed which of the most frequently employed techniques for the most common types of
prolapse (anterior and posterior vaginal wall prolapse) are most clinically effective and safe. The study also
assessed cost-effectiveness. This will guide gynaecologists in their surgical practice and purchasers in their
choice of provision of health care. Given the number of prolapse procedures currently performed (28,000
annually in the UK) and the anticipated rise in need for such surgery with an ageing population (a twofold
increase in the age group at risk in the next 30 years is predicted), the potential cost implications for the
health service are considerable.6
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Chapter 2 Methods and practical arrangements
Study design
PROSPECT comprised two RCTs within a comprehensive cohort (CC) study. It was designed to determine
the effectiveness (including safety) and cost-effectiveness of surgical treatment, primarily in terms of
improvement in prolapse symptoms, in women who were having anterior and/or posterior vaginal wall
pelvic organ prolapse surgery. Women who were having a primary prolapse repair and those having a
secondary prolapse repair were considered independently because different surgical options were deemed
to be appropriate for clinical reasons. If a woman did not receive surgery then no follow-up questionnaires
were issued.
Important changes to the design after trial commencement
The recruitment rate to both the Primary and Secondary trials proved to be slow initially, partly because of
the cost of sourcing all of the mesh types required for the study and lack of availability of certain mesh
types, and partly because of some clinicians’ preference for one of the mesh types. Therefore, with the
agreement of the Trial Steering Committee (TSC) and Data Monitoring Committee (DMC), a decision was
made in 2010 to allow surgeons to randomise between no mesh and only one of the mesh options,
creating three randomisation strata in both trials. The study design showing the comparisons options
available to surgeons is shown in the flow diagram in Figure 1.
Clinical centres
Both specialist urogynaecologists and general gynaecologists were eligible to take part if they had
extensive experience and training in urogynaecological reconstructive surgery. To participate they had to be
prepared to allow treatment allocation to be decided at random for at least a proportion of their patients:
the remainder could be entered into the CC study if the patient agreed. Before participating in the trial,
the surgeons had to formally choose to which comparisons they were willing to contribute.
Study population
All women under the care of a collaborating surgeon were potentially eligible for inclusion if a decision
had been made to have primary or secondary pelvic organ prolapse surgery for anterior and/or posterior
vaginal wall prolapse. Women undergoing concurrent hysterectomy/cervical amputation, vault surgery or
continence procedures were also eligible. Only women who were unable or unwilling to give competent
informed consent, or who were unable to complete study questionnaires, were deemed ineligible.
Two parallel but separate trials were conducted: one among women who were having a primary prolapse
repair and the other in women who were having a secondary prolapse repair. For the purposes of PROSPECT,
a secondary prolapse was defined as a recurrence of prolapse after a primary procedure, when the recurrence
was in the same compartment. If the prolapse was in a different compartment and the original site did not
require revision surgery, the woman was classed as having a primary repair of a de novo prolapse.
In addition, women who were unwilling or unsuitable for randomisation were eligible to be followed up
using the same protocol as part of the CC study. This included women who were having uterine or vault
surgery only.
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Consent to participate
All women who required pelvic organ prolapse surgery were identified by a dedicated recruitment officer
(RO) in each centre. A log was maintained of all of the women meeting the eligibility criterion (admission
for prolapse surgery), describing reasons if they did not agree to enter the study or be randomised
(see Appendix 1). Every woman was allocated a unique study number.
Every eligible woman was given a flyer containing a brief summary of the study when attending the initial
clinic appointment (the fliers are reproduced in Appendix 1). The women were then given the patient
All women requiring surgery for
POP
Baseline assessment (recruitment nurse and/or gynaecologist)
Patient-reported outcome instrument and
POP-Q by outcome assessor
Anterior +/– posterior POP
Consent to randomisation
6 months after prolapse operation: patient-reported outcome instruments and adverse effects
Primary outcome at 12 months after prolapse operation:
patient-reported outcome instruments, resource use and adverse effects, and (for randomised women only)
POP-Q at clinical examination by outcome assessor, blinded to randomisation and intervention
24 months after prolapse operation: patient-reported outcome instruments, need for further surgery,
resource use, cost-effectiveness and adverse effects
18 months after prolapse operation: patient cost questionnaire
CC1
CC2
Assessed for eligibility
Eligible participants given study information and
consented to study (by recruitment nurse)
Not recruited
(declined study/missed)
Ineligible
Not having POP surgery
Assessed for eligibility for randomisation
RCT1 or RCT2
(by gynaecologist)
CC1 and CC2
Anterior or posterior POP but 
woman or gynaecologist not
willing to randomise
CC3
Vault or uterine
prolapse only
CC3
Primary repair RCT1
(stratum A, stratum B, stratum C)
Secondary repair RCT2
(stratum A, stratum B, stratum C)
Standard
midline repair
Standard
midline repair
Mesh kita
non-absorbable/
hybrid mesh
Standard repair
with mesh inlay:
biological mesh
Standard repair
with mesh inlay:
non-absorbable/
hybrid mesh
Standard repair
with mesh inlay:
non-absorbable/
hybrid mesh
FIGURE 1 Flow diagram of study design. a, Only gynaecologists trained in the use of mesh kits will randomise
women to this option. POP, Pelvic Organ Prolapse.
METHODS AND PRACTICAL ARRANGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
information leaflet (PIL; see Appendix 1) with their admission documents (which could be during the initial
clinic appointment or by separate mail, if the woman agreed). Women were given the opportunity to
discuss all aspects of the study with their general practitioner (GP) and/or family members before admission,
their gynaecologist, the RO, staff at preadmission clinics and/or when admitted to hospital. In addition,
all documentation contained the PROSPECT Study office contact details to enable women to obtain
information from the study organisers. Signed consent was obtained from each woman to participate
(and, if suitable, to be randomised) and followed up after her prolapse surgery by questionnaires and an
examination in Gynaecology Outpatients (the latter in randomised women only). The PIL and the consent
form (see Appendix 1) both refer to the possibility of long-term follow-up, being contacted about other
prolapse research and access to their NHS records for these purposes. A letter and GP information sheet
were also sent to the woman’s GP (see Appendix 2). A copy of the consent form, together with a summary
of the study, was filed in the woman’s hospital notes.
Women who did not wish to be randomised, or who were not suitable for randomisation, were still eligible
to be followed up using the same study protocol as part of the CC study. They completed all of the study
procedures and documents including follow-up, except for the clinical examination at 12 months.
Women who initially agreed to enter the study but later decided to withdraw or became unable to
continue were asked for verbal consent to enable us to retain their existing data and access relevant NHS
data. Women who did not agree to participate in the study (randomised or cohort) were logged
anonymously along with a minimum data set of age and type of prolapse (anterior, posterior, uterine,
vault; primary or secondary procedure) (see Appendix 1).
Health technologies being compared
Women were randomised to an intervention according to their surgical history (previous prolapse repair or
not), the availability of the mesh (non-absorbable, biological and/or mesh kits) and the skill capacity of
their operating gynaecologist (trained in mesh kit use or not). The study design is shown in the flow
diagram in Figure 1.
If one of the mesh types was temporarily or permanently unavailable (owing to financial constraints) then
the women could be randomised to one of the other two arms.
In addition, the expectation was that mesh kits would normally be used only for women who had been
randomised to this option. If the operating gynaecologist was not trained in the use of mesh kits then the
women under their care could be randomised to one of the other two arms only. Furthermore, in view of
the scarcity of data about their safety and efficacy, mesh kits were used only for women who were having
a secondary procedure, who have a more complex prolapse problem.
Therefore, women who were having a primary repair were randomised to:
l standard anterior and/or posterior repair (with native tissue only) (reference technique)
l standard anterior and/or posterior repair with a synthetic non-absorbable or hybrid mesh inlay or
l standard anterior and/or posterior repair with biological graft inlay.
Women who were having a secondary repair were randomised to:
l standard anterior and/or posterior repair (with native tissue only) (reference technique)
l standard anterior and/or posterior repair with a synthetic non-absorbable or hybrid mesh inlay or
l a mesh kit (using an introducer device/trochar) with a non-absorbable or hybrid mesh.
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Treatment allocation
After entering contact details, essential baseline information and confirmation of signed consent into the
internet-based PROSPECT database, the local researcher was able to randomise the woman (if appropriate)
to one of the arms for which she was eligible. Randomisation was carried out as close to the time of
surgery as was practical, taking into account the hospital routines and time needed for setting up the
operating theatre.
Randomisation utilised the existing proven remote automated computer randomisation application at the
study administrative centre in the Centre for Healthcare Randomised Trials [CHaRT, a fully registered UK
Clinical Research Network clinical trials unit] in the Health Services Research Unit (HSRU), University of
Aberdeen. This randomisation application was available only as an internet-based service.
Randomisation was computer allocated and stratified depending on whether a woman was having a
primary or secondary repair. If not eligible for randomisation, the woman was allocated to the CC.
Primary prolapse (de novo) was defined as a prolapse in a compartment that had not been previously
repaired. If the woman was having two primary procedures (i.e. both anterior and posterior vaginal wall
prolapses required repair) then the randomised allocation applied to both prolapse repairs.
Secondary prolapse was defined as a recurrence of prolapse after a previous procedure, when the
recurrence was in the same compartment. If the woman also required a concomitant primary repair of a
de novo prolapse in a different compartment, this procedure was chosen on clinical grounds/surgeon
choice (i.e. not dictated by the randomisation allocation for the secondary procedure).
If the new prolapse was in a different compartment (de novo) and the original site did not require revision
surgery, the woman was classed as having a primary repair of the de novo prolapse and randomised in the
Primary trial.
The allocation was computer-generated in ratios of 1 : 1 : 1 for the Primary trial and 1 : 1 : 2 for the
Secondary trial. Randomisation was unbalanced in the Secondary trial in favour of mesh kits to account
for the skill set of the available surgeons (not all surgeons would be trained in their use). Allocation was
further minimised according to:
l the woman’s age (< 60 years or ≥ 60 years)
l type of prolapse being randomised (anterior, posterior or both)
l need for a concomitant continence procedure (e.g. TVT) or not
l need for a concomitant upper vaginal prolapse procedure (e.g. hysterectomy, cervical amputation, vault
repair) or not and
l surgeon.
Clinical management
Within the randomised comparisons, surgeons could use any mesh, graft or mesh kit, providing that any
synthetic mesh was monofilament macroporous polypropylene and mesh inlays were secured with peripheral
sutures. Surgeons used their mesh material of choice and followed their standard practice so that the
technique that they normally used was not modified for the purposes of the trial. All of the other aspects of
care were left to the discretion of the responsible surgeon. Each surgeon was asked to complete a surgical
standardisation form (see Appendix 3) so that their preferred method of surgical repair could be recorded.
We did suggest, however, that the mesh or graft should be inserted under the fascial layer and secured at
five points around the periphery of the inlay. If they did so, or wished to secure the inlay in another way
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(e.g. attach the inlay to the white line), we asked them to record the method used in the surgical
standardisation form, but did not obtain information on whether or not this was actually done for
individual participants.
Data collection and processing
Participant-reported outcomes were assessed by self-completed questionnaires at baseline (before surgery;
see Appendix 4) and self-completed postal questionnaires at 6, 12, 18 (Participant Cost Questionnaire only)
and 24 months following surgery (see Appendix 4). Where participants ticked more than one box for each
question, we recorded this using the worst-case scenario. For randomised women, following one postal
reminder, participants who had not returned the questionnaire were telephoned and offered the option of
completing the questionnaire over the telephone. For cohort women, only a second postal reminder was
issued. A number of other measures were taken to promote ongoing interest in, and commitment to,
the trial, including participant newsletters and annual Christmas cards (both randomised and CC women,
and collaborators at the clinical centres).
The study-specific questionnaires also included questions about care in general practice, physiotherapy and
outpatient consultations related to their prolapse, as well as any complications, readmissions, reoperations
and costs. Reported hospital readmissions and complications were confirmed with the clinical centre
when required.
Intraoperative and postoperative data were collected by the gynaecologists, supported by ROs. This
involved completing a questionnaire (see Appendix 3) at the time of surgery, providing details of the
operative procedures, complications and resource use, and a short clinical questionnaire (see Appendix 3)
at the 12-month outpatient review appointment, including a Pelvic Organ Prolapse Quantification (POP-Q)
measurement (only randomised women).
Study outcome measures
We identified three primary outcome measures.
1. Women’s symptoms of prolapse were measured using the patient-reported Pelvic Organ Prolapse
Symptom Score (POP-SS)22 at 12 months after surgery. This scale was derived from the seven questions
that were judged to be most directly related to prolapse symptoms (see Appendix 4) and has been
shown to reflect the range and intensity of symptoms experienced by women, as well as being
responsive to change over time.23,24 Scores were determined for each of the seven items (ranging from
0 for ‘never’ to 4 for ‘all of the time’) with an overall POP-SS out of 28. Participants who only partially
completed the seven-item response schedule were assumed to have no symptoms, when no response
had been given to any individual items. Women were considered to be symptomatic if their overall
score was > 0.
2. QoL (condition-specific) was measured as the woman’s rating of the overall effect of prolapse
symptoms on everyday life on a 0–10 visual analogue scale (VAS), for which 10 is worst.
3. The primary economic outcome measure of cost-effectiveness was the incremental cost per
quality-adjusted life-years (QALYs), based on the EuroQol-5 Dimensions, 3-level version (EQ-5D-3L).25
Other outcome measures included objective prolapse measurement; urinary, bowel and sexual symptoms
[using the International Consultation on Incontinence (ICI) suite of validated questionnaires];26 intraoperative
and postoperative complications, including the need for additional surgery (repeat surgery for prolapse
recurrence or incontinence, and surgery required for adverse effects); cost; and cost-effectiveness.
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Objective prolapse measurement
We intended that, at baseline and (for randomised women) at 12 months after surgery, women would
have objective measurements of their prolapse compartments. Objective prolapse staging was carried
out using the POP-Q system.27 This measures the maximum descent of each of the three prolapse
compartments (anterior, posterior and upper) relative to the hymen (at 0 cm): measurements inside the
vagina are negative, whereas those outside are positive. A measure of prolapse (classified from stage 0 to
4) was determined for anterior, posterior and uterine/vault, with the leading edge of the most descended
compartment used to define overall stage. An algorithm was used to ensure that POP-Q staging was
correctly calculated from the component measurements of the POP-Q [Aa, Ba, C, D, Bp, Ap and total
vaginal length (TVL)] in which common recording errors (e.g. Ba measurement less than Aa) were corrected
or queried. If data were discrepant, they were corrected by consultation with the local hospital records to
obtain additional data. If POP-Q data were missing, we accepted the surgeon’s qualitative record of stage,
both overall and in individual compartments (i.e. surgeons could specify the stage without giving the
POP-Q measurements).
Usually, using the classic Bump et al.27 criteria for the POP-Q system, any measurement from –1 cm (inside
the hymen) to 1 cm outside counts as stage 2. However, we further subdivided stage 2 into prolapse at
the hymen or within (–1 cm to 0 cm; stage 2a or less) compared with prolapse at > 0 cm (stage 2b).28,29
Thus, women were classified as having objective prolapse if the leading edge was at any point outside the
hymen (measured at > 0 cm, stage 2b, 3 or 4).
Urinary, bowel and sexual symptoms
Symptoms related to other aspects of pelvic floor dysfunction were measured using the ICI suite of
validated questionnaires.26
Urinary incontinence was assessed using the International Consultation on Incontinence-Urinary Incontinence
Short Form (ICIQ-UI-SF). Other urinary symptoms were recorded by the ICIQ-Female Lower Urinary Tract
Symptoms (ICIQ-FLUTS). The latter provides subscales for filling, voiding and incontinence symptoms.
The International Consultation on Incontinence Questionnaire (ICIQ)-Bowel Symptom was not finalised when
we began PROSPECT. We therefore adapted draft questions to produce a short summary of relevant bowel
symptoms. We used similar questions to map on to the ROME criteria to define constipation (Table 1).30
We assessed vaginal and sexual symptoms using the International Consultation on Incontinence
Questionnaire-Vaginal Symptoms (ICIQ-VS). The ICIQ-VS provides a brief and robust measure to assess the
impact of vaginal symptoms and associated sexual matters on QoL and outcome of treatment. It provides
subscales for vaginal symptoms, sexual matters and the overall impact of vaginal symptoms on QoL.
Women were asked if they were sexually active and, if not, whether or not this was because of their
vaginal or prolapse symptoms, or for another reason, including no partner. Women’s responses to this
TABLE 1 Comparison between ROME criteria and equivalent questions for the PROSPECT questionnaires
ROME criteria – any two of: Equivalent PROSPECT questions
Fewer than three bowel movements per week Stool passing once a week or less
Straining Straining most or all of the time
Lumpy or hard stools Hard stools
Sensation of incomplete defecation Feeling that bowel has not completely emptied most or all of the time
Manual manoeuvring required to defecate Manual manoeuvre to empty bowel most or all of the time (splinting
of perineum or vagina, or digital evacuation of the bowel)
Sensation of anorectal obstruction No equivalent PROSPECT question
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question were post-coded to ensure reliability and consistency. Data were included in the analysis of sexual
outcomes for women who were sexually active or for women who were sexually inactive because of
prolapse symptoms.
Safety reporting
Adverse effects were notified to the study office in a variety of ways. They could be recorded by the
centre staff using the recruitment officer case report form (RO CRF; see Appendix 3) or at the time of the
12-month clinic review. Women also reported effects and readmissions in the follow-up questionnaires.
If an adverse effect was suspected, it was verified if possible.
All related serious adverse effects [serious adverse events (SAEs)] and adverse effects [adverse events (AEs)]
were recorded on the serious adverse event report form (see Appendix 3). Unrelated SAEs or AEs were
not recorded.
Within PROSPECT, a SAE or an AE was defined as ‘related’ if it occurred as a result of a procedure
required by the protocol (i.e. prolapse surgery), whether or not this procedure was the specific intervention
under investigation, and whether or not it would have been administered outside the study as normal
care. Signs or symptoms of the disease being studied were not considered an adverse effect.
An AE was defined as a SAE if it resulted in death, was life-threatening, required hospitalisation or
prolongation of an existing admission, resulted in significant disability/incapacity or was otherwise
considered medically significant by the investigator.
Adverse effects that were expected after prolapse surgery are listed below. Any AEs that were deemed to
be related and serious but unexpected (i.e. not on the list below) required expedited onward reporting
to the sponsor. During the conduct of PROSPECT no unexpected SAEs were reported.
Within PROSPECT the following occurrences were potentially expected:
l Possible (expected) intraoperative occurrences associated with surgery were injury to organs or blood
vessels, excess blood loss, blood transfusion, anaesthetic complications, death.
l Possible (expected) occurrences following surgery were thrombosis, infection [urinary tract infection
(UTI), sepsis, abscess], pain, urinary retention, bowel obstruction, constipation, mesh erosion, excess
blood loss, haematoma, vaginal adhesions, skin tags, granulation tissue, new or persistent urinary tract
symptoms, death.
Reported SAEs and AEs were further classified using the International Urogynecological Association (IUGA)/
International Continence Society (ICS) joint terminology and classification of complications that are related
directly to the insertion of prostheses (meshes, implants, tapes) and graft in female pelvic floor surgery,31
and complications related to native tissue female pelvic floor surgery.32
Sample size calculation
Primary trial
Pilot data showed a conservative estimate of the standard deviation (SD) of the primary participant-
reported outcome POP-SS at 1 year to be eight units, and we considered a difference in means of two
units to be a clinically important difference. The sample size calculation for the Primary trial was, therefore,
based on a standardised effect size of 0.25. To detect a difference of 0.25 SDs with 90% power and alpha
equal to 0.025 (to maintain the nominal p-value at 0.05 with tests for two comparisons), we planned to
follow-up 400 women in each arm of the primary repair RCT (a total of 1200 participants). The sample size
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was inflated to 1450 participants, which allowed for a dropout rate of 17.5%. A trial of this size is also
adequately powered to detect important differences in the economic and secondary outcomes.
Secondary trial
It was estimated that 30% of women requiring anterior and/or posterior repair would receive a secondary
or subsequent repair. Therefore, during the proposed time period required for recruiting 1450 women
to the primary repair RCT above, it was anticipated that approximately 620 women who were having
secondary surgery would be randomised to the secondary repair RCT (assuming the same rate of eligibility
and willingness to participate as in the primary repair RCT. The total expected recruitment across both trials
was therefore 2070 randomised women.
Pilot data indicated that women who were having secondary repairs have a higher level of symptoms at
baseline. Therefore, we considered it to be biologically plausible that these women might show a larger
benefit from surgical treatment than women who were having their first repair. We therefore calculated
that it would be possible to detect, with 90% power and alpha equal to 0.025, a standardised effect size
of 0.38, which equates to three points on the Pelvic Organ Prolapse Symptom scale.
Avoidance of bias, including blinding
Group allocation was concealed from the woman and the ward staff, although blinding in theatre was not
possible, given that this was a surgical trial. Women were not informed after their surgery of the procedure
actually carried out unless they specially requested this information. Outcome assessment was largely by
participant self-completed questionnaires, so avoiding interviewer bias.
Where possible, the clinical review at 12 months in outpatients was conducted by research staff who were
blinded to allocation, rather than the clinical staff caring for the woman. Although women and research
staff were not explicitly informed of which operation was randomly selected, examination may have
revealed which operation was actually carried out.
A researcher who was blinded to allocation conducted the data collection, data entry and analysis, using
study numbers only to identify women and questionnaires. In the RCTs, an intention-to-treat approach was
used in all primary analyses. In addition, all analyses were clearly predefined to avoid bias (see Appendix 5).
Statistical analysis
The trial analysis was by intention to treat (all participants remained in their allocated group for analysis),
giving the least biased estimate of effectiveness between interventions. Two comparisons were analysed
in the primary repair RCT – standard repair compared with synthetic mesh (trial 1, combining the strata
1A and 1B; see Figure 1) and standard repair compared with biological mesh (trial 2, combining strata 1A
and 1C) and three comparisons were analysed in the secondary repair RCT – standard repair compared
with synthetic mesh (trial 3, combining strata 2A and 2B) and standard repair compared with mesh kit
(trial 4, combining strata 2A and 2D). Study analyses were conducted according to a statistical analysis
plan (SAP), using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) (see Appendix 5).
For each time point (baseline, 6, 12 and 24 months), all outcome measures are presented as summaries of
descriptive statistics (mean and SD for continuous measures, and proportion for ordinal and dichotomous
measures). Comparisons between randomised groups were analysed at 12 months and 24 months
using general linear regression models (GLMs). POP-SS, prolapse-related QoL, EQ-5D-3L and readmissions
data at 6 months were also analysed. Models were adjusted using minimisation covariates (age group, type
of prolapse, concomitant continence procedure and concomitant upper compartment prolapse surgery), the
equivalent baseline measure, where appropriate, and (in the primary repair trial) for randomisation stratum.
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Continuous outcomes were analysed using linear mixed models, with surgeon fitted as a random effect.
POP-Q stage, bowel frequency and satisfaction scales were analysed using ordinal logistic regression, and
dichotomous outcomes were analysed using binary logistic regression (proportional odds models with
cumulative logits). Estimates of treatment effect size were expressed as the fixed-effect solution for the
mean difference (MD) in the mixed models, ORs in the ordinal models and risk ratios (RRs) in the binary
models. For all estimates, 95% CIs were calculated and reported.
Subgroup analyses were carried out on the primary outcome in the primary repair RCTs (POP-SS at 1 year)
to test subgroup by treatment interaction effects. Subgroups were determined a priori to be age group
(< 60 years or ≥ 60 years), type of planned prolapse repair (anterior, posterior or both), planned
concomitant continence procedure (yes or no), planned concomitant upper prolapse procedure (yes or no)
and parity (0–2 or 3+).
The main analysis was a complete case analysis with no imputation of missing values. Sensitivity analyses,
however, were carried out on the primary outcome in the primary repair RCTs (POP-SS at 1 year) to
investigate the impact of missing data under various assumptions. The first sensitivity analysis used multiple
imputation (MI) using fully conditional specification, which assumed the data to be missing at random.
Imputed values were obtained from the generation of 10 data sets and based purely on observed values
(minimisation covariates and Pelvic Organ Prolapse Symptom scale scores at baseline). Subsequent
sensitivity analyses assumed data to be missing not at random, with scenarios for systematic differences
between missing and observed values being examined, and whether or not this might have differed
between randomised groups. These analyses adjusted the imputed values in the initial sensitivity analysis
by either adding two points to the imputed Pelvic Organ Prolapse Symptom scale scores or subtracting
two points. These adjustments were then repeated in one arm only, and repeated again by applying the
adjustments in the other arm only. We consider two points on the Pelvic Organ Prolapse Symptom scale
to be the minimum clinically important difference and hence a meaningful systematic difference to test in
the sensitivity analyses. An additional sensitivity analysis was performed whereby individual unanswered
Pelvic Organ Prolapse Symptom scale items were assumed to be missing (rather than assumed to
be asymptomatic).
Health-economic evaluation
This section outlines the methods for the trial-based economic evaluation. The methods are applicable to
both the analysis of the Primary and Secondary trial data at 1-year and 2-year follow-up. Further detailed
methods regarding how the trial data are used to inform the development of a decision-analytic model for
the choice of primary prolapse surgical repair, as well as detailed model methods, will be reported in the
decision modelling chapter (see Chapter 9). Data were analysed at 1-year follow-up, thus following the
timeline for the Primary trial outcome analysis. A further analysis was undertaken using 2-year follow-up
data, which improve the information relating to recurrence/failure and the associated resource implications
in terms of NHS resources consumed as well as QoL. All health-economic analyses within the RCT were
based on the intention-to-treat principle. Results from the within-trial economic evaluation are presented
as incremental cost-effectiveness ratios (ICERs). The primary framework of analysis for the health-economic
evaluation is a cost–utility analysis, reporting results as incremental cost per QALY gained of adopting one
treatment approach over another.
For all comparisons of costs and QALYs undertaken in the primary repair trial, results are based on
complete case data and are presented for the following comparisons:
1. synthetic mesh repair versus standard repair
2. biological graft repair versus standard repair.
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For assessments of the probability of cost-effectiveness, data are considered within a net benefit
framework for complete cost and QALY pairs, and for a three-way comparison as per RCT1A (women
randomised across all treatment options). For the secondary repair trial, tables of results are presented in a
similar manner; however, data from all randomised women are used, not just those randomised to the
three-way comparison as above. The justification of the alternative approach is to ensure best use of
limited data available. For both the Primary and Secondary trial analyses, we have conducted sensitivity
analysis around the choice of data used in the comparisons to explore the impact of these decisions on
cost-effectiveness results.
Quality of life (quality-adjusted life-years)
The primary health-economic analysis is based on a cost–utility framework, with results reported as
incremental cost per QALY gained. The purpose of a cost–utility analysis is to provide information to
health-care decision-makers regarding the scarce allocation of health resources at a health-care level.
It allows for a determination of value for money of one treatment approach over another and is used
to guide recommendations to UK policy-makers, such as NICE.
The EQ-5D-3L25 generic QoL instrument was administered to all trial participants at baseline and at
6-month, 1-year and 2-year follow-up. The EQ-5D-3L measure divides health status into five dimensions
(mobility, self-care, usual activities, pain/discomfort and anxiety/depressions). Each of these dimensions
have three levels, so 243 possible health states exist. EQ-5D-3L responses are presented in graphical
format, illustrating the percentage of respondents with any or severe problems on each health domain,
split by randomised arms of the trial. The results are presented in accordance with EuroQoL guidelines.25
The responses to the EQ-5D-3L questionnaire were valued using UK general population tariffs, based on
the time trade-off technique to generate a utility score for every participant within the trial.25 QoL data
derived from the EQ-5D-3L were combined with mortality data from the trial, using the standard
assumption that all participants who have died in the trial will have a utility value of 0 from the date of
death to the end of follow-up. QALYs were then calculated on the basis of these assumptions, using an
area beneath the curve approach, assuming linear extrapolation of utility between time points.
Resource use and costs
The perspective of the primary economic analysis is that of the NHS. A supplementary analysis presents
costs from a wider patient/societal perspective. In all cases, resource use and costs relate to consultations in
primary and secondary care which are related to women’s prolapse or prolapse-related symptoms.
Health services costs
The resource-use data were sourced from participant-completed questionnaires and supplemented with
data that were post-coded to patient records for secondary care resource use. Post-coding was conducted
by checking all reported cases of secondary care resource use against patient notes to verify reported length
of stay, category of care use (so, outpatient or inpatient) and to verify that the reported use of care was for
issues related to prolapse and not for some other unrelated reason. Data were obtained from the clinical
centres for the price of mesh and clinical expert opinion was sought to bridge any data gaps relating to staff
requirements for surgery. National average unit costs were applied to resource-use data to generate total
costs to the health services. The sources of unit costs were the British National Formulary (BNF) and the NHS
Business Services Authority electronic drug tariff online catalogue33 for medications resource use;34
Information Services Division (ISD) Scotland35 and NHS reference costs36 for secondary care resource-use
data; and Personal and Social Services Research Unit (PSSRU) unit costs of health and social care for primary
care resource-use data.37 The costs were reported in 2013–14 UK pound sterling (£). The costs incurred in
the second year of follow-up were discounted at a rate of 3.5% per annum. The sensitivity analysis explored
the impact of varying the discount rate in accordance with NICE recommendations.38
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The resource-use data and costs for the health-economic analysis were broken into the following
categories of NHS resource use:
l intervention costs (including costs of completing the surgery, preparation costs and hospital
resource-use costs in theatre, based on operation time, staff time and other additional treatments)
l postoperative costs (from surgery to discharge) including time on ward, return to theatre and cost of
treating any infections or complications
l inpatient costs (cost of any follow-up operations and length of stay in hospital related to prolapse
symptoms, including overnight and day-case admissions)
l outpatient costs (including all outpatient contacts over the trial follow-up)
l primary care costs (including GP contacts, occupational therapist, physiotherapist and nurse contacts)
l medications and other treatments related to treating prolapse and UI symptoms.
Unit costs
Costs to the health services are estimated by combining resource-use data with unit costs of resource use.
Table 2 includes a list of all unit costs used in the within-trial economic analysis, together with their source
and any assumptions used to develop the unit cost used for analysis. Further details regarding calculations
underpinning the unit costs presented in Table 2 are outlined in more detail in Appendix 6. Unit costs
applied to the Primary and Secondary trial analyses were similar with the exception of the unit cost of
mesh materials to complete the operative procedure.
TABLE 2 Unit costs of resource use for the within-trial economic analysis
Resource-use
item Unit
Cost per
unit (£) Comments Source
Synthetic mesh
material
Per mesh
unit
111.09 Average per unit cost of meshes used at all
participating sites. Mean cost imputed for
centres not returning data
Direct contact with
sites/manufacturer
price lists
Biological graft
materials
Per mesh
unit
305.41 Average per unit cost of meshes used at all
participating sites using biological graft. Mean
cost imputed for centres not returning data
Direct contact with
sites/manufacturer
price lists
Anterior mesh kits
(Secondary trial
only)
Per mesh kit 645.45 Average per unit cost of meshes used at all
participating sites using anterior mesh kits. Mean
cost imputed for centres not returning data
Direct contact with
sites/manufacturer
price lists
Posterior mesh kits
(Secondary trial
only)
Per mesh kit 583.00 Average per unit cost of meshes used at all
participating sites using posterior mesh kits.
Mean cost imputed for centres not returning
data
Direct contact with
sites/manufacturer
price lists
Gynaecologist/
anaesthetist time
(consultant)
Per hour 142 If surgery was supervised, assume supervision
provided by a consultant grade. Includes
qualification costs
PSSRU 201437
Gynaecologist/
anaesthetist time
(registrar)
Per hour 124 Includes qualification costs PSSRU 201437
Gynaecologist/
anaesthetist time
(associate)
Per hour 71 Includes qualification costs PSSRU 201437
Band 5 theatre
nurse
Per hour 100 Including qualification costs, cost per 1 hour of
patient contact. Assume three band 5 nurses
present for all procedures (Dr Karen Cranfield,
Aberdeen Royal Infirmary, 2015, personal
communication)
PSSRU 201437
continued
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TABLE 2 Unit costs of resource use for the within-trial economic analysis (continued )
Resource-use
item Unit
Cost per
unit (£) Comments Source
Band 4 theatre
nurse
Per hour 91.59 Per hour of client contact, including qualification
costs. Assume one band 4 nurse present for
duration of all procedures (Dr Karen Cranfield,
personal communication)
General
anaesthesia
Per case 20.60 Based on calculation (see Appendix 6) BNF;34 personal
communication
Spinal anaesthesia Per case 1.85 Based on calculation (see Appendix 6) BNF;34 personal
communication
Local anaesthesia Per case 0.40 Based on calculation (see Appendix 6) BNF;34 personal
communication
Surgical antibiotics Per case 1.06 Assume co-amoxiclav (Augmentin®; GSK,
Middlesex, UK); Dr Karen Cranfield, personal
communication
BNF;34 personal
communication
Other surgical
drugs
Per case 6.45 For general and spinal anaesthesia only; resource
use provided by Dr Karen Cranfield (see
Appendix 6 for detailed calculation)
BNF;34 personal
communication
Theatre overheads Per hour 352.69 Currently excludes consumables ISD35 Scotland
R140X
Cost of
catheterisation
Per catheter 6.25 Assume Folysil® all-silicone catheters, female
(Coloplast Ltd, Peterborough, UK); NHS EDT,
April 2015 – assume no additional procedure
time required if catheterised during surgery
NHS EDT33
Vaginal pack Cost per
vaginal pack
4.67 Sorbsan packing (Aspen Medical Europe Ltd,
Ashby-de-la Zouch, UK) 30 cm/2 g: £3.47
plus
Hibitane obstetric cream (Derma UK,
Bedfordshire, UK): £1.20
NHS EDT33
Other treatments during admission for intervention
Return to theatre Per case 814 No data available on time in theatre for returns;
conservatively assume duration was 1 hour
Direct cost, ISD35
R142
Laxatives Per pack of
tablets
3.43 Bisacodyl 5 mg BNF34
Length of stay
(gynaecology ward)
Per day 179 Payment by results tariff of £1433 spread over
8 days, so £179 per day
Payment by results,
2014 tariffs36
Consultations with secondary and primary health-care professionals/procedures for subsequent treatment or
consultations
New prolapse
procedure
Per
procedure
2331 Weighted calculation of appropriate HRG codes
for surgery for prolapse. See Appendix 6 for
further details
NHS Reference
Costs 2013–1436
New incontinence
procedure
Per
procedure
1372.48 Weighted average of elective and day-case
procedures for HRG code M533 (introduction of
TVT/TOT); see Appendix 6 for calculation details
NHS Reference
Costs 2013–1436
Other readmission Cost per
admission
853.64
(weighted
average)
Weighted average of elective in patient/day-case
procedures for HRG codes MA22/MA23
minimal/minor genital tract procedures: £803.81
(day case)
£1207.85 (> 0 nights’ admission)
See Appendix 6 for detailed calculations
Payment by results,
2014 tariffs36
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TABLE 2 Unit costs of resource use for the within-trial economic analysis (continued )
Resource-use
item Unit
Cost per
unit (£) Comments Source
Outpatient
consultation
(first attendance)
Per
consultation
133 NHS reference costs NHS Reference
Costs 2013–1436
Outpatient
consultation
(repeat)
Per
consultation
81 NHS reference costs NHS Reference
Costs 2013–1436
GP visit Per visit 46 Per 11.7-minute consultation, including
qualification costs
PSSRU 201437
Practice nurse Per visit 13.69 Per 15.5-minute consultation, including
qualification costs
PSSRU 201437
Community
physiotherapist
Per visit 23.94 Per 30-minute consultation, including
qualification costs
PSSRU 201437
Hospital clinical
nurse specialist
Per visit 22.50 Based on a per-hour cost of £90 per hour of
client contact, assuming average appointment of
15 minutes’ duration
PSSRU 201437
Community
pharmacist
Per visit 32.50 Based on per-hour cost of £142, including
qualification costs, and average appointment
duration of 15 minutes
PSSRU 201437
Accident and
emergency
Per visit 103 Cost per visit (see Appendix 6 for more details
on calculation)
NHS Reference
Costs 2013–1436
Urodynamics Per
consultation
186 See Appendix 6 for calculation details. Based on
HRG code LB42, assume outpatients
NHS Reference
Costs 2013–1436
Ultrasound scan Per visit to
have scan
52 Diagnostic imaging in outpatients assumed. See
Appendix 6 for further details
NHS Reference
Costs 2013–1436
Other treatments
Absorbent pads Per pad –
day
0.61 Based on average across a number of products
and data reported in Fader 2008. Data inflated
to present-day values. Unit costs multiplied by
frequency of leakage to generate cost per
woman (see Appendix 6 for more details)
Fader 2008;39
PSSRU 2014;37
HCIS inflation
indexPer pad –
night
0.66
Permanent/
indwelling catheter
Per woman
(yearly cost)
390.52 Based on a number of assumptions.
See Appendix 6 for calculation details
NHS EDT 201533
Reusable/
intermittent
catheter
Per woman
(yearly cost)
1816.50 Based on a number of assumptions.
See Appendix 6 for more details
NHS EDT;33 NHS
Warrington40 Trust
documentation for
guidance of care
Oestrogen
treatment
Per
24-applicator
pack
16.72 Estradiol (Vagifem®; Novo Nordisk, West Sussex,
UK) vaginal tablets, 10 µg, in disposable
applicators. Multiplied by resource-use
requirement over follow-up
BNF 201534
Ring pessary Per pessary 19.98 Average across EDT products (see Appendix 6
for calculation)
EDT 201533
Shelf pessary Per pessary 21.51 Average across EDT products (see Appendix 6
for calculation)
EDT 201533
Drug treatment for
bladder problems
Per 56-tablet
pack
2.92 Assume tolterodine tartrate, generic version, to
cover frequency and urgency symptoms, 2 mg
twice daily dose assumed
BNF 201534
EDT, Electronic Drug Tariff; HCIS, Health Care Information Systems; HRG, Healthcare Resource Group; TOT, transobturator tape.
Further details of unit cost data are presented in Appendix 6.
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Intervention costs
The resource-use data required to deliver each intervention were collected prospectively for every
participant in the study. The operative details were recorded at the time of surgery (e.g. time in theatre,
grade of operating gynaecologist, grade of anaesthetist and grade of surgical supervision if present).
The details of concomitant surgery and catheterisation were recorded and incorporated into the costing
analysis. The details were sourced from data recorded on the CRFs (see Appendix 3). The data from the
CRFs were supplemented with centre-specific data for the costs of mesh products. Each centre was asked
to provide information on the mesh products used by each surgeon at their site for each trial intervention.
The surgeon-specific data on mesh use were costed using NHS list prices, sourced from participating
centres financial departments.
For some cases, we were not able to identify mesh costs directly from the participating surgeons. This
resulted in some missing data for mesh costs. In such cases, we imputed mean costs of mesh calculated
from those surgeons/centres that provided data. It is possible that there is heterogeneity across surgeons in
terms of the size of mesh product used, or within individual surgeons, who may use different mesh sizes
on a case-by-case basis. Where possible, we have costed the same (or similar) mesh sizes across different
mesh products so as to avoid any bias against individual mesh products. It should be noted that the
analysis does not seek to make statements about the effectiveness or cost-effectiveness of individual mesh
products, but rather seeks to develop an average cost for each arm of the trial, which is relevant and
generalisable to clinical practice in the UK.
When data regarding surgical resource use (particularly regarding the number of supplementary staff
present during a typical surgical procedure, such as nurses and theatre assistants) were unavailable from
formal records, we have made assumptions based on the clinical opinion of experts working on the trial
team. When there was uncertainty in the resource-use estimates to complete the intervention, and when
any assumptions were required, sensitivity analysis explored the impact of these assumptions on the total
intervention cost and on the estimates of cost-effectiveness.
The purpose of the intervention costing analysis was to find an average procedure cost, based on typically
used meshes at participating centres. Data on mesh usage were available from the 35 participating
centres. Unit costs of mesh usage were also sourced through a separate costing exercise directly from
centres, which were asked to provide NHS list prices. When data were missing for individual mesh
products at centres, the average of all mesh products within that category (e.g. synthetic mesh) was
assumed and applied as the unit cost. A similar approach was taken for biological graft repair.
Inpatient costs over follow-up
As length of stay is one of the secondary outcomes of the trial, we collected detailed data on inpatient
length of stay in relation to both the participant’s prolapse surgery and their UI. The hospital-based costs
in the immediate aftermath of the surgery (up until date of discharge of the patient) were recorded on
the RO CRF (see Appendix 3), eliciting information on whether or not the patient returned to theatre for
a procedure-related event within 72 hours of having their operation and if catheterisation was required
in the first 10 days postoperatively. Longer-term inpatient resource-use data were collected from the
participant-completed questionnaires issued at 6-month, 1-year and 2-year follow-up. When participants
reported having a hospital readmission, these were checked against patient records to determine the
reason for admission. Furthermore, this post-coding exercise identified any participant reporting errors
(e.g. patient confused follow-up surgery with index operation; participant double-counted single admissions
on both 1-year and 2-year questionnaires; participant misidentified reason for readmission). The costs of
additional surgery related to prolapse and/or urinary leakage were estimated using national tariffs, as well
as any other inpatient costs. The data collected from both the 1-year and the 2-year follow-ups were used
to inform the economic model extrapolating resource use over the patient’s lifetime.
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Outpatient costs
The participant-completed questionnaires were used to determine outpatient contacts related to the
women’s prolapse symptoms over follow-up. Again, these were post-coded against patient records to
check the accuracy of the data and resolve any discrepancies.
Owing to the post-coding exercises undertaken, we have a high degree of confidence in the estimates
of secondary care resource use across the trial for each individual woman returning a questionnaire.
Therefore, if a woman did not report a secondary care event, it was assumed that no resource use was
incurred. If a woman did not return a questionnaire then data were treated as missing.
Primary care costs
Participants were asked to provide detailed information on contacts with primary care health professionals
in relation to their prolapse symptoms and UI (see Appendix 4). This included visits to the GP, practice
nurse, occupational therapist and physiotherapist at each follow-up time point.
For primary care resource-use questions that are left blank on a returned participant questionnaire,
resource use is assumed to be zero. The reason for this is to ensure the best possible use of the available
data to generate a reasonably sized complete case data set for the economic analysis. Sensitivity analysis
explored the effect of multiply imputed data. As with the secondary care data, if a participant
questionnaire is not returned then data are treated as missing.
Total NHS costs
The total costs from the health services perspective were calculated by summing all intervention treatment
and follow-up costs related to the respective prolapse repairs for each participant in the data set. If one
of the component costs was missing because of a non-returned questionnaire then that participant was
dropped from the complete case analysis. If a component cost was missing for primary care consultations
then these data were treated according to the assumptions outlined above. The total NHS costs and
individual component costs incurred within the second year were discounted by 3.5%.
Participant- and companion-incurred costs and indirect costs, including
opportunity costs of time and travel
Participant resource utilisation comprised three main elements: self-purchased health care; travel costs
for making return visit(s) to NHS health care (such as petrol, public transport and parking); and time
costs of travelling and attending NHS health care (such as time involved away from usual activities or
work). All self-purchased health care relate to treatment purchased for the management or treatment of
prolapse-related symptoms. Likewise, time and travel costs relate to time spent travelling to and attending
hospital or primary care for prolapse symptoms. Estimation of travel costs required information from
participants about the number of visits to, for example, their GP or physiotherapist (estimated from the
health-care utilisation questions) and the unit cost of making a return journey to each type of health-care
provider (from the participant time and travel cost questionnaire; see Appendix 4).
The cost of participant time was estimated in a similar manner. The participant was asked, in the participant
time and travel cost questionnaire, how long they spent travelling to, and attending, their last visit to each
type of health-care provider. Participants were also asked what activity they would have been undertaking
(e.g. paid work, leisure, housework) had they not attended the health-care provider. They were further asked
if they were accompanied by a friend or a relative. If so, their time and travel costs were also incorporated
into the analysis. These data are presented in their natural units, for example hours, and also costed using
standard economic conventions, using the Department of Transport estimates for the value of work and
leisure time.41 These unit time costs were then combined with the number of health-care contacts derived
from the health-care utilisation questions to elicit a total time and travel cost from a patient perspective.
The data collected through the health services resource-use questionnaire were used to estimate the
costs of self-purchased health care, including pads bought by the participant, prescription costs and
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over-the-counter medications. The cost to the participant of any self-purchased health care was collected
directly within the questionnaire.
Indirect costs were defined as the production losses resulting from treatment when the participant was
unable to return to work or was required to take sick leave due to her prolapse problems. The cost
of days lost was estimated using the average UK gross hourly wage in the economy. When a participant’s
own reported costs associated with a specific type of health service visit were missing, the mean cost for
that type of visit was imputed. Participants completing the annual health resource utilisation questionnaire
were asked how many days they were off work in the last 12 months as a result of prolapse symptoms
or problems. Questions were asked at both 1-year and 2-year follow-up. The data were recorded as
natural units and multiplied by standard economic costings as reported below (see Table 3). The total
production losses due to time away from work for non-retirees as a result of prolapse symptoms were
estimated and compared across treatment groups.
The unit costs applied to the participant (and companion) time, travel and indirect economic costs data are
outlined in Table 3. The unit costs were based on standard economic sources and were inflated, where
appropriate, to 2014 values. For the purposes of inflation, we utilised the Cochrane economics group
inflation calculator application, using International Monetary Fund-reported inflation data.44
The data on time and travel costs, participant-incurred medical costs and time away from work or usual
activities (to attend medical appointments and as a result of recovery from surgery) were all summed
together to generate a total participant cost. The incremental cost differences between groups from a
participant perspective were estimated using the same methods outlined in the statistical analysis of
economic data detailed in the following section.
Statistical analysis of economic data
The economic analysis was conducted following the intention-to-treat principle. The perspective was
predominantly that of the NHS, with a supplementary wider economic and patient perspective conducted.
The period of follow-up was 2 years and costs and QALYs in the second year were discounted at a rate of
3.5%. All components of costs were described with the appropriate descriptive statistics where relevant:
mean and SD for continuous and count outcomes; numbers and percentages for dichotomous and
categorical outcomes (e.g. numbers reporting problems on EQ-5D-3L). All analyses were conducted using
Stata® version 14.1 software (StataCorp LP, College Station, TX, USA).
To investigate the potential for skewed cost data (i.e. a small proportion of participants incurring very high
costs), we used GLMs, testing alternative model specifications for appropriate fit to the data. The GLM
models allow for heteroscedasticity by selecting and specifying an appropriate distributional family
for the data. This family offers alternative specifications to reflect the relationship between the mean and
variance of the estimates under consideration.49,50 Two diagnostic actions were performed to select the
most appropriate distributional family: (1) a modified Park test, which identified two potentially viable
distributional families for costs, namely Gaussian or gamma, and (2) as a check on the most appropriate
model, the Akaike information criterion (AIC) was consulted, which identified a Gaussian model with an
identity link as having the lowest AIC score and the most appropriate model fit. This suggests a standard
ordinary least squares (OLS) model should be fitted for cost data. The next-best model fit according to the
AIC criteria was a gamma regression with log link, and this was explored in sensitivity analysis. Regression
models applied to cost components (such as ‘other treatments’ and ‘hospital costs’) in the analyses above
are also assumed to follow the same distributional assumptions as the total cost data. A standard OLS
model was also identified as the most appropriate model and applied to the analysis of incremental QALY
gains. All analyses were conducted using heteroscedastic robust standard errors (SEs).
Analysis models were run to estimate the incremental effect of treatment group on costs and QALYs. Models
were adjusted using minimisation covariates (age group, type of prolapse, concomitant continence procedure
and concomitant upper compartment prolapse surgery), as well as surgeon and baseline EQ-5D-3L score.51
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For the Secondary trial, using all available data, analyses were further adjusted for randomised stratum. The
coefficient on treatment in the respective linear OLS models is taken as the estimate of incremental costs for
use in the economic evaluation.49,50
Overall results of the cost–utility analysis are reported as incremental cost per QALY gained for different
treatment arms (relative to standard repair). The cost per QALY is presented using the ICER, calculated as
the coefficient of treatment effect on costs divided by the coefficient of treatment effect on QALYs from
the respective linear regression models. Estimates of the ICER are then compared with the recommended
TABLE 3 Unit costs of participant (and companion) time, travel and wider indirect economic costs of
prolapse repairs
Activity
Unit cost
(£, 2014) Assumptions made/notes Source of data
Unit costs applied to participant and companion travela
Cost per mile travelled
by car
0.45 per mile HMRC-approved mileage rate (most recent
data: year 2013)
HMRC42
Car parking charges Various Specified in participant questionnaire Participant-reported data
Cost of public transport
fares (bus, train, taxi)
Various Specified in participant questionnaire Participant-reported data
Cost of return journey
by hospital car
18.00 per
return journey
Various costs across NHS Trusts (data from
South Devon publicly available and applied
to all)
Torbay and South Devon
NHS Foundation Trust43
Cost of non-emergency
patient transport service
(via ambulance)
44.65 per
return journey
Not included in reference costs since 2011
(therefore indicative cost only)
Note: incurred directly by PCTs, so not
included in total participant cost calculation
NHS Reference Costs
2009–1036,44,45
Unit costs applied to participant and companion time
Paid work 13.21 per hour Based on average economic wage per week
of £518, assuming 39.2-hour working week
ONS; annual survey of
hours and earnings
201446
Housework 10.53 per hour Costs of housework in the NHS (assumed
annual salary of £21,000 gross; 2012 values
inflated to 2014)
NHS pay review body
report 201247
Child care 13.21 per hour As paid work ONS 201448
Caring for a friend/
family member
13.21 per hour As paid work ONS 201448
Voluntary work 13.21 per hour As paid work ONS 201448
Leisure activities 6.54 per hour Value of non-working time (2010 values
inflated to 2014)
TAG data book, autumn
201341
Retired 6.54 per hour Value of non-working time (2010 values
inflated to 2014)
TAG data book, autumn
201341
Unemployed 6.54 per hour Value of non-working time (2010 values
inflated to 2014)
TAG data book, autumn
201341
Ill/disabled (long term,
unrelated to prolapse)
6.54 per hour Value of non-working time (2010 values
inflated to 2014)
TAG data book, autumn
201341
HMRC, Her Majesty’s Revenue and Customs; ONS, Office for National Statistics; PCT, Primary Care Trust; TAG, Transport
Analysis Guidance.
a It is assumed that all of the travel costs were incurred directly by the patients themselves, as it was highly unlikely that
the vast majority of women in the study would have qualified for reimbursement of travel expenses from the NHS.
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willingness-to-pay (WTP) decision-making threshold in the UK, currently between £20,000 and £30,000
per QALY gained.38
We used non-parametric bootstrapping methods to estimate 95% CIs for treatment effects on costs and
QALYs, using 1000 repetitions.52 These were further used to summarise the uncertainty surrounding the
estimated ICERs, which was illustrated using:
i. Incremental scatterplots of bootstrapped repetitions for incremental costs and incremental QALY pairs
for the respective mesh treatments compared with standard repair.53,54 Presentation of the bootstrapped
iterations of costs and outcomes on the cost-effectiveness plane allows the reader to see the probability
of one intervention outperforming another in terms of cost-effectiveness, illustrating the probability of
that said intervention falling into each quadrant of the cost-effectiveness plane being (1) less costly and
more effective; (2) more costly and less effective; (3) less costly and less effective; or (4) more costly and
more effective.
ii. The bootstrapped estimates of treatment effect were further used to generate cost-effectiveness
acceptability curves (CEACs).54 CEACs were generated using estimates of net monetary benefit (NMB),
generated using the bootstrapped replications, in accordance with the net benefit statistic given in
Equation 1:
NMB = QALY × λ−cost, (1)
where ‘QALYs’ and ‘cost’ are the estimated total QALYs and total costs for a treatment strategy and
lambda (λ) represents the ceiling ratio of a decision-maker’s WTP for a QALY gained. For the purposes
of the base-case analysis, λ is set to £30,000, the upper end of the commonly accepted range of ICERs
considered to offer good value for money at NICE. However, for the base-case analyses, a number of
alternative threshold values presented at £0, £10,000, £20,000, £30,000 and £50,000 are explored,
presented numerically within the tables and visually represented on the CEACs presented.53,54
The study initially planned to present results as cost per woman cured for the trial-based analyses. However,
it is not clear how ‘cure’ should be defined. For example, it may be subjective improvement, anatomical
improvement or a change in QoL: these are not always in accord with each other. Although many women
experienced improvements in their prolapse symptoms, few achieved a state of being completely symptom
free. As we are unable to explicitly define cure for the clinical effectiveness analysis, it would be misleading,
therefore, to do so for the economic evaluation. The greatest value to decision-makers in the UK NHS relates
to an assessment of cost per QALY gained, which is the primary economic outcome and has been used as
the basis of all the economic analyses.
Deterministic sensitivity analyses
Although the presentation of CEACs and scatterplots addresses the issue of sampling uncertainty in the
data, other assumptions surrounding the most appropriate discount rate and analysis models undertaken
may create additional uncertainty, which are not captured in the presented CEACs. Furthermore, the
impact of missing data on cost-effectiveness outcomes is explored. All sensitivity analyses (other than the
use of imputed data sets) were conducted using complete case 2-year follow-up data for total cost and
QALY pairs.
Missing data
We have used a combination of pragmatic and statistical approaches to deal with missing data. Pragmatic
approaches have been outlined through this chapter where relevant and were applied to all base-case
analyses. As base analyses were conducted using complete case data for cost and QALY pairs, there was
a substantial proportion of missing data. This can pose significant problems for data analysis, especially
surrounding data reported using participant-completed questionnaires. Therefore, we have undertaken
statistical MI of missing data as a sensitivity analysis. The imputation analysis was undertaken using Stata’s
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multiple imputation (MI) procedure.55 Missing component costs (e.g. cost of primary care, outpatient care)
and utility values were imputed at each questionnaire time point (6 months, 1 year and 2 years).
Components of cost data were imputed, based on linear regression models that were adjusted for
minimisation variables, baseline utility and treatment allocation group. Missing utility values were imputed
using predictive mean matching, accounting for the five closest estimates. Chained equations were used
for the imputations. The imputation procedure predicted 10 plausible alternative imputed data sets, which
was found to be sufficient to provide stable estimates. An analysis of incremental costs and outcomes
was undertaken across the 10 imputed data sets and combined to generate one imputed estimate of
incremental costs and QALYs.
We also explore the impact of changing the discount rate used for second-year costs and QALYs in
accordance with NICE best practice recommendations, ranging the discount rate from 0% to 6% per
annum. Furthermore, to ensure comparability of our economic analysis with the clinical effectiveness
analyses presented in following chapters, we have conducted a secondary analysis for trial-based
cost-effectiveness using data from all of the women randomised to the Primary trial arm.
All of the analysis methods for base case, uncertainty and sensitivity analyses were conducted similarly
for both the Primary trial analyses (see Chapter 5) and Secondary trial analyses (see Chapter 7) unless
otherwise stated. As noted at the outset, the main difference between the economic analyses across the
two chapters pertains to the data considered for the base-case analysis. For the base-case Primary trial
analysis, we consider RCT1A (women randomised only across the three-way comparison), whereas for the
base-case Secondary trial analysis we consider all women who were having a secondary prolapse surgical
repair (RCT2).
Subgroup analyses
We did not identify any additional subgroup analyses that were required to estimate cost-effectiveness for
the within-trial analysis.
Decision-analytic model
Owing to the chronic nature of prolapse repair and the potential for different failure rates over time, data
from the trial analysis are extrapolated over a longer-term time horizon using a Markov decision-analytic
model. The data to populate the model are informed by the trial in terms of costs, utility weights, time to
failure and other key parameters. Data on further analysis of trial data to populate the economic model
and the modelling methods themselves are reported in Chapter 9.
Management of the study
The study office team
The study office was based at CHaRT in Aberdeen and provided day-to-day support for the clinical centres.
It was responsible for all data collection (such as mailing questionnaires), follow-up, data processing
and analysis. It was also responsible for randomisation and communicating with the centres about
PROSPECT-specific issues. PROSPECT newsletters were developed for participants and collaborators to
inform everyone of progress and maintain enthusiasm.
The PROSPECT Study office team (Aberdeen-based grant-holders and study office members) met formally
at least monthly during the course of the study to ensure smooth running and trouble-shooting.
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Project Management Group
The study was supervised by the Project Management Group (PMG), which consisted of the grant-holders
and representatives from the study office. The PMG met, in person or by teleconference every 3 months
on average.
Trial Steering Committee
The study was overseen by an independent TSC. The membership comprised four independent members
(see Acknowledgements for membership details), the Chief Investigator and grant-holders. Observers or
members of the host university (Aberdeen) and the funders (the NIHR HTA) were invited to attend, as were
other members of the PROSPECT Study office. The committee met 11 times between August 2009 and
July 2015 at approximately 6-monthly intervals, as decided by the Committee.
Data Monitoring Committee
A separate and independent DMC was convened (see Acknowledgements for membership details) and
comprised four members: an academic clinician (as the independent chairperson); a gynaecologist, who
was not involved in the trial; a statistician with experience of monitoring accumulating RCT data; and a
consumer representative.
The members met once to agree terms of reference (August 2009) and a further five times between
September 2011 and September 2014 to monitor accumulating data and oversee safety issues. During
the period of recruitment to the study, interim analyses were supplied, in strict confidence, to the DMC,
together with any other analyses that the committee requested. In the light of these interim analyses,
the DMC would have advised the TSC if, in its view:
(a) one of the methods of prolapse surgery had been proven, beyond reasonable doubt, to be different
from the control (standard management) for all or some types of women (with respect to either
effectiveness or unacceptable safety concerns), and
(b) the evidence from the economic data was sufficient to guide a decision from health-care providers
about choosing operations.
On each occasion, the DMC recommended continuation of the trial with no change of protocol. All other
groups, the TSC, PMG, clinical collaborators and study office team (except the trial statistician, who
supplied the confidential analyses) remained ignorant of the interim results considered by the committee.
METHODS AND PRACTICAL ARRANGEMENTS
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Chapter 3 Results: all
Between January 2009 and August 2013, 4083 women were identified as potential participants in thePROSPECT Study, of which 3089 (76%) were eligible and gave their consent. The flow of women
through the study is shown in the CONSORT (Consolidated Standards of Reporting Trials) diagram
(Figure 2) in line with CONSORT recommendations.56
Of the 3089 women participating in the study, 2478 were recruited to the primary group (1352
randomised to the Primary trial (RCT1); 1126 to the Primary CC (CC1), 396 to the secondary group (155 to
the Secondary trial (RCT2); 241 to the Secondary CC (CC2) and a further 215 women were in the third CC
(CC3) if they were thought to need only uterine or vault prolapse surgery (see Figure 2). There were two
post-randomisation exclusions that were not included in the study analyses (see Figure 2), leaving 3087
women analysed in the PROSPECT Study.
This chapter describes how these women were identified from the women admitted for prolapse surgery in
the 37 hospitals, 35 of which recruited women. It reports the baseline differences between the comparable
groups of women and their baseline characteristics up to the point of entry to the RCTs or the CCs. The
subsequent findings are described in Chapter 4 (primary prolapse surgery), Chapter 6 (secondary prolapse
surgery) and Chapter 8 (upper compartment prolapse surgery only: uterine and vault prolapse).
Study recruitment
As described in Chapter 2, women who attended gynaecology outpatient departments with symptomatic
pelvic organ prolapse and then chose to have prolapse surgery, and women on the waiting list for
prolapse surgery, were invited to participate in the PROSPECT Study. Women were asked if they were
willing to be randomised to the appropriate options for their type of prolapse, and if not, they were asked
to consent to follow-up by questionnaire as part of the CC. The centres and surgeons who participated in
PROSPECT, the operations they offered and the numbers they recruited are listed in Table 4. The rate of
recruitment is illustrated in Figure 3.
Non-recruited women
Of the 4083 women approached regarding trial participation, 994 did not enter any of the study groups
because they were either missed (n = 339), ineligible (n = 261) or declined (n = 394) (see Figure 2). The
994 women who were not recruited to any part of the study are described in Figure 2. The most common
reasons were ‘not interested’ (394/994; 40%), a missed opportunity to recruit the potential participant
(339/994; 34%), operation cancelled because it was no longer required (117/994; 12%) or because the
woman was unfit for surgery (45/994; 5%). Excluding the 339 women who were missed, and the 117
who were found not to need surgery, they represented 538 of 3627 (15%) of all of the potentially eligible
women in the centres.
Age was recorded for all recruited women and for 936 of 994 (94%) of non-recruited women. The mean age
of non-recruited women was 63.4 years (SD 11.9 years) n = 936, compared with 59.7 years (SD 11.0 years)
n = 3089 for recruited women: the recruited women were significantly younger (p < 0.001). We could
determine the primary/secondary status of 580 of the ineligible women, and only 13.8% were having further
prolapse surgery – the same as the proportion in the recruited women. Therefore, the discrepancy in age
was not explained by a larger proportion of women who were having further surgery among the
non-recruited women.
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Identified
(n = 4083)
Missed (n = 339)a
Screened
(n = 3744)
Ineligible (n = 261)b
Eligible
(n = 3483)
Declined (n = 394)
Recruited
(n = 3089)
Primary
(n = 2478)
Secondary
(n = 396)
Uterine/
vault
(n = 215)
Randomised
RCT1
(n = 1352) 
Cohort
CC1
(n = 1126)c
Randomised
RCT2
(n = 155)
Cohort
CC2
(n = 241)d
Cohort
CC3
(n = 215)
Post-randomisation
exclusions
Randomised in error  (n = 2)e
(n = 2)f
N/A
N/A
N/A
N/A
(n = 0)
(n = 1)gRandomised in error,
but joined CC2  
Included in analysis  (n = 1348) (n = 1126) (n = 154) (n = 215)
N/A
N/A
(n = 244)
FIGURE 2 CONSORT diagram of women who were recruited to the PROSPECT Study. a, Missed [operation
performed in a different hospital/Trust, private hospital or by a different consultant; research nurse not aware of
the operation date because of cancellations/fast tracking/lack of communication between the research team;
surgery date after the end of the study; not consented prior to operation date – research nurse not available;
consent form not returned, unable to contact, inappropriate to approach (personal/medical reasons). Eligible for
cohort only and trial no longer recruiting to cohort study; Other, e.g. moved away, did not attend, etc.; 339 women].
b, Reasons for ineligibility (261 women): surgery not required [e.g. no prolapse, changed mind about needing surgery
(117); removed from waiting list/unfit for surgery (45); unable to give informed consent (32); unable to complete
questionnaires (16); other reasons for non-recruitment (‘psychological or family problems’, ‘not clinically or medically
suitable to take part in a research study’ and ‘consultant wished to decide procedure’ 32); reason not recorded (19)].
c, Reasons for non-randomisation in Primary trial (entry to CC1): ‘Clinical decision’ includes ‘wanted to use mesh’,
‘did not want to use mesh’ and ‘other clinical reason’ (379); ‘Participant decision’ includes ‘wanted mesh’, ‘did not
want mesh’ ‘wanted surgeon to decide’ and ‘did not want to be randomised’ (613); ‘Other’ reasons include ‘mesh
unavailable’, ‘operating surgeon not trained in mesh inlays/kits’, ‘theatre time issues’ and ‘not recorded’ (134).
d, Reasons for non-randomisation in Secondary trial (entry to CC2: ‘Clinical decision’ includes ‘wanted to use mesh’, ‘did
not want to use mesh’ and ‘other clinical reason’ (133); ‘Participant decision’ includes ‘wanted mesh’, ‘did not want
mesh’ ‘wanted surgeon to decide’ and ‘did not want to be randomised’ (96); ‘Other’ reasons include ‘mesh unavailable’,
‘operating surgeon not trained in mesh inlays/kits’, ‘theatre time issues’ and ‘not recorded’ (12). e, Randomised in error:
one woman had baseline comorbidities that made her ineligible for PROSPECT; one woman had prolapse surgery
privately after declining to participate but prior to randomisation. f, Two women should have been randomised in the
Secondary trial. The women remained eligible for PROSPECT and were followed up in the secondary cohort CC2. g, One
woman had secondary prolapse surgery after consenting but prior to randomisation. She remained eligible for
PROSPECT and is followed up in the secondary cohort CC2. N/A, not applicable.
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The baseline characteristics of the 3087 women who agreed to participate in PROSPECT and were truly
eligible for the study are described in Table 5. More women were randomised if they were having a
primary procedure (n = 1348) than those who went into the non-randomised cohort (n = 1126), whereas
for those having a secondary (repeat) procedure, fewer were randomised (n = 154) than not (n = 244).
At preoperative assessment, a further 215 women were not thought to have an anterior or posterior
prolapse that required surgical repair, but did have uterine or vault prolapse. These women are described
and compared in detail in Chapter 8 and are not further analysed in this chapter. However, their data are
provided in the tables for completeness (CC3).
Epidemiological characteristics
There were no significant differences between the women who were having primary prolapse surgery who
were randomised and those who were not randomised (RCT1 vs. CC1) or between women who were
having a second or subsequent repair (RCT2 vs. CC2) according to randomisation status (see Table 5).
However, those having a repeat repair were, on average, 2.6 years older than those having a primary
procedure, and those having uterine or vault surgery only (CC3) were, on average, 1.2 years older than
those having primary surgery.
There were also no differences between any of the groups with respect to:
l body mass index (BMI)
l parity (the median number of children was two)
l delivery mode history.
Generic quality of life: EuroQol-5 Dimensions (3-level version)
There were no significant differences between randomised and cohort women who were having first or
repeat surgery with respect to EQ-5D-3L scores at baseline. However, those having repeat surgery or
uterine or vault operations had slightly lower (worse) scores than those having their first repair.
Previous conservative treatment
Around one-quarter to one-third of women had PFMT for prolapse symptoms, supervised by a
physiotherapist, before resorting to surgery, with this being slightly more common for women who were
having a repeat procedure (see Table 5). Fewer than 15% of women who were having a primary repair,
and around 10% of those having a secondary repair, were currently using a vaginal pessary (ring or other
type). Just over 15% of women in each group had already had supervised PFMT for UI, and 10–15% had
used drug treatment for this problem in the past.
Previous surgery
From Table 5, around 10–12% of women in the primary groups were having a second anterior or
posterior prolapse repair. However, these women were classed as primary because the compartment that
required surgery as part of PROSPECT was the opposite to that which had previously been repaired. This is
in accordance with the recommended IUGA/ICS terminology.57 If the woman thought she had had a
previous prolapse repair but it was not possible to discover in which compartment, she was classed as
primary for the purpose of allocation, but this applied to only 60 women across the five groups.
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Very few women who were having a primary repair had had a previous vault repair (around 2%), whereas
this was more common for women who were having a repeat repair (10–15%).
Fewer than 10% of women who were having their first repair had previous concomitant continence
surgery, whereas it was around 15% for those having a repeat repair, a similar proportion to those having
an upper compartment procedure only.
Slightly more women had undergone previous uterine surgery (hysterectomy) in the cohorts than in the
randomised groups, both for primary and secondary repairs, but this was statistically significant for only the
latter (p = 0.023; see Table 5). Among women who were having their first repair, more had undergone a
previous abdominal hysterectomy than a vaginal hysterectomy (or cervical amputation, which is necessarily
carried out via the vagina), whereas for those having a second repair, more women had had a previous
vaginal hysterectomy than abdominal. Overall, many more women who were having a repeat repair had
already had a previous hysterectomy than those having their first repair (around 62–73% of the Secondary
group and just under 30% of the Primary group).
Planned surgery
Although it is known that in about 20% of case the actual operation carried out differs from that planned
in advance,29 PROSPECT was designed so that women would remain in the group to which they were
allocated, irrespective of the actual procedure performed. In order to randomise women appropriately,
taking account of minimisation criteria, gynaecologists had to specify in advance which compartments they
thought would need to be repaired.
Gynaecologists planned surgery for the women based on their preoperative findings on examination. Table 6
shows that just under half of the women were expected to require an anterior repair, about one-quarter
a posterior repair, and the remainder both procedures. The proportions were the same whether the
procedure was primary or repeat, and whether or not the women were randomised.
In terms of concomitant prolapse surgery, hysterectomy was planned more frequently in women in the
Primary trial, whereas in the Secondary trial more women were thought to need a vault repair (see Table 6).
The need for vault repair was higher in both cohort groups (although statistically significant only in the
larger Primary trial), suggesting that women who might need a concomitant upper compartment procedure
were less likely to be randomised. Cervical amputation was planned much less commonly (< 2% in any
group). Between RCT and CC cohort groups, there was little difference in the frequency of women who
were thought to need continence surgery, but the proportions were fewer in the secondary groups.
Preoperative objective measurements
Although gynaecologists were expected to use the POP-Q,27 not all did so. However, attempts were made
to locate important missing data from the centres, using alternative sources such as medical notes,
correspondence and asking the centre staff. The aim was to have as complete a set of prolapse staging as
possible, separately in each compartment. The leading edge of the most descended compartment relative
to the hymen was used for overall (POP-Q) stage.
The most common stage for women who were having an anterior or posterior repair was stage 2 (around
60%; Table 7). The majority of the remaining women were stage 3, and very few were stage 4, or indeed
stage 0 or 1. Using a more strict definition of ‘leading edge of prolapse beyond the hymen (> 0 cm on
POP-Q; stage 2b, 3 or 4), 61–67% of women in the Primary trial and 52–58% in the Secondary trial had
an objective prolapse (see Table 7). Significantly more women had objective prolapse in the randomised
arm of the Primary trial than in the primary cohort; the small excess among cohort women in the
Secondary trial was not significant.
RESULTS: ALL
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Clinical baseline data
Prolapse symptoms at baseline
The overall prolapse symptom score (POP-SS) was around 13.5 in the women who were having their first
repair [with no difference between the randomised and cohort women (13.7 vs. 13.3; Table 8)] but
significantly higher in those having a repeat procedure [with no difference between the randomised and
cohort women (14.4 vs. 14.9)]. Using a POP-SS of 0 to indicate absence of symptoms, > 99% of women
had at least one symptom. The women who were having a uterine or vault repair only (CC3) had an
intermediate score, with a mean POP-SS of 14.5 (see Table 8). The latter group will be further described
separately in Chapter 8.
The most common individual prolapse symptom was ‘a feeling of something coming down from or in your
vagina’, which was reported in > 90% of women, with two-thirds of women reporting this most or all of
the time (Table 9). The QoL score (‘overall, how much do your prolapse symptoms interfere with your
everyday life?’) ranged from 6.6 to 7.0 of 10 (see Table 8). About half of the women found the prolapse
to pose hygiene problems, and about one in five needed to relieve pressure or discomfort from the
prolapse using their fingers (see Table 9). Women had been symptomatic for ≥ 3 years and bothered by
their symptoms for about a year less.
Among women having a recent repair, there was a significant difference in duration of symptoms in the
cohort women (CC2, 3.8 years) compared with the randomised women (RCT2, 3.8 vs. 2.8 years; p = 0.034).
There were no other differences between any of the groups with respect to:
l duration of prolapse symptoms (the mean duration ranged from 2.8 to 4.3 years)
l duration of bothersome symptoms (the mean ranged from 2.4 to 3.2 years of bother)
l mean prolapse symptom score (the mean ranged from 13.3 to 14.9 out of a maximum score of 28 on
the Pelvic Organ Prolapse Symptom scale.
Urinary symptoms at baseline
Using the ICIQ-UI-SF,26 up to 80% of women reported at least some UI; however, 20–23% had more
severe leakage based on a higher score (Table 10). The most common type of UI was stress UI: women
were counted as symptomatic if they had the symptom ‘most or all of the time’. There were no systematic
differences between the groups of women.
Bowel symptoms at baseline
Using ROME58 criteria to define bowel symptoms, around one-quarter or more of the women reported
constipation (Table 11). Over one-third had FI, defined as loss of solid or liquid stool, but not including loss
of flatus (wind). Three-quarters of the FI was ‘passive,’ defined as ‘not accompanied by bowel urgency’.
There were no systematic differences between the groups of women at baseline.
Vaginal and sexual symptoms at baseline
We used the ICI-validated instruments to measure a variety of vaginal and sexual symptoms. These were
common, and had important effects on QoL. Although the majority of women were not sexually active, in
about 40% of women this was most often attributable to their prolapse symptoms (Table 12). Among the
women who were sexually active, or whose reason for no sex life was ‘due to prolapse symptoms’, around
10% had dyspareunia at baseline. There were no systematic differences between the groups of women.
Comparison between women who were having a first repair and those who
were having a repeat repair
From Table 5, it might seem that around 11% of women in the primary repair groups (RCT1, CC1) had
had previous prolapse surgery, but the compartment that required surgery was the opposite to that which
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had previously been repaired. The compartment of previous surgery was unknown in 60 women, who
were therefore classified as having a first repair.
We identified a number of important demographic and clinical differences between women who were
having a primary and a secondary repair. Those having a primary repair were, on average, 2.7 years older
than those having a secondary procedure (59.4 years vs. 62.1; p < 0.001; see Table 5).
Among women who were having a primary repair, fewer had had a previous hysterectomy than those
having a repeat repair (28% vs. 69%; p < 0.001; see Table 5), and in the repeat repair group, the previous
hysterectomy was more likely to have been via the vaginal, rather than abdominal, route. Very few women
who were having a primary repair had experienced a previous vault repair (2%), whereas this was more
common for women who were having a second repair (13%; p < 0.001; see Table 5). Only 7% of women
who were having their first repair had previously had continence surgery, whereas 15% of those having a
second procedure had done so (p < 0.001; see Table 5).
Women who were having their first prolapse repair had a slightly lower (better) level of symptoms
measured on the Pelvic Organ Prolapse Symptom scale (13.5) compared with those having repeat surgery
(14.7; p < 0.001; see Table 8). This was reflected in a higher (better) score for the primary group on the
generic QoL scale [EuroQol-5 Dimensions (EQ-5D) 0.71 vs. 0.67; p = 0.001; see Table 5]. Significantly more
women who were having their first prolapse operation (64%) had a prolapse beyond the hymen (> 0 cm)
than those (55%) having a repeat repair (p = 0.001; see Table 7).
Finally, more than three times as many women who were having a first repair were expected to require a
concomitant vaginal hysterectomy (34% vs. 9%), and twice as many were expected to have concomitant
continence surgery (12% vs. 6%), compared with those having a repeat repair, whereas women who were
having a repeat repair were more likely to require a concomitant vault repair (25% vs. 18% for the primary
group; see Table 6).
Summary
The women (both randomised and CC) enrolled in the PROSPECT Study represent 85% of the UK women
who had prolapse surgery in the PROSPECT centres. We used strict definitions according to IUGA/ICS
recommendations to categorise them and allocate them to clinically meaningful groups. In this chapter,
we compared randomised and non-randomised women.
Summary of findings
The average age for a first prolapse repair was just < 60 years, with women who were having repeat
(secondary) surgery being around 2.5 years older (see Table 5). Most women’s babies had been delivered
vaginally. Although the mean BMI was < 30 kg/m2, 43 morbidly obese women with a BMI of ≥ 40 kg/m2
did receive surgery.
Women who were having a repeat repair were more likely to have had a previous vaginal hysterectomy,
vault repair or continence surgery. This difference in clinical characteristics justified our initial decision to
conduct two separate trials among women who were having a first repair (primary) and a repeat
repair (secondary).
Prolapse symptoms and measurements
Most women were expected to have surgery for an anterior vaginal wall prolapse (see Table 6). The majority
of women had stage 2 prolapse, whereas around one-third had stage 3 or 4 (see Table 7). When prolapse
was redefined as the leading edge beyond the hymen (> 0 cm on POP-Q), around 63% of women had a
protruding prolapse: this was most common among women who were randomised in the Primary trial
(67% compared with both the Primary CC (61%) and the Secondary women [52% (RCT2), 58% (CC2)].
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Women had a high level of prolapse symptomatology, as shown by their POP-SSs, of around 14 out of
a maximum score of 28 (see Table 8). The most common symptom was a feeling of something coming
down (over 90%; see Table 9). Women who were having repeat surgery were less likely to have prolapse
beyond the hymen (see Table 7) but their symptom score was, on average, one point higher (worse) than
those having their first repair, and their prolapse-related QoL score was significantly worse (see Table 8).
Other clinical symptoms
Over three-quarters of women had UI, and this was slight or moderate in most cases (see Table 10).
Nevertheless, at least one in five women had severe urine leakage, defined using the ICI-UI SF score of
≥ 13, and most of them had stress UI (‘most or all of the time’). However, only around 10% of those with
UI having a first repair, and 5% having a repeat repair, were expected to undergo continence surgery (see
Table 6); on the other hand, 1 in 20, and 1 in 8, respectively, had already had previous continence surgery
(see Table 5).
Around 1 in 10 women had bowel urgency or severe FI, and over one-third of women reported at least
occasional faecal leakage, mostly passive (see Table 11). The pattern of bowel problems was remarkably
similar in women who were having first or repeat prolapse surgery, and within these groups.
Just over one-third of the women were sexually active at baseline (see Table 12). Around 10% of them
reported dyspareunia before surgery: as more women answered this question than the number professing
to be sexually active, it can be inferred that some women may have refrained from intercourse because of
dyspareunia or other prolapse symptoms. We allowed for this by including the women who were sexually
inactive because of prolapse symptoms in the denominator for this analysis. Interestingly, the proportion with
dyspareunia was similar in women who were having first or repeat prolapse surgery, around 10–15%.
In summary, there were no important clinical differences between women randomised in PROSPECT,
and the comparable CC populations who were not randomised.
Strengths and weaknesses
PROSPECT is the most comprehensive study of women who were having prolapse surgery in the UK.
The large number of women (over 3000), centres (35) and recruiting gynaecologists (70), and recruitment
of 80% of their patients who had prolapse surgery, ensured that the findings are representative of the
majority of general gynaecological practice within the NHS in the UK. The centres were a mix of secondary
and tertiary referral hospitals.
We used a tightly defined classification of primary and secondary repair using international
recommendations to separate our population of women. Within each group, there were few systematic
differences between women who were randomised, and those who were not. On the other hand, there
were clear clinical and demographic differences between women who were having a first or a repeat
procedure, thus justifying our decision to analyse these groups of women in separate trials.
Our definition of secondary surgery was prespecified to refer to ‘repeat surgery in the same compartment’.
This resulted in some women who had a previous repair in another compartment being classified as
‘primary’. Although we do not know the original denominator, we can calculate an approximation of the
total number of women who were having any further prolapse surgery: dividing the number of women who
were having any repeat repair (n = 674) by the number presenting for a first operation (2474 – 276 = 2198)
suggests that the population rate of further surgery is 30.7%, very similar to that published by Olsen et al.4
for further prolapse surgery in any compartment.
Conflict of interest
The study was not at risk of bias because it was publicly funded, and the investigators did not have
personal or professional links with industry. The commercial companies which manufactured the mesh
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and mesh kits did not provide any funding or material in kind (such as the supply of free materials) to the
centres, the surgeons or the investigators.
Choice of validated outcome measures
We chose outcome measures for PROSPECT to reflect international standards57 of reporting and ensure
that the findings would be relevant to the needs of all groups that were likely to be affected by the
findings, including patients, clinical staff and policy-makers. These outcomes were measured at baseline
to provide values for later statistical adjustments. Our primary measure of prolapse symptoms was the
subjective woman-reported prolapse symptom scale (Pelvic Organ Prolapse Symptom scale), developed and
validated in a variety of populations for both research and in clinical practice.27 This tool is relevant to
women and, arguably, focused on the symptoms that led them to seek treatment.
We used validated instruments to measure secondary urinary and vaginal symptoms.26 Similar short
validated measures for bowel function were not available in the ICI suite of outcome measures when we
started our study. We therefore adapted the questions used in the long ICIQ-Bowel Symptom instrument.
We are currently validating them. In addition, we adapted some of these bowel function questions to
approximate those advocated in the ROME consultation (see Table 1).
The objective assessment of prolapse stage was carried out using the standardised and internationally
recognised POP-Q system.27 Although the majority of women were classed as stage 2, based on the
leading edge of the prolapse, some researchers have called into question whether or not this is an
appropriate cut-off point for the diagnosis of prolapse. The mismatch between symptoms and objective
findings is well recognised.3,59,60 Based on this argument, Nygaard et al.28 chose to define objective
prolapse as leading edge beyond the hymen (> 0 cm) in a prolapse surgery trial. We have therefore used
this cut-off point to dichotomise the ordinal POP-Q findings in the women who had individual
measurements recorded at baseline (83% of all women).
Blinding of participants
Clinical baseline data were reported by women before randomisation using self-completed questionnaires.
The objective assessment of prolapse stage before surgery was also carried out, as far as possible, by
observers who did not have knowledge of the randomised operations, normally before a decision for
surgery had been made.
Objective outcome measures
We were able to ascribe a prolapse stage to 93% of women at baseline, although only 83% had at least
one recorded measurement on the POP-Q examination. It is difficult to explain why a small minority of
women appeared not to have significant prolapse (stage 0 or 1). We can offer a number of suggestions.
These measurements may have been recorded:
l without the use of provocation, such as Valsalva manoeuvre or coughing, or
l without the use of position and gravity to demonstrate the maximum descent, or
l at a time when the prolapse was not evident (e.g. in the morning), or
l in theatre under anaesthetic, or
l with a pessary in place, or
l incorrectly.
We did check that the patients’ symptoms were bothersome (according to the Pelvic Organ Prolapse
Symptom scale). These women clearly requested surgery, with which their gynaecologists concurred.
During the study we placed emphasis on the importance of accurate recording of stage and compartment
using the POP-Q guideline.27 We hope that demonstration of these few apparently anomalous women
will improve clinical practice with respect to selection of women for prolapse surgery, and/or their
better assessment.
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Conclusions and further research
The wide inclusion criteria, minimal exclusion criteria and high recruitment rate have ensured that the
women studied in PROSPECT are representative of those having prolapse surgery in the UK and the clinical
practice of the gynaecologists who treat them. There were clear clinical and demographic differences
between women who were having a first and a repeat repair, justifying our decision to study these groups
in separate trials. However, within each trial, women who were and were not randomised were broadly
similar. The findings of the randomised trials in PROSPECT will therefore be generalisable to the wider
population of women with prolapse.
The findings in this chapter will serve as a benchmark for future research in women with prolapse.
The clinical messages regarding symptoms and clinical practice may be helpful in improving prolapse
management in the UK and internationally.
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Chapter 4 Results: Primary trial (randomised
controlled trial 1, comprehensive cohort 1)
This chapter describes the women who were having their first anterior or posterior prolapse repair, boththose randomised (RCT1) and those who were not randomised but agreed to be followed up in the CC
(CC1). The baseline characteristics of the women enrolled in RCT1 and CC1 have been described and
compared in Chapter 3; by and large, the populations were similar.
The flow of women through the study is shown in the CONSORT diagram (Figure 4) in line with
recommendations of CONSORT.56
The women received surgery in 35 centres across the UK (see Table 4). Although 1348 women were
randomised in total, they are further subdivided according to the panel of operations against which they
were randomised. Therefore, RCT1 consists of three strata: RCT1A, for which women were randomly
allocated to any of the three options for this trial; RCT1B, for which women were randomised between
standard repair with no mesh and synthetic mesh inlay; and RCT1C, for which women were randomised
between no mesh and a biological graft inlay.
In this chapter, the data are presented according to the strata:
1. Trial 1 Standard repair (no mesh) compared with synthetic mesh inlay [stratum 1A (three-way
randomisation) and stratum 1B (two-way randomisation)], and
2. Trial 2 Standard repair (no mesh) compared with biological graft inlay [stratum 1A (three-way
randomisation) and stratum 1C (two-way randomisation)].
Because the analyses were carried out separately for each trial, some women in the ‘no mesh’ group from
stratum 1A are included in the standard repair arm in both trial 1 and trial 2.
Baseline comparability of randomised groups
Women’s characteristics at baseline
There were no important epidemiological or clinical differences between the randomised groups of
women, including the EQ-5D-3L (trial 1, trial 2; Table 13) or between the randomised women in RCT1 and
the non-randomised in CC1 (see Table 13). In this chapter, the data for the cohort women are provided in
the outcome tables for comparison with the randomised groups but they have not been formally
statistically compared.
The ages of the recruited women ranged from 24 to 90 years. The mean BMI was < 30 kg/m2 for all groups
of women but 10% had a BMI of > 35 kg/m2. The majority of women were parous: only 1% had not had
any deliveries. Most babies had been born by spontaneous vaginal delivery. All of the groups were
comparable at baseline.
Regarding previous treatment, 13.1–17.5% were using a vaginal pessary, and 25.8–30.1% had seen a
physiotherapist for prolapse symptoms, but rather fewer for UI; and around 1 in 10 had used drugs for UI.
Regarding previous prolapse surgery, 8.2–12.9% had prior treatment, but these were all in the compartment
opposite to the one now requiring repair. In terms of upper compartment procedures, 23.3–28.8% of
women had a prior hysterectomy (more than half of those were via the abdominal route); and 5.4–7.2%
had already had continence surgery.
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1348 
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1348
Trial 1
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Trial 2
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RCT1A
762
RCT1B
358
RCT1C
228
Treatment arm
Standard
repaira
545
Standard
repair
430
Standard
repair
367
Standard
repair
252
Standard
repair
178
Synthetic
meshb
435
Synthetic
mesh
435
Synthetic
mesh
255
Synthetic
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180
Standard
repair
115
Biological
graft
113
Biological
graftc
368
Biological
graft
368
Biological
graft
255
Received surgery
537
(99%)
425
(98%)
363
(99%)
425
(99%)
425
(98%)
359
(98%)
363
(99%)
247 250 251 178 175 112 112
• Standard repair
512
(95%)
60
(14%)
57
(16%)
403
(95%)
60
(14%)
342
(95%)
57
(16%)
233 28 35 170 32
• Synthetic mesh
2
(0%)
341
(80%)
6
(2%)
2
(0%)
341
(80%)
1
(0%)
6
(2%)
1 132
• Biological graft
2
(0%)
5
(1%)
294
(81%)
0
(0%)
5
(1%)
2
(1%)
294
(81%)
• Mesh kit
2
(0%)
1
(0%)
0
(0%)
2
(0%)
1
(0%)
0
(0%)
0
(0%)
0 0 0
0 4 205
1 209 5
2 1
0 1
0 0
2 89
0 1
109 22
• Other surgeryd
19
(4%)
18
(4%)
6
(2%)
18
(4%)
18
(4%)
14
(4%)
6
(2%)
5 9 1 0
No surgery
8
(1%)
10
(2%)
5
(1%)
5
(1%)
10
(2%)
8
(2%)
5
(1%)
5 5 4
13 9 6
0 5 3 1
Baseline
questionnaire
510
(94%)
414
(95%)
342
(93%)
409
(95%)
414
(95%)
340
(93%)
342
(93%)
239 239 241 170 175 101 101
6-month
questionnaire
504
(94%)
381
(90%)
335
(92%)
398
(93%)
381
(88%)
338
(92%)
335
(91%)
232 224 228 166 157 106 107
Withdrawals within
6 months
0
(0%)
1
(0%)
1
(0%)
0
(0%)
1
(0%)
0
(0%)
1
(0%)
0 1 1 0 0 0 0
Deaths within 
6 months
0
(0%)
0
(0%)
0
(0%)
0
(0%)
0
(0%)
0
(0%)
0
(0%)
0 0 0 0 0 0 0
12-month short
questionnaire
504
(94%)
389
(92%)
337
(93%)
395
(92%)
389
(89%)
342
(93%)
337
(92%)
233 226 230 162 163 109 107
12-month long
questionnaire
468
(87%)
362
(85%)
316
(87%)
368
(86%)
362
(83%)
319
(87%)
316
(86%)
219 212 214 149 150 100 102
12-month clinic
assessment
477
(89%)
374
(88%)
320
(88%)
381
(89%)
374
(86%)
319
(87%)
320
(87%)
223 217 221 158 157 96 99
Withdrawals within
12 months
2
(0%)
4
(1%)
2
(1%)
2
(0%)
4
(1%)
1
(0%)
2
(1%)
1 4 2 1 0 0 0
Deaths within 
12 months
1
(0%)
1
(0%)
1
(0%)
1
(0%)
0
(0%)
0
(0%)
0
(0%)
0 0 1 1 0 0 0
24-month
questionnaire
445
(82%)
343
(79%)
300
(82%)
348
(81%)
343
(79%)
299
(81%)
300
(82%)
202 202 210 146 141 97 90
Withdrawals within
24 months
13
(2%)
11
(3%)
5
(1%)
11
(3%)
11
(3%)
8
(2%)
5
(1%)
6 8 4 5 3 2 1
Deaths within 
24 months
2
(0%)
0
(0%)
1
(0%)
1
(0%)
0
(0%)
1
(0%)
1
(0%)
0 0 1 1 0 1 0
FIGURE 4 CONSORT diagram for Primary trial. a, Reasons for non-compliance with randomised allocation –
standard: no prolapse surgery (4); no anterior or posterior repair (14); mesh not required (0); mesh required
(5); morbidity/surgical complications (0); patient decided did not want mesh post randomisation (0); theatre not
informed/wrong information given (1); mesh not available (0); not enough theatre time (0); consultant not in
theatre (0); no reason given for non-compliance (1). b, Reasons for non-compliance with randomised allocation –
synthetic: no prolapse surgery (4); no anterior or posterior repair (14); mesh not required (17); mesh required
(1); morbidity/surgical complications (17); patient decided did not want mesh post randomisation (5); theatre not
informed/wrong information given (11); mesh not available (1); not enough theatre time (2); consultant not in
theatre (1); no reason given for non-compliance (11). c, Reasons for non-compliance with randomised allocation –
biological: no prolapse surgery (0); no anterior or posterior repair (7); mesh not required (13); mesh required
(4); morbidity/surgical complications (7); patient decided did not want mesh post-randomisation (5); theatre not
informed/wrong information given (10); mesh not available (7); not enough theatre time (8); consultant not in
theatre (2); no reason given for non-compliance (6). d, ‘Other surgery’ includes tape for UI, vaginal hysterectomy or
suspension, cervical amputation, vault repair without anterior or posterior repair.
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Preoperative prolapse measurements
Women in the randomised groups in each trial were comparable in terms of the maximum descent of the
three different prolapse compartments. Using qualitative descriptions of prolapse stage to supplement
missing POP-Q data, > 98% of the women had prolapse stage 2 or greater before surgery. For the women
who had a quantitative score measured using the POP-Q system, about two-thirds were found to have the
leading edge of the prolapse outside the hymen (> 0 cm). Table 14 shows the level of prolapse in the
individual compartments.
Prolapse symptoms at baseline
Women had noticed symptoms of prolapse for a mean of 3.3–3.8 years, and had been bothered for
2.4–2.8 years before surgery (Table 15). The Pelvic Organ Prolapse Symptom scale is composed of seven
individual prolapse symptoms (each scored from 0 to 4, where 0 is ‘never’ and 4 is ‘all the time’; see Chapter 2).
The mean POP-SS ranged from 13.7 to 13.8 out of a maximum score of 28. Almost all women (over 99%)
were deemed to be symptomatic using the criterion of scoring at least 1 on the Pelvic Organ Prolapse Symptom
scale (see Table 15). The most common symptom was ‘a feeling of something coming down from or in the
vagina’, and over 90% of women reported this symptom at least occasionally, whereas about two-thirds had a
visible prolapse outside the hymen (see Table 14).
As well as the women in each trial being comparable at baseline for the overall score, there were no
systematic differences in any individual prolapse symptoms or other measures of the effect of prolapse on
QoL or in modifying women’s behaviour to ameliorate the effects of prolapse.
Urinary symptoms at baseline
The urinary symptoms reported by women were captured using a variety of validated questionnaires and
scales from the ICI Modular Questionnaire suite26 (Table 16). Around four in five women had at least some
urinary leakage, and this was severe for one in five.
There were no systematic differences between the women in either trial but urinary symptoms were
common in women with prolapse.
Bowel symptoms at baseline
We captured a variety of bowel symptoms (Table 17). There were no systematic differences between the
randomised groups in terms of frequency of bowel movements, constipation, bowel urgency or FI, or in
the effect bowel symptoms had on QoL. Around 30% of the women had constipation (using the ROME30
criteria) and over one-third reported FI at least occasionally.
Vaginal and sexual symptoms at baseline
We used the validated ICIQ-VS and the ICI Sexual Matters instruments to capture aspects of vaginal and sexual
function.26 Between 59.9% and 64.9% of women were not sexually active (Table 18); around one-quarter of
these women did not have sexually active partners, and the most common reason in the remainder was ‘due
to their prolapse symptoms’. Around 6.6–11.4% of women who answered the question reported pain with
intercourse (dyspareunia). There were no systematic differences between the randomised groups in terms of
these clinical measures at baseline.
Surgery planned before surgery and actually received
during surgery
Planned operations
The most common operation (anticipated for three-quarters of women) was anterior repair, with just over
half of the women planning to have a posterior repair: of these women, around 30% were having a
joint procedure (Table 19). Concomitant surgery included about one-third of the women who were
thought to need a vaginal hysterectomy, and a further 12.6–18.2% requiring a vault repair. Finally,
9.5–11.7% were thought to require a continence procedure. There were no differences between the
women in different arms of the study (see Table 19).
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Surgeons could use any mesh, graft or mesh kit, providing that any synthetic mesh was monofilament
macroporous polypropylene and mesh inlays were secured with peripheral sutures.
In line with expectations, most women received the surgery planned. Twenty-three women did not receive
surgery at all; reasons were being unfit for surgery, change of patient’s mind, surgeon finding that the
prolapse surgery was unnecessary, etc. (see Figure 4). Forty-three women did not have either an anterior or
a posterior repair once anaesthetised because the surgeon did not deem it necessary for clinical reasons,
and therefore they were unable to receive their randomised allocation (see Figure 4).
Surgery actually received
In both trials, more women had a vaginal hysterectomy in the standard arms than in the intervention arms,
but this was not significant. It is possible that knowledge of the allocated intervention influenced the
surgery actually performed. However, overall there were no substantial differences between the groups in
the panel of operations carried out.
Compliance with randomised allocation
In addition to women who did not have any prolapse surgery (N = 23; see Figure 4) or did not require either
an anterior or posterior repair (N = 43), and therefore could not receive their randomised allocation, six
women who were randomised to standard repair received mesh (N = 2), graft (N = 2) or mesh kit (N = 2);
66 women who were randomised to synthetic mesh did not receive any (N = 60) or received a biological graft
(N = 5) or mesh kit (N = 1); and 63 women who were randomised to biological graft did not receive it (N = 57)
or received synthetic mesh (N = 6). In some cases, the reason for these protocol deviations were as a result of
the appropriate mesh not being available in theatre or failure to inform the theatre staff in good time.
In trial 1, more women failed to receive their allocated (randomised) intervention in the synthetic mesh arm
than in the control standard arm because of a clinical decision by the surgeon that mesh was not required,
or because of morbidity or complications. Similarly in trial 2, more women did not receive their allocated
biological graft than a standard repair because the surgeon decided that graft was or was not indicated
and due to morbidity (see Figure 4).
Surgical characteristics and protocols
The majority of the operations were carried out by consultant gynaecological surgeons or specialty (staff
grade) doctors (Table 20). Between 18.8% (synthetic mesh arm) and 30.5% (standard repair arm of trial 2)
were undertaken by a junior doctor, but in those cases nearly 90% were supervised by a consultant.
However, consultants were more likely to operate on women randomised to mesh or graft than standard
repair. Around 80% of the women had a general anaesthetic, with no systematic differences between
the groups.
Duration of surgery was significantly longer in the mesh group (by 5.9 minutes), but not significantly
longer in the graft group (3.6 minutes) (Table 21). Blood loss was higher in the mesh group but not
significantly so in the graft group compared with standard repair. The mean length of stay ranged from
2.4 to 2.9 days, with no differences between the randomised groups. This time included any preoperative
days if the women were admitted a day before surgery.
Outcomes
The outcomes are compared between women within each of trial 1 and trial 2. The data for the equivalent
outcomes for the cohort women are provided for comparison only but are not formally statistically
compared with either trial.
RESULTS: PRIMARY TRIAL (RANDOMISED CONTROLLED TRIAL 1, COMPREHENSIVE COHORT 1)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
TA
B
LE
20
D
es
cr
ip
ti
o
n
o
f
su
rg
ic
al
ch
ar
ac
te
ri
st
ic
s
an
d
p
ro
to
co
ls
:P
ri
m
ar
y
tr
ia
l
Su
rg
ic
al
ch
ar
ac
te
ri
st
ic
Tr
ia
l
1:
st
an
d
ar
d
vs
.s
yn
th
et
ic
Tr
ia
l
2:
st
an
d
ar
d
vs
.b
io
lo
g
ic
al
C
C
1
(N
=
11
02
w
o
m
en
)
St
an
d
ar
d
re
p
ai
r
(N
=
42
5
w
o
m
en
)
Sy
n
th
et
ic
m
es
h
(N
=
42
5
w
o
m
en
)
St
an
d
ar
d
re
p
ai
r
(N
=
35
9
w
o
m
en
)
B
io
lo
g
ic
al
g
ra
ft
(N
=
36
3
w
o
m
en
)
G
ra
de
of
gy
na
ec
ol
og
is
t
C
on
su
lta
nt
70
.6
%
30
0
42
5
78
.6
%
33
1
42
1
59
.4
%
21
2
35
7
68
.0
%
24
7
36
3
70
.8
%
77
7
10
98
Sp
ec
ia
lty
do
ct
or
7.
1%
30
42
5
2.
6%
11
42
1
10
.1
%
36
35
7
7.
2%
26
36
3
12
.9
%
14
2
10
98
Sp
ec
ia
lty
do
ct
or
su
pe
rv
is
ed
69
.2
%
18
26
80
.0
%
8
10
76
.7
%
23
30
83
.3
%
20
24
69
.4
%
84
12
1
Re
gi
st
ra
r/
ju
ni
or
22
.4
%
95
42
5
18
.8
%
79
42
1
30
.5
%
10
9
35
7
24
.8
%
90
36
3
16
.3
%
17
9
10
98
Re
gi
st
ra
r/
ju
ni
or
su
pe
rv
is
ed
87
.6
%
78
89
89
.7
%
70
78
87
.5
%
91
10
4
89
.7
%
78
87
82
.9
%
14
1
17
0
Pr
op
hy
la
ct
ic
an
tib
io
tic
92
.4
%
38
7
41
9
96
.9
%
40
9
42
2
91
.8
%
32
5
35
4
97
.2
%
35
1
36
1
95
.5
%
10
16
10
64
Ty
pe
of
an
ae
st
he
tic
G
en
er
al
80
.0
%
34
0
42
5
78
.5
%
33
2
42
3
84
.9
%
30
4
35
8
87
.1
%
31
6
36
3
84
.8
%
92
4
10
90
Sp
in
al
20
.7
%
88
42
5
22
.9
%
97
42
3
15
.6
%
56
35
8
15
.2
%
55
36
3
16
.3
%
17
8
10
90
Lo
ca
l
10
.8
%
46
42
5
11
.8
%
50
42
3
8.
7%
31
35
8
6.
3%
23
36
3
14
.0
%
15
3
10
90
D
ur
at
io
n
(m
in
ut
es
)
78
.3
(3
4.
6)
41
2
84
.2
(3
2.
0)
41
2
84
.4
(4
1.
6)
35
2
88
.0
(3
8.
6)
35
5
82
.7
(3
7.
0)
10
52
Es
tim
at
ed
bl
oo
d
lo
ss
(m
l)
13
2.
7
(1
32
.4
)
39
4
16
0.
6
(1
52
.7
)
38
7
13
5.
7
(1
45
.7
)
33
1
14
6.
3
(1
14
.0
)
32
6
13
8.
6
(1
58
.2
)
97
4
V
ag
in
al
pa
ck
in
se
rt
ed
81
.4
%
34
1
41
9
86
.9
%
35
3
40
6
83
.1
%
29
4
35
4
88
.8
%
31
7
35
7
74
.8
%
79
6
10
64
C
at
he
te
r
in
se
rt
ed
91
.7
%
38
7
42
2
96
.7
%
40
5
41
9
91
.3
%
32
7
35
8
96
.1
%
34
9
36
3
93
.4
%
10
20
10
92
Su
pr
ap
ub
ic
1.
8%
7
38
7
0.
5%
2
40
4
1.
8%
6
32
7
1.
4%
5
34
9
0.
3%
3
10
16
U
re
th
ra
l
98
.2
%
38
0
38
7
99
.0
%
40
0
40
4
97
.9
%
32
0
32
7
98
.3
%
34
3
34
9
99
.7
%
10
13
10
16
Bo
th
0.
0%
0
38
7
0.
5%
2
40
4
0.
3%
1
32
7
0.
3%
1
34
9
0.
0%
0
10
16
Le
ng
th
of
st
ay
(d
ay
s)
2.
4
(1
.5
)
42
3
2.
6
(1
.5
)
41
9
2.
6
(1
.6
)
35
6
2.
9
(2
.7
)
36
3
2.
3
(1
.6
)
10
92
C
on
tin
uo
us
va
ria
bl
es
ar
e
pr
es
en
te
d
as
‘m
ea
n
(S
D
)
N
’;
di
ch
ot
om
ou
s
va
ria
bl
es
ar
e
pr
es
en
te
d
as
‘%
n
N
’.
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
TA
B
LE
21
C
o
m
p
ar
is
o
n
o
f
su
rg
ic
al
ch
ar
ac
te
ri
st
ic
s
(w
o
m
en
w
h
o
re
ce
iv
ed
su
rg
er
y
o
n
ly
):
Pr
im
ar
y
tr
ia
l
Su
rg
ic
al
ch
ar
ac
te
ri
st
ic
Tr
ia
l1
:
st
an
d
ar
d
re
p
ai
r
vs
.s
yn
th
et
ic
m
es
h
Tr
ia
l
2:
st
an
d
ar
d
re
p
ai
r
vs
.b
io
lo
g
ic
al
g
ra
ft
C
C
1
(N
=
11
04
w
o
m
en
)
St
an
d
ar
d
(N
=
42
5
w
o
m
en
)
Sy
n
th
et
ic
(N
=
42
5
w
o
m
en
)
Ef
fe
ct
si
ze
95
%
C
I
p
-v
al
u
e
St
an
d
ar
d
(N
=
35
9
w
o
m
en
)
B
io
lo
g
ic
al
(N
=
36
3
w
o
m
en
)
Ef
fe
ct
si
ze
95
%
C
I
p
-v
al
u
e
D
ur
at
io
n
(m
in
ut
es
)
78
.3
(3
4.
6)
41
2
84
.2
(3
2.
0)
41
2
5.
91
2.
05
to
9.
76
0.
00
3
84
.4
(4
1.
6)
35
2
88
.0
(3
8.
6)
35
5
4.
29
–
0.
05
to
8.
62
0.
05
2
82
.7
(3
7.
0)
10
52
Bl
oo
d
lo
ss
(m
l)
13
2.
7
(1
32
.4
)
39
4
16
0.
6
(1
52
.7
)
38
7
28
.1
9.
5
to
46
.8
0.
00
3
13
5.
7
(1
45
.7
)
33
1
14
6.
3
(1
14
.0
)
32
6
13
.5
–
4.
3
to
31
.3
0
0.
13
8
13
8.
6
(1
58
.2
)
97
4
Le
ng
th
of
st
ay
2.
4
(1
.5
)
42
3
2.
6
(1
.5
)
41
9
0.
11
–
0.
06
to
0.
27
0.
21
8
2.
6
(1
.6
)
35
6
2.
9
(2
.7
)
36
3
0.
26
–
0.
03
to
0.
56
0.
08
1
2.
3
(1
.6
)
10
92
C
on
tin
uo
us
va
ria
bl
es
ar
e
pr
es
en
te
d
as
‘m
ea
n
(S
D
)
N
’.
RESULTS: PRIMARY TRIAL (RANDOMISED CONTROLLED TRIAL 1, COMPREHENSIVE COHORT 1)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
Serious and related adverse effects in first and second years
The diagnoses in Table 22 are confined to those that met our definition of ‘serious’ (see Chapter 2).
An adverse effect (AE) was defined as ‘serious’ (SAE) if it was related to prolapse surgery and resulted in
death; was life-threatening; required hospitalisation or prolongation of an existing admission; resulted
in significant disability/incapacity; or was otherwise considered medically significant by the investigator.
If it did not meet the requirement for ‘serious’ then it was classed as ‘other’.
Serious non-mesh adverse effects
The proportion of women reporting a serious adverse effect related to prolapse surgery but not mesh-related
ranged from 6.3% to 9.8% in the first year, and 0.9% to 1.4% in the second year (Table 22). There was no
statistically significant difference between the randomised groups in either trial and the rates were similar to
those observed in the cohort. Individual serious effects were rare, the most common being infection, pain and
urinary retention, all of which are common after gynaecological surgery, generally of short duration and easily
treated. The data from the cohort women were similar.
Other related adverse effects in first and second years
The pattern for other (non-serious) adverse effects was very similar in both trials (Table 23). The overall
number of effects was similar, and there were no statistically significant differences between the
randomised groups in either trial.
Prolapse symptoms at 6 months, 1 year and 2 years
The women’s report of prolapse symptoms, measured using the Pelvic Organ Prolapse Symptom scale,
was less than half of the preoperative level (mean score before surgery 13.7/28; at 6 months 5.0/28; at
1 year 5.4/28; at 2 years 5.2/28) and the improvement remained at 2 years (Tables 24 and 25). There were
no statistically significant differences between the randomised groups in either trial 1 or trial 2 at any
time point.
Specifically the primary outcome was the POP-SS at 1 year (see Table 24).
1. In trial 1, the MD in the POP-SSs for standard repair (5.4, SD 5.5) compared with synthetic mesh
inlay (5.5, SD 5.1), adjusted for baseline values and based on data only from women in stratum 1A
(three-way randomisation) and stratum 1B (two-way randomisation), was MD 0.00 (95% CI –0.70
to 0.71).
2. In trial 2, the MD for standard repair (5.5, SD 5.6) compared with biological graft (5.6, SD 5.6), adjusted
for baseline values and based on data only from women in stratum 1A (three-way randomisation) and
stratum 1C (two-way randomisation), was MD –0.15, 95% CI –0.93 to 0.63.
At 2 years, the POP-SSs remained relatively stable, still with no difference between the groups (see
Table 24).
1. In trial 1, the MD in the POP-SSs for standard repair (4.9, SD 5.1) compared with synthetic mesh inlay
(5.3, SD 5.1), adjusted for baseline values and based on data only from women in stratum 1A (three-
way randomisation) and stratum 1B (two-way randomisation) was MD 0.32, 95% CI –0.39 to 1.03.
2. In trial 2, the MD for standard repair (4.9, SD 5.1) compared with biological graft (5.5, SD 5.7), adjusted
for baseline values and based on data only from women in stratum 1A (three-way randomisation) and
stratum 1C (two-way randomisation) was MD 0.32, 95% CI –0.48 to 1.12.
The lack of difference between the groups was supported by (see Tables 24 and 25):
l data from individual prolapse symptoms (whether measured as ‘any’ or occurring ‘most or all of
the time’)
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l the proportion of women who had at least one prolapse symptom (‘symptomatic’ defined as
POP-SS of > 0)
l the prolapse-related QoL score measured as the interference of prolapse symptoms with everyday
life, and
l the need to undertake extra hygiene measures or manoeuvres to ease discomfort or to assist pelvic
floor functions, such as emptying the bladder or bowel.
All of these measures demonstrated significant improvements from before surgery, but no difference
between the randomised groups at any time point in either trial (see Tables 24 and 25).
The improvement at 1 year was maintained at 2 years, with respect to all of the prolapse outcomes and
QoL outcomes measured. However, there were still no statistically significant differences between the
randomised groups in either trial. The data from the cohort women were similar (see Tables 24 and 25).
EuroQol-5 Dimensions (3-level version)
There were no statistically significant differences between the randomised groups in the generic EQ-5D-3L
QoL scores at 6 months, 1 year or 2 years in either trial 1 or trial 2 (Table 26). However, the score
improved from baseline levels in all the groups of women. The data from the cohort women were similar.
This outcome is further explored in the section on economic outcomes in Chapter 5.
Specifically the EQ-5D-3L scores at 1 year were compared (see Table 26).
1. In trial 1, the MD in the EQ-5D-3L scores for standard repair (0.830) compared with synthetic mesh inlay
(0.834), adjusted for baseline values and based on data only from women in stratum 1A (three-way
randomisation) and stratum 1B (two-way randomisation), was MD 0.01, 95% CI –0.02 to 0.04.
2. In trial 2, the MD for standard repair (0.81) compared with biological graft (0.82), adjusted for baseline
values and based on data only from women in stratum 1A (three-way randomisation) and stratum 1C
(two-way randomisation), was MD 0.02, 95% CI –0.01 to 0.06.
The EQ-5D-3L scores at 2 years were virtually unchanged (see Table 26):
1. In trial 1, the MD in the EQ-5D-3L scores for standard repair (0.81) compared with synthetic mesh inlay
(0.83), adjusted for baseline values and based on data only from women in stratum 1A (three-way
randomisation) and stratum 1B (two-way randomisation), was MD 0.02, 95% CI –0.02 to 0.06.
2. In trial 2, the MD for standard repair (0.81) compared with biological graft (0.82), adjusted for baseline
values and based on data only from women in stratum 1A (three-way randomisation) and stratum 1C
(two-way randomisation), was MD 0.03, 95% CI –0.01 to 0.07.
Urinary symptoms
Detailed information on urinary symptoms was obtained at baseline, 1 year and 2 years. The proportion of
women who had concomitant continence surgery ranged from 9.7% to 12.1% (see Table 19). There was
an overall decrease of 10% in the proportion of women who had any UI (from around 77% to around
65%) and the proportion with severe UI more than halved (from around 20% to around 7%) at 1 year
(see Tables 16 and 27).
The findings were virtually unchanged by 2 years: there did not appear to be any further recovery or
deterioration in urinary symptoms over that time span. However, there was no difference between the
randomised groups with respect to any of the urinary outcomes measured at 1 or 2 years in either trial
(Table 27). The data from the cohort women were similar.
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Bowel symptoms
Detailed information on bowel symptoms was obtained at baseline, 1 year and 2 years. Bowel frequency
and urgency were largely unchanged after prolapse surgery (Table 28). However, fewer women had
constipation or FI; this improvement was reflected in the bowel symptoms QoL score, which was around
half of the baseline level at both 1 year and 2 years after surgery (see Tables 17 and 28). Nevertheless,
there was no difference between the randomised groups with respect to any of the bowel outcomes
measured at 1 year or 2 years in either trial (see Table 28). The data from the cohort women were similar.
Vaginal and sexual symptoms
Detailed information on vaginal and sexual symptoms was obtained at baseline, 1 year and 2 years
(see Tables 18 and 29). Both the mean vaginal symptom score and the QoL decreased (improved) after
prolapse surgery (Table 29).
More women were sexually active after surgery (increased from < 40% before to around 50% after) and
fewer cited prolapse symptoms as a reason for not having a sex life (reduced from > 40% to < 15%).
This was reflected in a halving of the ICI Sexual Matters score, and a greater reduction (improvement) in
the sex life QoL score. The rates for dyspareunia were low both before (around 9%) and after surgery
(around 5%; see Tables 18 and 29). However, there was no difference between the randomised groups
with respect to any of the vaginal or sexual symptom outcomes measured. The improvements in these
outcomes were maintained at 2 years, but still with no differences between the randomised groups in
either trial (see Table 29). The data from the cohort women were similar.
Postoperative prolapse measurements in randomised women
A 1-year clinic review was offered to all randomised women and 88% attended. Objective measurement
showed improvement in each of the three prolapse compartments (Table 30). The proportion of women
with the leading prolapse edge beyond the hymen (> 0 cm) reduced substantially. Nevertheless, just under
20% of women still had residual prolapse.
Specifically, the RR for the proportion of women with residual prolapse beyond the hymen at 1 year
(see Table 30) was:
1. In trial 1, in the standard repair group (13.9%) compared with synthetic mesh inlay (16.1%), adjusted
for baseline values and based on data only from women in stratum 1A (three-way randomisation) and
stratum 1B (two-way randomisation), RR 1.12, 95% CI 0.79 to 1.60.
2. In trial 2, in the standard repair group (15.5%) compared with biological graft (18.1%), adjusted for
baseline values and based on data only from women in stratum 1A (three-way randomisation) and
stratum 1C (two-way randomisation), RR 1.14, 95% CI 0.80 to 1.62.
Thus, the finding that more women appeared to have residual prolapse after mesh or graft repair than
after standard repair was not statistically significant, and the difference was so small that it is not likely to
be clinically significant.
Readmissions and further treatment required for failure and
adverse effects at 6 months, 1 year and 2 years
When women reported that, at 6 months or later, they had been readmitted to hospital, we verified the
information by enquiry from centre staff when necessary and post-coded the corrected information.
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If it was related to the initial prolapse surgery, a hospital readmission was automatically counted as a SAE.
Surgery for recurrence of prolapse (repeat if same compartment, further surgery if in the opposite
compartment), or for continence surgery, was differentiated from readmission for complications related to
prolapse surgery, such as bleeding, infection and mesh removal (Table 31).
Readmission (not related to mesh exposure or further surgery for prolapse
or incontinence)
The overall rate of readmission was low, and there was no significant difference between the randomised
groups (see Table 31). The rate in the first 6 months, ranging from 2.7% to 4.2% (see Table 31), was
mostly related to adverse effects, whereas after that time the rate reduced (1.0–1.8%) and readmissions
were more likely to be related to treatment failure than adverse effects. There were no statistically
significant differences between the randomised groups in either trial (see Table 31).
Treatment for repeat or further prolapse
Thirty women (from all the randomised groups) reported that they had had further prolapse surgery in the first
year and another 50 women had more prolapse surgery in the second year: a total of 74 women. Six women
had surgery in both years. Of the 1073 randomised women who completed questionnaires at both 1 year
and 2 years, 66 had further prolapse surgery, making a total further surgery rate of 6.2% (see Table 31).
Similarly, 50 of 837 (6.0%) of the cohort women had undergone further prolapse surgery. Overall, there was
no statistically significant difference between the randomised groups in either trial in the number of women
who were having further prolapse surgery at 1 year or 2 years (see Table 31); for example:
1. In trial 1, comparing the number of women who had further prolapse surgery in the first year in the
standard repair group (1.5%) with synthetic mesh inlay (3.1%), adjusted for baseline values and based
on data only from women in stratum 1A (three-way randomisation) and stratum 1B (two-way
randomisation), RR 1.99, 95% CI 0.76 to 5.24.
2. In trial 2, comparing the number of women who had further prolapse surgery in the first year in the
standard repair group (2.0%) with biological graft (3.0%), adjusted for baseline values and based
on data only from women in stratum 1A (three-way randomisation) and stratum 1C (two-way
randomisation), RR 1.44, 95% CI 0.56 to 3.73.
In the second year, more women received another prolapse repair:
1. In trial 1, comparing the number of women who had further prolapse surgery in the second year in
the standard repair group (4.6%) with synthetic mesh inlay (4.4%), adjusted for baseline values and
based on data only from women in stratum 1A (three-way randomisation) and stratum 1B (two-way
randomisation), RR 0.94, 95% CI 0.47 to 1.88.
2. In trial 2, comparing the number of women who had further prolapse surgery in the second year in the
standard repair group (5.0%) with biological graft (5.0%), adjusted for baseline values and based
on data only from women in stratum 1A (three-way randomisation) and stratum 1C (two-way
randomisation), RR 0.99, 95% CI 0.49 to 1.98.
Few women required other treatment, such as pessaries or physiotherapy for persistent or recurrent
prolapse symptoms, and there were no differences between the randomised groups in either trial
regarding further use of services (also see Chapter 5). The data from the cohort women were similar.
Treatment for urinary incontinence and other bladder problems
Fourteen women had continence surgery in the first year, and a further 16 in the second year (one had
continence surgery in both years): a total of 29 women. Of the 1073 randomised women who completed
questionnaires at both years, 26 had continence surgery, thus a rate of 2.4%. Similarly, 15 of 837 (1.8%)
of the cohort women had had repeat continence surgery. However, around 30% of women were using
absorbent pads for urine leakage, and just under 10% were using drugs for urine problems, with similar
proportions among the cohort women. Twelve women were using intermittent catheterisation for
RESULTS: PRIMARY TRIAL (RANDOMISED CONTROLLED TRIAL 1, COMPREHENSIVE COHORT 1)
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obstructed or incomplete voiding by 2 years, and 13 in the cohort. There were no statistically significant
differences between the women in either trial, and the data from the cohort women were similar.
Treatment for mesh complications
In the synthetic mesh trial, there were 34 instances of serious adverse effects associated with mesh
complications in the first year for randomised women, but only 25 women required surgery to remove
part of the mesh, of whom two were in the standard group: 18 (72%) were asymptomatic and 16 (64%)
had exposures of < 1 cm2 (see Table 31). One of these women had total mesh removal within 2 weeks
of surgery because of severe infection causing rejection. A further eight women (see Table 31) had
conservative treatment only (such as local oestrogen, cautery with silver nitrate, or antibiotics) in the first
year and one needed no treatment. In the second year, 26 women had a mesh complication (see Table 31),
of whom 17 had surgical removal: 13 (76%) were asymptomatic and 10 (59%) had exposures of < 1 cm2.
Five received conservative treatment and another four required no treatment (see Table 31).
In the biological graft trial, four women had a mesh complication in the first year but all had concomitant
synthetic mesh and only three required surgical intervention (none were symptomatic or had exposures
of > 1 cm2). Two women had a mesh complication in the second year but neither required surgical treatment.
The cumulative mesh complication rates over 2 years were 2 of 430 (0.5%) for standard repair (trial 1),
46 of 435 (10.6%) for mesh inlay and 2 of 368 (0.5%) for biological graft.
Satisfaction with treatment at 1 year and 2 years
Women reported that they took around 3 months to recover, with no differences between any of the
randomised groups (Table 32). Over 80% of the women were very much or much better than before
surgery, and similar proportions were completely or fairly satisfied. Over 90% of women would ‘recommend
the surgery to a friend’. The data were similar at 1 year and 2 years, suggesting that, on average, the positive
benefits of surgery were sustained, with no statistically significant differences between the randomised
groups, and the findings were similar among the cohort women (see Table 32). These data are in line with
the clinical outcome data, supporting the positive benefits of prolapse surgery for the majority of women.
Analysis by treatment received
Post hoc analysis of the primary outcome measure, the POP-Q data and a selection of key secondary
outcomes for the primary repair trials (trials 1 and 2) was undertaken following discussion at the
collaborators’ meetings on 17 October 2014 and 4 September 2015. This analysis compared randomised
groups but used the actual type of prolapse repair that the women had received rather than the planned
procedure to define the subgroups. Results are presented for all women who received prolapse surgery
(Table 33), the subgroup of women who received an anterior repair only (Table 34), a posterior repair only
(Table 35) and those who received both an anterior and posterior repair concomitantly (Table 36).
There were no significant differences in the POP-SS at 1 year between groups (standard repair vs. synthetic
mesh or standard repair vs. biological graft) for any of the subgroups or for the combined group. For
women who had an anterior repair only, the rate beyond the hymen for the anterior edge (POP-Q stage
2b or more) was 12.3% for standard compared with 13.3% for synthetic mesh and 15.4% for standard
compared with 25.9% for biological graft. However, these differences were not significant (see Table 34).
Similarly, for women who had a posterior repair only, the rate beyond the hymen for the posterior
edge was 4.0% for standard compared with 5.9% for synthetic mesh, and 4.6% for standard compared
with 5.1% for biological graft, and these differences were not significant (see Table 35). There were
no significant differences between groups in any of the other outcome measures, except serious
mesh complications.
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Subgroup analysis
The results of the subgroup analyses are summarised in Table 37. There are no significant subgroup
interaction effects from any of the planned subgroup analyses.
Sensitivity analysis
Several sensitivity analyses were carried out on the primary outcome (POP-SS at 1 year) to examine the
impact of missing data under varying assumptions and test the assumption of treating unanswered
individual Pelvic Organ Prolapse Symptom scale items as asymptomatic (Table 38). In the main analysis
comparing standard repair with synthetic mesh, the point estimate for the effect size was 0.00, and this
estimate varied between –0.17 and 0.29 in the sensitivity analyses. In the comparison between standard
repair and biological graft, the point estimate in the main analysis was –0.15, which varied between –0.19
and 0.18 in the sensitivity analyses (see Table 38). None of the sensitivity analyses showed any significant
difference between groups and, therefore, the results of the sensitivity analyses are consistent with the
main analysis.
Missing POP-SSs in the standard repair arm would need to be 11 points higher than their missing-at-random
imputed values for there to be a significant benefit for synthetic mesh or missing POP-SSs would need to
be seven points higher in the synthetic mesh arm for there to be a significant benefit for standard repair.
Similarly, missing POP-SSs would need to be nine points higher for standard repair for there to be a significant
benefit for biological graft or missing POP-SSs would need to be eight points higher for biological graft for
there to be a significant benefit for standard repair.
Discussion
Summary of findings
Effectiveness
There were no statistically significant differences at 1 year in the primary clinical outcomes after prolapse
surgery using native tissue, synthetic non-absorbable mesh or biological graft material to reinforce the
repair. In particular, the CI around the primary measure of women’s symptoms, the POP-SS, was smaller
than the minimally important clinical difference of two,23 suggesting that it would be unlikely that there
was a clinically significant difference between the groups in both trials. There were also no important
differences in the secondary clinical or objective outcomes, or in the proportion of women requiring further
treatment in either of the trials.
Adverse effects
The overall incidence of serious adverse effects was low, and there was no excess in the mesh or graft
groups, other than mesh related, compared with the standard repair groups in either trial. Although
women could have a mesh-related complication only if they received mesh, in about one-third of cases this
was treated conservatively.
In the synthetic mesh trial, some women had mesh complications but most were small mesh exposures
measuring < 1 cm2 and many were asymptomatic or did not require treatment. Although there was no
evidence of difference in other adverse effects up to 2 years after surgery, synthetic mesh use did result in
additional surgical procedures for removal of a small part of the mesh, which may be considered to be an
unnecessary risk.
Only six women in the biological graft trial had mesh exposure, all in women who had concomitant
procedures with synthetic mesh; three of them required surgical correction.
RESULTS: PRIMARY TRIAL (RANDOMISED CONTROLLED TRIAL 1, COMPREHENSIVE COHORT 1)
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Cost-effectiveness
See Chapter 5.
Strengths and weaknesses
Strengths
The PROSPECT trial is the largest trial of the use of mesh or graft in prolapse surgery to date. It was powered
to detect a clinically meaningful difference in the primary outcome, prolapse symptoms, in women who
were having a first anterior or posterior prolapse operation. Owing to experience or availability of resources
locally, some surgeons were not able to randomise between all three options, hence the comparison
between standard and biological graft did not quite reach the expected sample size of 400. However,
because of the high response rates we reached within 2% of our target at 1 year for the standard compared
with synthetic comparison.
Generalisable because of the wide range of UK centres and gynaecologists
Women who enrolled in RCT1 and CC1 have been described and compared in Chapter 3; by and large, the
populations were similar, suggesting that the findings from the randomised women will be generalisable
to the larger population of women who were having prolapse surgery in the UK.
Data available separately for primary and secondary surgery
Our ability to differentiate between women who were having a first or a repeat procedure in a particular
compartment ensured that our findings can be applied to the needs of specific categories of women. It is
possible that women who require a repeat repair will present a greater anatomical challenge because of
previous scarring and hence may require a different surgical approach (see Chapter 6).
TABLE 38 Sensitivity analyses of Pelvic Organ Prolapse Symptom scale at 1 year
Analysis
Trial 1: standard repair vs. synthetic
mesh
Trial 2: standard repair vs. biological
graft
Effect size 95% CI p-value Effect size 95% CI p-value
Main analysis 0.00 –0.70 to 0.71 0.989 –0.15 –0.93 to 0.63 0.706
Assuming missing at random 0.08 –0.66 to 0.82 0.839 0.01 –0.77 to 0.79 0.985
Missing POP-SSs assumed to be
2 points higher
0.01 –0.76 to 0.77 0.985 0.03 –0.79 to 0.85 0.950
Missing POP-SSs assumed to be
2 points lower
–0.09 –0.85 to 0.67 0.818 –0.04 –0.86 to 0.78 0.922
Missing POP-SSs assumed to be
2 points higher in the standard
repair arm only
–0.09 –0.83 to 0.66 0.821 –0.13 –0.91 to 0.65 0.745
Missing POP-SSs assumed to be
2 points lower in the standard
repair arm only
0.24 –0.50 to 0.98 0.528 0.14 –0.64 to 0.93 0.717
Missing POP-SSs assumed to be
2 points higher in the mesh arm
only
0.29 –0.46 to 1.03 0.448 0.18 –0.61 to 0.96 0.658
Missing POP-SSs assumed to be
2 points lower in the mesh arm
only
–0.13 –0.88 to 0.61 0.722 –0.16 –0.95 to 0.62 0.686
Unanswered Pelvic Organ Prolapse
Symptom scale items treated as
missing
–0.17 –0.89 to 0.56 0.652 –0.19 –1.00 to 0.62 0.647
POP-SS: range 0–28, where 0= no symptoms and 28 = all seven symptoms all of the time; primary clinical outcome.
RESULTS: PRIMARY TRIAL (RANDOMISED CONTROLLED TRIAL 1, COMPREHENSIVE COHORT 1)
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Non-randomised cohort
Another strength was the inclusion of women who were not randomised. Data collection using the same
questionnaires as the trial women demonstrated that our population was representative of the majority of
women who were having prolapse surgery in the UK (see Chapter 3). Outcome data collected from the cohort
women demonstrated that their outcomes were similar to those from the randomised women, thus ensuring
generalisability of the findings. A further benefit was the ability to identify less common adverse effects.
Pragmatic nature of the research
One of the strengths of the trial was its pragmatic reflection of actual practice in a representative sample
of UK prolapse surgeons across a large number of hospital settings, including a wide range of surgical
techniques and types of mesh and graft. We did not standardise the surgical techniques used: surgeons
varied in whether they placed the mesh under or over the fascia, and whether they repaired fascial defects
or lateral detachment. Furthermore the operations were performed by a variety of staff, although primarily
consultant surgeons. This was reflected in the range of concomitant surgery performed. Consultants were,
however, more likely to operate on women who were randomised to mesh or graft than to standard repairs.
Validated outcome measures
We used validated outcome measures such as the Pelvic Organ Prolapse Symptom scale and ICI suite of
instruments to measure women’s symptoms of pelvic floor dysfunction, ensuring that our findings are
comparable with other trials and can be combined within a meta-analysis.23,26 We captured a wide range of
adverse effects, and made efforts to verify these from alternative sources, such as hospital records, when
possible. Essential missing data were actively sought from the women. Participants, outcome assessors and
data entry clerks were blinded to randomisation and, as far as possible, to treatment actually received.
Weaknesses
The limitations of our study should be acknowledged. The large number of interventions and outcomes
make it likely that some differences may have occurred by chance. However, the findings from all of the
outcomes were remarkably consistent, and leave little room for doubt regarding the findings of the trials.
We have presented data from women who were having a first repair in the compartment requiring
surgery, although around 10% of the women had undergone a previous repair in the opposite
compartment. Thus, these results do not apply to women who were having repeat surgery in that
compartment, who are presented in Chapter 6.
Because of the chronic and relapsing nature of prolapse, longer follow-up is required: the average time to
a repeat operation is around 12 years.4 Although we did not identify differences in the repeat surgery rate
between the groups, it is likely that 2 years is too short a time scale to provide a definitive answer. We
were able to identify complications, early recurrence and need for extra treatment, however. We have
commenced follow-up for at least 6 years after surgery, and also plan electronic data linkage to capture
outcomes from non-responders.
Pelvic Organ Prolapse Quantification stage (controversy over dividing up Stage 2)
The POP-Q system classes measurements from –1 cm inside the hymen to 1 cm as Stage 2.27 We and other
researchers28 have arbitrarily used a measurement of > 0 cm to indicate objective failure, while recognising
that women with worse findings may not have symptoms and, vice versa, women with objective ‘cure’
may still have prolapse symptoms. However, Table 30 shows that the findings would have been the same
whichever stage of prolapse was chosen as the cut-off.
Women with no prolapse at baseline/relationship between symptoms and
objective findings
A small number of women were classed as having stage 0 or 1 on the POP-Q system before surgery.
All of these women were symptomatic, and clearly their surgeons felt that prolapse surgery was indicated
despite lack of objective measurable prolapse: in some cases there was evidence that the full descent had
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not been measured. The lack of concordance between prolapse symptoms and objective prolapse descent
has been noted previously.62 It is still unclear why some women appeared to have surgery in the absence
of measured descent; there may be a training issue.
We agree that although the primary purpose of surgery should be improvement in the woman’s
symptoms, if the woman has persistent symptoms but no prolapse it is difficult to justify repeat surgery.
Comparison with other research
The PROSPECT trial has shown that, in the first 2 years after surgery, there is no benefit to women who
were having their first repair either in terms of prolapse symptoms or anatomical cure from the use of
synthetic mesh or biological graft to reinforce a standard anterior or posterior repair. This is in stark
contrast with the conclusions of the most recent Cochrane review,18 which found both a reduction in the
number of women with prolapse symptoms with synthetic mesh (29% vs. 21%, RR 1.44, 95% CI 1.15 to
1.80; six RCTs, including 930 women) and improved anatomical measurements (45% vs. 21%, RR 2.45,
95% CI 1.64 to 3.67; 11 RCTs, 1155 women).
On the other hand, our findings concur with the uncertainty of the evidence for a difference for biological
grafts (RR for number of women with symptoms 1.03, 95% CI 0.61 to 1.75; 3 RCTs, 401 women; RR for
objective failure 1.35, 95% CI 0.74 to 2.46; 6 RCTs, 565 women) but with narrower CIs. Given that
surgical failures requiring repeat repair occur, on average, 12 years after initial surgery, longer-term
follow-up is required to determine true effectiveness and other sequelae of mesh or graft insertion.
Importantly, complications from mesh insertion were similar in frequency to those reported in the
Cochrane review,18 and, in general, minor and easily resolved.
Differences in concomitant operations actually carried out in both trials were observed. More women
had a vaginal hysterectomy in the standard arms than in the intervention arms but these differences
were not significant. It is possible that knowledge of the allocated intervention influenced the surgery
actually performed (so that if the woman was randomised to mesh or graft, she was less likely to have a
concomitant hysterectomy). However, overall there were no substantial differences between the groups in
the panel of operations that was carried out. This emphasises the importance of taking into consideration
concomitant symptoms when managing women whose primary complaint is prolapse.
Summary
In both trials, the difference between the groups, and the size of the CI to either side, was considerably
less than the prespecified minimally important clinical difference of two. The finding that more women
appeared to have residual prolapse after mesh or graft repair than after standard repair was not statistically
significant, and the difference was so small that it is not likely to be clinically significant. We conclude that
although prolapse surgery was very effective in reducing women’s prolapse symptoms, the use of synthetic
mesh or biological graft did not provide additional benefit in women who were having their first repair.
Conclusions
There appears to be no benefit to women who were having their first prolapse repair from using synthetic
mesh or biological graft to reinforce the repair, in terms of prolapse symptoms, anatomical cure of
prolapse or non-mesh adverse effects. However, a minority of women required an additional surgical
procedure to remove exposed mesh, which may be considered to be an unnecessary risk. This additional
risk suggests that mesh should be used in the future only in the context of RCTs aimed at identifying
benefit from modifying mesh type or insertion techniques or in defined categories of high-risk women.
RESULTS: PRIMARY TRIAL (RANDOMISED CONTROLLED TRIAL 1, COMPREHENSIVE COHORT 1)
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Chapter 5 Health economics results: Primary trial
This chapter describes the within-trial cost–utility analysis of the randomised women who were havingtheir first anterior or posterior prolapse repair (RCT1).
In this chapter, the data are presented as incremental cost per QALY gained over 2-year follow-up.
The perspective of the analyses is primarily that of the UK NHS, with a supplementary analysis incorporating
wider perspective costs, including participant travel costs, opportunity costs of time for participants and
companions spent attending appointments, self-purchased health care and time off work as a result of
prolapse symptoms. This latter analysis provides a wider scope on the economic consequences of
prolapse surgery.
The base-case health-economic analysis is presented for complete case data for women who were
randomised to the three-way comparison of standard repair, synthetic mesh and biological graft (i.e. all
women randomised to RCT1A for the Primary trial (see Chapter 2 for further information). The rationale
for taking this approach for the economic analysis, and for taking a slightly different base-case approach
to that of the statistical analysis of effect size, is that, in order to conduct a meaningful economic analysis
and follow best practice economic evaluation procedures, all treatment options need to be considered
together in a single analysis. This enables the exclusion of any treatment options that may be more costly
and less effective than any other treatment alternative. The approach allows for the calculation and
comparison of net benefits for all treatment strategies, to determine the strategy with the greatest
probability of cost-effectiveness. Data presented for the estimation of incremental costs, QALYs and ICERs
throughout the chapter are thus based on women randomised to RCT1A only. A sensitivity analysis
reproduces the base-case cost-effectiveness analysis utilising all of the available data across the Primary
trial. This considers the impact on results of considering two-way comparisons, thus making use of all of
the data that are available for analysis.
The trial-based analysis seeks to inform short-term cost-effectiveness of prolapse treatment options. Data
from the three-way comparison are further used to populate a Markov cohort decision-analytic model,
which explores longer-term costs and QALY implications of prolapse treatment. The methods underpinning
the model and the longer-term cost-effectiveness results are presented in Chapter 9.
EuroQol-5 Dimensions (3-level version), quality-adjusted
life-years
The proportion of women with any health problems reported on the EQ-5D-3L measure of generic QoL is
shown in Figures 5–7. These figures present the data as reported by women across randomised groups at
6 months, 1 year and 2 years, respectively. The descriptive data in Figures 5–7 are based on all of the
available data recorded. This contrasts with the economic evaluation data in later sections, which are
based on complete cost and QALY pairs. The figures illustrate the percentage of women who were having
any problems on each of the domains of QoL (i.e. women scoring a ‘2’ or a ‘3’). In general, a substantial
proportion of women appear to have some pain or discomfort, with little difference between 6-month and
1-year follow-up. The fewest problems were experienced in self-care, with only a small proportion of
women reporting any problems. A visual inspection of the graphical data does not indicate any substantial
differences between the percentage of women reporting problems across the randomised groups in any of
the individual dimensions of generic QoL at 6 months or 1- or 2-year time points.
Figures 5–7 indicate the individual aspects of QoL that impact on overall utility for these women. Table 39
provides descriptive data of mean utility scores (generated using time trade-off tariffs, based on UK
general population norms25) and QALYs generated by combining utilities with duration (length) of life
over follow-up.
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Results for incremental QALYs gained are presented comparing synthetic mesh/biological graft with
standard repair for both raw differences between QALY estimates and also modelled differences. The
modelled differences are based on linear regression (OLS) models, with adjustment for baseline covariates,
including baseline EQ-5D-3L score, surgeon, age, BMI, concomitant continence procedure at baseline and
compartment of prolapse.
Analyses were conducted using heteroscedastic robust SEs. Table 40 presents the incremental QALYs
gained for each group at both 1 year and 2 years, calculated using an area-under-the-curve approach.
There were no statistically significant differences in QALYs between treatment groups over 1 year of
follow-up. In terms of covariates included within the analysis model, baseline utility was the only significant
predictor of overall QALYs in the model, indicating that QALYs were influenced by baseline EQ-5D-3L
score. This is to be expected, given that we use an area-under-the-curve approach to calculate QALYs
gained between EQ-5D-3L-reported time points, which are thus influenced by the starting point EQ-5D-3L
score. Furthermore, the age of the women was not found to impact on QALY estimates or was the result
impacted by type of prolapse (anterior/posterior) or whether or not the woman had a concomitant
continence procedure. Overall, there is no evidence of any difference in generic QoL between randomised
groups over the first year of follow-up.
TABLE 39 EuroQol-5 Dimensions (3-level version) at each time point: Primary trial
Treatment group
Standard repair:
mean (SD); n
Synthetic mesh:
mean (SD); n
Biological graft:
mean (SD); n
EQ-5D-3L: baseline 0.722 (0.245); 231 0.711 (0.233); 234 0.697 (0.265); 230
EQ-5D-3L: 6 months 0.810 (0.284); 222 0.816 (0.229); 219 0.798 (0.268); 215
EQ-5D-3L: 12 months 0.816 (0.273); 227 0.827 (0.217); 223 0.809 (0.267); 228
QALYs gaineda (baseline to 1 year) 0.792(0.235); 197 0.808 (0.174); 196 0.778 (0.231); 193
EQ-5D-3L: 24 months 0.796 (0.293); 196 0.825 (0.230); 198 0.810 (0.270); 207
QALYsb (baseline to 2 years) 1.573 (0.498); 169 1.644 (0.302); 171 1.579 (0.452); 173
a QALYs gained are based on an area under the curve analysis, whereas EQ-5D-3L utilities are point estimates at the
follow-up time-points.
b QALYs in second year are discounted at a rate of 3.5% per annum.
TABLE 40 Incremental QALYs (three-arm RCT1A only)
QALYs
1-year outcomes 2-year outcomesb
Mean (SD);
n
Raw MD
(vs. standard)
Adjusted MD
(vs. standard);
(95% CI)a
Mean (SD);
n
Raw MD
(vs. standard)
Adjusted MD
(vs. standard);
(95% CI)a
Standard
repair
0.792
(0.235); 197
– – 1.573
(0.498); 169
– –
Synthetic
mesh
0.808
(0.174); 196
0.016 0.0109
(–0.021 to 0.043)
1.644
(0.302); 171
0.071 0.071
(–0.004 to 0.145)
Biological
graft
0.778
(0.231); 193
–0.014 –0.001
(–0.036 to 0.033)
1.579
(0.452); 173
0.006 0.039
(–0.041 to 0.120)
a Regression analysis based on non-parametric bootstrapped OLS regression, with adjustment for age, BMI, whether or
not the surgeon performing the operation was based as a main lead site (Aberdeen, Manchester and Plymouth),
concomitant continence procedure, anterior prolapse or baseline utility. Heteroscedastic robust SEs are used.
b QALYs in second year discounted at 3.5% per annum.
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There were no significant differences between the groups regarding QALYs gained at 2 years. However,
the point estimates of QALYs were higher in both synthetic mesh and the biological graft groups,
especially synthetic mesh, with a large proportion of the distribution predicting positive QALY gains for
synthetic mesh. Nevertheless, there remains some uncertainty regarding the most beneficial treatment
strategy in terms of QALYs gained from the trial-based analysis.
NHS resource use and costs
Costs to health services
Costs include intervention procedure costs, inpatient and follow-up secondary care costs, and costs of
primary care services relating to the index prolapse surgery. This may include for example treatment of
complications, treatment failure or increased contact with health-care professionals for prolapse-related
issues. Similarly to the presentation of QALY data, the descriptive statistics and the regression analyses are
based on complete case data for those women randomised across all three groups (i.e. RCT1A). The total
NHS costs are calculated by multiplying resource use by the appropriate unit cost estimates outlined in
Table 2 (see Chapter 2).
Intervention costs
The total costs to the NHS, based on the microcosting approach using data collected within the trial are
presented in Table 41. There were no significant differences between groups in terms of staff time and
length of hospitalisation costs. This is suggestive of similar operation, equipment and surgical expertise
required to perform all types of procedures (whether mesh based or not). Despite substantial variation in
costs of length of initial hospitalisation for a prolapse procedure, there was substantial uncertainty and no
clear statistical differences between groups.
The intervention costs of synthetic mesh and biological graft repairs were substantially and statistically
significantly more expensive than standard midline repairs as a result of the additional cost of materials
required to carry out the procedures. There was substantial variation in the price of mesh across different
products within similar groups. These analyses make no statements about the effectiveness of one
material relative to another, and are based on the assumption that mesh or graft material products within
a category are equally effective (i.e. assuming all types of synthetic mesh are equally effective and all
types of biological graft are equally effective). The variability in the price of mesh procedures across
participating sites, using alternative mesh products is evident through the large SDs for mesh costs
presented in Table 41.
Health services resource-use costs over trial follow-up
The additional costs of mesh procedures are combined with costs to the health services over the trial
follow-up period for each treatment group and are presented in Table 42. These include all secondary care
(readmissions, reoperations, visits to ward, outpatient consultations) and primary care (e.g. GP, nurse,
physiotherapist) contacts with health professionals. We have taken the following approach to presentation
of cost data. Each category of cost is presented for full cases within that category (e.g. hospital resource
use, primary care costs). These are then summed, along with the intervention cost, for complete cases
across all the categories, and presented as the total cost to the health services at 2 years. Data presented
in Table 42 and for the statistical analyses are based on the three-way comparison (i.e. RCT1A).
At 1 year post operation, based on the data available from RCT1A, synthetic mesh and biological graft are
both significantly more costly than the standard repair, with biological graft being the most expensive
treatment option. Biological graft is significantly more expensive over 2 years of follow-up. There remains
some weak evidence (p < 0.1) that synthetic mesh is also more costly to the health services over 2 years.
These outcomes would be expected, given that the additional cost of mesh is applied to these arms
in the intervention costing. It is important to conclude that there is no evidence of differences in costs of
follow-up care between any of the trial interventions. Overall, over a 2-year time horizon, including
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intervention and follow-up health services costs, synthetic mesh is, on average, £363 more costly than
standard repair (95% CI –£32 to £758) based on costs discounted at a rate of 3.5% per annum, applied
to the second year of follow-up. Biological graft is estimated to be £565 more expensive than standard
repair (95% CI £180 to £950). It is clear that from the perspective of NHS payers that mesh products,
and in particular biological graft prolapse repairs, present significant cost outlay for provision of care.
Base-case cost-effectiveness results (NHS perspective)
Given that there are no substantial counteracting cost savings of follow-up care over the shorter-term time
horizon, it is necessary to compare the additional costs of mesh repairs with any potential gains in QoL.
The base-case economic (cost–utility) analysis is presented according to the regression models outlined for
costs and QALYs in Chapter 2. The base-case economic analysis is presented for complete case data of
cost and QALY pairs, ensuring that the joint distribution of costs and effects is not broken. As with the
data presented in previous tables, all analyses are for women randomised to the three-way (RCT1A)
trial comparison.
One-year cost-effectiveness results
Table 43 presents the main results of the economic analysis from a NHS perspective over a 1-year time
horizon. Based on these data, at 1-year follow-up, biological graft is not a cost-effective alternative to
either standard repair or synthetic mesh, as it is more costly and generates fewer QALYs. Furthermore,
at 1-year follow-up, it is unlikely that synthetic mesh would offer a cost-effective treatment option, with an
ICER of £35,750 per QALY gained, it is above the £20,000–30,000 threshold value of cost-effectiveness
commonly accepted by UK decision-makers. Figure 8 illustrates the scatterplot of incremental costs and
incremental QALYs for this analysis, showing substantial uncertainty in QALYs gained, but definitively
showing that in nearly all of the simulations both mesh procedures are more expensive than standard
repair. The CEAC in Figure 9 shows that at 1-year follow-up, based on the NMB, there is substantial
uncertainty regarding the most cost-effective treatment strategy. On the balance of probabilities, data from
the CEACs indicate that standard repair has a slightly higher probability of being the most cost-effective
treatment strategy than alternative options up to a WTP of approximately £40,000 per QALY gained.
Considering that decision-makers may be willing to pay £30,000 for a QALY gained, there is a 57%
chance that standard repair and 40% chance that synthetic mesh are the most cost-effective treatments.
There is little chance biological graft would be cost-effective. However, as the threshold of WTP for a
QALY increases, the probability that synthetic mesh becomes cost-effective increases. Overall, the data do
not allow one to draw clear conclusions on cost-effectiveness over a 1-year follow-up.
Two-year cost-effectiveness results
The results of the cost-effectiveness analysis over 2 years is presented in Table 44. Two analyses are
undertaken: the base-case analysis presents complete case data, and the secondary analysis presents the
results from an imputed data set. In all cases, costs and outcomes for the second year of follow-up are
discounted at a rate of 3.5% in accordance with economic evaluation best practice guidelines.
Complete case analysis
The results of the complete case analysis show that synthetic mesh provides greater QALYs than standard
repair, for an analysis in which complete case cost and QALY pairs are considered. This leads to a
favourable point estimate of the ICER for synthetic mesh compared with standard repair of £4493 per
QALY gained, falling well below a threshold value of WTP for a QALY gained. Biological graft repair is not
cost-effective. Although its ICER compared with standard repair is just over £13,000 per QALY, it is more
costly and less effective than synthetic mesh. Biological graft is therefore dominated by synthetic mesh
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and, based on current data, is not a cost-effective use of resources. However, this estimate should be
interpreted in light of the considerable uncertainty surrounding it. Figures 10 and 11 present the
scatterplot and CEACs, respectively, for the 2-year outcomes. Despite the favourable point estimate of the
ICER for synthetic mesh repair, there remains some uncertainty, with an 84% probability, that synthetic
mesh is the most cost-effective treatment strategy. The probability of biological repair being the preferred
treatment option is substantially lower, never reaching a probability of cost-effectiveness of > 13% at
threshold values of up to £50,000 per QALY gained.
Based on the complete case analysis of 2-year cost-effectiveness outcomes, there is no definitive evidence
regarding the most cost-effective treatment strategy, although synthetic mesh may offer a cost-effective
alternative to standard repair, depending on the threshold of WTP for a QALY gained adopted by a
decision-maker. The higher the threshold value, the more likely it is that synthetic mesh would be
considered a cost-effective use of NHS resources.
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Missing data
The complete case analysis results showed potential improvements in QALY gains for synthetic mesh at
2 years. However, the analysis of complete case QALY data ignored some important missing data
information, with a substantial proportion of participants missing complete QALY data at each time point
up to 2 years. Data completeness for QALYs at 2 years was evenly distributed across the different arms of
the trials with missing data 83 of 252 (33%), 84 of 255 (33%) and 82 of 255 (32%) for standard repair,
synthetic mesh and biological graft, respectively. Further analysis shows that participants suffering from
failures or complications tended to report less-complete EQ-5D-3L data than those not experiencing such
effects. For example, missing data for 2-year QALYs for those with severe complications was between 40%
and 45% across the randomised groups. Furthermore, we investigated the mechanism of missingness of
data by exploring the impact of baseline covariates on missing data. Missing data were found to differ
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FIGURE 10 Scatterplot of incremental costs and QALYs for mesh treatments compared with standard repair:
complete case analysis, 2-year follow-up data.
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FIGURE 11 Cost-effectiveness acceptability curves: complete case analysis, 2-year follow-up data.
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significantly between age groups, with older women reporting more complete data. We therefore
excluded the assumption that missing QALY data were missing at random. This finding, together with the
extent of missingness, particularly among respondents experiencing negative health effects, is suggestive
that the complete case analyses may overestimate true QALYs for women who are experiencing prolapse.
Multiple imputed data analysis explores the impact of missing data on results. The analysis reported in
the lower section of Table 44 imputes data based on predictive mean matching for QALYs and standard
multivariate regression models for costs. Estimates of incremental costs were not found to impact on
overall results. It can be seen from the results that there remains substantial uncertainty regarding the most
cost-effective treatment strategy, but, based on data imputation, the potential QALY gains for mesh in
the complete case analysis have been removed and all of the strategies generate broadly similar outcomes.
Given that there remain no QALY differences between mesh and standard repairs in the imputed data
set, mesh is no longer a viable alternative from a cost-effectiveness point of view, and both meshes
are dominated by the standard repair approach. As with all of the other analyses, however, there remains
substantial uncertainty surrounding the point estimates of cost-effectiveness, with a probability of
cost-effectiveness of standard repair (52%), synthetic mesh (29%) and biological repair (20%) at a WTP
of £30,000 per QALY gained in the imputed data set compared with 5%, 84% and 12%, respectively,
in the base-case analysis.
Considering the two analyses presented for complete case and imputed data sets, there is some uncertainty
regarding cost-effectiveness from the within-trial analyses. Although the within-trial analysis is informative
regarding short-term cost-effectiveness, and determining drivers of uncertainty, it is likely that the true
cost-effectiveness of mesh materials will not be determined by such a short time horizon, which may be
insufficient to capture longer-term risk of recurrence and any associated complications. It is therefore
necessary to consider longer-term outcomes of cost-effectiveness. This will be achieved by continuing the
PROSPECT follow-up to a minimum of 6 years, and through the development of a decision-analytic model
presented in Chapter 9. The decision model will make initial projections of longer-term cost-effectiveness,
which will be validated using the longer-term trial follow-up once the data become available.
Costs directly incurred by participants and indirect costs
A further analysis was conducted incorporating both participant and indirect costs into the analysis over
the 2-year study follow-up.
Table 45 reports mean costs (from a wider economic perspective) of attending primary care, outpatient
appointments and inpatient admissions, respectively. We have taken the following approach to presentation
of data in Table 45. Each category of cost is presented for full cases within that category (e.g. time off work
due to prolapse symptoms). These are then summed together, across all the categories for all available cost
data for participant and companion time and travel costs, and presented as the total participant cost at
2 years. Complete case data for participant total cost and NHS total cost are then added together to
generate a wider economic cost.
The analysis includes participant-incurred costs for attending their PROSPECT surgery. As women with
prolapse symptoms attended a large number of consultations and appointments with the health services,
the personal and economic cost was also substantial. However, there were no differences across
randomised groups, and it is important to note large SDs, which indicate great uncertainty in participant
time and travel costs across the groups.
Furthermore, a small proportion of women incurred direct private health-care costs or self-purchased
medication. However, the majority did not and, as with the analyses above, there were no differences
across groups.
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Mean indirect costs of sick leave taken by participants over 2 years for reasons related to prolapse
symptoms were £1376, £1207 and £1310 per woman for standard repair, synthetic mesh and biological
graft, respectively. This large value reflects the fact that prolapse symptoms have a substantial impact on
everyday life for women in terms of financial consequences. However, there were no differences across the
randomised groups in terms of time taken as sick leave in relation to prolapse problems and symptoms.
The wider economic impact is likely to be greater still if one were to consider the lost productivity of
days spent at work, where bothersome symptoms interfered with women’s normal work activities but may
not necessarily have required sick leave. Therefore, the estimates of true economic cost are likely to
be underestimated.
Combining all of the costs of sick leave, opportunity costs of time for participants and companions to attend
appointments, travel costs to attend appointments and total costs to the NHS, we can estimate a wider
overall economic cost to society. This is limited, of course, to the costs considered, and the true economic
costs may be much higher. Nonetheless, the analysis gives an overall impression of the most immediate
wider economic costs associated with prolapse surgery and the alternative treatment options considered in
the PROSPECT Study. Total economic costs were estimated as £5431, £5685 and £5897 for standard repair,
synthetic mesh and biological graft, respectively. By incorporating indirect costs and economic productivity
losses of time off work, it is evident that there are substantial costs to prolapse beyond the health sector
with substantial impact on prolapse patients, their families and the wider economy. However, incorporating
these estimates into the overall analysis greatly increases overall uncertainty, as is evident from the costs
presented in Table 46, with large SDs surrounding overall economic costs.
Combining the indirect and participant costs with the total NHS costs does not have any substantial impact
on overall findings, except to increase the uncertainty surrounding the preferred treatment option.
Although the initial point estimates of incremental costs and incremental QALYs tend to favour mesh,
with, on average, cost savings and QALY gains, these are meaningless unless considered in the light of the
uncertainty surrounding the data. To further explore and illustrate the associated uncertainty, a scatterplot
of incremental costs and effectiveness for synthetic mesh and biological graft (compared with standard
repair), as well as a CEAC derived from the results of 1000 bootstrapped replicates of mean costs and
QALYs are presented. Figures 12 and 13 illustrate that the probability of standard repair, synthetic mesh or
biological graft being the most cost-effective treatment strategy at a threshold value of WTP for a QALY
gained of £30,000 are 4%, 84% or 11%, respectively.
The uncertainty surrounding both the NHS- and participant-incurred costs as well as uncertain QALY gains
means that there is no clearly definitive cost-effectiveness strategy, even when a wider perspective of
economic costs is considered.
Deterministic sensitivity analyses
As demonstrated in the CEACs and scatterplots presented, there is substantial uncertainty driven by data
variability in our analysis. Although the complete case analysis indicates that synthetic mesh may be
cost-effective with approximately 80% probability at a threshold value of WTP for a QALY gain of
£30,000, there remains some uncertainty, particularly in relation to missing data, with no definitively
cost-effective strategy emerging. Furthermore, although CEACs and scatterplots based on bootstrapped
iterations are important in presenting sampling uncertainty, they do not consider the impact of
methodological assumptions, such as the discount rate or the choice of comparison used in the analysis.
A number of sensitivity analyses were carried out, as described in Chapter 2, to assess the uncertainty in
our results to these data choices and assumptions, particularly around missing data for cost and QALY
outcomes. The results of all deterministic sensitivity analyses undertaken are presented in Table 47.
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The data on the right-hand side of the table present the probability of cost-effectiveness of each strategy
for each analysis undertaken, based on the net benefit statistic, for a £30,000 ceiling ratio of a
decision-maker’s WTP for a QALY gained. All deterministic sensitivity analyses were carried out on the
complete case data set.
Table 47 indicates that for the majority of scenario analyses undertaken, the conclusions remain unchanged,
with substantial uncertainty regarding the most cost-effective treatment option. Including an analysis of all
women in the Primary trial (i.e. RCT1A, RCT1B and RCT1C) gives broadly similar conclusions. Point estimates
of the ICER increase but remain well below £20,000 for the comparison of synthetic mesh with standard
repair. The ICER for the comparison of biological graft with standard repair falls. However, in terms of
uncertainty, the probability that synthetic mesh is a cost-effective use of resources is lower for the analysis of
all women (51%) than the base case (84%) at a £30,000 threshold value of WTP for a QALY gained. It is
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FIGURE 12 Scatterplot of incremental costs and QALYs for mesh treatments vs. standard repair: 2-year follow-up,
wider economic perspective.
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FIGURE 13 Cost-effectiveness acceptability curves: 2-year follow-up, wider economic perspective.
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worth noting in this analysis that the probability of biological graft being the most cost-effective treatment
strategy increases somewhat. This is due to a combination of factors, namely (1) higher and significant
incremental costs for SM using all of the data; (2) less difference in point estimates of incremental QALYs
compared with the base-case analysis. The net result is a slightly higher probability of biological graft being
the most cost-effective treatment when compared against the base case. The analysis is not sufficiently
different from the base case to change any of the conclusions drawn. In order to provide data for
comparison with the trial-based clinical effectiveness analysis, we have presented the scatterplots and
CEACs from this analysis for completeness in Figures 14 and 15. These results further illustrate the
uncertainty in the 2-year data and emphasise that there is no clear cost-effective treatment strategy for
prolapse repair based on trial data.
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FIGURE 15 Primary trial, RCT1: CEAC – complete case analysis, 2-year outcomes, all randomised women to
Primary trial.
– 0.1
0
200
– 200
400
600
800
1000
1200
– 0.05 0 0.1 0.15 0.20.05
Effectiveness QALYs
St
ra
te
g
y 
co
st
 (
£)
Synthetic mesh vs. standard repair
Biological graft vs. standard repair
FIGURE 14 Primary trial, RCT1: incremental scatterplot of cost-effectiveness plane – complete case analysis, 2-year
outcomes, all randomised women to Primary trial.
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Discussion
Summary of findings
For women requiring a primary prolapse surgery procedure, synthetic mesh and biological graft were both
more costly procedures, driven by the cost of the mesh materials. There were no differences in costs of
time or equipment to perform the respective procedures, nor were there any differences evident in terms
of follow-up care required across groups. The estimated ICER for the 2-year follow-up from a NHS
perspective was £4493 per QALY gained for synthetic mesh. Considering that society might be willing to
pay up to £20,000 or £30,000 for a QALY gain, this result is favourable for synthetic mesh. Biological graft
repair had a higher ICER, of £13,537 per QALY relative to standard repair, but was dominated (being more
costly and generating fewer QALYs) compared with synthetic mesh. However, these potentially favourable
ICERs for synthetic mesh should be interpreted in light of the uncertainty surrounding the results. Based on
bootstrapped replications and calculated net benefit statistics, synthetic mesh had the greatest probability
of cost-effectiveness at a threshold value of £30,000 WTP for a QALY gained (84%). This indicates that
there is a 16% chance that one of the other treatment strategies may be the most cost-effective. There is
thus some uncertainty in the data regarding the most cost-effective strategy.
A further level of uncertainty is explored through deterministic sensitivity analysis and, in particular,
the impact of missing data on cost-effectiveness conclusions. Using MI models to address any bias or
systematic patterns of missingness in the data indicates that mesh remains more costly but no longer
generates potential QALY gains, and is thus not a cost-effective treatment strategy using imputed
data sets. Overall, across the deterministic analyses undertaken, there is some uncertainty as to the
cost-effectiveness of synthetic mesh ranging from 84% for the most favourable base-case analysis
and falling to 51% when considering all randomised women who were having a primary repair
(analysis comparable with statistical clinical effectiveness analysis), and falling further to 29% for the
analysis imputing missing data.
Based on the uncertainty illustrated in the trial-based data and the potential impact of missing data on
results, there is no strong evidence to suggest that synthetic mesh is a cost-effective use of resources.
A complete case analysis is most favourable to synthetic mesh. Despite potentially favourable ICERs, the
estimates are surrounded by considerable uncertainty and definitive conclusions cannot be drawn based on
2-year data alone.
Conclusions of the cost-effectiveness analysis are robust to changes in the model used to analyse the data.
We explored a gamma family, log link regression model for costs, as both this and a normal distribution
passed the modified Park’s test for distributional family. Furthermore, both models had similar AIC values,
with the normal having only a slightly lower score, hence its choice for the base-case analysis. However,
the conclusions remain broadly robust to the choice of analysis model for the data.
Strengths
A key strength of the study was the UK-wide multicentre design randomising women from 35 centres
across the UK. This adds to the external validity and generalisability of the results UK wide. Including a
full within-trial cost-effectiveness analysis is a key strength, although data may be of limited value in
determining longer-term cost-effectiveness results. The main strength from the within-trial analysis is that a
comprehensive microcosting approach was undertaken, further adding to the generalisability of results
across participating centres. The incorporation of a wider economic perspective on costs as a secondary
analysis adds value – in terms of a broader economic perspective and understanding of the non-health-care
costs to women, their families and the economy – more generally of prolapse symptoms and problems.
The analysis of QALYs based on EQ-5D-3L patient-level responses follows best practice methods and is
another advantage, and will be informative for developing utility weights to populate the decision-analytic
model reported in Chapter 9.
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Limitations
Despite the strengths outlined, there were a number of limitations. First, the estimates of mesh costs are
based on average prices across mesh categories and we make no statements about the cost-effectiveness
of individual mesh products. This is an area requiring further research to determine if individual products
provide better outcomes and more cost-effective treatment options for women. Second, there were
some missing data for cost and QALY outcomes. MI of missing cost and EQ-5D-3L data were conducted.
Imputation did not alter the cost estimates from the analysis, but did alter the QALY outcomes
substantially, removing any potential benefit of mesh procedures. This adds further uncertainty to the
trial-based economic analysis and renders it impossible to draw definitive conclusions on cost-effectiveness
over a short 2-year time horizon. It should be noted that this short time horizon provides a further
limitation, as it fails to address the cost and QoL impacts of any long-term complications or treatment
failures and any differences in time to failure/time to experiencing serious complications following
initial surgery.
Conclusion
To summarise, over 2-year follow-up, there was no strong evidence on the grounds of cost-effectiveness to
recommend the adoption of either synthetic mesh or biological graft for women who were having their
first prolapse procedure. There was some evidence that synthetic mesh may improve QoL outcomes but
results were subject to biases associated with missing data, which may have over-represented the QALY
gains and hence cost-effectiveness outcomes. The probability of cost-effectiveness varied substantially
across analyses undertaken, further illustrating the uncertainty in the short-run cost-effectiveness results.
It is likely, however, that the cost-effectiveness of mesh procedures will be determined over the longer
term, where it will be possible to observe treatment failures, reoperations for prolapse and associated
complications. As a result, Chapter 9 reports on the findings of a Markov cohort decision-analytic model,
extrapolating these cost-effectiveness findings over 5 years and making initial projections of time to events
such as surgery for prolapse failure and surgery for severe complications. Extended follow-up to 6 years
will further provide an opportunity to validate the results of the economic modelling exercise.
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Chapter 6 Results: Secondary trial (randomised
controlled trial 2, comprehensive cohort 2)
This chapter describes the women who were having a repeat anterior or posterior prolapse repair, boththose randomised (RCT2) and those who were not randomised but agreed to be followed up in the CC
(CC2). The baseline characteristics of RCT2 and CC2 have been compared in Chapter 3; by and large,
the populations were similar, suggesting that the findings from the randomised women are generalisable
to the larger population of women who were having secondary prolapse repair in the UK.
The flow of women through the study is shown in the CONSORT diagram (Figure 16). The women
received surgery in 35 centres across the UK (see Table 4). Although 154 women were randomised in
total, they can be further subdivided according to the panel of operations offered by their surgeon. RCT2,
therefore, consists of three strata: RCT2A, in which women could be randomly allocated to any of the
three options for this trial; RCT2B, in which women were randomised between two options – standard
repair with no mesh and synthetic mesh inlay; and RCT2D, in which they were randomised between no
mesh and a mesh kit.
In this chapter, the data are presented according to the strata:
1. Trial 3 No mesh compared with synthetic mesh inlay [stratum 2A (three-way randomisation) and
stratum 2B (two-way randomisation)].
2. Trial 4 No mesh compared with mesh kit [stratum 2A (three-way randomisation) and stratum 2D
(two-way randomisation).
Because the analyses were carried out separately for each trial, some women in the ‘no mesh’ group from
stratum 2A will be represented twice.
Baseline comparability of randomised groups
Women’s characteristics at baseline
There were no important differences between the randomised groups of women (trial 3, trial 4; Table 48)
or between the randomised women in RCT2 and the non-randomised in CC2 (see Table 5). In this chapter,
the data for the cohort women are provided in the outcome tables for comparison with the randomised
groups, but they have not been formally statistically compared. Women who were having secondary repair
were much less likely to agree to be randomised (39%) than those in the Primary trial (54%).
The mean ages of the randomised women ranged from 61.4 to 64.3 years (see Table 48), on average
about 2.5 years older than the women who were having their first repair. The mean BMI was < 30 kg/m2
for all groups of women, but 10% had a BMI of > 35 kg/m2. The previous obstetric history was very similar
to women who were having their first prolapse operation. All the women were parous. Most babies were
born by spontaneous vaginal delivery.
Generic QoL was captured using the EQ-5D-3L validated tool.25 Women in the synthetic mesh arm in trial 3
had a significantly higher (better) EQ-5D-3L score at baseline than those who were randomised to standard
repair (t-test p = 0.024), whereas in trial 4 the score was lower in the mesh kit arm than the standard
repair arm, but this was not significant (t-test p = 0.243; see Table 48).
Regarding previous treatment, 3.8–14.0% were using a vaginal pessary; 34.6–48.0% had already seen a
physiotherapist for prolapse symptoms; rather fewer (13.7–22.2%) had seen a physiotherapist for UI;
and more than 1 in 10 had used drugs for UI (see Table 48). Compared with the women who were having
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FIGURE 16 CONSORT diagram for Secondary trial. a, Reasons for non-compliance with randomised allocation:
standard – no prolapse surgery (0); no anterior or posterior repair (3); mesh not required (0); mesh required (3);
morbidity/surgical complications (0); patient decided did not want mesh post randomisation (0); theatre not
informed/wrong information given (0); mesh not available (0); not enough theatre time (0); consultant not in
theatre (0); no reason given for non-compliance (1). b, Reasons for non-compliance with randomised allocation:
synthetic – no prolapse surgery (0); no anterior or posterior repair (3); mesh not required (0); mesh required (0);
morbidity/surgical complications (6); patient decided did not want mesh post randomisation (0); theatre not
informed/wrong information given (1); mesh not available (0); not enough theatre time (1); consultant not in
theatre (0); no reason given for non-compliance (3). c, Reasons for non-compliance with randomised allocation:
mesh kit – no prolapse surgery (0); no anterior or posterior repair (3); mesh not required (0); mesh required (0);
morbidity/surgical complications (2); patient decided did not want mesh post-randomisation (1); theatre not
informed/wrong information given (0); mesh not available (7); not enough theatre time (0); consultant not in
theatre (0); no reason given for non-compliance (1). d, Other surgery includes tape for UI, vaginal hysterectomy or
suspension; cervical amputation; vault repair.
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primary surgery, many more had already had a hysterectomy (63.5–68.5%) of which around 35% were
carried out via the vaginal route, and 11.1–14.8% had already had continence surgery. All women had
had previous anterior or posterior prolapse surgery and were presenting for repeat surgery in at least one
of those compartments.
Preoperative prolapse measurements
Women in the randomised groups were comparable in terms of the maximum descent of the three
different prolapse compartments. Using qualitative descriptions of prolapse stage to supplement missing
POP-Q data, all randomised women were found to have a prolapse stage 2 or greater before surgery
(Table 49). For the women who had a quantitative score measured using the POP-Q system, women were
found to have the leading edge of the prolapse outside the hymen (> 0 cm) most often in the groups
randomised to mesh inlay (54.0%) or mesh kit (65.9%) compared with the standard repair groups
(38.9%, 50.0%, respectively).
Prolapse symptoms at baseline
Women had noticed symptoms of prolapse for 2.6–3.5 years in total, and had been bothered for
2.2–2.7 years before surgery (Table 50). The POP-SS is composed of seven individual prolapse symptoms
(each scored from 0 to 4, where ‘0’ is never and ‘4’ is all the time; see Chapter 2). At baseline, the mean
POP-SS ranged from 13.5 to 15.3 out of a maximum score of 28 (see Table 50). All women were deemed
to be symptomatic using the criterion of scoring at least one on the Pelvic Organ Prolapse Symptom scale
(apart from one woman in CC2). The most common symptom was ‘a feeling of something coming down
from or in the vagina’ and > 90% of women reported this at least occasionally, whereas > 50% had a
visible prolapse outside the hymen (see Table 50).
As well as the groups being comparable at baseline for the overall score, there were no systematic
differences between the groups in any individual prolapse symptoms or other measures of the effect of
prolapse on QoL or in modifying women’s behaviour to ameliorate the effects of prolapse (see Table 50).
Urinary symptoms at baseline
The urinary symptoms reported by women were captured using a variety of validated questionnaires and
scales from the ICI Modular Questionnaire suite.26 Around four in five women had at least some urinary
leakage, and this was severe for one in five (Table 51).
There were no systematic differences between the groups but urinary symptoms were common in women
with secondary prolapse (e.g. around 80% reported some UI). This emphasises the importance of taking
into consideration concomitant symptoms when treating women whose primary complaint is prolapse.
Bowel symptoms at baseline
There were no systematic differences between the groups in terms of frequency of bowel movements,
constipation, bowel urgency or FI, or in the effect bowel symptoms had on QoL (Table 52). Around
one-quarter of the women had constipation (classified according to the ROME30 criteria). Two in five
women reported FI at least occasionally, whereas around 1 in 10 had severe FI (sometimes or more often;
see Table 52).
Vaginal and sexual symptoms at baseline
We used the validated ICIQ-VS and the ICIQ Sexual Matters instruments to capture aspects of vaginal and
sexual function.26 About two-thirds of the women were not sexually active (Table 53); of these, over one-third
did not have sexually active partners, and the most common reason in the remainder was attributable to their
prolapse symptoms. Only six of the randomised women who answered the question reported pain with
intercourse (dyspareunia) before surgery (and a further 15 in the non-randomised cohort; see Table 53).
There were no systematic differences between the groups in terms of these parameters at baseline.
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Surgery planned before surgery and actually received
during surgery
Planned operations
The most common operation (anticipated for about half of the women) was anterior repair only, with
about one-quarter planning to have a posterior repair only, whereas a further quarter were having both.
Planned concomitant surgery included 8.0–21.7% of women who were thought to need a vaginal
hysterectomy, and a further 19.2–28.0% requiring a vault repair. Finally, 2.2–7.3% were thought to
require a continence procedure.
Surgery actually received
Most women received the surgery planned (see Figure 16 and Table 54). In trial 3, in the standard repair
group, more women (27.3%) had a combined anterior/posterior repair than in the other two groups
(synthetic mesh 13.7% and mesh kit 13.3%) and more had a concomitant vault repair (25.5% compared
with 9.8% and 13.3%, respectively) (see Table 54). It is possible that knowledge of the allocated
intervention influenced the surgery actually carried out, but the numbers were too small to draw
definite conclusions.
Compliance with randomised allocation
Two women did not receive surgery at all (see Figure 16). Ten women were not thought to need an
anterior or posterior repair once anaesthetised because the surgeon did not deem it necessary, and
therefore they were unable to carry out the randomised allocation (see Figure 16).
Three women randomised to standard repair alone received a mesh inlay because the surgeon thought it
was clinically indicated, but none had a mesh kit. In trial 3, a further 14/51 women failed to receive their
allocated (randomised) intervention in the synthetic mesh arm: this was most often due to surgical
complications. Similarly in trial 4 a further 14/45 women did not receive their allocated mesh kit, most
often (n = 7) because the kit was not available on the day of surgery (see Figure 16).
Summary
Overall there were no important differences in clinical characteristics at baseline between the women
randomised to the two groups in trial 3 (standard repair vs. synthetic mesh inlay) or in trial 4 (standard
repair vs. mesh kit).
Outcomes
Description of surgery and operative characteristics
There were no statistically significant differences in the duration of surgery (Table 55). Blood loss was
higher in the synthetic mesh group (by 36.8 ml), but not significantly so in the mesh kit group, compared
with standard repair. The mean length of stay ranged from 2.4 to 3.0 days, with no differences between
the randomised groups (see Table 55). This time included any preoperative days if the women were
admitted a day before surgery.
Serious related adverse effects in first and second years
The diagnoses in Tables 57 and 58 are confined to those that met our definition of ‘serious’ (see Chapter 2).
An adverse effect (AE) was defined as ‘serious’ (SAE) if it was related to prolapse surgery and resulted in
death; was life-threatening; required hospitalisation or prolongation of an existing admission; resulted in
significant disability/incapacity; or was otherwise considered medically significant by the investigator. If it did
not meet the requirement for ‘serious’ it was classed as ‘other’.
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Non-mesh serious adverse effects in first and second years
Very few women had any serious adverse effects, excluding mesh exposure (see Table 57). The overall
number of women experiencing at least one serious adverse effect during the first year after surgery ranged
from 6.5% (in the mesh kit group) to 12.7% (in the standard repair group of trial 3; see Table 57). One
woman in the synthetic mesh inlay group experienced excess blood loss during surgery (> 500 ml) and one in
the mesh kit group required a blood transfusion. Individual serious events thereafter were rare, the most
common being infection, pain and urinary retention, all of which are common after gynaecological surgery,
generally of short duration and easily treated. There were no statistically significant differences between the
randomised groups.
Only two women had any serious adverse effects in the second year: both were in the mesh kit group.
Other non-mesh adverse effects in first and second years
Fifteen women experienced at least one minor adverse effect in the first year and a further four in the
second year (see Table 58).
There were no statistically significant differences between the randomised groups in either trial 3 or trial 4
in terms of any adverse effects (excluding mesh exposure), as there were very few events.
Prolapse symptoms at 6 months, 1 year and 2 years
The women’s report of prolapse symptoms, measured using the POP-SS at 6 months, 1 year and 2 years,
was less than half of the preoperative level (mean score before surgery 14.5/28; at 6 months 5.9/28; at
1 year 6.3/28; at 2 years 5.2/28; see Tables 50 and 59). There were no differences between the
randomised groups at any outcome time point.
Specifically the primary clinical outcome was the POP-SS at 1 year (Table 59).
1. In trial 3, the MD in the POP-SSs for standard repair (6.6, SD 6.0) compared with synthetic mesh
(6.1, SD 6.4), adjusted for baseline values and minimisation variables, and based on data only from
women in stratum 2A (three-way randomisation) and stratum 2B (two-way randomisation), was –0.41
(95% CI –2.92 to 2.11).
2. In trial 4, the MD for standard repair (6.6, SD 5.5) compared with mesh kit (5.9, SD 5.3), adjusted
for baseline values and minimisation variables, and based on data only from women in stratum 2A
(three-way randomisation) and stratum 2D (two-way randomisation), was –1.21 (95% CI –4.13 to 1.72).
At 2 years:
1. In trial 3, the MD in the POP-SSs for standard repair (4.8, SD 5.0) compared with synthetic mesh (5.4, SD
5.5), adjusted for baseline values and minimisation variables, and based on data only from women in stratum
2A (three-way randomisation) and stratum 2B (two-way randomisation), was 0.58 (95% CI –1.68 to 2.84).
2. In trial 4, the MD for standard repair (3.9, SD 4.4) compared with mesh kit (5.4, SD 5.3), adjusted
for baseline values and minimisation variables, and based on data only from women in stratum 2A
(three-way randomisation) and stratum 2D (two-way randomisation), was 0.65 (95% CI –2.20 to 3.50).
Thus, the difference between the groups was small and not statistically significant. The size of the CIs
included the prespecified minimal clinically important difference of three, which we considered to be
clinically important for the Secondary trial.
We conclude that, although prolapse surgery was very effective in reducing women’s prolapse symptoms,
the trials were not powered to rule in or out whether or not the use of synthetic mesh inlay or a mesh kit
provided additional benefit for this outcome in women who were having a repeat repair.
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The lack of enough evidence of a difference between the groups was similar when we analysed:
l data from individual prolapse symptoms (whether measured as ‘any’ or occurring ‘most or all of the
time’ (Table 60);
l the proportion of women who had at least one prolapse symptom (‘symptomatic’);
l the prolapse-related QoL score measured as the interference of prolapse symptoms on everyday
life, and
l the need to undertake extra hygiene measures or manoeuvres to ease discomfort, or to assist pelvic
floor functions such as emptying the bladder or bowel (see Table 60).
All of these measures demonstrated significant improvements from before surgery, but not enough
evidence of difference between the randomised groups in either trial at any time point.
The improvement at 1 year was maintained at 2 years, with respect to all of the prolapse and QoL
outcomes measured. However, there were still no statistically significant differences between the
randomised groups in either trial at 2 years. The improvement in the cohort women was similar.
EuroQol-5 Dimensions (3-level version)
There were no statistically significant differences between the randomised groups in the generic QoL
scores at 6 months, 1 year or 2 years in either trial 3 or trial 4, but the sample size was too small to
differentiate reliably between the groups (Table 61). However, the score improved from baseline levels in
all the groups of women.
Specifically, the EQ-5D-3L scores at 1 year were compared (see Table 61).
1. In trial 3 the MD in the EQ-5D-3L scores for standard repair (0.74, SD 0.30) compared with synthetic mesh
inlay (0.83, SD 0.22), adjusted for baseline values and, based on data only from women in stratum 2A
(three-way randomisation) and stratum 2B (two-way randomisation), was 0.03 (95% CI –0.07 to 0.14).
2. In trial 4, the MD for standard repair (0.79, SD 0.27) compared with mesh kit (0.83, SD 0.19), adjusted
for baseline values and, based on data only from women in stratum 2A (three-way randomisation) and
stratum 2D (two-way randomisation), was 0.05 (95% CI –0.07 to 0.17).
The EQ-5D-3L scores at 2 years showed:
1. In trial 3, the MD in the EQ-5D-3L scores for standard repair (0.76, SD 0.29) compared with synthetic
mesh inlay (0.82, SD 0.19), adjusted for baseline values and, based on data only from women in stratum
2A (three-way randomisation) and stratum 2B (two-way randomisation) was 0.00 (95% CI –0.11 to 0.11).
2. In trial 4, the MD for standard repair (0.76, SD 0.29) compared with mesh kit (0.87, SD 0.14), adjusted
for baseline values and, based on data only from women in stratum 2A (three-way randomisation) and
stratum 2D (two-way randomisation), was 0.13 (95% CI 0.02 to 0.25).
The findings from the cohort women were similar. Although there was a statistically significant difference
in trial 4, with women who were having a mesh kit having a higher (better) QoL score than the standard
repair group even after adjustment for baseline imbalances, it may have been a chance finding and its
clinical significance is uncertain. This outcome is further explored in the section on economic outcomes in
Chapter 7, and in the modelling Chapter 9.
Urinary symptoms
Detailed information on urinary symptoms was obtained at baseline, 1 year and 2 years. The proportion of
women who had concomitant continence surgery ranged from 0.0% to 8.0% (see Table 54). There was a
decrease of > 10% in the proportion of women who had any UI [from 81% at baseline (see Table 51) to
69% at 1 year (Table 62)] and the proportion with severe UI more than halved (from 21% to 8%).
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However, there was no difference between the randomised groups in either trial 3 or trial 4 with respect
to any of the urinary outcomes measured.
The findings were virtually unchanged at 2 years (see Table 62): there did not appear to be any further
recovery or deterioration in urinary symptoms over that time span. The benefits of surgery, and the lack of
power to differentiate between the randomised groups in either trial 3 or trial 4, were largely maintained
at 2 years. The results for the cohort women were similar.
Bowel symptoms
Detailed information on bowel symptoms was obtained at baseline, 1 year and 2 years (see Tables 52 and 63).
Bowel frequency and constipation were largely unchanged after prolapse surgery. However, fewer women
had bowel urgency or FI, and the effect of bowel symptoms on QoL was less than before surgery (Table 63).
Nevertheless, there was no difference between the randomised groups with respect to any of the bowel
outcomes measured.
The benefits of surgery, were largely maintained at 2 years (see Table 63). The data from the cohort
women were similar.
Vaginal and sexual symptoms
Detailed information on vaginal and sexual symptoms was obtained at baseline, 1 year and 2 years
(see Tables 53 and 64). Both the mean vaginal symptom score and the QoL score decreased (improved)
after prolapse surgery (Table 64). However, there was no difference between the randomised groups for
these outcomes.
More women were sexually active after surgery, and many fewer cited prolapse symptoms as a reason for
not having a sex life (see Table 64). This was reflected in a halving of the ICI Sexual Matters score, and an
even greater reduction (improvement) in the sex life QoL score. Women in the synthetic mesh and mesh kit
groups did have higher (worse) scores on each of the outcomes measured, but this did not reach statistical
significance. In summary, there was no difference between the randomised groups with respect to any of
the vaginal or sexual symptom outcomes measured (see Table 64) due to the small sample size resulting in
a lack of power.
The benefits of surgery, and the lack of power to differentiate between the randomised groups, were
largely maintained at 2 years (see Table 64). The data from the cohort women were similar.
Postoperative prolapse measurements in randomised women
A 1-year clinic review was offered to all randomised women and 83% attended. Objective measurement
showed improvement in each of the three prolapse compartments. The proportion of women with the leading
prolapse edge beyond the hymen (> 0 cm) reduced substantially (Table 65). There was no statistically significant
difference between groups in the prolapse stage, based on POP-Q scores or clinician’s estimates of stage (see
Table 65) in trial 3 (RR 0.75, 95% CI 0.33 to 1.68; p= 0.479) or in terms of failure defined as ‘leading edge of
the prolapse at > 0 cm beyond the hymen on POP-Q’ (RR 0.59, 95% CI 0.18 to 1.92; p= 0.380).
There was statistical evidence of a difference between groups in trial 4: women who had a standard repair
were more likely to have residual prolapse than those who were randomised to mesh kit (RR 0.24, 95% CI
0.07 to 0.83; p = 0.024; see Table 65). This may have been a chance finding as a result of the small sample
size. Using the strict definition of failure of ‘leading edge of the prolapse at > 0 cm beyond the hymen on
POP-Q’, 3 of 18 (16.7%) of the women who had undergone standard repair had residual prolapse compared
with none of 35 women after receiving mesh kit treatment in trial 4.
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Further treatment required for failure or adverse effects at
6 months, 1 year and 2 years
When women reported at 6 months or later that they had been readmitted to hospital, we verified the
information by enquiry from site staff when necessary and corrected the information where necessary.
A hospital readmission was automatically counted as a SAE if it was related to the initial prolapse surgery.
Readmission for related adverse effects such as bleeding or infection was differentiated from (a) new
surgery for pelvic organ prolapse (repeat if same compartment, further if in the opposite compartment);
(b) readmission for continence surgery; and (c) readmission for surgical mesh removal.
Readmission for adverse effects
The overall rate of readmission was low, and there was no significant difference between the randomised
groups. The rate in the first 6 months, ranging from 0% to 6.4% (Table 66) was mostly related to adverse
effects (two cases of infection in the standard arm, one case each of retention, constipation and adhesions
in the mesh inlay arm), whereas after that time only one woman was readmitted (randomised to mesh
inlay, for a Fenton’s operation for vaginal tightness). There were no statistically significant differences
between the randomised groups at 1 year or 2 years (see Table 66).
Readmission for new prolapse surgery
Four women reported that they had had new prolapse surgery in the first year and a further eight in the
second year (at least one woman in each of the randomised groups), with one woman having surgery in
both years. The numbers were too few to draw conclusions (see Table 66). Complete questionnaire data
were received from 122 randomised women and 185 cohort women. The repeat prolapse surgery rate was
therefore 10 of 122 (8.2%) for the randomised women and 17 of 185 (9.2%) in the cohort (see Table 66).
Readmission for continence surgery
Only three randomised women had continence surgery in the first year, and another three in the second
year (see Table 66). The numbers were too few to differentiate between the groups. The surgery rate was
5 of 122 (4.1%) for the randomised women. In the cohort, three women had continence surgery in the
first year, and four in the second year, with one woman having continence surgery in both years. The
surgery rate was 6 of 186 (3.2%) in the cohort.
Treatment for mesh complications in the Secondary trials
In the first year, none of the women in the standard group and 6/52 (11.5%) in the mesh inlay group had
a mesh complication (see Table 66). There were a further 3 of 46 (6.5%) mesh complications in the mesh
kit group. Three women in the mesh inlay group had surgery to remove or overlay the mesh, and one in
the mesh kit group. In the second year, none of the women in the standard group and 2/52 (3.8%) in the
mesh inlay group had a mesh complication, with a further 2 of 46 (4.3%) in the mesh kit group. Of these,
only one of the women in the mesh inlay group and one in the mesh kit group required surgical correction
of the mesh exposure.
So in total, six women required mesh surgery in the 2 years of follow-up. A further six women received
conservative treatment (such as mesh trimming in outpatients, oestrogen treatment or cautery with silver
nitrate) and the rest did not require any treatment (see Table 66).
The cumulative mesh complication rates over 2 years were 7 of 52 (13.5%) for mesh inlay and 4 of 46
(8.7%) for mesh kit, with no mesh exposures after standard repair.
Other treatment for prolapse symptoms
Few women required other treatment – such as pessaries or physiotherapy – for symptoms, and there was
no difference between the randomised groups regarding further use of services (see also Chapter 7).
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Satisfaction with treatment at 1 year and 2 years
Women reported that they took around 3 months to resume normal activities (Table 67), with no differences
between the randomised groups in trial 3, but in trial 4 the 19 women in the standard arm took significantly
longer than those who were randomised to a mesh kit (p = 0.011). Over 80% of the randomised women
reported that they were very much or much better than before surgery at 1 year, and similar proportions
were completely or fairly satisfied. At 1 year, 89.7% of randomised women reported that they would
‘recommend the surgery to a friend’. The data were similar at 1 year and 2 years (see Table 67), suggesting
that, on average, the positive benefits of surgery were sustained, with no statistically significant differences
between the groups in either trial. The results for the cohort women were similar (see Table 67).
These findings are in line with the clinical outcome data, supporting the positive and sustained benefits of
prolapse surgery for the majority of women.
Discussion
Summary of findings
Effectiveness
There were no statistically significant differences at 1 year in the primary clinical or economic outcomes
after prolapse surgery using native tissue, synthetic non-absorbable mesh or a mesh kit to reinforce the
repair in either trial 3 or trial 4. However, because of the smaller numbers, these trials did not have enough
statistical power to rule out any potentially true clinical differences. This was reflected in the wide CIs
around the primary outcome – prolapse symptoms measured by the POP-SS at 1 year – of –0.41 (95% CI
–2.92 to 2.11) in trial 3 and –1.21 (95% CI –4.13 to 1.72) in trial 4 (see Table 59). Although there were
also no differences in the secondary clinical or objective outcomes, or in the proportion of women
requiring further treatment in either of the trials, these analyses were not sufficiently powered to
be conclusive.
Adverse effects
The overall incidence of serious adverse effects was around 10% (see Table 66), primarily pain, infection
and urinary retention. Women could have a mesh-related complication only if they received mesh: the total
numbers are very small. The cumulative mesh complication rates over 2 years were 7 of 52 (13.5%) for
mesh inlay and 4 of 46 (8.7%) for mesh kit, with no mesh exposures after standard repair.
Cost-effectiveness
See Chapter 7.
Strengths and weaknesses
Strengths
As the women who were having a repeat repair were recruited opportunistically alongside the women who
were having their first repair, the numbers were, as expected, too small to achieve statistical power for any
of the outcomes. The numbers were reduced by our very strict definition of ‘repeat repair’, which required
that the previous surgery had to be in the same compartment. About 10% of women who had previous
surgery in the opposite compartment were therefore recruited into the Primary trial (see Chapter 4).
In addition, women were less likely to be randomised than in the Primary trial (around 61% declined
randomisation, further reducing the numbers).
The PROSPECT Study is rare in being one of the few RCTs to distinguish between primary and secondary
surgery. Although the trial on its own was not sufficiently powered to detect a difference, this had two
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important implications. First, the information is now available for meta-analysis with other trials if women
who were having a further repair are reported separately. If this happens, a meta-analysis in the future will
shed more light on the fate of women whose surgery has already failed. It has therefore set a marker to all
future trials (and indeed past ones) that prolapse surgery trials should be reported using the subgroups of
primary and secondary surgery (defined as repeat in the same compartment). Second, it has made the
clinical community more aware of the distinction, both in the presentation of their patients and that
different treatment might be appropriate for these women.
Another one of the strengths of the Secondary trial was its pragmatic reflection of actual practice in a
representative sample of UK prolapse surgeons across a large number of hospital settings. This was
reflected in the range of concomitant surgery, and our ability to differentiate between women who were
having a first or a repeat procedure in a particular compartment. Owing to preference or local resources
available, surgeons were not all able to randomise between all three options but the analysis by strata took
account of this.
Non-randomised cohort
Another strength was the inclusion of women who were not randomised. Data collection using the same
questionnaires as for the randomised (trial) women demonstrated that our population was representative
of the majority of women who were having prolapse surgery in the UK (see Chapter 3). Outcome data
collected from those cohort women demonstrated that their outcomes were similar to those from the
randomised women, thus ensuring generalisability of the findings. A further benefit was the ability to
identify rare adverse effects.
Pragmatic nature of the research
Our secure and effective randomisation programme ensured that women were comparable at baseline and
that concomitant surgery and other confounding variables were accounted for.
Validated outcome measures
We used validated outcome measures – such as the Pelvic Organ Prolapse Symptom scale and ICI-Q suite
of instruments – to measure women’s symptoms of pelvic floor dysfunction, ensuring that our findings are
comparable with other trials and can be combined in meta-analysis. We captured a wide range of adverse
effects and made efforts to verify these from alternative sources when possible. Essential missing data
were actively sought from the women. Participants, outcome assessors and data entry clerks were blinded
to randomisation and, as far as possible, to treatment actually received.
Weaknesses
Limitations of our study should be acknowledged. The large number of interventions and outcomes make
it likely that some differences may have occurred by chance. Furthermore, the smaller numbers in the
Secondary trial meant that we would have been able to identify only large differences, which we did
not find.
The number of women randomised to the secondary RCT was small. The trial was not designed so that a
prespecified level of power should be achieved (unlike the primary RCT). Further to this, there were
fewer recruits to the Secondary trial than had been anticipated as a result of our stricter definition of a
secondary repair.
Because of the chronic and relapsing nature of prolapse, longer follow-up is required: the average time to
a repeat operation is around 12 years.4 Although we did not identify differences in the repeat surgery rate
between the groups, it is likely that 2 years is too short a time scale to provide a definitive answer. We
have commenced follow-up of the PROSPECT women for at least 6 years after surgery, and also plan
electronic data linkage to capture outcomes from non-responders.
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The POP-Q system classes measurements from –1 cm inside the hymen to 1 cm as stage 2. We and other
researchers28 have arbitrarily used a measurement of > 0 cm to indicate objective failure, while recognising
that women with worse findings may not have symptoms and vice versa (women with objective ‘cure’ may
still have prolapse symptoms). However, Table 65 shows that the findings would have been the same
whichever stage of prolapse was chosen as the cut-off.
Conclusions
The information from the Secondary trial has been inconclusive either in terms of symptoms or anatomical
cure from the use of synthetic mesh or a mesh kit in women who were having repeat prolapse surgery.
We encourage existing and future triallists to report results for primary and repeat prolapse surgery
separately, so that more information can be identified for this group of women who are at even higher risk
of failure than after their first repair.4
We are unable to say whether or not mesh or a mesh kit confers benefit to women who were having a
repeat prolapse repair, in terms of prolapse symptoms or anatomical cure of prolapse in the first 2 years
after surgery. However, some women required an additional surgical procedure to remove exposed mesh,
which may be considered to be an unnecessary risk. Long-term follow-up may show whether or not the
excess risk is compensated for by a decreased need for repeat surgery in the future.
RESULTS: SECONDARY TRIAL (RANDOMISED CONTROLLED TRIAL 2, COMPREHENSIVE COHORT 2)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
Chapter 7 Health economics results:
Secondary trial
This chapter describes the results of the within-trial cost–utility analysis over 2 years of follow-up forwomen who were having a secondary prolapse surgical procedure. These are the results pertaining to
women randomised to RCT2A (three-way comparison of mesh kits vs. mesh inlay vs. standard repair) and
RCT2B (comparisons of mesh inlay vs. standard repair).
For the purposes of the Secondary trial analysis, we have chosen to present the base case for all secondary
repair women receiving a randomised treatment. This approach differs from that adopted for the base-case
analysis of the economic analysis for women receiving a primary prolapse repair (see Chapter 5). The
rationale for taking this alternative approach for the economic analysis of the Secondary trial data is that
because of the small sample size available for the Secondary trial, the approach generates the greatest
power for analysis. The approach outlined here is similar to that undertaken for the statistical analysis of the
clinical outcomes data. A sensitivity analysis will explore the use of a more purist approach to analysis,
including data from the three-way comparison only (i.e. RCT2A).
As with the primary repair trial analysis in Chapter 5, the chapter begins with a presentation of the EQ-5D-3L
and QALY results, followed by costs and cost-effectiveness, measured as incremental cost per QALY gained.
The analysis perspective remains that of NHS decision-makers for the base case; however, a supplementary
analysis is presented, which outlines the results of the economic analysis, incorporating a wider economic
perspective (including the cost of participant and companion time and travel, participant-purchased health
care and wider personal and economic costs as a result of time off work because of prolapse symptoms and
problems). The chapter concludes with a range of deterministic sensitivity analyses to explore uncertainty in
the results presented. Where appropriate, aggregate data from the secondary repair trial will be adapted and
combined with data from the Secondary CC (CC2) to populate the secondary repair arms of the economic
decision-analytic model in Chapter 9.
Generic quality-of-life outcomes (EuroQol-5 Dimensions,
quality-adjusted life-years)
The proportion of women with any health problems reported on the EQ-5D-3L measure of generic QoL is
shown in Figures 17–19. These figures present the data as reported by women across randomised (standard
repair, mesh inlay and mesh kit) groups at 6 months, 1 year and 2 years, respectively. The descriptive data in
Figures 17–19 are based on all of the available data recorded. This contrasts with the economic evaluation
data in later sections, which are based on complete cost and QALY pairs. The figures illustrate the percentage
of women who were having any problems on each of the domains of QoL (i.e. women scoring a ‘2’ or a ‘3’).
Over half of all of the women responding to the EQ-5D-3L questionnaire report having some pain or
discomfort at baseline and 1 year after surgery. There are some indications that the proportion experiencing
pain and discomfort may fall after 2 years. However, because of the small sample size in the Secondary trial,
it is difficult to draw any clear conclusions regarding potential differences across treatment groups and time
points. Across the randomised arms, the fewest problems were experienced in self-care, with only a small
proportion of women reporting any problems. A visual inspection of the graphical data appears to show some
differences in the percentage of women experiencing problems; however, this variation is not consistent
across time points, and there does not appear to be any systematic differences evident. Instead, the variation
evident on the graph is most likely to be due to the relatively small sample size for the Secondary trial.
Figures 17–19 indicate the individual aspects of QoL that impact on overall utility for these women. Table 68
provides the utility weights generated using time trade-off tariffs, which use population preferences to value
health outcomes on a scale for which ‘1’ represents full health and ‘0’ represents death. These utility values
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are used for QALY calculations. Note that in Table 68, data are presented for summary statistics for all of the
randomised women to the Secondary trial (i.e. all women randomised to RCT2).
On initial visual inspection of the data, it would appear as if QALYs for the mesh inlay and mesh kit groups are
substantially higher than in the standard repair group (discounted 2-year QALY = 1.476). However, these results
should be considered in the light of substantial variation across secondary repair women who also reported
better health outcomes on the EQ-5D-3L at baseline. It is important, therefore, to adjust QALY estimates for
these baseline imbalances across groups. Table 69 presents these incremental QALYs gained as two effect sizes:
the first for mesh inlay compared with standard repair and the second for mesh kit compared with standard
repair. The estimates of QALYs gained are based on non-parametric bootstrapped linear regression (OLS)
models, with adjustment for baseline covariates, including baseline EQ-5D-3L score, centre, age, BMI,
concomitant continence procedure at baseline and compartment of prolapse. Additionally, the analysis model
includes a fixed effect for randomised stratum. Analyses were conducted using heteroscedastic robust SEs.
There were no differences in QALYs between treatment groups at 1 year or 2 years. As with the Primary
trial analysis, baseline EQ-5D-3L utility score was a significant predictor of overall QALYs, thus emphasising
the importance of controlling for baseline utility when estimating QALY gains or losses between treatment
groups. None of the other variables included in the estimation models was found to have a significant
effect on QALYs gained. Overall, there is no evidence of any difference in generic QoL or QALYs between
TABLE 68 EuroQol-5 Dimentions (3-level version) at each time point: Secondary trial
Treatment group Standard pair: mean (SD); n Mesh Iay: mean (SD); n Mesh kit: mean (SD); n
EQ-5D: baseline 0.641 (0.296); 52 0.749 (0.161); 50 0.692 (0.238); 42
EQ-5D: 6 months 0.769 (0.306); 48 0.826 (0.209); 46 0.771 (0.263); 42
EQ-5D: 12 months 0.743 (0.304); 50 0.830 (0.218); 43 0.827 (0.194); 41
QALYs gaineda (baseline to 1 year) 0.727 (0.268); 45 0.816 (0.148); 42 0.764 (0.191); 38
EQ-5D: 24 months 0.764 (0.294); 42 0.818 (0.194); 38 0.867 (0.142); 38
QALYs gaineda (baseline to 2 years) 1.476 (0.501); 38 1.606 (0.332); 35 1.614 (0.306); 34
a QALYs gained are based on an area-under-the-curve analysis, whereas EQ-5D utilities are point estimates at the follow-up
time points. QALYs in the second year are discounted at a rate of 3.5% per annum.
TABLE 69 Incremental QALYs (all Secondary trial women)
QALYs
Outcomes
1 year 2 yeara
Mean (SD); n
Raw MD
(vs. standard)
Adj. MD
(vs. standard)
(95% CI)b Mean (SD); n
Raw MD
(vs. standard)
Adjusted MD
(vs. standard)
(95% CI)b
Standard
repair
0.727 (0.268);
45
1.476 (0.501);
38
Mesh inlay 0.816 (0.148);
42
0.089 0.011 (–0.061
to 0.084)
1.606 (0.332);
35
0.13 0.018 (–0.149
to 0.185)
Mesh kit 0.764 (0.191);
38
0.037 –0.011 (–0.086
to 0.064)
1.614 (0.306);
34
0.138 0.096 (–0.081
to 0.274)
a QALYs in second year discounted at 3.5% per annum.
b Regression analysis based on non-parametric bootstrapped OLS regression, with adjustment for age, BMI, whether the
centre was a main lead site (Aberdeen, Manchester and Plymouth), concomitant continence procedure, anterior prolapse
or baseline utility. Heteroscedastic robust SEs are used.
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randomised groups over the follow-up period. The lack of any significant effect is likely to be due, in part,
to the small sample size recruited to RCT2. Based on current evidence, there is insufficient information to
definitively determine a favourable treatment approach for secondary prolapse repair in terms of QALYs
gained and further research is required to determine the repair strategy that generates greatest QALY
improvement for women who were having a secondary surgical prolapse repair. Despite uncertainty
regarding the most beneficial strategy in terms of QALYs gained, it is important to consider this uncertainty
alongside cost implications of different surgeries within a cost-effectiveness analysis framework.
NHS resource use and costs
Costs to health services
This section outlines the results of our analysis for costs to the health services of alternative strategies for
secondary prolapse repair surgery. Costs include intervention procedure costs, inpatient and follow-up
secondary care costs, and costs of primary care services relating to the prolapse surgery. This may include, for
example, treatment of complications, treatment failure or increased contact with health-care professionals for
prolapse-related issues. The descriptive statistics and the regression analyses are based on complete case cost
data for all women who were having a secondary prolapse repair (RCT2). The total NHS costs are calculated
by multiplying resource use by the appropriate unit cost estimates outlined in Table 2 (see Chapter 2).
Intervention costs
Table 70 reports the total intervention costs for each of the secondary surgical prolapse repairs considered.
All surgical procedures had similar costs associated with staff requirements, time in theatre and overheads
to complete the respective procedures. Regarding the cost of materials, mesh kits were the most costly,
followed by mesh inlays and standard repair. Summing these components together, there was no statistically
significant difference in total intervention cost between mesh inlay and standard repair. However, this is
probably because of the small sample size. Owing to the substantial additional cost of mesh kit materials, the
total intervention cost for mesh kits was statistically significantly higher than a standard repair. It should be
noted that the cost of materials for secondary mesh interventions were highly variable across centres and
suppliers, as is evident in the large SDs reported. These analyses make no statements about the effectiveness
or cost-effectiveness of one mesh inlay material relative to another, or one type of mesh kit relative to another.
Health services resource-use costs over trial follow-up
The additional costs of mesh procedures (in particular mesh kits) are combined with costs to the health
services over the trial follow-up period for each treatment group and are presented in Table 71. These
include all secondary care (readmissions, reoperations, visits to ward, outpatient consultations) and primary
care (e.g. GP, nurse, physiotherapist) contacts with health professionals. We have taken the following
approach to the presentation of cost data. Each category of cost is presented for full cases within that
category (e.g. hospital resource use, primary care costs). These are then summed, along with the
intervention cost, for complete cases across all of the categories, and presented as the total cost to the
health services at 2 years. Data presented in Table 71 and for the statistical analyses are based on all
women who were randomised to receive a secondary repair surgery (i.e. all women randomised to RCT2).
Owing to the small sample size, non-parametric bootstrapping is used to create CIs around MDs in costs.
Regression models include a fixed effect for randomised stratum and heteroscedastic robust SEs are
used for all models. The costs presented are presented in accordance with the assumptions outlined in
Chapter 2 regarding handling of missing data.
At 1 year post operation, based on the data available from the Secondary trial, mesh kits are significantly
more costly than the standard repair and are the most costly of the three treatment options. There were
no significant differences between mesh inlays and standard repair in 1-year total costs to the health
services. The cost results are primarily driven by the additional intervention cost of mesh kit repairs as
outlined in the preceding section.
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At 2-year follow-up, based on the data available from RCT2, there is some (weak; p < 0.1) evidence to
suggest that women who were randomised to the mesh kit group incurred greater costs than standard
repair. On average, mesh kits were £873 more costly than standard repair (95% CI –£27 to £1774). These
additional costs to the health services was driven almost entirely by differences in the price of the original
mesh product used for the surgical procedure. This evidence, although classified as weak, is based on a very
small sample size, and is indicative of the substantial extra costs associated with the mesh kit intervention.
There was not enough evidence to make any statements on the differences in treatment costs for the
comparison of mesh inlay with standard repair. Incremental costs are £238 (95% CI –£929 to £1405). It
should be noted that this estimate of incremental health services costs is surrounded by substantial
uncertainty, large SDs and wide CIs.
Base-case cost-effectiveness results (NHS perspective)
Although there are no clear differences in costs evident as a result of the uncertainty surrounding estimates
of incremental costs, it is important to consider the joint uncertainty across costs and outcomes within a
cost-effectiveness analysis framework. The base-case economic (cost–utility) analysis is presented according
to the regression models outlined for costs and QALYs in the methods section (see Chapter 2) and the
presentation of results follows a similar approach to that of the Primary trial cost-effectiveness analysis.
The base-case economic analysis is presented for complete case data of cost and QALY pairs, ensuring that
the joint distribution of costs and effects is not broken. As with the data presented in previous tables, all
analyses are for all women who were randomised to the Secondary trial comparison (RCT2). Owing to the
small sample size, alternative combinations of costs and QALYs will be explored (e.g. considering complete
case cost and complete case QALY data separately).
Cost-effectiveness results
One-year cost-effectiveness results
Table 72 presents the main results of the economic analysis from a NHS perspective over a 1-year time
horizon. An initial interpretation of the results suggests that, based on ICERs presented, over a 1-year time
horizon, neither mesh inlays nor mesh kits would offer a cost-effective use of NHS resources, based on
commonly accepted threshold values of WTP for a QALY gained, set at between £20,000 and £30,000 per
QALY. Data are based on complete case analysis of cost and QALY pairs. Owing to the small sample
size, the point estimates of the ICERs are based on highly uncertain data, and estimates of incremental
costs and QALYs that are surrounded by very wide CIs. Therefore, point estimates of the ICER are not
particularly meaningful for the Secondary trial analysis and should be interpreted in light of the uncertainty
surrounding them. Based on the data presented in the tables, there is insufficient evidence to draw any
clear cost-effectiveness conclusions regarding the most cost-effective secondary repair strategy. The most
appropriate interpretation of the cost-effectiveness data can be made using the simulations from the
bootstrapped estimates of incremental costs and QALYs, with 1000 repetitions. Figure 20 illustrates the
scatterplot of incremental costs and incremental QALYs for the 1-year analysis of the Secondary trial
data for mesh inlay compared with standard repair, and also for mesh kit versus standard repair, although
Figure 21 shows the CEACs, illustrating the probability of each strategy being cost-effective at alternative
threshold values of WTP for a QALY gained. As can be seen from these figures, there is great uncertainty
surrounding the optimal strategy in terms of cost-effectiveness. Using data presented in the CEACs, the
probability of the interventions being cost-effective over a 1-year time horizon are as follows: standard
repair (55%), mesh inlay (39%) and mesh kits (6%), demonstrating that there is no clearly cost-effective
strategy, based on the current data. The only reasonable conclusion to draw from these data is that mesh
kits do not appear to be cost-effective over 1 year. This is because of the substantial additional cost of the
kits themselves.
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Two-year cost-effectiveness results
The results of the analysis over a 2-year time horizon, with costs and QALYs in the second year discounted
at a rate of 3.5% per annum, are presented in Table 73 and Figures 22 and 23 for the base-case results,
scatterplots of incremental cost-effectiveness and CEACs, respectively. Considering the same £30,000
threshold value of WTP for a QALY gained, the probability of cost-effectiveness for each treatment strategy
is as follows: standard repair (32%), mesh inlay (19%) and mesh kit (49%). Based on the current data,
at 2 years’ follow-up the mesh kits are the most likely to be cost-effective, followed by standard repair and
mesh inlay. There is insufficient evidence, however, to clearly recommend any one treatment strategy for
secondary prolapse repair, based on the data available, as none of the treatment strategies is definitively
cost-effective. The figures illustrate that the estimates of incremental costs and QALYs are surrounded by
considerable uncertainty as a result of the small sample size for the Secondary trial. Further research, based
on larger samples, is required to definitively determine the most cost-effective strategy for women who
were having a secondary prolapse repair.
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FIGURE 20 Scatterplot of incremental costs and QALYs for mesh treatments compared with standard repair:
secondary prolapse repair (1-year follow-up data).
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FIGURE 21 Cost-effectiveness acceptability curves: secondary prolapse repair (1-year follow-up data).
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As with the Primary trial analysis, the true clinical effectiveness and cost-effectiveness of mesh materials for
secondary prolapse repair cannot be determined by such a short time horizon, which may be insufficient to
capture longer-term risk of recurrence and any associated complications. Longer-term data are thus required
on costs and QALYs to accurately determine cost-effectiveness. Currently, the data available for secondary
repairs are too sparse to populate an accurate economic modelled projection of longer-term outcomes,
with too few data to develop time to effect analysis for probability of failures and serious complications.
We therefore await the completion of longer-term follow-up of PROSPECT women to determine a more
accurate estimate of cost-effectiveness for secondary prolapse repair.
Costs directly incurred by participants and indirect costs
A further analysis was conducted incorporating both participant and indirect costs into the analysis.
Table 74 reports mean costs (from a wider economic perspective) of attending primary care, outpatient
appointments and inpatient admissions, respectively. Inpatient admissions also includes participant-incurred
costs for attending their PROSPECT surgery. As well as admissions for surgery (main PROSPECT surgery and
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FIGURE 22 Scatterplot of incremental costs and QALYs for mesh treatments compared with standard repair:
secondary prolapse repair (2-year follow-up data).
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FIGURE 23 Cost-effectiveness acceptability curves: secondary prolapse repair (2-year follow-up data).
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any follow-up admissions) and outpatient consultations, PROSPECT women who were having a secondary
repair also experienced a large number of primary care consultations, either with GPs, practice nurses,
specialist nurses or physiotherapists. As a result, the economic cost of time spent travelling to, and
attending, appointments for participants and their companions (if they reported being accompanied on a
visit) was substantial. However, there was no evidence of any differences across randomised groups,
and it is important to note large SDs, which indicate great uncertainty in participant time and travel costs
across the groups. However, one should also consider that the estimates are highly uncertain and based
on very small sample sizes.
Furthermore, a small proportion of women incurred direct private health-care costs or self-purchased
medication. However, the majority did not and there were no differences across groups.
Mean indirect costs of sick leave taken as a result of prolapse symptoms were £707, £1017 and £805
per woman for standard repair, mesh inlay and mesh kits, respectively, over the 2-year trial period.
The large values reflect the fact that prolapse symptoms have a substantial impact on everyday life for
women in terms of financial consequences. However, there were no differences across the randomised
groups in terms of time taken as sick leave in relation to prolapse problems and symptoms. The wider
economic impact is likely to be greater still if one were to consider the lost productivity of days spent at
work, where bothersome symptoms interfered with women’s normal work activities but may not necessarily
have required sick leave. Therefore, the estimates of true economic cost are likely to be underestimated.
Combining all of the costs of sick leave, opportunity costs of time for participants and companions to
attend appointments, travel costs to attend appointments and total costs to the NHS, we can estimate a
wider overall economic cost to society. This is, of course, limited to the costs considered and the true
economic costs may be much higher. Nonetheless, the analysis gives an overall impression of the most
immediate wider economic costs associated with prolapse surgery and the alternative treatment options
considered in the PROSPECT trial. Total economic costs were estimated as £4905, £5572 and £5222 for
standard repair, mesh inlay and mesh kit, respectively. There were no differences between groups either
for the total economic costs or for any individual component of travel, time or productivity costs.
Incorporating indirect costs and economic productivity losses of time off work into the analysis of costs
significantly increases the cost burden to society, showing that the costs of prolapse treatment go far
beyond the health service implications. Incorporating these estimates into the overall cost-effectiveness,
from a wider and more societal perspective of analysis, further increases the uncertainty for an analysis
that was already highly uncertain due to the small sample recruited to the Secondary trial. The results of
the analysis incorporating wider economic costs is presented in Table 75, with large SDs surrounding
estimates of overall economic costs.
To further explore the impact of the wider costing approach on conclusions, and in the light of the
significant uncertainty, it is best to interpret the results using the scatterplot of incremental costs and
effectiveness for mesh inlay and mesh kits (compared with standard repair), as well as the CEAC calculated
using the net benefit statistic derived from the results of 1000 bootstrapped replicates of mean costs and
QALYs. Figures 24 and 25 illustrate that the probabilities of standard repair, mesh inlay and mesh kit being
the most cost-effective treatment strategy at a threshold value of WTP for a QALY gained of £30,000 are
33%, 11% and 56%, respectively.
The uncertainty surrounding both the NHS and participant-incurred costs, as well as uncertain QALY gains,
means that there is insufficient evidence to draw conclusions on cost-effectiveness from a wider economic
perspective for women who were having their second prolapse repair surgery.
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Deterministic sensitivity analyses
As demonstrated in the CEACs and scatterplots presented in this chapter for the Secondary trial analysis,
there is substantial uncertainty driven by the small sample size of women randomised to the secondary
comparison. Although CEACs and scatterplots based on bootstrapped iterations are important in
presenting sampling uncertainty, they do not consider the impact of missing data, methodological
assumptions such as the discount rate or the choice of comparison used in the analysis.
A number of sensitivity analyses were carried out as described in the Chapter 2 to assess the uncertainty in
our results to these data choices and assumptions. Complete cost data at 2 years of follow-up were used
for the sensitivity analyses. We explored a gamma family, log link regression model for costs, as both this
and a normal distribution passed the modified Park’s test for distributional family. Furthermore, both
models had similar AIC values, with the normal distribution having only a slightly lower score, hence its
choice for the base-case analysis. However, the conclusions remain broadly robust to the choice of analysis
model for the data.
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FIGURE 24 Scatterplot of incremental wider economic costs and QALYs for mesh treatments compared with
standard repair – secondary prolapse repair (2-year follow-up).
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Our results were also consistent across alternative discount rates applied to costs and QALYs in the second
year. Overall, the ranking of treatment options based on the net benefit statistic (at a threshold value of
WTP of £30,000 per QALY gained) remained unchanged for the exploration of alternative discount rates
and analysis model, with mesh kits and standard repairs being slightly preferred over mesh inlay.
The base case was conducted for all women randomised to the Secondary trial. The approach differed to the
primary economic analysis, as it was felt that because of the small sample size, the trade-offs of presenting a
three-way comparison were outweighed by the advantages of increasing the power of the analysis as much
as possible. However, we also explore the impact of re-running the analysis for the Secondary trial using data
provided by only those women who were randomised to the three-way comparison (RCT2A). The choice
of comparison for the data analysis was found to impact on the treatment rankings, with standard repair
having the highest probability of cost-effectiveness for this analysis. However, as with all other analyses, no
one treatment strategy was clearly cost-effective and substantial uncertainty surrounding estimates
was illustrated.
Missing data
Missing data are likely to be particularly important for the secondary comparison given the limited sample,
for which even small differences between numbers of women with missing data between groups can
have a large impact on outcomes. It was not possible to impute individual resource-use item data for every
category of costs, given that the number of parameters was greater than the number of observations for
some imputed parameters. Therefore, imputation was undertaken at a total cost level. QALYs were based
on calculation of imputed EQ-5D-3L scores at 6 months, 1 year and 2 years. The point estimates from the
regressions of incremental costs and QALYs remain broadly unchanged for the comparison of mesh kit
compared with standard repair. However, point estimates become more favourable to the mesh inlay
comparison under the assumptions of the imputed data set. On first impression, this seems like a substantial
difference in conclusions; however, when considering the width of the CIs, the conclusion that there is no
evidence of any difference between the groups remains unchanged (both in terms of costs to the NHS and
QALYs gained). Considering the assessment of sampling uncertainty for the imputed data set, the probability
of cost-effectiveness at a threshold value of WTP for a QALY gained for each strategy is as follows: standard
repair (14%), mesh inlay (56%) and mesh kit (30%). These probabilities compare with 32%, 19% and 49%,
respectively, for each of the three strategies that were estimated in the base-case analysis. The probability of
cost-effectiveness is higher for mesh inlay under the assumptions of the imputed data set. However, again,
substantial uncertainty exists with no strategy presenting a probability of cost-effectiveness of > 60%.
The results across all of the deterministic sensitivity analyses and imputation models undertaken for the
Secondary trial comparison are presented in Table 76. Data on the right-hand side of the table present the
probability of cost-effectiveness of each strategy for each analysis undertaken, based on the net benefit
statistic, for a £30,000 ceiling ratio of a decision-maker’s WTP for a QALY gained.
Across all of the analyses undertaken, as with the base-case analysis, there was substantial uncertainty in all
the estimates of incremental costs, incremental QALYs and ICERs. Conclusions should be drawn in the light of
this uncertainty and not necessarily on the point estimates of the ICERs presented, which, as a result of the
very wide CIs, were found to be quite unstable. In summary, there is no clear evidence that any one treatment
is particularly cost-effective for the surgical repair of secondary prolapse. This conclusion was consistent across
alternative analyses. There was some further uncertainty, however, regarding cost-effectiveness, depending
on whether imputed data were used or not. However, across all analyses explored, none of the treatment
options has a probability of cost-effectiveness of > 60% if decision-makers were willing to pay a maximum of
£30,000 per QALY gained. Therefore, substantial sampling uncertainty remained for all of the analyses
considered. Further research, over a longer time horizon is required to determine the long-run trade-offs
between costs and QALYs, which will probably be driven primarily by any differences that may emerge over
the longer-term in risk of complications and risk of prolapse surgery failure.
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Discussion
Summary of main findings
For the base-case economic analysis of mesh inlays and mesh kits compared with standard repair for women
requiring a secondary prolapse surgery procedure, there is evidence to suggest that mesh kits are substantially
more expensive as a result of the additional cost of materials over and above standard repairs and, indeed,
mesh inlays. There were no differences, however, in costs of time or equipment to perform the respective
procedures, nor were there any differences evident in terms of follow-up care required across groups. There
was no strong evidence that either mesh strategy provides QALY gains relative to standard repair. It should
be noted that point estimates of incremental costs, incremental QALYs and hence incremental cost per
QALY gained were surrounded by very wide CIs, illustrating the uncertainty surrounding the estimates. This
is primarily due to a small sample size and a lack of power to estimate cost-effectiveness outcomes. As such,
point estimates of the estimated ICER should be interpreted with extreme caution and in the light of the
uncertainty surrounding these estimates. The best way to interpret the estimates of cost-effectiveness in the
light of this uncertainty is to consider the data presented in scatterplots of incremental costs and QALYs
gained and the CEACs presented. The latter suggest that, were society willing to pay up to £30,000 for a
QALY gain, there are probabilities of 32%, 19% and 49% that standard repair, mesh inlays and mesh kits,
respectively, are the optimal treatment strategy from a cost-effectiveness point of view. These probabilities
clearly illustrate great uncertainty regarding the most cost-effective strategy. Similarly, uncertain estimates are
presented for all of the deterministic sensitivity analyses undertaken and also for the exploratory imputation of
missing data. Under none of the circumstances considered would any one treatment option represent a
> 60% probability of being the most cost-effective option. Under these uncertain estimates, there is no
evidence to draw conclusions regarding cost-effectiveness of any of the treatment options considered for
secondary prolapse repair on the basis of 2-year follow-up data.
Strengths
Despite the uncertainty and the small sample size for this trial, the data presented are the only data
available specifically in relation to costs and QALYs for women experiencing a secondary prolapse repair.
Furthermore, the sample, although small, is the largest trial and body of evidence considered to date for
secondary repairs. By following these women up over a longer time, it will be possible to gain a better
picture of the longer-term trade-offs between complications and recurrences, which will probably have a
heavy impact on longer-term cost-effectiveness estimates.
As with the Primary trial, a key strength of the study was the UK-wide multicentre design randomising
women from 35 centres across the UK. This adds to the external validity and generalisability of the results
UK-wide. Including a full within-trial cost-effectiveness analysis is a key strength, although data may
be of limited value in determining longer-term cost-effectiveness results. The main strength from the
within-trial analysis is that a comprehensive microcosting approach was undertaken, further adding to
the generalisability of results across participating centres.
The incorporation of a wider economic perspective on costs as a secondary analysis adds value in terms of
providing initial indications of the costs to women and economic costs to society of secondary prolapse
symptoms and problems. The estimates generated from the time and travel cost estimates can be applied
in future studies of prolapse repair, to expand the perspective of the analysis. The analysis of QALYs,
based on EQ-5D-3L patient-level responses, follows best practice methods; this is another advantage,
which will be useful for any future modelling exercises of secondary prolapse repair. For the purposes of
this evaluation, there are insufficient numbers of observations with long enough follow-up to accurately
project time to effect analysis to populate a decision-analytic model specifically for secondary prolapse
repair. However, once longer-term data are available, this will be possible and thus forms a part of the
longer-term plan for this project.
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Limitations
The main limitation of the Secondary trial economic analysis is the small sample size available for analysis.
This greatly limits the statistical power of the analysis and limits the interpretation of the results presented
because of the wide CIs and unstable point estimates of incremental costs, incremental QALYs and
hence ICERs.
Furthermore, as with the Primary trial, we have conducted a microcosting approach to develop intervention
costs, based on data available from the trial, supplemented by contact with trial-participating surgeons to
glean information on mesh materials used to conduct prolapse repairs. Although the microcosting is an
advantage, it has also generated some limitations. First, the estimates of mesh costs are based on average
prices across mesh categories and we make no statements about the cost-effectiveness of individual mesh
products. This is an area requiring future research to determine if individual products provide better
outcomes and more cost-effective treatment options for women. Second, the data are presented for
average practice for each surgeon, and are not available at an individual patient level for all of the women
participating in the trial.
For the Secondary trial data analysis, we have chosen to include all women who were randomised,
not just those who were randomised to the three-way comparison, as we did for the Primary trial. From a
cost-effectiveness perspective, sourcing data for net benefit calculations from the three-way comparison
is the preferable approach to take. However, in this case, because of the small randomised sample for
the Secondary trial, the advantages of a straight ‘purist’ three-way comparison are outweighed by the
disadvantages of a substantial loss in already limited statistical power. Readers should note the potential
limitations of this approach for cost-effectiveness analysis in a net benefit framework.
There were some missing data for cost and QALY outcomes, which are particularly problematic given the
small sample size. Exploratory imputations of missing total cost and EQ-5D data were conducted,
indicating wide variability in ICERs presented, although a consideration of uncertainty and the CEACs
presented broadly similar results to the base-case analysis.
Furthermore, it should be noted that this short time horizon provides a further limitation, as it fails to
address the cost and QoL impacts of any long-term complications or treatment failures, and any
differences in time to failure/time to experiencing serious complications following initial surgery.
Conclusions
There was no clear evidence of the most cost-effective treatment strategy for secondary prolapse repair.
Estimates of ICERs and cost-effectiveness were highly uncertain and should be interpreted in light of this
uncertainty and the limitations outlined. It is unlikely that a 2-year follow-up is of sufficient duration to
capture all of the costs and QALYs that are of importance to women and the NHS, and hence longer-term
follow-up of the PROSPECT Study will be used to update the cost-effectiveness results. This will also
provide an opportunity to develop more robust methods of extrapolation over a lifetime, which will enable
the development of a longer-term decision-analytic model specifically for secondary prolapse repair.
Unfortunately, as a result of the small sample size, there are insufficient data to develop robust or stable
models of time-to-event data to develop an economic model at this time for secondary prolapse repair.
Extended follow-up to 6 years will be used to rerun the cost-effectiveness analyses for secondary repairs
and provide better cost-effectiveness evidence. Furthermore, longer-term data will provide more accurate
estimates of failures and complications and provide an opportunity to build a model for secondary
prolapse repair.
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Chapter 8 Results upper compartment: uterine
and vault prolapse (comprehensive cohort 3)
This chapter describes the women who, when assessed clinically before surgery, were not thought toneed an anterior or posterior prolapse repair. If they had, they would have been eligible for
randomisation in the mesh trials (see Chapters 4 and 5). These women had an upper compartment (uterine
or vault) procedure and agreed to be followed up as part of the CC (CC3).
The flow of women through the study is shown in the CONSORT diagram (Figure 26). The women received
surgery in centres across the UK (see Table 4). Although 215 women had uterine or vault surgery in total,
Type of repair Uterine/vault
215
Treatment arm CC3
n = 251
Uterine
n = 69
Vault
n = 146
Received surgery 
n = 212 (99%)
Received surgery 
n = 68 (99%)
Received surgery 
n = 144 (99%)
   Standard repair n = 17 (8%) n = 12 (18%) n = 5 (3%)
   Synthetic mesh n = 3 (1%) n = 0 (0%) n = 3 (2%)
   Biological graft n = 0 (0%) n = 0 (0%) n = 0 (0%)
   Mesh kit n = 1 (0%) n = 0 (0%) n = 1 (1%)
   Other surgery n = 191 (90%) n = 56 (82%) n = 135 (94%)
No surgery n = 3 (1%) n = 1 (1%) n = 2 (1%)
Baseline questionnaire n = 202 (94%) n = 65 (94%) n = 137 (94%)
6-month questionnaire n = 175 (83%) n = 54 (79%) n = 121 (84%)
Withdrawals within 6 months n = 1 (0%) n = 0 (0%) n = 1 (1%)
Deaths within 6 months n = 1 (0%) n = 0 (0%) n = 1 (1%)
12-month short questionnaire n = 173 (82%) n = 57 (84%) n = 116 (81%)
12-month long questionnaire n = 158 (75%) n = 46 (68%) n = 112 (78%)
12-month clinic assessment n = 0 (0%) n = 0 (0%) n = 0 (0%)
Withdrawals within 12 months n = 5 (2%) n = 1 (1%) n = 4 (3%)
Deaths within 12 months n = 1 (0%) n = 0 (0%) n = 1 (1%)
24-month questionnaire n = 152 (72%) n = 48 (71%) n = 104 (72%)
Withdrawals within 24 months n = 11 (5%) n = 3 (4%) n = 8 (6%)
Deaths within 24 months n = 4 (2%) n = 2 (3%) n = 2 (1%)
FIGURE 26 CONSORT diagram for uterine and vault groups.
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they have been reported separately because of the fundamental clinical differences between them.
The most important difference is that women who have a vault prolapse must have had a hysterectomy in
the past. Therefore, in this chapter, the data are presented according to clinical presentation, statistical
comparisons are not made between the groups and the information is presented and discussed separately.
It is important to realise that the total number of women in CC3 is not representative of the distribution of
uterine and vault prolapse in the UK. There are an artificially high number of women who were having
vault prolapse because several of the PROSPECT centres were tertiary referral centres for vault prolapse or
specialised in its laparoscopic treatment. The true ratio of uterine–vault prolapse is around 4 : 1, suggesting
that one in four women who have a hysterectomy go on to have a subsequent vault prolapse repair. These
numbers are in line with Health Episode Statistics (HES) data, which suggest that 25% of women who
were having a hysterectomy will go on to require a vault repair.6
Interestingly, although most (but not all) vaginal hysterectomies are carried out for prolapse and most
(but not all) abdominal hysterectomies for other gynaecological conditions, the number of women with
prolapse was marginally greater after an abdominal hysterectomy (543/961, 56.5%) than after a vaginal
hysterectomy (418/961, 43.5%; see Table 5). This must be set against the much higher number of women
who were having an abdominal hysterectomy in the past (e.g. > 31,000 women who were having an
abdominal hysterectomy compared with around 6500 having a vaginal hysterectomy in 2004–5).6
Overall, around 25% of women who were having a uterine prolapse repair can expect to have a vault
repair later.6 This information is derived from online HES data, and so may underestimate total procedures,
as it was based only on numbers of main operations and therefore did not count concomitant procedures.
Baseline characteristics of women who were having a uterine
or a vault prolapse repair
Women who were having surgery for a uterine prolapse were, on average, 5.6 years younger than those
having a vault repair (Table 77). However, compared with women who were having a uterine prolapse
repair, women who were having a vault repair had a higher prolapse symptom score (POP-SS of 15.3 vs.
12.8); higher score on QoL (7.3 vs. 6.5); worse generic QoL score (EQ-5D-3L score of 0.63 vs. 0.69); more
severe incontinence (23.8% vs. 21%) and prior surgery for UI (16.8% vs. 7.4%) and were more likely to
have had prolapse surgery before (57.5% vs. 14.5%). They were less likely to be currently using a pessary
(11.8% vs. 15.9%) or to have received physiotherapy for their prolapse symptoms (27.5% vs. 34.3%).
Although not all of these differences were statistically significant, together they provide an impression of the
qualitative differences between the populations of women with the two types of prolapse: this supports
our decision not to combine or directly compare the data from the two groups. Thus, in summary, women
who were having vault prolapse surgery were older, had more severe symptoms and had received more
invasive treatment than those presenting with a uterine prolapse alone. For that reason, the two samples of
women will be described separately in the rest of this chapter.
Uterine prolapse: women requiring a prolapse repair for descent of
the uterus only
Women’s characteristics at baseline
The mean age of women presenting with a uterine prolapse alone was 56.9 years (see Table 77). This is
considerably younger than the other groups of women in PROSPECT, including those with a primary or
secondary anterior or posterior prolapse (see Table 5) or a vault prolapse (see Table 77). However, the
groups were generally all comparable on other characteristics such as parity, BMI and delivery mode history.
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About one-third of the women with a uterine prolapse had seen a physiotherapist for prolapse, and about
one in eight had used a pessary for prolapse symptoms (see Table 77). One in five women had seen a
physiotherapist for urine symptoms and fewer than 1 in 10 had used drugs for urinary problems.
Preoperative prolapse measurements
The leading edge of the upper compartment (point C on the POP-Q) was, on average, at or beyond the
hymen (1.7 cm for uterine prolapse; Table 78). The majority of women had stage 3 or 4 prolapse, unlike
those having only an anterior or posterior repair, for which the most common preoperative stage was
TABLE 77 Baseline characteristics: uterine/vault cohort (CC3)
Baseline characteristic Uterine Vault
Number of women N = 69 N= 146
Age (years) 56.9 (15.2) 69 62.5 (10.1) 146
Parity (mean) 2.6 (1.4) 69 2.8 (1.4) 146
Parity (median) 2.0 (0–7) 69 3.0 (0–12) 146
BMI (kg/m2) (mean) 27.4 (4.3) 64 27.1 (4.3) 138
BMI (kg/m2) (median) 27.8 (19–36) 64 26.6 (19–40) 138
Delivery mode history
Spontaneous vaginal delivery 2.3 (1.5) 68 2.6 (1.5) 143
Forceps 0.2 (0.4) 68 0.1 (0.4) 143
Breech 0.0 (0.0) 68 0.1 (0.3) 143
Elective CS 0.0 (0.2) 68 0.0 (0.2) 143
Emergency CS 0.0 (0.0) 68 0.0 (0.1) 143
Vacuum 0.0 (0.0) 68 0.0 (0.1) 143
EQ-5D-3L
Score 0.69 (0.30) 60 0.63 (0.34) 129
Conservative treatment
Vaginal pessary 15.9% 11 69 11.8% 17 144
Physiotherapy for POP 34.3% 23 67 27.5% 39 142
Physiotherapy for UI 17.9% 12 67 17.7% 25 141
Drugs for UI 7.7% 5 65 12.1% 17 140
Previous surgery
Hysterectomy 0.0% 0 69 100.0% 146 146
Vaginal 0.0% 0 69 47.3% 69 146
Cervical amputation 2.9% 2 69 2.1% 3 146
Abdominal 0.0% 0 69 51.4% 75 146
UI surgery 7.4% 5 68 16.8% 24 143
Prolapse repair 14.5% 10 69 57.5% 84 146
Anterior 10.1% 7 69 34.2% 50 146
Posterior 5.8% 4 69 25.3% 37 146
Anterior plus posterior 4.3% 3 69 17.1% 25 146
Vault 2.9% 2 69 15.8% 23 146
Unknown 1.4% 1 69 4.1% 6 146
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
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stage 2 (see Table 7). Using a more strict definition of prolapse (leading edge > 0 cm beyond the hymen),
77.0% of women had a prolapse beyond the hymen.
Prolapse symptoms at baseline
All women had at least one prolapse symptom on the Pelvic Organ Prolapse Symptom scale, the most common
of which was ‘a feeling of something coming down from or in (your) vagina’ (Table 79). Women who were
having a uterine prolapse repair had a lower prolapse symptom score (POP-SS of 12.8) and less bother from
their prolapse, based on their prolapse-related QoL score (6.5) than women who were having anterior or
posterior repair (see Tables 15 and 50) or vault repair (see Table 79). The principal individual prolapse symptom
was a feeling of ‘something coming down’. They were also less likely to need to use preventative manoeuvres
or extra hygiene measures to relieve their prolapse and other symptoms of pelvic floor dysfunction.
TABLE 78 Preoperative objective measures of prolapse: uterine/vault cohort (CC3)
POP-Q measurement/stage Uterine Vault
Number of women N= 69 N = 146
POP-Q measurement (cm)
Ba (anterior edge) 2.0 (2.3) 60 2.0 (2.4) 133
C (cervix/vault) 1.7 (3.1) 51 –0.4 (3.9) 133
Bp (posterior edge) 0.2 (2.9) 59 0.9 (2.6) 133
TVL 8.5 (1.3) 51 8.4 (1.9) 108
Overall POP-Q stage
0 0.0% 0 64 0.0% 0 139
1 4.7% 3 64 0.0% 0 139
2 37.5% 24 64 37.4% 52 139
3 43.8% 28 64 48.9% 68 139
4 14.1% 9 64 13.7% 19 139
2b, 3 or 4 77.0% 47 61 84.3% 113 134
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Prolapse
Ba, the leading edge of the anterior vaginal wall; Bp, the leading edge of the posterior vaginal wall; C, the leading edge of
the uterus/vault.
TABLE 79 Prolapse symptoms at baseline: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women N= 65 N= 137
POP-SS overall 12.8 (6.3) 61 15.3 (6.6) 136
Individual prolapse symptoms
SCD any 98.4% 60 61 96.3% 131 136
SCD freq. 70.5% 43 61 80.9% 110 136
Pain any 83.6% 51 61 86.8% 118 136
Pain freq. 31.1% 19 61 55.1% 75 136
Abdo. any 75.4% 46 61 82.4% 112 136
Abdo. freq. 26.2% 16 61 39.0% 53 136
Back any 62.3% 38 61 74.3% 101 136
Back freq. 31.1% 19 61 27.9% 38 136
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Urinary symptoms at baseline
Based on a variety of validated measures of assessing bladder function, women with uterine prolapse were
similar to the other groups of women who were having prolapse surgery on nearly every measure. In
particular, UI was just as prevalent, four in five women had any incontinence, and one in five had severe
symptoms (Table 80).
TABLE 79 Prolapse symptoms at baseline: uterine/vault cohort (CC3) (continued )
Symptom Uterine Vault
Strain blad. any 59.0% 36 61 73.5% 100 136
Strain blad. freq. 27.9% 17 61 34.6% 47 136
Blad. not empty any 82.0% 50 61 85.3% 116 136
Blad. not empty freq. 32.8% 20 61 42.6% 58 136
Bowel not empty any 68.9% 42 61 85.3% 116 136
Bowel not empty freq. 24.6% 15 61 33.8% 46 136
Other measures of prolapse symptoms
Symptoms (years) 5.2 (6.3) 57 3.9 (4.5) 127
Bother (years) 3.2 (3.4) 55 3.2 (3.8) 122
Number of women symptomatic 100.0% 61 61 100.0% 136 136
Prolapse-related QoL score 6.5 (3.0) 61 7.3 (2.8) 132
Actions necessitated by prolapse symptoms
Fingers to ease discomfort 17.5% 11 63 33.3% 42 126
Extra hygiene measures 49.2% 30 61 63.4% 83 131
Fingers to help empty bladder 8.2% 5 61 12.4% 16 129
Fingers to help empty bowel 1.6% 1 62 6.2% 8 130
Digital evacuation of bowel 3.2% 2 63 5.3% 7 133
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Individual prolapse symptoms
Abdo. any: ‘A heaviness or dragging feeling in your lower abdomen (tummy)?’ (any = occasionally or more); Abdo. freq.:
frequent =most or all of the time; Back any: ‘A heaviness or dragging feeling in your lower back?’ (any = occasionally or
more); Back freq.: frequent =most or all of the time.; Blad. not empty any: ‘A feeling that your bladder has not emptied
completely?’ (any = occasionally or more); Blad. not empty freq.; frequent =most or all of the time; Bowel not empty any:
‘A feeling that your bowel has not emptied completely? (any = occasionally or more); Bowel not empty freq.:
frequent =most or all of the time; Pain any: ‘An uncomfortable feeling or pain in your vagina which is worse when
standing?’ (any = occasionally or more); Pain freq.: frequent =most or all of the time; SCD any: ‘A feeling of something
coming down from or in your vagina?’ (any = occasionally or more); SCD freq.: frequent =most or all of the time; Strain
blad. any: ‘A need to strain (push) to empty your bladder?’ (any= occasionally or more); Strain blad. freq.: frequent =most
or all of the time.
Prolapse
POP-SS: range 0–28, where 0= no symptoms and 28= all seven symptoms all of the time; primary clinical outcome;
Prolapse-related QoL score: ‘Overall, how much do prolapse symptoms interfere with everyday life?’ – using a VAS, score
range from 0 (not at all) to 10 (a great deal); primary quality-of-life outcome. Symptomatic prolapse: at least one prolapse
symptom (POP-SS > 0).
Actions necessitated by prolapse symptoms
Digital evacuation of bowel: Do you have to insert a finger into your back passage to help empty stool (faeces, motion)
from your bowel? (most or all of the time). Extra hygiene measures: Do you have to take extra measures to ensure the
prolapse does not cause personal hygiene problems? (most or all of the time). Fingers to ease discomfort: Do you have to
insert a finger into your vagina to push up the prolapse to ease discomfort or pain? (most or all of the time). Fingers to help
empty bladder: Do you have to use your fingers to push up the prolapse to help empty your bladder (pass water)? (most or
all of the time). Fingers to help empty bowel: Do you have to insert a finger into your vagina to help empty your bowels?
(most or all of the time).
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Bowel symptoms at baseline
Women with uterine prolapse were similar with respect to most aspects of bowel function to those with
other types of prolapse. At least one-fifth had constipation and almost one-third had FI (Table 81). Passive
FI was much more common than active (FI accompanied by bowel urgency).
Vaginal and sexual symptoms at baseline
About two in five women were sexually active (Table 82). For those who did have a partner, the most
common reason for no sex life was their prolapse symptoms. Very few of the women (3.1%) had
dyspareunia (pain with intercourse) but the numbers were small.
Planned surgery and surgery actually carried out
Planned surgery
To be enrolled in CC3, women were clinically assessed as not needing an anterior or posterior repair. Only
three women were thought to need continence surgery (despite > 20% having severe UI; Table 83).
Surgery actually received
Although the women in this cohort were thought to have a uterine prolapse, only around 30% had a
vaginal hysterectomy. A total of 14.7% of uterine women had a hysterectomy with a concomitant vault
repair (see Table 83).
TABLE 80 Urinary symptoms at baseline: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women N= 65 N = 137
Any incontinence 77.8% 49 63 73.7% 98 133
ICIQ-UI-SF score 7.1 (5.8) 62 7.1 (6.1) 130
Severe incontinence 21.0% 13 62 23.8% 31 130
Incontinence QoL 3.8 (3.6) 57 3.8 (3.6) 124
Stress UI 21.4% 12 56 22.6% 26 115
Urgency UI 9.5% 6 63 13.0% 17 131
Overactive bladder 6.3% 4 63 7.8% 10 129
ICIQ-FLUTS filling score 5.0 (3.1) 62 6.0 (3.1) 127
ICIQ-FLUTS voiding score 3.4 (2.8) 62 3.4 (2.7) 130
ICIQ-FLUTS incontinence score 5.5 (4.1) 56 5.8 (4.3) 113
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Urinary symptoms
Any incontinence: Defined as ‘How often do you leak urine? (any frequency) and/or ‘How much urine do you usually leak?’
(whether you wear protection or not) (any amount); Incontinence-related quality-of-life score: ‘Overall, how much does
leaking urine interfere with your everyday life?’ – using a VAS, score range from 0 (not at all) to 10 (a great deal);
International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score: sum of responses to
above three questions – range 0 (no incontinence symptoms) to 21 (leaking all the time, a large amount and affecting
quality of life = 10); Overactive bladder, nocturia twice or more, and urinary urgency ‘most or all of the time’ and urinary
frequency nine or more times per day; Severe urinary incontinence: International Consultation on Incontinence
Questionnaire-Urinary Incontinence Short Form score of 13–21; Stress urinary incontinence, ‘Does urine leak when you are
physically active, exert yourself, cough or sneeze?’ (most or all of the time); Urgency urinary incontinence, ‘Does urine leak
before you can get to the toilet?’ (most or all of the time).
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Description of surgical characteristics and protocols
The majority of women with a uterine prolapse received surgery from a consultant gynaecologist (70.6%);
junior doctors were supervised in > 90% of cases (Table 84). Most women had a general anaesthetic,
received prophylactic antibiotics and were in theatre for approximately 2 hours. The mean length of stay
was > 2 days.
Outcomes for women who were having a uterine prolapse repair
Serious and related adverse effects in first and second years
The proportion of women who had at least one serious adverse effect in the first year (excluding mesh
complications) was 4.3% in the uterine group (three women had seven events; Table 85). One woman
had urinary tract symptoms in the second year. Five women also had at least one non-serious adverse
event in the first year (excluding mesh complications; Table 86).
Prolapse symptoms and EuroQol-5 Dimensions (3-level version)
At 6 months, the women’s report of their prolapse symptoms, using the POP-SS (maximum score 28),
fell from 12.8 (see Table 79) for the uterine group to 4.3 (Table 87). Similarly, each individual prolapse
symptom also improved (Table 88), as did the prolapse-related QoL scores (Table 87).
TABLE 81 Bowel symptoms at baseline: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women N= 65 N = 137
Bowel frequency
> 3 times a day 3.3% 2 61 5.2% 7 134
1–3 times a day 34.4% 21 61 31.3% 42 134
About once a day 34.4% 21 61 41.0% 55 134
Once every 2–3 days 21.3% 13 61 19.4% 26 134
Weekly or less 6.6% 4 61 3.0% 4 134
Constipation 21.0% 13 62 25.4% 33 130
Bowel urgency 7.9% 5 63 11.9% 16 134
Any FI 31.7% 20 63 32.6% 43 132
Passive FI 75.0% 15 20 69.8% 30 43
Active FI 25.0% 5 20 30.2% 13 43
Severe FI 4.8% 3 63 11.4% 15 132
Bowel symptoms QoL 2.9 (3.3) 62 3.4 (3.3) 133
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Bowel symptoms
Active faecal incontinence: Any faecal incontinence when bowel urgency ‘most or all of the time’ is also reported; Bowel
symptoms QoL score: ‘Overall, how much do bowel symptoms interfere with your everyday life?’ – measured using a VAS,
score range from 0 (not at all) to 10 (a great deal); this could be due to any one or a combination of the above bowel
symptoms. Bowel urgency: ‘Do you have to rush to the toilet when you need to open (move) your bowels?’ (most or all of
the time); Constipation (ROME criteria, adapted): any two of stool passing once a week or less, straining most or all of the
time, hard stools, bowel not feeling empty most or all of the time, manual manoeuvre to empty bowel most or all of the
time. Faecal incontinence (any/severe): faecal incontinence of solid or liquid stool – ‘Do stools (faeces, motion) leak at
inappropriate time or place, or before you can get to the toilet?’ (any= occasionally or more often; severe = sometimes,
most or all of the time); Passive faecal incontinence: any faecal incontinence not accompanied by bowel urgency ‘most or
all of the time’.
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At 1 year, this improvement was maintained (POP-SS of 5.2 for the uterine group; see Table 87).
The improvement from baseline was supported by data from individual prolapse symptoms (measured as
occurring ‘ever’ or ‘most or all of the time’); the proportion of women who had at least one prolapse
symptom (‘symptomatic’); QoL data based on the interference of prolapse symptoms on everyday life; the
generic QoL measure EQ-5D-3L; and the need to undertake extra hygiene measures or manoeuvres to
assist pelvic floor functions (see Tables 88 and 89). All of these measures demonstrated significant
improvements from before surgery.
The improvement at 1 year was maintained at 2 years, with respect to all the prolapse outcomes and QoL
outcomes measured.
Urinary symptoms
Detailed information on urinary symptoms was obtained at baseline, 1 year and 2 years (see Tables 80 and
90). The number of women who had concomitant continence surgery was 3 of 69 in the uterine group
(see Table 83).
At 1 year in the uterine group, the proportion of women who had any UI decreased from 77.8% to
65.2% (see Tables 80 and 90), and the proportion with severe UI more than halved (from 21% to 6.7%).
There were similar moderate improvements in all the other measures of bladder function measured.
TABLE 82 Vaginal and sexual symptoms at baseline: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women n= 65 n= 137
Vaginal
ICIQ-VS score 23.6 (9.6) 56 24.5 (10.4) 115
Vaginal symptoms QoL score 5.1 (3.5) 59 5.4 (3.6) 128
Vagina too tight 3.3% 2 60 3.2% 4 125
Sexual
Sex life at present (yes) 41.0% 25 61 32.8% 44 134
Reason for no sex life
No partner 44.4% 16 36 32.2% 29 90
Vaginal symptoms 5.6% 2 36 2.2% 2 90
Prolapse symptoms 36.1% 13 36 46.7% 42 90
Other reason 8.3% 3 36 14.4% 13 90
Reason not given 5.6% 2 36 4.4% 4 90
Dyspareunia 3.1% 1 32 14.8% 9 61
Sexual Matters Score 21.1 (14.1) 30 24.4 (15.5) 59
Sex life QoL score 6.4 (3.5) 37 6.9 (3.4) 77
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Vaginal and sexual symptoms
Dyspareunia (any, severe): pain during sexual intercourse (any = a little or somewhat; severe = a lot); Dyspareunia at baseline:
denominator includes number of women who were sexually active and those who did not have a sex life because of
prolapse symptoms. International Consultation on Incontinence vaginal symptoms score: combination of responses to vaginal
symptom questions; Sex life quality of life: ‘Overall, how much do you feel that your sex life has been spoilt by vaginal
symptoms?’ – measured using a VAS, score range from 0 (not at all) to 10 (a great deal); Vagina too tight: ‘Do you feel that
your vagina is too tight? (most or all of the time); Vaginal symptoms QoL score: ‘Overall, how much do your vaginal
symptoms interfere with your everyday life?’ – measured using a VAS, score range from 0 (not at all) to 10 (a great deal).
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TABLE 83 Planned surgery and surgery actually carried out: uterine/vault cohort (CC3)
Type of surgery Uterine Vault
Number of women N= 69 N= 146
Planned prolapse surgery
Anterior repair 0.0% 0 69 0.0% 0 146
Posterior repair 0.0% 0 69 0.0% 0 146
Anterior and posterior repair 0.0% 0 69 0.0% 0 146
Upper compartment repair only 100.0% 69 69 100.0% 146 146
Concomitant prolapse surgery
Vaginal hysterectomy 31.9% 22 69 0.0% 0 146
Abdominal hysterectomy 5.8% 4 69 0.7% 1 146
Cervical amputation 4.3% 3 69 0.7% 1 146
Vault repair 72.5% 50 69 99.3% 145 146
Concomitant UI surgery 4.3% 3 69 4.1% 6 146
Surgery actually received
Anterior repair only 10.3% 7 68 2.8% 4 144
Posterior repair only 4.4% 3 68 1.4% 2 144
Anterior and posterior repair 2.9% 2 68 2.1% 3 144
Neither 82.4% 56 68 93.8% 135 144
Vaginal hysterectomy 29.4% 20 68 0.0% 0 144
Vault repair 14.7% 10 68 89.6% 129 144
Continence surgery 4.4% 3 68 3.5% 5 144
Dichotomous variables are presented as ‘% n N’.
TABLE 84 Description of surgical characteristics and protocols: uterine/vault cohort (CC3)
Surgical characteristic Uterine Vault
Number of women N= 68 N= 144
Grade of gynaecologist
Consultant 70.6% 48 68 78.3% 112 143
Specialty doctor 0 68 1.4% 2 143
Specialty doctor supervised N/A 0 0 100.0% 2 2
Registrar/junior 29.4% 20 68 20.3% 29 143
Specialty doctor supervised 94.4% 17 18 89.7% 26 29
Type of anaesthetic
General 86.8% 59 68 93.7% 134 143
Spinal 14.7% 10 68 6.3% 9 143
Local 1.5% 1 68 5.6% 8 143
Prophylactic antibiotic 92.6% 63 68 98.6% 139 141
Estimated blood loss (ml) 246.9 (353.6) 54 52.9 (62.7) 106
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TABLE 84 Description of surgical characteristics and protocols: uterine/vault cohort (CC3) (continued )
Surgical characteristic Uterine Vault
Duration (minutes) 121.8 (44.1) 67 131.9 (47.2) 142
Vaginal pack inserted 51.5% 34 66 15.7% 22 140
Catheter inserted 98.5% 65 66 99.3% 142 143
Suprapubic 1.5% 1 65 1.4% 2 142
Urethral 98.5% 64 65 98.6% 140 142
Both 0.0% 0 65 0.0% 0 142
Length of stay (days) 2.4 (3.3) 68 1.8 (1.5) 143
N/A, not applicable.
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
TABLE 85 Serious and related adverse effects in years 1 and 2: uterine/vault cohort (CC3)
Adverse effect Uterine Vault
Number of women in first year N= 69 N= 146
Intraoperative
Injury to organs 0.0% 0 69 0.7% 1 146
Excess blood loss 1.4% 1 69 0.0% 0 146
Blood transfusion 2.9% 2 69 0.0% 0 146
Anaesthetic complications 0.0% 0 69 0.7% 1 146
Death 0.0% 0 69 0.0% 0 146
Postoperative
Thrombosis 0.0% 0 69 0.0% 0 146
Infection 1.4% 1 69 0.0% 0 146
Pain 0.0% 0 69 0.7% 1 146
Urinary retention 0.0% 0 69 0.0% 0 146
Bowel obstruction 0.0% 0 69 0.7% 1 146
Constipation 1.4% 1 69 0.0% 0 146
Excess blood loss 2.9% 2 69 0.0% 0 146
Vaginal adhesions 0.0% 0 69 0.0% 0 146
Haematoma 0.0% 0 69 0.0% 0 146
Skin tags 0.0% 0 69 0.0% 0 146
Granulation tissue 0.0% 0 69 0.0% 0 146
Urinary tract symptoms 0.0% 0 69 0.0% 0 146
Death 0.0% 0 69 0.0% 0 146
Number of women with any
serious complication in first year
4.3% 3 69 2.7% 4 146
Number of women in second year N= 69 N= 146
Thrombosis 0.0% 0 69 0.0% 0 146
Infection 0.0% 0 69 0.7% 1 146
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TABLE 85 Serious and related adverse effects in years 1 and 2: uterine/vault cohort (CC3) (continued )
Adverse effect Uterine Vault
Pain 0.0% 0 69 0.7% 1 146
Urinary retention 0.0% 0 69 0.0% 0 146
Bowel obstruction 0.0% 0 69 0.0% 0 146
Constipation 0.0% 0 69 0.0% 0 146
Excess blood loss 0.0% 0 69 0.0% 0 146
Vaginal adhesions 0.0% 0 69 0.0% 0 146
Haematoma 0.0% 0 69 0.0% 0 146
Skin tags 0.0% 0 69 0.0% 0 146
Granulation tissue 0.0% 0 69 0.0% 0 146
Urinary tract symptoms 1.4% 1 69 0.0% 0 146
Death 0.0% 0 69 0.0% 0 146
Number of women with any
serious complication in second
year
1.4% 1 69 0.7% 1 146
N/A, not applicable.
Dichotomous variables are presented as ‘% n N’.
Serious: Causing death, requiring hospitalisation or prolongation of existing hospital admission, threatening life, resulting in
significant incapacity or disability, or otherwise considered important by the investigator.
TABLE 86 Other related adverse effects in years 1 and 2: uterine/vault cohort (CC3)
Adverse effect Uterine Vault
Number of women in first year N= 69 N= 146
Intraoperative
Injury to organs 0.0% 0 69 1.4% 2 146
Excess blood loss 0.0% 0 69 0.0% 0 146
Blood transfusion 1.4% 1 69 0.0% 0 146
Anaesthetic complications 0.0% 0 69 0.0% 0 146
Postoperative
Thrombosis 0.0% 0 69 0.0% 0 146
Infection 0.0% 0 69 1.4% 2 146
Pain 0.0% 0 69 0.7% 1 146
Urinary retention 0.0% 0 69 0.0% 0 146
Bowel obstruction 0.0% 0 69 0.0% 0 146
Constipation 0.0% 0 69 0.0% 0 146
Excess blood loss 0.0% 0 69 0.0% 0 146
Vaginal adhesions 0.0% 0 69 0.0% 0 146
Haematoma 0.0% 0 69 0.0% 0 146
Skin tags 0.0% 0 69 0.0% 0 146
Granulation tissue 0.0% 0 69 0.0% 0 146
Urinary tract symptoms 0.0% 0 69 0.0% 0 146
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TABLE 86 Other related adverse effects in years 1 and 2: uterine/vault cohort (CC3) (continued )
Adverse effect Uterine Vault
Death 0.0% 0 69 0.0% 0 146
Number of women with any
complication in first year
1.4% 1 69 2.7% 4 146
Number of women in second year N= 69 N= 146
Thrombosis 0.0% 0 69 0.0% 0 146
Infection 0.0% 0 69 0.7% 1 146
Pain 0.0% 0 69 0.0% 0 146
Urinary retention 0.0% 0 69 0.0% 0 146
Bowel obstruction 0.0% 0 69 0.0% 0 146
Constipation 0.0% 0 69 0.0% 0 146
Excess blood loss 0.0% 0 69 0.0% 0 146
Vaginal adhesions 0.0% 0 69 0.0% 0 146
Haematoma 0.0% 0 69 0.0% 0 146
Skin tags 0.0% 0 69 0.0% 0 146
Granulation tissue 0.0% 0 69 0.0% 0 146
Urinary tract symptoms 0.0% 0 69 0.0% 0 146
Death 0.0% 0 69 0.0% 0 146
Number of women with any other
complication in second year
0.0% 0 69 0.7% 1 146
Dichotomous variables are presented as ‘% n N’.
TABLE 87 Prolapse symptoms at 6 months, 1 year and 2 years: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women at 6 months N= 54 N= 121
POP-SS at 6 months 4.3 (4.7) 53 5.8 (6.2) 120
Number of women symptomatic 81.1% 43 53 82.5% 99 120
Prolapse-related QoL score 2.4 (3.1) 50 2.8 (3.4) 119
Number of women at 1 year N= 57 N= 116
POP-SS (overall score at 1 year) 5.2 (5.5) 55 5.5 (5.8) 115
Number of women symptomatic 83.6% 46 55 80.0% 92 115
Prolapse-related QoL score 2.4 (3.2) 53 2.5 (3.3) 113
Number of women at 2 years N= 48 N= 104
POP-SS (overall score at 2 years) 5.3 (5.9) 47 5.6 (5.7) 104
Number of women symptomatic 80.9% 38 47 79.8% 83 104
Prolapse-related QoL score 1.9 (3.0) 45 2.3 (2.9) 104
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Prolapse
POP-SS: range 0–28, where 0= no symptoms and 28 = all seven symptoms all of the time; primary clinical outcome.
Prolapse-related QoL score: ‘Overall, how much do prolapse symptoms interfere with everyday life?’ – using a VAS, score
range from 0 (not at all) to 10 (a great deal); primary quality-of-life outcome. Symptomatic prolapse: at least one prolapse
symptom (POP-SS > 0).
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TABLE 88 Individual prolapse symptoms at 6 months, 1 year and 2 years: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women at 6 months N= 54 N= 121
SCD any 24.5% 13 53 30.0% 36 120
SCD freq. 7.5% 4 53 11.7% 14 120
Pain any 20.8% 11 53 25.0% 30 120
Pain freq. 5.7% 3 53 8.3% 10 120
Abdo any 34.0% 18 53 37.5% 45 120
Abdo freq. 0.0% 0 53 7.5% 9 120
Back any 35.8% 19 53 36.7% 44 120
Back freq. 3.8% 2 53 7.5% 9 120
Strain blad. any 34.0% 18 53 30.8% 37 120
Strain blad. freq. 5.7% 3 53 10.0% 12 120
Blad. not empty any 49.1% 26 53 58.3% 70 120
Blad. not empty freq. 7.5% 4 53 19.2% 23 120
Bowel not empty any 50.9% 27 53 70.8% 85 120
Bowel not empty freq. 7.5% 4 53 19.2% 23 120
Actions necessitated by prolapse symptoms
Fingers to ease discomfort N/A N/A N/A N/A N/A N/A
Extra hygiene measures N/A N/A N/A N/A N/A N/A
Fingers to help empty bladder N/A N/A N/A N/A N/A N/A
Fingers to help empty bowel N/A N/A N/A N/A N/A N/A
Digital evacuation of bowel N/A N/A N/A N/A N/A N/A
Number of women at 1 year N= 57 N= 116
POP-SS (overall score at 1 year) 5.2 (5.5) 55 5.5 (5.8) 115
SCD any 29.1% 16 55 32.2% 37 115
SCD freq. 12.7% 7 55 13.9% 16 115
Pain any 30.9% 17 55 26.1% 30 115
Pain freq. 3.6% 2 55 7.0% 8 115
Abdo any 30.9% 17 55 33.0% 38 115
Abdo freq. 9.1% 5 55 7.0% 8 115
Back any 36.4% 20 55 39.1% 45 115
Back frequent 7.3% 4 55 9.6% 11 115
Strain blad. any 29.1% 16 55 32.2% 37 115
Strain blad. freq. 5.5% 3 55 7.0% 8 115
Blad. not empty any 49.1% 27 55 56.5% 65 115
Blad. not empty freq. 12.7% 7 55 13.0% 15 115
Bowel not empty any 60.0% 33 55 66.1% 76 115
Bowel not empty freq. 12.7% 7 55 13.0% 15 115
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TABLE 88 Individual prolapse symptoms at 6 months, 1 year and 2 years: uterine/vault cohort (CC3) (continued )
Symptom Uterine Vault
Actions necessitated by prolapse symptoms
Fingers to ease discomfort 2.4% 1 42 0.0% 0 110
Extra hygiene measures 7.1% 3 42 8.4% 9 107
Fingers to help empty bladder 0.0% 0 46 0.9% 1 109
Fingers to help empty bowel 0.0% 0 44 1.9% 2 108
Digital evacuation of bowel 4.3% 2 46 4.6% 5 109
Number of women at 2 years N= 48 N= 104
SCD any 38.3% 18 47 36.5% 38 104
SCD freq. 12.8% 6 47 8.7% 9 104
Pain any 21.3% 10 47 23.1% 24 104
Pain freq. 2.1% 1 47 2.9% 3 104
Abdo any 27.7% 13 47 34.6% 36 104
Abdo freq. 4.3% 2 47 5.8% 6 104
Back any 36.2% 17 47 43.3% 45 104
Back frequent 10.6% 5 47 10.6% 11 104
Strain blad. any 38.3% 18 47 38.5% 40 104
Strain blad. freq. 12.8% 6 47 9.6% 10 104
Blad. not empty any 57.4% 27 47 55.8% 58 104
Blad. not empty freq. 17.0% 8 47 13.5% 14 104
Bowel not empty any 61.7% 29 47 69.2% 72 104
Bowel not empty freq. 17.0% 8 47 13.5% 14 104
Actions necessitated by prolapse symptoms
Fingers to ease discomfort 0.0% 0 47 2.0% 2 101
Extra hygiene measures 10.6% 5 47 6.9% 7 101
Fingers to help empty bladder 0.0% 0 48 2.0% 2 102
Fingers to help empty bowel 2.1% 1 48 2.0% 2 102
Digital evacuation of bowel 2.1% 1 48 2.9% 3 102
N/A, not applicable.
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Individual prolapse symptoms
Abdo. any: ‘A heaviness or dragging feeling in your lower abdomen (tummy)?’ (any= occasionally or more); Abdo. freq.:
frequent=most or all of the time; Back any: ‘A heaviness or dragging feeling in your lower back?’ (any= occasionally or
more); Back freq.: frequent=most or all of the time; Blad. not empty any: ‘A feeling that your bladder has not emptied
completely?’ (any= occasionally or more); Blad. not empty freq.; frequent=most or all of the time; Bowel not empty any: ‘A
feeling that your bowel has not emptied completely?’ (any= occasionally or more); Bowel not empty freq.: frequent=most or
all of the time; Pain any: ‘An uncomfortable feeling or pain in your vagina which is worse when standing?’ (any= occasionally
or more); Pain freq.: frequent=most or all of the time; SCD any: ‘A feeling of something coming down from or in your
vagina?’ (any= occasionally or more); SCD freq.: frequent=most or all of the time; Strain blad. any: ‘A need to strain (push)
to empty your bladder?’ (any= occasionally or more); Strain blad. freq.: frequent=most or all of the time.
Actions necessitated by prolapse symptoms
Digital evacuation of bowel: Do you have to insert a finger into your back passage to help empty stool (faeces, motion)
from your bowel? (most or all of the time). Extra hygiene measures: Do you have to take extra measures to ensure the
prolapse does not cause personal hygiene problems? (most or all of the time). Fingers to ease discomfort: Do you have to
insert a finger into your vagina to push up the prolapse to ease discomfort or pain? (most or all of the time). Fingers to help
empty bladder: Do you have to use your fingers to push up the prolapse to help empty your bladder (pass water)? (most or
all of the time). Fingers to help empty bowel: Do you have to insert a finger into your vagina to help empty your bowels?
(most or all of the time).
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TABLE 89 EuroQol-5 Dimensions (3-level version) at 1 year: uterine/vault cohort (CC3)
EQ-5D-3L Uterine Vault
Number of women at 6 months N= 54 N= 121
Score 0.83 (0.22) 54 0.79 (0.27) 115
Number of women at 1 year N= 57 N= 116
Score 0.83 (0.26) 57 0.78 (0.27) 112
Number of women at 2 years N= 48 N= 104
Score 0.79 (0.28) 48 0.80 (0.31) 104
Continuous variables are presented as ‘mean (SD) N’.
TABLE 90 Urinary symptoms at 1 year and 2 years: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women at 1 year N = 46 N = 112
Any incontinence 65.2% 30 46 68.5% 76 111
ICIQ-UI-SF score 4.7 (4.4) 45 5.0 (5.1) 108
Severe incontinence 6.7% 3 45 8.3% 9 108
Incontinence-related QoL score 2.1 (2.8) 45 2.0 (2.7) 106
Stress UI 17.9% 7 39 18.3% 17 93
Urgency UI 0.0% 0 46 0.9% 1 109
Overactive bladder 2.2% 1 46 0.9% 1 106
ICIQ-FLUTS filling score 3.5 (2.4) 46 4.2 (2.3) 106
ICIQ-FLUTS voiding score 1.5 (1.8) 46 1.7 (2.4) 108
ICIQ-FLUTS incontinence score 4.6 (3.0) 38 4.8 (4.0) 92
Number of women at 2 years N= 48 N = 104
Any incontinence 64.6% 31 48 65.4% 68 104
ICIQ-UI-SF score 4.7 (4.8) 46 4.5 (5.0) 103
Severe incontinence 8.7% 4 46 7.8% 8 103
Incontinence-related QoL score 1.9 (2.6) 46 1.8 (2.7) 98
Stress UI 17.1% 7 41 17.2% 15 87
Urgency UI 6.4% 3 47 2.9% 3 102
Overactive bladder 4.3% 2 46 2.0% 2 102
ICIQ-FLUTS filling score 4.0 (3.0) 46 4.1 (2.5) 102
ICIQ-FLUTS voiding score 1.7 (2.5) 48 1.7 (2.2) 102
ICIQ-FLUTS incontinence score 4.7 (3.5) 39 4.9 (4.3) 87
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Urinary symptoms
Any incontinence: Defined as ‘How often do you leak urine?’ (any frequency) and/or ‘How much urine do you usually
leak?’ (whether you wear protection or not) (any amount); Incontinence-related quality-of-life score: ‘Overall, how much
does leaking urine interfere with your everyday life?’ – using a VAS, score range from 0 (not at all) to 10 (a great deal);
International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score: sum of responses to
above three questions – range 0 (no incontinence symptoms) to 21 (leaking all the time, a large amount and affecting
quality of life= 10); Overactive bladder, nocturia twice or more, and urinary urgency ‘most or all of the time’ and urinary
frequency nine or more times per day; Severe urinary incontinence: International Consultation on Incontinence
Questionnaire-Urinary Incontinence Short Form score of 13–21; Stress urinary incontinence, ‘Does urine leak when you are
physically active, exert yourself, cough or sneeze?’ (most or all of the time); Urgency urinary incontinence, ‘Does urine leak
before you can get to the toilet?’ (most or all of the time).
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The improvement at 1 year was maintained at 2 years, with respect to all the urinary outcomes and
bladder-related QoL outcomes measured (Table 90).
Bowel symptoms
Detailed information on bowel symptoms was obtained at baseline, 1 year and 2 years (see Tables 81 and
91). Frequency of bowel movements, constipation, bowel urgency and FI were common and largely
unchanged from baseline to after prolapse surgery in the uterine group at both 1 year and 2 years
(Table 91).
Vaginal and sexual symptoms
Detailed information on vaginal and sexual symptoms was obtained at baseline, 1 year and 2 years (see
Tables 82 and 92). Both the mean vaginal symptom score and the QoL score decreased (improved) after
prolapse surgery, and this was maintained at 2 years (Table 92). More women were sexually active after
surgery, and many fewer cited prolapse symptoms as a reason for not having a sex life (reduced from
36.1% to 12.0%). This was reflected in a more than halving of the ICI Sexual Matters score, and a
reduction (improvement) to one-third of baseline levels in the sex life QoL score (see Tables 82 and 92).
These improvements were maintained at 2 years.
Further treatment required for failure or adverse effects at 6 months, 1 year
and 2 years
When women reported, at 6 months or later, that they had been readmitted to hospital, we verified the
information by enquiry from site staff when necessary and post-coded the corrected information. A
hospital readmission was automatically counted as a SAE if it was related to the initial prolapse surgery.
Repeat surgery for recurrence of prolapse (failure if same compartment, de novo if in the opposite
compartment), or for continence surgery, was differentiated from readmission for related complications
such as bleeding, infection and surgery for mesh removal.
The overall rate of readmission was low (two women in the uterine group in the first 6 months; Table 93).
Admissions in the first 6 months were related to adverse effects (pain). After that time, one woman had
further surgery for prolapse in a different compartment, and one in the second year (see Table 93).
No women required surgery for mesh removal at any time point.
Few women required other treatment – such as pessaries or physiotherapy – for symptoms.
Satisfaction with treatment at 1 year and 2 years
Although most women were better than before surgery by 1 year, around 10% (four women) were worse,
with similar findings at 2 years (Table 94). This was reflected in the satisfaction rates and in the proportion
of women who would recommend surgery to a friend.
Vault prolapse: women requiring a prolapse repair for vault
descent alone
Women’s characteristics at baseline
The mean age of women presenting with a vault prolapse alone was 62.5 years (see Table 77). This is
older than the women who were having primary or uterine-only surgery in PROSPECT (see Table 5).
However, the groups were generally all similar on other characteristics, such as parity, BMI and delivery
mode history.
About one-third of the women with a vault prolapse had seen a physiotherapist, and about 1 in 10 were
using a pessary for prolapse symptoms (see Table 77). One in five women had seen a physiotherapist for
urine symptoms and around 1 in 10 had used drugs for urinary problems.
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TABLE 91 Bowel symptoms at 1 year and 2 years: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women at 1 year N= 46 N= 112
Bowel frequency
≥ 4 times a day 2.2% 1 46 0.9% 1 110
1–3 times a day 30.4% 14 46 30.0% 33 110
About once a day 43.5% 20 46 48.2% 53 110
Once every 2 or 3 days 21.7% 10 46 16.4% 18 110
Weekly or less 2.2% 1 46 4.5% 5 110
Constipation 21.7% 10 46 17.6% 19 108
Bowel urgency 2.2% 1 46 10.8% 12 111
FI (any) 23.9% 11 46 36.0% 40 111
Passive FI 100.0% 11 11 70.0% 28 40
Active FI 0.0% 0 11 30.0% 12 40
Severe FI 6.5% 3 46 13.5% 15 111
Bowel symptoms QoL score 1.8 (3.1) 46 2.3 (2.9) 110
Number of women at 2 years N= 48 N= 104
Bowel frequency
≥ 4 times a day 0.0% 0 47 3.9% 4 103
1–3 times a day 25.5% 12 47 26.2% 27 103
About once a day 55.3% 26 47 47.6% 49 103
Once every 2 or 3 days 17.0% 8 47 19.4% 20 103
Weekly or less 2.1% 1 47 2.9% 3 103
Constipation 10.6% 5 47 19.2% 20 104
Bowel urgency 6.3% 3 48 3.9% 4 103
FI (any) 29.2% 14 48 37.9% 39 103
Passive FI 85.7% 12 14 87.2% 34 39
Active FI 14.3% 2 14 10.3% 4 39
Severe FI 10.4% 5 48 10.7% 11 103
Bowel symptoms QoL score 2.2 (3.2) 46 2.3 (2.9) 101
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Bowel symptoms
Active faecal incontinence: Any faecal incontinence when bowel urgency ‘most or all of the time’ is also reported; Bowel
symptoms QoL score: ‘Overall, how much do bowel symptoms interfere with your everyday life?’ – measured using a VAS,
score range from 0 (not at all) to 10 (a great deal); this could be due to any one or a combination of the above bowel
symptoms. Bowel urgency: ‘Do you have to rush to the toilet when you need to open (move) your bowels?’ (most or all of
the time); Constipation (ROME criteria, adapted): any two of stool passing once a week or less, straining most or all of the
time, hard stools, bowel not feeling empty most or all of the time, manual manoeuvre to empty bowel most or all of the
time. Faecal incontinence (any/severe): faecal incontinence of solid or liquid stool – ‘Do stools (faeces, motion) leak at
inappropriate time or place, or before you can get to the toilet?’ (any= occasionally or more often; severe = sometimes,
most or all of the time); Passive faecal incontinence: any faecal incontinence not accompanied by bowel urgency ‘most or
all of the time’.
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TABLE 92 Vaginal and sexual symptoms at 1 year: uterine/vault cohort (CC3)
Symptom Uterine Vault
Number of women at 1 year N= 46 N = 112
Vaginal
ICIQ-VS score 8.2 (10.5) 41 7.2 (7.8) 97
Vaginal symptoms QoL score 2.0 (3.2) 43 1.8 (2.7) 105
Vagina too tight 2.3% 1 43 1.0% 1 104
Sexual
Sex life at present 46.8% 22 47 36.9% 41 111
Reason for no sex life
No partner 48.0% 12 25 40.0% 28 70
Vaginal symptoms 4.0% 1 25 4.3% 3 70
Prolapse symptoms 12.0% 3 25 7.1% 5 70
Other reason 28.0% 7 25 42.9% 30 70
Reason not given 8.0% 2 25 5.7% 4 70
Dyspareunia 8.3% 2 24 4.7% 2 43
ICI Sexual Matters score 11.0 (14.1) 24 10.8 (12.5) 42
Sex life QoL score 3.2 (3.7) 25 2.6 (3.3) 43
Number of women at 2 years N= 48 N = 104
Vaginal
ICIQ-VS score 7.8 (8.2) 46 7.9 (8.6) 96
Vaginal symptoms QoL score 1.7 (2.6) 46 1.8 (2.8) 98
Vagina too tight 2.1% 1 48 2.0% 2 98
Sexual
Sex life at present 47.9% 23 48 43.4% 43 99
Reason for no sex life
No partner 52.0% 13 25 30.4% 17 56
Vaginal symptoms 0.0% 0 25 5.4% 3 56
Prolapse symptoms 8.0% 2 25 5.4% 3 56
Other reason 20.0% 5 25 44.6% 25 56
Reason not given 20.0% 5 25 14.3% 8 56
Dyspareunia 8.3% 2 24 2.3% 1 44
ICI Sexual Matters score 13.3 (13.9) 23 9.5 (11.4) 43
Sex life QoL score 2.8 (3.2) 25 2.4 (3.2) 46
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Vaginal and sexual symptoms
Dyspareunia (any, severe): pain during sexual intercourse (any= a little or somewhat; severe = a lot); International
Consultation on Incontinence vaginal symptoms score: combination of responses to vaginal symptom questions; Sex life
quality of life: ‘Overall, how much do you feel that your sex life has been spoilt by vaginal symptoms?’ – measured using a
VAS, score range from 0 (not at all) to 10 (a great deal); Vagina too tight: ‘Do you feel that your vagina is too tight?’ (most
or all of the time); Vaginal symptoms QoL score: ‘Overall, how much do your vaginal symptoms interfere with your everyday
life?’ – measured using a VAS, score range from 0 (not at all) to 10 (a great deal).
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TABLE 93 Further treatment required at 6 months, 1 year and 2 years: uterine/vault cohort (CC3)
Further treatment Uterine Vault
Number of women at 6 months N= 54 N= 121
Readmitted (0–6 months)a 3.7% 2 54 1.7% 2 121
Number of women at 1 year N= 57 N= 116
Readmitted (6–12 months)b 0.0% 0 57 0.9% 1 116
New prolapse surgery 1.8% 1 57 4.3% 5 116
Same compartment 0.0% 0 57 1.7% 2 116
Different compartment 1.8% 1 57 2.6% 3 116
Waiting for prolapse surgery 0.0% 0 57 2.6% 3 116
Continence surgery 0.0% 0 57 0.0% 0 116
Waiting for continence surgery 0.0% 0 57 0.9% 1 116
Stitches removed since operation 0.0% 0 56 1.8% 2 114
Mesh complication 0.0% 0 57 0.0% 0 116
Treatment for urinary problems
Pads 28.6% 16 56 38.6% 44 114
Permanent catheter 1.8% 1 56 0.9% 1 107
Intermittent catheter 3.6% 2 56 1.8% 2 109
Drugs for UI 3.5% 2 57 10.3% 12 116
Treatment for prolapse
Medicines for prolapse 12.5% 7 56 20.4% 23 113
Oestrogens 17.5% 10 57 16.4% 19 116
Ring pessary 1.8% 1 57 2.6% 3 116
Shelf pessary 0.0% 0 57 0.0% 0 116
Physiotherapy 12.5% 7 56 9.1% 10 110
GP for prolapse 17.5% 10 57 21.3% 23 108
Practice nurse for prolapse 8.9% 5 56 2.7% 3 110
GOPD to see gynaecologist 41.8% 23 55 45.5% 50 110
Number of women at 2 years N= 48 N= 104
Readmitted (12–24 months)c 2.1% 1 48 0.0% 0 104
New prolapse surgery 2.1% 1 48 4.8% 5 104
Same compartment 0.0% 0 48 1.0% 1 104
Different compartment 2.1% 1 48 3.8% 4 104
Waiting for prolapse surgery 0.0% 0 48 0.0% 0 104
Continence surgery 0.0% 0 48 3.8% 4 104
Waiting for continence surgery 0.0% 0 48 0.0% 0 104
Stitches removed since operation 0.0% 0 46 1.0% 1 100
Mesh complication 0.0% 0 48 0.0% 0 104
Surgical removal in theatre 0.0% 0 48 0.0% 0 104
Conservative/GOPD procedure 0.0% 0 48 0.0% 0 104
continued
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TABLE 93 Further treatment required at 6 months, 1 year and 2 years: uterine/vault cohort (CC3) (continued )
Further treatment Uterine Vault
Treatment for urinary problems at 2 years
Pads 31.3% 15 48 32.4% 33 102
Permanent catheter 0.0% 0 48 1.0% 1 101
Intermittent catheter 0.0% 0 47 0.0% 0 102
Drugs for UI 8.3% 4 48 10.6% 11 104
Treatment for prolapse in year 2
Medicines for prolapse 8.3% 4 48 11.8% 12 102
Oestrogens 8.3% 4 48 16.3% 17 104
Ring pessary 4.2% 2 48 1.9% 2 104
Shelf pessary 2.1% 1 48 1.9% 2 104
Physiotherapy 10.9% 5 46 6.7% 7 104
GP for prolapse 21.3% 10 47 11.7% 12 103
Practice nurse for prolapse 6.4% 3 47 1.0% 1 102
GOPD to see gynaecologist 21.3% 10 47 13.6% 14 103
GOPD, Gynaecology Outpatients Department.
a Reasons for readmission (0–6 months): infection (1), other (3).
b Reasons for readmission (6–12 months): infection (1).
c Reasons for readmission (12–24 months): constipation (1).
Dichotomous variables are presented as ‘% n N’.
TABLE 94 Participant recovery and satisfaction: uterine/vault cohort (CC3)
Recovery/satisfaction Uterine Vault
Number of women at 1 year N= 46 N= 112
Time to recovery (months) 2.8 (1.5) 40 3.4 (2.2) 101
Comparison of prolapse with before surgery
Very much better 65.9% 27 41 64.7% 66 102
Much better 19.5% 8 41 18.6% 19 102
A little better 4.9% 2 41 4.9% 5 102
No change 0.0% 0 41 3.9% 4 102
A little worse 4.9% 2 41 2.9% 3 102
Much worse 2.4% 1 41 2.0% 2 102
Very much worse 2.4% 1 41 2.9% 3 102
Satisfaction with surgery
Completely satisfied 63.4% 26 41 57.5% 61 106
Fairly satisfied 19.5% 8 41 26.4% 28 106
Fairly dissatisfied 4.9% 2 41 6.6% 7 106
Very dissatisfied 9.8% 4 41 6.6% 7 106
Not sure 2.4% 1 41 2.8% 3 106
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Preoperative prolapse measurements
The leading edge of the upper compartment (point C on the POP-Q) was, on average, just inside the
hymen (–0.4 cm for vault prolapse; see Table 78). The majority of women had stage 3 or 4 prolapse, unlike
those having only an anterior or posterior repair, for whom the most common preoperative stage was
stage 2 (see Table 7). Using a more strict definition of prolapse (leading edge > 0 cm beyond the hymen),
84.3% of women had a prolapse beyond the hymen.
Prolapse symptoms at baseline
All women had at least one prolapse symptom on the Pelvic Organ Prolapse Symptom scale, the most
common of which was ‘a feeling of something coming down from or in (your) vagina’ (see Table 79).
Women who were having a vault prolapse repair had a higher prolapse symptom score (POP-SS of 15.3)
and more bother from their prolapse, based on their prolapse-related QoL score (7.3) than women who
were having anterior or posterior repair (see Tables 15 and 50) or uterine-only repair (see Table 79). The
principal individual prolapse symptom was a feeling of ‘something coming down’. They were also more
likely to need to use preventative manoeuvres or extra hygiene measures to relieve their prolapse and
other symptoms of pelvic floor dysfunction (see Table 79).
TABLE 94 Participant recovery and satisfaction: uterine/vault cohort (CC3) (continued )
Recovery/satisfaction Uterine Vault
Recommend to a friend 87.5% 35 40 93.3% 97 104
Number of women at 2 years N= 48 N= 104
Comparison of prolapse with before surgery
Very much better 55.3% 26 47 59.2% 61 103
Much better 14.9% 7 47 24.3% 25 103
A little better 12.8% 6 47 6.8% 7 103
No change 6.4% 3 47 3.9% 4 103
A little worse 4.3% 2 47 2.9% 3 103
Much worse 0.0% 0 47 2.9% 3 103
Very much worse 6.4% 3 47 0.0% 0 103
Satisfaction with surgery
Completely satisfied 56.3% 27 48 58.3% 60 103
Fairly satisfied 16.7% 8 48 27.2% 28 103
Fairly dissatisfied 8.3% 4 48 4.9% 5 103
Very dissatisfied 14.6% 7 48 8.7% 9 103
Not sure 4.2% 2 48 1.0% 1 103
Recommend to a friend 82.6% 38 46 90.0% 90 100
Continuous variables are presented as ‘mean (SD) N’; dichotomous variables are presented as ‘% n N’.
Satisfaction with surgery
How is prolapse compared with before surgery? Very much better = cured [1]; much or a little better (or very much
better) = improved or cured [< 4]; no change or worse = failed [> 3]. Satisfied with results of operation? Completely
satisfied = cured [1]; fairly satisfied = improved or cured [1 or 2]; fairly or very dissatisfied = failed [3 or 4]; not sure =
separate category [5].
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Urinary symptoms at baseline
Based on a variety of validated measures of assessing bladder function, women with vault prolapse were
similar to the other groups of women who were having prolapse surgery on nearly every measure. In
particular, UI was just as prevalent: three in four women with any incontinence, and one in four with
severe symptoms (see Table 80).
Bowel symptoms at baseline
Similarly, women with vault prolapse were similar to those with other types of prolapse with respect to
most aspects of bowel function (see Table 81). About one-quarter had constipation and almost one-third
had FI. Passive FI was much more common than active (FI accompanied by bowel urgency).
Vaginal and sexual symptoms at baseline
About one-third of women were sexually active (see Table 82). For those who did have a partner, the most
common reason for no sex life was their prolapse symptoms. Around 15% of the women had dyspareunia
(pain with intercourse) but the numbers were small.
Planned surgery and surgery actually carried out
To be enrolled in CC3, women were clinically assessed as not needing an anterior or posterior repair.
Only six women were thought to need continence surgery (see Table 83), despite > 20% having severe
urine incontinence.
Surgery actually received
The women in this cohort were thought to have a vault prolapse, and nearly 90% did, in fact, have a vault
repair (see Table 83).
Description of surgical characteristics and protocols
The majority of women with a vault prolapse received surgery from a consultant gynaecologist (78.3%;
see Table 84); if carried out by a junior doctor, the surgeon was supervised in around 90% of cases. Most
women had a general anaesthetic, received prophylactic antibiotics and, on average, were in theatre for
approximately 2 hours. The mean length of stay was just under 2 days.
Outcomes for women who were having a vault prolapse repair
Serious and other related adverse effects in first and second years
The proportion of women who had at least one serious adverse effect in the first year (excluding mesh
complications) was 2.7% in the vault group (four women; see Table 85). One woman had serious infection
and pain in the second year. No women had any incidence of mesh exposure.
Prolapse symptoms and EuroQol-5 Dimensions
At 6 months, the women’s report of their prolapse symptoms, using the POP-SS (maximum score 28),
fell from 15.3 for the vault group to 5.8 (see Table 87). Similarly, each individual prolapse symptom also
improved (see Table 88), as did the prolapse-related QoL scores (see Table 87).
At 1 year, this improvement was maintained (POP-SS of 5.5 for the vault group; see Table 87). The
improvement from baseline was supported by data from individual prolapse symptoms (measured as
occurring ‘ever’ or ‘most or all of the time’); the proportion of women who had at least one prolapse
symptom (‘symptomatic’); QoL data, based on the interference of prolapse symptoms on everyday life (see
Table 87); the generic QoL measure EQ-5D-3L (see Table 89); and the need to undertake extra hygiene
measures or manoeuvres to assist pelvic floor functions. All of these measures demonstrated significant
improvements from before surgery.
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The improvement at 1 year was maintained at 2 years, with respect to all of the prolapse outcomes and
QoL outcomes measured.
Urinary symptoms
Detailed information on urinary symptoms was obtained at baseline, 1 year and 2 years (see Tables 80
and 90). The number of women who had concomitant continence surgery was 5/146 in the vault group
(see Table 83).
At 1 year in the vault group, the proportion of women who had any UI decreased from 73.7% to 68.5%
and the proportion with severe UI more than halved (from 23.8% to 8.3%; see Tables 80 and 90). There
were similar moderate improvements in all of the other measures of bladder function measured. The
improvement at 1 year was maintained at 2 years, with respect to all of the urinary outcomes and bladder-
related QoL outcomes measured (see Table 90).
Bowel symptoms
Detailed information on bowel symptoms was obtained at baseline, 1 year and 2 years (see Tables 81
and 91). Frequency of bowel movements, constipation, bowel urgency and FI were common, and largely
unchanged from baseline to after prolapse surgery in the vault group at both 1 year and 2 years
(see Table 91).
Vaginal and sexual symptoms
Detailed information on vaginal and sexual symptoms was obtained at baseline, 1 year and 2 years (see
Tables 82 and 92). Both the mean vaginal symptom score and the QoL score decreased (improved) after
vault prolapse surgery, and this was maintained at 2 years. More women were sexually active after surgery,
and many fewer cited prolapse symptoms as a reason for not having a sex life (reduced from 46.7% to
5.4% in the second year; see Tables 82 and 92). This was reflected in a more than halving of the ICI Sexual
Matters score and a reduction (improvement) to one-third of baseline levels in the sex life QoL score.
Further treatment required for failure or adverse effects at 6 months, 1 year
and 2 years
When women reported, at 6 months or later, that they had been readmitted to hospital, we verified
the information by enquiry from site staff when necessary and post-coded the corrected information.
A hospital readmission was automatically counted as a SAE if it was related to the initial prolapse surgery.
Repeat surgery for recurrence of prolapse (failure if same compartment, de novo if in the opposite
compartment), or for continence surgery, was differentiated from readmission for related complications,
such as bleeding, infection and surgery for mesh removal.
The overall rate of readmission was low (two women in the vault group in the first 6 months; Table 93).
Admissions in the first 6 months were related to adverse effects (constipation and pain). After that time,
five women had further surgery for prolapse (two in the same and three in a different compartment, and
five in the second year; see Table 93). No women required surgery for mesh removal at any time point.
Few women required other treatment – such as pessaries or physiotherapy – for symptoms.
Satisfaction with treatment at 1 year and 2 years
Although most women were better than before surgery by 1 year, around 12% (12 women) were
unchanged or worse, with similar findings at 2 years (see Table 94). This was reflected in the satisfaction
rates, and in the proportion of women who would recommend surgery to a friend (90.0%).
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Discussion
Summary of findings
This chapter has reported the findings for the cohort of women (CC3) who were not eligible for the
randomisation arms of PROSPECT because they were not thought to need either an anterior or posterior
repair. The women who were having vault prolapse were clearly a different population from those with
uterine prolapse, based on epidemiological and clinical characteristics. They have therefore been
described separately.
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Chapter 9 Modelling
L ittle is known about the prevalence and effectiveness of different types of treatments for prolapse,except that they are prone to failure: around 30% of women undergo further operations. The mean
time interval to the first secondary operation is about 12 years, and the time interval between subsequent
procedures decreases with each successive repair.4
Gynaecologists have recognised for some time that both anatomical failure of supporting pelvic structures
and recurrence of prolapse after surgery are common. It has also been recognised that surgery can be
followed by a greater impairment of QoL than the original prolapse itself (e.g. new UI after surgery). In
addition, repair of one type of prolapse may predispose the women to the development of a different type
of prolapse (a new, or de novo, prolapse) in another compartment of the vagina due to alteration in the
dynamic forces within the pelvis.4
This chapter focuses on presenting the methods and the results of a de novo economic model to guide
decision-makers on the cost-effectiveness of alternative surgical procedures for primary prolapse repair.
Although the within-trial cost-effectiveness results are informative regarding short-run costs and QALYs for
alternative treatments for the surgical management of primary prolapse repair, it is important to note that
prolapse is a chronic condition and the effects of treatment on costs and outcomes may persist into the
future. Therefore, we have developed a model to extrapolate the findings of the 2-year within-trial analysis
to a longer-term period.
Modelling approach
A probabilistic Markov model was developed (Treeage Pro™ software 2014, TreeAge Software, Inc.,
Williamstown, MA, USA) to estimate expected values for costs and QALYs for different primary surgical
prolapse repair strategies (standard repair, synthetic mesh and biological graft) over a base-case time
horizon of 5 years. Results were obtained with a Monte Carlo (probabilistic or second-order) simulation of
the developed Markov model with 1000 iterations. The model parameters were drawn from appropriate
distributions attached to baseline data, relative effect sizes, costs and utilities. Baseline results were
presented as mean costs and QALYs from the iterations, and the simulation was used to present
uncertainty in modelled outcomes. Uncertainty is presented as incremental scatterplots on the cost-
effectiveness plane and CEACs.
The model describes the treatment outcomes and follow-up of women who were having a primary
prolapse repair. The perspective adopted is that of the UK NHS. Costs were based on 2013–14 UK pound
sterling (£) values.
Model framework
The model was developed to extrapolate results of the Primary trial analysis (2-year follow-up) to a longer
(5-year) time horizon. As prolapse is a chronic condition, with the potential for long-term failure and
complications following surgery, a Markov state-transition decision-analytic model was used to represent
these stochastic processes that evolve over time (in this case, monthly cycle lengths). The structure of a
Markov model allows patients to move between defined mutually exclusive health states in a controlled
manner over specified time periods. The pathways presented and transitions allowed within the model
were developed in consultation with clinicians and trial collaborators.
The Markov model structure is outlined in Figure 27.
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All women enter the model in the ‘primary prolapse repair’ health state, for which they receive surgery.
This initial ‘primary prolapse repair’ surgical state is set to the duration of three monthly cycles to reflect
the likely time to recovery from prolapse surgery. After their initial surgical treatment, women then move
into one of four mutually exclusive health states.
1. They may enter the ‘post-prolapse surgery’ health state (defined as women who are not experiencing
serious complications or requiring repeat prolapse surgery). Within this health state, some women will
still experience some prolapse-related symptoms or other (non-serious) complications* and may receive
treatments for this, including physiotherapy or oestrogen treatments. Others will not require any further
treatment in that cycle and are considered to be ‘stable’. Women might stay in this state for the
duration of the model (if they do not experience serious complications or require repeat prolapse
surgery). At the end of each monthly cycle, they may transition from this state if they have serious
complications, require further prolapse surgery or die.
2. Women may suffer serious complications at any point (as defined in the clinical classification of
complications) following their surgery. If a woman experiences serious complications, she enters the
‘serious complications’ health state and receives treatment. Serious complications may be mesh or non-
mesh related. Some will require surgery to address their complications. A woman who is experiencing
serious complications might have these resolved during a single monthly cycle or might require to
remain in the health state for a longer time period until the complications resolve.
3. Women might suffer a recurrence of their prolapse, which requires further repeat prolapse surgery at any
time. For these women, surgery is deemed to have failed. For the purposes of this model, a failure is
considered as a requirement for further prolapse surgery. Women who experience failures that are not
requiring surgery remain in the post-prolapse surgery health state (see ‘1’, above). Women who were
having a failure requiring surgery enter the ‘second surgery’ health state, for which they go through a
similar model process as those following their first repair. A failure requiring surgical repair is considered
to be any repeat prolapse surgery, whether it occurs in the same or a different compartment.
4. There is a small chance that a woman may die from natural causes. The ‘death’ state considers that
women may die from any causes at any point in time and this is assumed to be all-cause mortality.
[Note: *The complications have been classified in accordance with the trial reporting of adverse effects as
serious mesh complications, serious non-mesh complications, other mesh complications and other non-
mesh complications. ‘Other’ complications have been defined as those that were not categorised as serious
adverse effects for trial reporting, but may still have had a significant impact on quality of life and use of
health services. Complications were considered ‘serious’ if they met one or more of the following criteria:
the complications (1) resulted in the patient’s death, in which case they progressed straight to the death
state in the model; (2) resulted in hospitalisation; (3) resulted in prolongation of an existing hospital stay;
(4) lead to persistent or significant disability or incapacity; (5) were life-threatening; and (6) were
considered medically significant by the trial investigator.]
Table 95 illustrates the treatment sequences for primary prolapse repair and any further repair surgery.
The women receive a maximum of two further prolapse surgical repairs. Women who are still found to
have prolapse failure after the third surgical procedure are assumed to proceed to containment
management. This includes the use of pessaries, physiotherapy and regular outpatient consultation.
TABLE 95 Treatment sequence
First treatment Second treatment Third treatment
Standard repair Second surgery Third surgery
Synthetic mesh inlay
Biological graft
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The follow-up treatments are assumed to be the same for all the women, as there is no evidence to inform
the specific follow-up treatments. Clinical expert opinion (Professor Cathryn Glazener, University of
Aberdeen, July 2015, personal communication) indicates that women may get any of the considered
options as a secondary repair (e.g. standard, mesh inlay or mesh kit). Therefore, for the purposes of the
economic analysis, all of the types of surgery are grouped together for the second and third prolapse
repair as an aggregate of outcomes reported for the Secondary trial (see Chapter 5).
Survival analysis, based on time-to-event data, is used to guide the proportion of the modelled cohort
progressing to repeat surgery health states and is outlined in more detail later in the chapter.
Women can continue moving through the states in the model for a maximum of 5 years (equivalent to
60 monthly cycles). A monthly cycle length has been chosen to reflect the time increments for which data
regarding time of treatment failure and complications requiring surgery were available. This time horizon
was selected as the study follows up patients for only 2 years and there are no long-term follow-up data.
Costs and benefits that occur in the future were discounted following the standard practice, that is the
recommended 3.5% for both costs and benefits (NICE 201338).
Summary of the key assumptions made in the economic model
Details regarding the choice of data used to populate the model together with justifications for any
assumptions made are outlined throughout the remainder of this section.
Assumptions related to the structure of the model
l The average age of women considered in the model is 59 years. This is the average age of the women
who took part in the primary RCT. In the sensitivity analysis, different ages were considered.
l The cycle length of the model is 1 month. This cycle length was chosen to take in account the time to
failure that was recorded in the trial.
l Cumulative costs and benefits are estimated for the 5-year period. In sensitivity analysis, the effect of a
longer-term follow-up (10 years) was considered, although data to populate longer time to effect
analysis are sparse and highly uncertain.
l Women who are in the ‘post-prolapse repair’ health state may be stable, but may also experience
prolapse-related symptoms, and may also have prolapse failure (not requiring surgery). These are
defined as women using containment products and they receive a utility decrement and additional cost
within the ‘post-prolapse surgery’ health state. However, they do not require or receive surgery in that
state but may do so at a point in the future.
l Women experiencing a repeat surgery are assumed to remain in the ‘second prolapse repair’ health
state for a duration of 6 months. This is to allow for the time required to diagnose the failure, waiting
list for treatment and a period of convalescence following surgery.
l Women experiencing serious complications may have their complications resolved within 1 month, or a
proportion will remain with longer-term unresolved complications, assumed to be 25% resolved within
1 month, 50% within 3 months, 75% within 6 months and all resolved within 1 year.
Assumptions relating to the treatments offered
l The treatment strategies compared different initial treatments, namely standard midline repair,
synthetic mesh and biological graft. Women requiring secondary repair surgery were assumed to
receive the costs and outcomes associated with an aggregate of all of the secondary repairs (i.e.
standard repair, mesh inlay or mesh kits). In reality, women may decide to receive specific secondary
treatments that are deemed appropriate in conjunction with their clinicians.
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l In the model, women were assumed to move into the containment failure management state (which
is an absorbing state as they cannot leave it) after they had three surgeries. In reality, women whose
symptoms recur may continue to seek surgical treatment until their symptoms are satisfactorily resolved.
However, there are no data to populate this level of detail within the model, and, as such, the impact on
cost-effectiveness is likely to be small, given the low proportion of women receiving three prolapse
repairs within our modelled time horizon.
l Women are assumed to enter the containment arm of the model if they receive containment products
that included medicines, oestrogens, pessaries and physiotherapy. Women may also receive these
products without surgical repair, in which case they receive a utility decrement and additional cost within
the ‘post-prolapse surgery’ state of the model (if they have not progressed through all three surgical
repairs). This allows for the fact that women may get containment products on an ongoing basis,
without surgical repair, or although they wait to see if symptoms clear up before requiring surgery.
Assumptions relating to data to populate the economic model
l Long-term estimates of failures and complication rates were based on the extrapolation of trial data
from the three-way comparison (RCT1A).
l It was assumed that probabilities of failure and complications following a third repair surgery were
equal to those following a second repair surgery.
l The costs of the second and third surgery were based on the aggregate cost of all three secondary
treatment (standard midline repair, synthetic mesh and mesh introducer kits) surgeries from the trial
data, as it was considered there was an equal chance that patients could receive any of the treatments.
l The model also took into account that some of the women did not have any further surgical
treatments but may have had no surgical treatments, such as pessaries and other containment products
as well as physiotherapy. Costs were attached to a proportion of the women in different cycles, as well
as those in the containment state.
Estimation of model parameters
The model is parameterised using data from the three-way trial comparison (RCT1A) and relates only to
women who were having a primary prolapse repair. When sufficient data were not available for individual
model parameters from the trial, published and unpublished evidence in the field was consulted and,
laterally, clinical expert opinion was used to populate any remaining parameters.
The methods used to assemble data followed recognised methodology, which varied according to the type
of parameter, extent of uncertainty and role within the model. The modelling exercise complied with
recent recommendations on good practice for modelling63 and the results are presented in terms of
incremental cost per QALY gained.
Mortality parameters
As women move through the model there is a chance that they may die. This chance is based on the
annual rates of age-specific all-cause mortality for women (Office for National Statistics interim life
tables46). As there were no intraoperative deaths reported during the PROSPECT trial in primary repair
women, we have not added any additional surgical mortality to treatments. Furthermore, as there were
relatively few deaths and no difference across arms regarding mortality over follow-up, no additional
mortality risk that was specifically related to prolapse was applied.
Probability parameters
The main probabilities for the model are the probabilities of developing failures and complications.
Probabilities reported in the tables to follow are adjusted, as appropriate, to reflect the model cycle length
of 1 month using Treeage Pro’s ‘probtoprob’ function.
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Treatment failures
The probability of treatment failure is included within the model in two distinct ways. First of all there is a
probability of failure, which may not require surgery and may be managed using conservative/containment
techniques, as outlined above. Probabilities of conservatively managed failure are elicited directly from
RCT1A of the trial for 1 year and 2 years, respectively. The longer run probability of failure requiring
containment products is assumed to remain static at the 2-year probability over the remainder of the model
time horizon. Table 96 presents data for the probability of failure requiring conservative treatment
management. Uncertainty was incorporated surrounding the estimates by sampling from a beta distribution,
for which the alpha parameter is the number of events of interest (in this case the number of women with a
conservatively managed failure) in the standard repair arm. The beta parameter is given as the total number
of women in the standard repair arm minus the number of women with the event of interest.
The probability of failure, managed conservatively, following a secondary repair was assumed to be equal
to that following a primary repair procedure, but was not incorporated as treatment-specific estimate
within the model. The probability of having a conservative failure (not requiring surgery) beyond 2 years
was assumed to remain constant for the remainder of the modelled time horizon.
Second, the more serious failures are defined as those that require further surgery (i.e. a secondary
prolapse repair). There is conflicting evidence on the long-term failure (requiring surgery) rates for prolapse
repairs, and hence significant uncertainty regarding the transition probabilities for the model. Transition
probabilities to the health state of second and, subsequently, third prolapse surgery were estimated using
survival analysis of time-to-event data over 2-year follow-up for the primary (RCT1A) and secondary (RCT2)
trials, respectively. As outlined previously, women who were having a third failure were assumed to be
treated using conservative management for the remainder of the model beyond having a third failure.
Extrapolation of the long-term reoperation rates for time to first failure (and time to second failure from
the Secondary trial data) were presented using Kaplan–Meier survival curves, using a Weibull distribution.
The formula used for the survival function is given as Equation 2. Equation 3 presents the formula that was
used to estimate transition probabilities for the baseline standard repair treatment:
S(t) = exp(−λtγ) (2)
tp = 1−f(exp(−λtγ)=exp(−λ(t−1)γ)g, (3)
where:
l S(t) is the survival function representing the probability of success (i.e. not experiencing a
prolapse failure).
l tp represents the formula for calculating transition probabilities to the failure health state for each
monthly cycle in the model.
l t is the time (measured in terms of the number of cycles, for which each cycle is equivalent to
1 month).
l λ is the constant parameter from the regression model; this is the scale parameter that shows the
probability that a woman’s prolapse will recur in the next period, given the fact that she was successful
in the current period.
TABLE 96 Baseline probabilities applied to conservative failure events
Variable
Time point
(year)
Point
estimate Alpha Beta
Distribution
applied Source
Conservative managed failure
(primary repair)
1 0.0837 18 197 Beta RCT1A trial data
2 0.0576 11 180
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l γ is the shape parameter that describes the rate of change in the probability that a woman will have a
recurrence of prolapse over time (i.e. that she will have failure). Shape parameters of > 1 indicate an
increasing rate over time, whereas shape parameters of < 1 indicate a decreasing rate over time.
The above formula was adjusted by the appropriate hazard ratios to estimate transitions for the synthetic
mesh and biological graft repair arms, respectively. Uncertainty is incorporated into the model by using the
Cholesky decomposition of the covariance matrix estimated from the output of the Weibull regression
models. A multinormal distribution was used to sample from the appropriate table containing Cholesky
decomposition estimates multiplied by the coefficient of the log of the hazard ratios, lambda and gamma
parameters. All statistical analyses of time-to-event data were estimated using Stata version 14 statistical
analysis software. Using this process it was possible to estimate a hazard function using the values
reported in Table 97.
Figure 28 shows the shape of the Kaplan–Meier curves that were fitted to the data reported in Table 97.
Time until the first major surgical procedure for prolapse failure was estimated using the survival time
regression models with a Weibull distribution specified above. The hazard ratio was 1.075 (95% CI 0.495
to 2.335) for synthetic mesh compared with standard repair, and as 1.164 (95% CI 0.551 to 2.459) for
biological graft compared with standard repair, based on adjustment for all minimisation covariates
included in the regression model. Without adjustment, and examining only the hazard ratios, based on the
observed data directly, unadjusted hazard ratios were 1.214 (95% CI 0.598 to 2.462) and 1.359 (95% CI
0.681 to 2.710) for synthetic mesh and biological graft repairs, respectively.
TABLE 97 Values used in the estimation of long-term failure after receiving prolapse treatment
Treatment λ (lambda) γ (gamma)
Hazard ratio: mean (95% CI)
Non-adjusted Adjusteda
Standard midline 0.000615 1.408625
Synthetic mesh 0.000764 1.408625 1.214 (0.598 to 2.462) 1.075 (0.495 to 2.335)
Biological graft 0.000835 1.408625 1.359 (0.681 to 2.710) 1.164 (0.551 to 2.459)
a Adjusted for minimisation variables as outlined in Chapter 2.
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FIGURE 28 Kaplan–Meier survival estimates for surgery for prolapse failure.
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
233
Based on these data, there is no evidence of a difference between groups in terms of time to failure event
at 2 years, with hazard ratios close to ‘1’ indicating near equivalence between the groups. This estimate is
generated using a model specifying a Weibull distribution. In order to select the appropriate model, we
undertook a two-stage process. First, we tested and rejected (p= 0.66) the proportional hazards assumption
using a Cox proportional hazards model. The next step was to select an appropriate distribution for the
extrapolation model. A number of potentially appropriate distributions exist. Each was evaluated independently
and likelihood ratio tests reported. None of the explored distributions performed particularly well, given the
few data available. Likelihood ratio tests were conducted for log-logistic, Gompertz, exponential and Weibull
distributions. In reality, any of these distributions could have been chosen. We selected a Weibull because
of its wide use in economic evaluation literature and its flexible mathematical characteristics were deemed
appropriate for use in this analysis. [We rejected the proportional hazards assumption for the Cox proportional
hazards model (p= 0.6598). We then compared the following distributions on the basis of their likelihood
ratio (chi-squared) and associated p-values: (A) log-logistic (likelihood ratio 0.81; p = 0.67); (B) Gompertz
(likelihood ratio 0.77; p= 0.68); (C) exponential (likelihood ratio 0.76; p= 0.68); (D) Weibull (likelihood ratio
0.68; p= 0.68).]
Estimated CIs from both the adjusted and unadjusted regressions are wide, in part as a result of the
relatively small number of failures requiring surgery across all three groups. Nonetheless, there is evidence
that the prolapse failure rate increases over time, but at a declining rate, yet the proportional hazards
model cannot be rejected.
Transition probabilities to third prolapse surgery, that is, long-term failure (requiring surgery) following a
secondary repair surgery, are estimated using data from the Secondary trial analysis (see Chapters 6 and 7).
Analysis was not treatment specific and, instead, incorporated failures for all women in the Secondary trial.
Methods were similar to those estimating failure following a primary surgical repair. The associated
Kaplan–Meier plot for all secondary surgery repairs together is presented in Figure 29.
The probability of further failure, following a third surgical repair, was assumed to be equivalent to the
probability of failure following a secondary repair. At this point, it was assumed that women received only
containment management and entered the absorbing, containment state, at which they remained for the
duration of the model with a probability of all-cause mortality.
Complications
The probabilities of complications are divided into two distinct groups, namely mesh complications and
non-mesh-related complications. These are further subdivided according to whether they were classified as
SAEs within the trial or other adverse effects/complications. All of the complications included in the model
were related to the prolapse repair preceding their occurrence. For example, complications following a
primary repair were assumed to be related to the primary repair, complications following a secondary
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FIGURE 29 Kaplan–Meier survival estimates for surgery for prolapse failure (secondary). The Kaplan–Meier curve
relates to all women who were having a secondary prolapse repair regardless of treatment strategy. Data are
sourced from secondary repair trials (RCT2 and RCT3).
MODELLING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
234
repair were assumed to be related to the secondary repair, and so on. Data are incorporated separately
for 1- and 2-year outcomes to reflect the drop in complications over time. Baseline complications are
determined according to the events observed within RCT1A (primary three-way trial comparison) for the
standard repair arm of the trial.
Table 98 presents data for the probability of the various estimates of complications included in the model.
Uncertainty surrounding the estimates was incorporated by sampling from a beta distribution, for which
the alpha parameter is the number of events of interest (in this case, the number of women with a
conservatively managed failure) in the standard repair arm. The beta parameter is given as the total
number of women in the standard repair arm minus the number of women with the event of interest (i.e.
a complication). It should be noted that these data are based on RCT1A only, and, as such, are not directly
comparable with the complications data that were reported for trial 1 in Chapter 4.
TABLE 98 Baseline probabilities for complications events
Variable
Following
surgery
Time
point
Point
estimate Alpha Beta
Distribution
applied Source
Serious mesh complications Primary 1 year 0.004 1 251 Beta RCT1A data
Serious non-mesh
complications
0.063 15 237
Other mesh complications 0.000 0.00001 251.99999
Other non-mesh
complications
0.063 17 235
Serious mesh complications Primary 2 years 0.004 1 251 Beta RCT1A data
Serious non-mesh
complications
0.012 4 248
Other mesh complications 0.000 0.00001 251.99999
Other non-mesh
complications
0.024 8 244
Serious mesh complications Secondary 1 year 0.025 10 387 Beta RCT2, CC2
Serious non-mesh
complications
0.083 33 364
Other mesh complications 0.020 3 150
Other non-mesh
complications
0.092 14 139
Serious mesh complications Secondary 2 years 0.007 1 152 Beta RCT2, CC2
Serious non-mesh
complications
0.020 3 150 RCT1A data
Other mesh complications 0.007 1 152 RCT2, CC2
Other non-mesh
complications
0.033 5 148
Probabilities for secondary complications are based on all Secondary trial women plus those in the CC. Treatment-specific
estimates were not included for the Secondary trial.
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Beyond the trial follow-up period, because of the low numbers of complications reported at 2-year time
point in the trial, we assume that the probabilities of ‘other’ complications are ‘0’ beyond 2 years. The
probability of serious complications beyond 2 years is estimated using a time-to-event analysis to project
rates of complications requiring surgery over the longer time horizon of the model.
Surgery for complications
The probability of complications beyond 2 years was restricted to only those women requiring surgery,
as this is the most costly and serious of all complications, with the greatest impact on QoL. Owing to small
numbers at 2 years, there was insufficient evidence to project differences and relative risks for each of the four
categories of complications to the longer term. However, dates of surgery for women with complications
(e.g. mesh removal surgery) were available and included in a time-to-event analysis. The methods and
formulae used to generate model transition probabilities to the serious complications state for surgery are
similar to those reported in the above section, Treatment failures. Table 99 presents the parameters and
hazard ratios used for the analysis of time to first surgery for serious complications.
Figure 30 presents the Kaplan–Meier curves describing the data that were used to project longer-run
transition probabilities for complications requiring surgery, beyond the 2-year follow-up.
Analysis of time until the first surgical procedure for complications related to prolapse surgery estimated
the hazard ratio as 2.558 (95% CI 1.123 to 5.825) for synthetic mesh compared with standard repair, and
as 1.173 (95% CI 0.450 to 3.055) for biological graft compared with standard repair. Based on these data,
surgery for complications occurs more often and earlier in the synthetic mesh group than in the standard
repair group. This difference is driven by mesh complications in the synthetic mesh group. The estimation
models for the hazard ratio are adjusted for baseline utility (QoL) and other minimisation variables,
TABLE 99 Values used in the estimation of long-term serious complications requiring surgery
Treatment λ (lambda)a γ (gamma)a
Hazard ratio: mean (95% CI)
Non-adjusted Adjusted
Standard midline 0.00588 0.6588213
Synthetic mesh 0.0129 0.6588213 2.196 (1.108 to 4.353) 2.558 (1.123 to 5.825)
Biological graft 0.00681 0.6588213 1.158 (0.536 to 2.504) 1.173 (0.450 to 3.055)
a Lambda and gamma parameters refer to unadjusted raw data model with Weibull-fitted distribution assumed.
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FIGURE 30 Kaplan–Meier survival estimates for surgery for serious complications.
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as outlined in Chapter 2. Estimating the same hazard ratios, based on raw data only, without adjustment,
the hazard ratios were 2.196 (95% CI 1.108 to 4.353) and 1.158 (95% CI 0.536 to 2.504) for synthetic
mesh and biological graft repairs compared with standard repair, respectively.
There were no apparent differences in complications requiring surgery between the biological graft and
the standard repair groups, although CIs were wide, in part due to the relatively small number of
complications requiring surgery across these two groups.
Data from the estimates of time to event are used to estimate transition probabilities in the decision-analytic
model. As with the analysis of time to surgery for prolapse failure, the analysis of surgery for complications
is based on Weibull regression models to project data shown at 2 years in Figure 30 over the longer-term
time horizon required to populate the decision model. The decision to use a Weibull distribution followed
a similar logic to that for the extrapolation of failure data. [Details of likelihood ratio tests for alternative
distributional assumptions: we rejected the proportional hazards assumption for the Cox proportional hazards
model (p = 0.2934). We then compared the following distributions on the basis of their likelihood ratio
(chi-squared) and associated p-values: (A) log-logistic (likelihood ratio 6.48; p-value = 0.04); (C) log-normal
(likelihood ratio 5.39; p-value= 0.07); (D) Gompertz (likelihood ratio 6.48; p-value= 0.04); (E) exponential
(likelihood ratio 6.70; p-value= 0.04); and (F) Weibull (likelihood ratio 6.57; p-value = 0.04).] Following
examination of the goodness of fit of the respective models (all of the assumed distributions performed
equally well), we chose a Weibull because of its extensive use in economic evaluation literature and its flexible
mathematical properties. Transition probabilities are calculated for monthly cycles of the model. A similar, but
not treatment-specific, analysis was undertaken to project long-term complications for all of the women who
were having surgery following a secondary repair. Data from this analysis are presented in Appendix 6.
Owing to a lack of appropriate data to populate the model, we did not consider complications following a
third prolapse procedure.
Relative risk parameters
For time-to-event parameters, hazard ratios were used to assign relative effect sizes to the time to
experience a failure/surgery for complications. Uncertainty in these estimates was incorporated through the
use of Cholesky decomposition matrices, as outlined in the Probability parameters section above. In relation
to parameters based on proportions (conservative treatment for failure and non-surgical complications),
absolute parameter values for synthetic mesh repair and biological graft repair were calculated by applying
relative effect sizes (for synthetic mesh and biological graft vs. standard repair) to baseline probabilities.
All of the relative effect sizes were incorporated into the model as point estimates of relative RRs with
95% CIs, estimated using the within-trial data as detailed in Chapters 2 and 4. Owing to a lack of data
to inform longer-term extrapolation of each individual parameter beyond the trial follow-up, we have
projected the probabilities of only complications requiring surgery or failures requiring surgery beyond
2 years. We rely on the time-to-event analyses described above to guide these model probabilities.
Furthermore, in instances for which baseline data may not have been available or zero events were
observed in either the standard or comparison groups (e.g. serious mesh complications in the standard
repair arm at 2 years were zero), raw data on probabilities in the comparator arms was used to populate
the model in the place of relative risk estimates. When this is the case, it is clearly outlined in Table 100
and the probability distributions used are outlined in Table 101. Relative risk data were not applied to
probabilities following a secondary surgery, as it was not possible to know whether failure of a second
repair was linked to the original primary repair or the secondary repair that took place. We therefore
pragmatically assumed that all of the data following secondary repair (i.e. the Secondary trial and the
Secondary CC) provide the most reliable data for complications and failures following a second prolapse
surgery, and these data are applied to all of the secondary repairs in the model.
Table 100 details point estimates and 95% CIs of relative effect sizes used in the model. Uncertainty
surrounding the point estimates was characterised using log-normal distributions. Data used to define the
distributions are presented as mean and SE of the log estimates. Table 101 details the point estimates used
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for data for which relative risks were not calculable. For these parameters, beta distributions were applied,
based on count data as in Table 98.
Resource utilisation and cost parameters
Costs for use within the economic model are health state specific, based on health-care resource use
observed from women experiencing specific events from the trial-based analysis for RCT1A. Mean (SD) costs
for women who were experiencing health states were used to populate the economic model. Costs are
estimated from the perspective of the UK NHS, and reported in 2014 UK pound sterling (£) values. Costs
were based on resource-use data that were reported in the trials. All relevant unit costs underpinning the
cost distributions can be found in Chapters 2 and 5 and Appendix 6. Costs of secondary repair surgery are
based on intervention costs (microcosted) from the Secondary trial analysis. Base-case costs for secondary
repairs in the model were calculated assuming an aggregate of all of the intervention costs from the
Secondary trial, regardless of treatment received. Sensitivity analysis explored the impact of assuming that all
of the women receive standard repair or all women receive mesh kit for the secondary repair. A further
sensitivity analysis used cost estimates from the Primary trial (RCT1A) for those women experiencing a
prolapse failure. The latter analysis was based on NHS unit costs, rather than microcosting approach for the
base-case analysis of secondary intervention cost. Costs for health states applied to the base-case model
were calculated across all of the women who were randomised to RCT1A and were not treatment specific.
The way in which costs for health states were estimated in the base-case analysis depended on whether or
not dates of events were available from the trial data set. Costs for events for which no dates of event
were available are applied to health states as average costs of treatments incurred over the whole trial
follow-up and divided evenly across each model cycle. This includes the cost of conservatively treated
failures and women who had no further symptoms (i.e. were stable) in the ‘post-prolapse surgery’ health
state of the model. As many women would not have a clear cure and may still experience symptoms
related to prolapse, those women in the ‘post-prolapse surgery’ health state still incurred a cost. Women
categorised as being ‘stable’ in the ‘post-prolapse surgery’ health state were defined as those women not
reporting conservative management treatments, not having surgery for failure and not experiencing serious
adverse effects or any other prolapse-related complications.
Costs of health states for which dates of event were available (e.g. date of surgery for complications or
failures) were estimated only for women reporting resource use within 4 months of the event. This allowed
a more accurate reflection of resource use that was applied to the limited time in the respective health
states for those who experienced complications.
Furthermore, costs included in the model were split between 1- and 2-year follow-up. The justification for
this is that the costs of problems incurred over the second year of follow-up are more appropriate for
longer-term extrapolation, as they do not include routine follow-up care following surgery and furthermore
the patient reported costs in year 2 are unlikely to include trial-based consultations (such as 1-year
TABLE 101 Probabilities used in the model where relative risks were not calculable
Variable Treatment Time point
Point
estimate Alpha Beta
Distribution
applied Source
Serious mesh complicationsa Biological graft 1 year 0 0 255 Beta RCT1A
Other mesh complications Standard mesh 1 year 0.0235 6 249
Biological graft 0.00392 1 254
Standard mesh 2 year 0.0275 7 248
Biological graft 0.00392 1 254
a When no events were reported, a nominal value was included to allow the model to run (i.e. 0.00001).
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
239
prospect follow-up appointment). Costs applied to health states for each model cycle beyond 2 years were
assumed to be the same as those incurred between 1- and 2-year follow-up from the trial. Adjustments
were undertaken to apply costs to each monthly model cycle.
For the costs of treating serious and other complications, it was assumed that the treatment costs would
be similar in terms of resource use for both mesh and non-mesh complications. This is on the basis that to
be considered a serious adverse effect, women would have had a substantial contact with health-care
professionals and associated treatments. Furthermore, splitting the cost regressions from the trial, based on
four different categories (serious mesh, other mesh, serious non-mesh and other non-mesh complications),
generated great uncertainty, as a result of small numbers of participants reporting full-cost data within
each of these individual groups. Therefore, we pragmatically decided to group costs of serious
complications together. A similar approach was taken for ‘other’ complications.
As a summary, by using estimates of costs from the trial-based analysis in Chapter 5, the resource
utilisation and costs included in the model are a comprehensive reflection of all resource use, including:
l the interventions, incorporating the surgery, preparations and hospital resource use in theatre, based
on operation time, staff time and other additional treatments.
l postoperative resource use (from surgery to discharge), including time on ward, return to theatre,
catheterisation, cost of treating any infections, for example UTIs and any other adverse effects
l inpatient admissions (any follow-up operations and length of stay in hospital related to prolapse
symptoms, including overnight and day-case admissions)
l outpatient attendances (including all outpatient contacts over the trial follow-up period)
l primary care visits (including GP contacts, occupational therapist, physiotherapist and nurse contacts)
l medications related to treating prolapse and UI symptoms.
Detailed information on how unit costs were developed within the trial are provided in Chapters 2 and 5.
Costs from the data set were adapted to reflect the additional costs of experiencing prolapse-related
events. These health state-specific costs are applied within the model and were assumed to follow a
gamma distribution. Unit costs, together with alpha and beta parameters (where appropriate), are
presented in Table 102 in accordance with the specifications outlined by the Treeage software. All costs
used in the model were discounted by 3.5% per annum in line with current best practice guidance.38
Quality of life
As with the cost data reported above, utility estimates are applied to health states based on mean data for
women experiencing a health event from RCT1A. For the base-case analysis, utilities are applied to health
states on the assumption that all women in a health state will have equal utility. Utility weights were
adjusted to reflect the model cycle length of 1 year and were combined with length of time in a health state
to generate QALYs gained. QALYs were then discounted at a rate of 3.5% per annum in line with best
practice guidelines. As with costs, the utility of the ‘post-prolapse surgery’ health state was estimated for
those women who were not falling into any of the other health states. Rather than reflecting a health state
for which everyone is well or recovered, this state is more ‘all encompassing’, picking up the QoL impact of
prolapse for those not experiencing more major problems. Utility values were also estimated for the women
who had complications requiring hospitalisation and had a prolapse failure, requiring reoperation as well
as those who had complications that did not need hospitalisations. Furthermore, a separate utility was
estimated for those women who were in the ‘post-prolapse surgery’ health state, but experienced the need
for containment or conservative management of their prolapse symptoms. This value was less than for those
in a failure health state, but greater than for those requiring surgery for prolapse failure.
All health state-specific utility estimates calculated on the basis of RCT1A (primary repair surgery) were
also applied to women who were experiencing a similar health state following second and third repairs.
This assumption implies that utilities are not impacted on by the number of previous surgeries experienced.
There were insufficient data available from the Secondary trial to estimate health state-specific utilities for
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women who were having a second repair. However, data reported from the Primary and Secondary trial
analyses overall (see Tables 39 and 68) indicate that women who were having primary and secondary
repair had similar EQ-5D scores overall. It is therefore unlikely that, on the basis of currently available data,
this assumption has any substantial impact on results.
Table 103 reports the point estimate of all utilities applied to health states within the model. Uncertainty in
utility data is characterised and incorporated by sampling from beta distributions for the utility of each
modelled health state. Alpha and beta parameters are calculated using the method-of-the-moments
approach and the parameters of the distribution are presented in Table 103.
Assessment of cost-effectiveness
Cost–utility analysis
The costs and consequences (QALYs) of the different treatment options were estimated for women with
an average age of 59 years (the average age of women undergoing prolapse surgery in the primary repair
trial) over a 5-year time horizon. The model generated expected values of costs and QALYs, based on a
hypothetical cohort of n = 1000 women who were having a primary prolapse repair. The base-case model
results were calculated using a probabilistic analysis using second-order Monte Carlo simulation with
1000 repetitions. Results from the cost-effectiveness analyses were based on mean estimates of baseline
TABLE 102 Cost values used in Markov model health states
Variable
Point
estimate
(£) SE (£) Alpha Beta Distribution
Cost of primary repair (standard) 2831 1151 6.05 467.96 Gamma
Cost of primary repair (synthetic mesh) 3128 1042 9.01 347.11
Cost of primary repair (biological graft) 3258 1279 6.49 502.10
Cost of further surgery for failure (all secondary repairs: base case) 3112 1289 5.83 533.91
Cost of further surgery for failure (standard repair: sensitivity analysis) 2790 1295 4.64 601.08
Cost of further surgery for failure (mesh inlay: sensitivity analysis) 3099 1358 5.21 595.08
Cost of further surgery for failure (mesh kit: sensitivity analysis) 3522 1100 10.25 343.55
Cost of further surgery for failure (sensitivity analysis based on
Primary trial data)
782 942 0.6891 1134.74
Cost of surgery for complications (year 1) 1515 948 2.5539 593.20
Cost of surgery for complications (year 2) 937 1088 0.7417 1263.33
Cost of being stable in the ‘post-prolapse surgery’ health state (year 1) 306 475 0.42 737.34
Cost of being stable in the ‘post-prolapse surgery’ health state (year 2) 251 524 0.23 1093.93
Cost of serious complications (mesh and non-mesh; year 1) 1095 1045 1.098 997.28
Cost of serious complications (mesh and non-mesh; year 2) 858 1079 0.63 1356.92
Cost of other complications (mesh and non-mesh; year 1) 760 1044 0.53 1434.13
Cost of other complications (mesh and non-mesh; year 2) 738 1371 0.29 2546.94
Cost of conservatively managed failures and containment (year 1) 598 709 0.71 840.60
Cost of conservatively managed failures and containment (year 2) 529 766 0.48 1109.18
Notes
1. All costs were adjusted to reflect monthly model cycles.
2. Additional surgery costs were applied once only at the time or entering surgery health state.
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probabilities, relative effect sizes, utilities and costs that were drawn from the sampling distributions outlined
in the above tables of model inputs. Expected values of costs and QALYs were estimated according to the
sampled data for each treatment group (standard repair, synthetic mesh and biological graft).
The expected values of costs and QALYs were combined into a single measure of efficiency and reported
as incremental costs per QALY gained. These are ratios of the differences in costs of the interventions
divided by the differences in the benefits (QALYs). These data reflect the rate of return in QALYs to the
quantity of resources used measured in monetary terms. The ICER is used in conjunction with an identified
WTP threshold value to determine if the intervention can be judged to be cost-effective. Interventions
reporting an ICER of < £20,000–30,000 per QALY gained are generally considered to offer good value
for money to the NHS. Interventions that are less costly and generate greater QALYs than a comparator
are the dominant treatment, and offer an even stronger case for cost-effectiveness. Results of mean
probabilistic results for each treatment group are presented on the cost-effectiveness plane.
Sampling uncertainty is presented in two distinct ways. First, scatterplots of incremental costs and QALYs
generated from the simulations are plotted on the incremental cost-effectiveness plane to show the
differences in costs and QALYs for synthetic mesh and biological graft, respectively, compared with standard
repair. This specifically shows the uncertainty in the respective quadrants of the cost-effectiveness plane.
Second, CEACs are presented alongside the incremental scatterplots. CEACs illustrate the uncertainty in
cost-effectiveness outcomes caused by the combined statistical variability in the model’s parameter
estimates. They show the likelihood that each individual treatment strategy is the most cost-effective use
of resources at various threshold values of society’s WTP for a QALY gained. CEACs and scatterplots are
presented for the base-case and all secondary analyses. Further to these illustrations of cost-effectiveness,
TABLE 103 Health-state utilities
Health state Mean value SE Distribution Alpha Beta Notes/sources
Treatment failure 0.609 0.296 Beta 1.048 0.673 RCT1A
Complications requiring surgery 0.646 0.454 Beta 0.054 0.030
Stable in the ‘post-prolapse surgery’
health state
0.831 0.248 Beta 1.060 0.215
Serious mesh complications
(not requiring surgery)
0.722 0.297 Beta 0.923 0.356
Serious non-mesh complications
(not requiring surgery)
0.722 0.297 Beta 0.923 0.356
Other mesh complications
(not requiring surgery)
0.739 0.314 Beta 0.709 0.250
Other non-mesh complications
(not requiring surgery)
0.739 0.314 Beta 0.709 0.250
Failure (conservative management) 0.797 0.239 Beta 1.458 0.372
Baseline utility (standard repair) 0.722 0.245 Beta 1.692 0.652
Baseline utility (synthetic mesh) 0.711 0.233 Beta 1.980 0.805
Baseline utility (biological graft) 0.697 0.265 Beta 1.399 0.608
Baseline utility (all combined) 0.710 0.248 Beta 1.667 0.681
Additional treatment effect (synthetic
mesh): sensitivity analysis only
0.019 0.018 Beta 1.028 53.343
Additional treatment effect (biological
graft): sensitivity analysis only
0.006 0.020 Beta 0.091 14.190
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all results (base-case and sensitivity analyses) are also accompanied by an indication of the treatment
ranking in terms of the most likely treatment to be cost-effective at a threshold value of WTP of £30,000
per QALY, based on the assessment of NMB.
Deterministic sensitivity analysis
Cost-effectiveness acceptability curves illustrate the sampling uncertainty in the model parameters.
However, further uncertainty may exist in the choice of data used to populate the model, the
methodological or structural assumptions made or the subgroup analyses considered. Various sensitivity
analysis were undertaken to explore the importance of these uncertainties and assumptions.
Parameter uncertainty
In addition to exploring sampling uncertainty in parameters, there is uncertainty regarding the appropriate
choice of data that are used to populate the model.
Utilities
Alternative choices of utility weights were available from the trial data for use within the model to generate
QALY gains. The base-case analysis is informed by utilities generated for health states in the trial, on the
assumption that all women in a health state will experience equal utility. For example, all women suffering a
failure will have a utility of 0.609 and all women who are non-symptomatic in the ‘post-prolapse surgery’
health state will experience a utility of 0.831. Sensitivity analysis explores the impact on cost-effectiveness of
applying treatment-specific utilities to all model health states. This analysis is undertaken to reflect that the
complete case analysis of the Primary trial indicated some additional incremental utility that was associated
with synthetic mesh for all women, including those with complications or experiencing failures over and
above women in the same health state for standard repair and/or biological graft. Although the estimates of
treatment-specific utility are unexplained by clinical outcomes, and may be biased by substantial missing
data, they are included, nonetheless, in the model for completeness. Additional treatment-specific utility is
estimated for synthetic mesh and biological graft based on a GLM with adjustment for all model health
states and baseline covariates from the trial. The coefficient on treatment is added to the specific
health-state utility in the respective arms of the model to estimate a treatment-specific utility for each
modelled health state. This reflects the unexplained additional utility, which appears to be experienced by
women who are randomised to synthetic mesh in the complete case analysis of the trial-based economic
evaluation. It is likely that this analysis would provide an upper bound on the likelihood of cost-effectiveness
for synthetic mesh. The additional utility (see Table 103) effectively increases the utility of women in all
health states for which they received mesh as the baseline treatment. This analysis should be interpreted in
the light of the uncertainty in the surrounding trial data.
Costs
As with the trial-based analysis, the estimates of costs to the health services and hence cost-effectiveness of
treatments are subject to uncertainty surrounding the intervention cost applied in the model. Therefore, as a
sensitivity analysis, we have explored the impact of using the most costly meshes for all mesh repair and the
least costly meshes for all mesh repair as plausible upper and lower bounds of the intervention costs.
Furthermore, the costs included in the base-case analysis for treatment failure are generated using the
microcosting approach based on Secondary trial data for all of the treatments. A number of alternative
estimates are explored in sensitivity analysis, namely assume that all women who were having a
secondary repair:
1. get standard repair
2. get mesh inlay
3. get mesh kit
4. incur the costs of treatment failure within the Primary trial (based on the reference costs used to
generate the costs of resource use for these women within the trial).
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Structural uncertainty
As highlighted in the estimation of model probabilities, there was no reliable evidence on long-term
reoperation for prolapse surgery failure. Furthermore, we curtail the model to run for only 2 years for
which the most accurate data were available (i.e. the same time horizon as the trial follow-up). This allows
us to validate the structure of the model and the predicted results internally against the trial data that were
used to generate the model parameters.
The incidence of prolapse is likely to increase with age. The mean age of the participants in the trial was
59 years with a SD of 10 years. The costs and benefits in the model were estimated for 5 years. The sensitivity
analysis explores the implications of varying the age of women at the start of treatment and the impact of
adopting a longer-term period. Therefore, the starting age was changed to 49 and 69 years, and the time
horizon was increased to 10 years. A further exploratory analysis is run over a 30-year time horizon. However,
results should be interpreted cautiously, as estimates of time to event are highly uncertain for failures. The
model will be updated with data from the 6-year follow-up of PROSPECT and the time horizon extended,
based on a more comprehensive time-to-event analysis.
Methodological uncertainty
Discount rates were used at a rate of 3.5% per annum applied to costs and QALYs in the base-case
analysis. Sensitivity analysis explores the impact of varying these between 0% and 6% per annum in the
sensitivity analysis following best practice guidance.
Utility data in the model are based on trial results and, as such, the utility weights are specific to women
suffering from prolapse. As a sensitivity analysis, these utility weights are further adjusted to reflect
population norms, which are age adjusted according to the stage of the model, reflecting the fact that
utility is likely to fall over time as women get older.
Results
Base-case cost-effectiveness results
The base-case results for the estimates of cost-effectiveness from the probabilistic analysis are presented
with treatments ranked in ascending order of costs. Treatment strategies that are more costly and generate
fewer QALYs than a comparator are excluded on the basis of absolute dominance and are not considered
cost-effective. For the remaining strategies, ICERs are calculated. The treatment strategy with the highest
ICER falling under the threshold value is considered the most cost-effective treatment option (note, for the
purposes of interpretation, the threshold value of the ICER is considered to be < £20,000–30,000 per
QALY gained). The base-case results are presented numerically in Table 104 and graphically on the
cost-effectiveness plane in Figure 31.
For the base-case economic analysis, standard repair is considered the most cost-effective treatment
strategy, being less costly, with marginally greater QALYs gained. However, differences in QALYs are small
in magnitude and results are driven primarily by the additional intervention cost of mesh. Uncertainty in
the base-case results is illustrated according to the CEAC presented in Figure 32. The probabilities of
cost-effectiveness for the base-case results at a threshold value of WTP of £30,000 per QALY gained are
50%, 23% and 27% for standard repair, synthetic mesh and biological graft, respectively. The results of
the base-case cost-effectiveness analysis are comparable with the results of the within-trial analysis using
the imputed data set in Chapter 5. The sensitivity analysis section explores a direct comparison between
modelled results over 2 years, and the trial results are reported in Chapter 5.
Uncertainty in the individual comparisons of synthetic mesh with standard repair and biological mesh with
standard repair is presented in Figure 33 as scatterplots of the 1000 Monte Carlo simulation estimates of
expected costs and QALYs for the respective treatment groups.
MODELLING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
244
TA
B
LE
10
4
B
as
e-
ca
se
co
st
-e
ff
ec
ti
ve
n
es
s
an
al
ys
is
re
su
lt
s
St
ra
te
g
y
C
o
st
(£
)
In
cr
em
en
ta
l
co
st
Q
A
LY
s
In
cr
em
en
ta
l
Q
A
LY
In
cr
em
en
ta
l
co
st
-e
ff
ec
ti
ve
n
es
s
In
cr
em
en
ta
l
co
st
-e
ff
ec
ti
ve
n
es
s
(v
s.
st
an
d
ar
d
re
p
ai
r)
N
M
B
ra
n
ki
n
g
(t
h
re
sh
o
ld
=
£3
0k
)
St
an
da
rd
re
pa
ir
48
11
3.
75
3
0
0
1
Sy
nt
he
tic
m
es
h
in
la
y
52
64
45
3
3.
74
8
–
0.
00
47
D
om
in
at
ed
D
om
in
at
ed
3
Bi
ol
og
ic
al
gr
af
t
53
04
49
2
3.
74
9
–
0.
00
35
D
om
in
at
ed
D
om
in
at
ed
2
Ef
fe
ct
iv
en
es
s
m
ea
su
re
d
in
te
rm
s
of
Q
A
LY
s
ga
in
ed
.
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
245
3.748
4800
4840
4880
4920
4960
5000
5040
5080
5120
5160
5200
5240
5280
5320
5360
3.749 3.750 3.751 3.752 3.753
Biological graft
Standard repair
Synthetic mesh inlay
Dominated
Effectiveness
C
o
st
 (
£)
FIGURE 31 Base-case cost-effectiveness plane.
0
0
5
15
10
20
25
35
30
40
45
50
60
55
65
75
70
80
85
100
95
90
20 40 60 80 100
Biological graft
Standard repair
Synthetic mesh inlay
WTP (£000)
It
er
at
io
n
s 
co
st
-e
ff
ec
ti
ve
 (
%
)
FIGURE 32 Cost-effectiveness acceptability curve.
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Secondary analysis
Table 105 presents the results of a secondary analysis, which details the cost-effectiveness based on
treatment-specific utilities applied to the model. This analysis incorporates the coefficient of treatment
effect on QALYs that are generated from GLM models, adjusting for health state in the trial-based analysis
model. It essentially adds an additional utility to the synthetic mesh repair for all women in all of the health
states, and is more directly comparable with the data seen in the complete case analysis of the trial
outcomes reported in Chapter 5. Caution should be noted when interpreting the analysis, given that
complete case trial data may have been subject to the biases of missing data. The analysis is provided for
completeness. The base-case analysis model is more consistent with an imputed data set of missing utility
data from the trial. Figure 34 illustrates the uncertainty in this secondary analysis using CEACs. As with the
base-case analysis, a validation check will be explored in deterministic sensitivity analyses running the
model over a 2-year time horizon.
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FIGURE 33 Incremental cost-effectiveness for mesh repairs vs. standard repair.
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The secondary analysis including additional incremental QALYs for synthetic mesh indicates a lower ICER and
higher probability of cost-effectiveness for synthetic mesh. With an ICER of < £20,000 per QALY gained,
there may be an argument for adopting synthetic mesh on cost-effectiveness grounds under this analysis.
However, whether or not a decision-maker would consider this as evidence of cost-effectiveness would be
determined by whether or not he/she trusts the treatment-specific additional utility gained from synthetic
mesh across all of the health states. This analysis may be subjected to biases of missing data that are
generated in the trial-based cost-effectiveness analyses. More specifically, the base-case analysis, informed by
an imputed data set addressing biases, is more likely to accurately reflect cost-effectiveness. Furthermore,
there is some uncertainty in this result, as is illustrated in the CEAC in Figure 34. The probabilities of
cost-effectiveness at a threshold value of WTP of £30,000 per QALY gained are 22%, 57% and 21% for
standard repair, synthetic mesh and biological graft, respectively. The probability of cost-effectiveness of
synthetic mesh increases with the higher the threshold value of WTP for a QALY, but never reaches > 65%
probability of cost-effectiveness at thresholds up to £100,000 per QALY gained. There is thus substantial
uncertainty regarding the most cost-effective treatment strategy across both the base-case and secondary
analyses presented here. There is no clear evidence from either model by which to recommend either mesh
repair as a cost-effective use of scarce NHS resources. The probability of biological graft being cost-effective is
consistently lower than the alternative options, driven by the additional cost of providing the intervention,
with no clear gain in QoL over the modelled time horizon.
Results of deterministic sensitivity analyses
The results of the full range of deterministic sensitivity analyses undertaken and described through the methods
sections above are outlined in Table 106. The results are presented in a similar way to the base-case and
secondary analyses outlined above. ICERs are presented incrementally based on ranked treatment options, and
also compared with a common baseline comparator (standard repair). The most cost-effective treatment
option, following a net benefit approach, under each scenario, is indicated in the final column of the table.
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FIGURE 34 Secondary analysis, use of treatment-specific utility.
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Interpretation of sensitivity analysis results
Model validation checks
As a check on the face validity of our model results, we have undertaken two analyses of the model over a
2-year time horizon. Given that the trial-based follow-up was of 2 years’ duration, it is only reasonable to
assume that the model would reasonably accurately reflect the data that were seen in the trial. Therefore,
the model was rerun over a 2-year time horizon to determine how closely the results matched the trial
analysis. It should be noted that this analysis was conducted to check model face validity results and not as
a direct attempt to replicate the trial-based analyses. An analysis in which health-state utilities were not
treatment specific matches the conclusions and cost-effectiveness rankings of treatments seen in the
imputed data set for the Primary trial analysis. Adding an additional treatment-specific utility to the model
produces rankings similar to those found in the complete case analysis. This reflects the conclusions
of the trial-based analyses in which imputed data sets showed lower probabilities of mesh repairs being
cost-effective than in complete case analysis. The important note to take from this analysis is that the
direction of effect is the same, and conclusions remain unchanged from those estimated in the trial
analysis. This is reassuring for the internal validity of the model structure. The longer-term follow-up of the
trial data will provide an opportunity to validate the projections of long-term failures and complications up
to 6 years of follow-up.
Other sensitivity analyses
For a range of sensitivity analyses undertaken, the base-case model conclusions remain unchanged. Based on
current data and projected over 5 years, there is little chance of mesh being cost-effective. This is, in part,
due to the additional cost of mesh procedures and also to the additional costs and QoL decrements that are
associated with treating mesh-related complications. As a result, there would need to be a substantial fall in
mesh cost and/or a substantial change in failure rates over the extended follow-up period before mesh would
be considered a cost-effective use of scarce NHS resources. Despite the additional cost of biological grafts,
even relative to synthetic mesh, there is roughly equal chance of either mesh being cost-effective. This is
driven in the model by higher surgery rates for complications in the synthetic mesh group than with biological
grafts. In order to be considered cost-effective at a WTP of £30,000 per QALY gained, the total intervention
cost would need to reduce by 20% and 21% for synthetic meshes and biological grafts, respectively. The
price of the mesh products would be required to fall by a substantially higher percentage in order to achieve
this overall percentage reduction in total intervention cost. Furthermore, given current projections of
complications over 5 years, the true failure rate for standard repair would need to be substantially greater
than synthetic mesh and biological graft at 5 years for either mesh to become definitively cost-effective. In
order to fully understand the cost-effectiveness of mesh, more information is required on the longer-term
trade-offs between the additional risk of complications (particularly for synthetic meshes) and any longer-term
differences between treatment arms regarding failure rates.
Discussion
Summary of main findings
The base-case analysis indicates that standard repair costs less and has only marginally higher QALYs than
both synthetic mesh and biological graft procedures. The base-case ICER therefore indicates that standard
repair is the dominant treatment strategy. These results are similar to those of the imputed data set for the
within-trial analysis in Chapter 5. The cost-effectiveness results are driven primarily by the additional cost of
mesh materials. Considering that decision-makers would be willing to pay up to £30,000 for a QALY
gained, there are 23% and 27% chances of synthetic mesh and biological graft being considered to be
cost-effective, respectively.
The secondary analysis that takes into account the treatment-specific utilities indicates a more favourable
result for synthetic mesh. This analysis is most comparable with (and developed using) the complete case
analysis of cost and QALY pairs from the trial. This analysis includes the additional unexplained health-related
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QoL that is evident in the complete case trial analysis, which increases the likelihood of synthetic mesh being
cost-effective. This analysis provides a likely upper bound on the likelihood of mesh being cost-effective.
Under the assumptions of this analysis, adding treatment-specific utilities to health states, synthetic mesh and
biological grafts remain more expensive than standard repair. However, synthetic mesh also generates
greater QALY gains. The incremental cost per QALY gained when synthetic mesh is compared with standard
repair is £5933. When considering that society’s maximum WTP for a QALY gained might be £30,000, there
is 22% chance that standard repair would be considered to be the most cost-effective treatment option, a
57% chance for synthetic mesh and a 21% chance for biological graft. Therefore, despite the potentially
favourable ICERs, the reader’s attention is drawn to the uncertainty surrounding the most cost-effective
treatment option.
These analyses indicate two plausible estimates of incremental cost per QALY gained, and each are
surrounded by considerable uncertainty regarding the optimum treatment strategy for primary prolapse
repair. Owing to the additional costs of synthetic mesh and biological graft repairs, there is no strong
evidence from any of the considered economic models to recommend mesh as a cost-effective use of
scarce NHS resources, based on 2-year data. There would need to be a substantial increase in the failure
rate of standard repair over the longer term, relative to mesh, before the mesh repairs would become
cost-effective.
The results of the deterministic sensitivity analysis were similar to the base-case analysis, indicating that the
results were not particularly sensitive to choices around model structure, methodological assumptions or
the choice of data to populate the model. The cost of standard midline repair was always less than that of
both synthetic mesh and biological graft. The differences in QALYs were small throughout all the analyses
undertaken with no treatment strategy offering a clearly superior outcome in terms of QALYs gained.
Scatterplots of incremental QALYs show substantial uncertainty. There was also uncertainty in overall
modelled costs, but to a lesser degree than QALY outcomes.
Strengths
A strength of this analysis is that it is the first analysis that reports a model that is populated using data
derived from a large RCT and the model parameters – such as benefits, costs, reoperation and
complication rates – were derived from the trial participants. The study also included women who were
having secondary treatment and it was undertaken from a UK perspective.
Limitations
Modelling the cost-effectiveness analysis was a challenge as a result of the lack of long-term data, although
the trial participants were followed up for 2 years. The second and third prolapse treatment costs and
outcomes were informed by the results of the Secondary trial, which was based on women who had
already had a prolapse treatment. The costs and outcomes of women who had second and third treatments
were based on an aggregate of the three available treatments, as there was no difference in costs or
outcomes. This was considered appropriate as the number of women in this trial was small. The model had
a provision for only two follow-up surgeries, which may be considered to be an overestimation in a 5-year
follow-up period. Evidence from the Secondary trial suggested that, on average, women had prolapse
symptoms or are bothered by prolapse for at least 2 years before they had surgery. In addition, there were
some women in the Secondary trial who had a new prolapse operation, although the numbers were quite
low – about 5% – so the additional costs would be expected to be low as well.
It should be noted that in terms of comparison with the clinical trial data set, the model projections
performed reasonably well. However, caution should be noted when comparing the analyses directly as the
model is based on projections and assumptions from the trial data and does not exactly replicate the trial
analyses. Over a 2-year time horizon, the most valid data come from the economic evaluation alongside the
randomised trial. However, 2-year follow-up in itself is not particularly meaningful, and cost-effectiveness
conclusions overall should be drawn on the best possible projection of longer-term costs and QALYs
generated using the modelling approach.
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We present results from the decision-analytic model as incremental cost per QALY gained. Given
recommendations for best practice and requirements for decision-making bodies, such as NICE, cost per QALY
is the most appropriate method by which to judge the value of new technologies to NHS decision-makers.
We initially planned to run the model on the basis of cost per woman cured. However, given the low
proportion of women completely symptom-free across the trial groups at 2 years, such an analysis would not
be meaningful. Furthermore, given difficulty in reaching a consensus on what constitutes ‘cure’, we are
unable to estimate the model for cost per symptom-free woman: such an analysis would lead to misleading
recommendations to decision-makers. We would encourage decision-makers to draw opinions on economic
value from the cost-per-QALY analyses that are presented in the decision modelling chapter (see Chapter 9).
The within-trial results highlighted the uncertainty on the costs and QALYs, and this was reflected in the
modelling analysis. Several assumptions had to be made because of the lack of data. Although there were
data on the number of participants who had further treatment, there were no data on the specific
additional surgery the women had.
Generalisability of results
The base-case analysis results are similar to those that have been previously published;64 however, the
analysis that uses treatment-specific utilities differs, as they indicate that synthetic mesh has a > 50% chance
of being considered to be cost-effective at a society’s WTP threshold of between £20,000 and £30,000.
However, these results have to be treated with caution, taking into account that there is great uncertainty.
Future research
The modelled results project 2-year outcomes over a longer time horizon. However, there is no information
to accurately predict long-term trends and the model essentially extrapolates trends of surgery for
failure and complications over time. This may or may not be an accurate reflection of true failure and
complication rates. It is therefore imperative that further research from the long-term follow-up of the
PROSPECT trial is included before a definitive decision on cost-effectiveness can be reached. The current
model time horizon of 5 years is also too short to definitively determine cost-effectiveness, which should
be estimated over an individual’s whole lifetime. However, insufficient data were available at 2 years to
make this projection. Furthermore, there were insufficient data available in the literature to supplement the
trial data regarding differences in failure rates and complications between the randomised arms over a
longer time horizon. The PROSPECT long-term follow-up will therefore be used to validate or refute the
modelled projections of failures and complications, and will provide more accurate data of time to failure/
complications in order to further extend the modelled time horizon. At this point, there is likely to be a
much clearer knowledge of the true longer-term trade-offs between complications and failure rates for
meshes compared with standard midline repairs for women with primary prolapse repair.
Once the initial stage of longer-term follow-up has been completed, more accurate data will exist to make
longer-term model projections, especially around failure and complication rates. Once 6-year follow-up is
complete, we will conduct a value of information analysis to determine if evidence at this point is sufficient
to make recommendations to decision-makers on cost-effectiveness grounds or if further research is
worthwhile. If we determine positive expected value of perfect information at this stage, we will use
expected value of partial perfect information methods to determine the model parameters that require
more, longer-term data to definitively determine the most cost-effective prolapse surgery strategy for
women who are having their first primary prolapse repair.
Conclusions
Over the 5-year follow-up presented in the model, depending on the utilities used, there was conflicting
evidence regarding the most cost-effective treatment for women with prolapse. Although the outcome
data were extrapolated to 5 years, there is still uncertainty about the long-term failure rates and
complications of all the treatments for both primary and secondary prolapse. As stated in the within-trial
analysis summaries, there is need for longer-term follow-up to better inform decision-makers.
MODELLING
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Chapter 10 Overarching discussion
Summary of findings
The PROSPECT Study has shown that, compared with standard repair, there is no benefit in the first
2 years after surgery to women from the use of synthetic mesh inlay or biological graft inlay in the
treatment of women who were having their first repair of an anterior or posterior pelvic organ prolapse.
In the trial among women who were having a secondary (repeat) repair in either compartment, there was
not enough evidence to say whether synthetic non-absorbable mesh inlay or mesh kit was any more or
less effective than standard repair in the first 2 years after surgery, because the sample size was too small
to be conclusive.
However, there was clear evidence that the majority of women did report improvement in their prolapse
symptoms, QoL and other aspects of urinary and sexual function, whichever operation was chosen. The
majority of women felt that their health was better after surgery, and this effect was sustained for at least
the first 2 years after surgery.
Adverse effects were rare, other than those related to mesh exposure. Importantly, there was no excess
risk in the short term to women from the more complex surgery involved in the use of mesh (e.g. extra
dissection to insert and fix the mesh inlays): the incidence of ‘expected’ adverse effects, such as infection
and bleeding, was similar in all of the groups of women, and infrequent.
Both synthetic mesh inlay and biological graft inlays were more costly than standard repair for women who
were having their first pelvic organ prolapse repair. There was no evidence of differences between treatments
in terms of use of health services over 2 years of follow-up. Despite some uncertainty in cost-effectiveness,
there was no clear compelling evidence to recommend mesh as a cost-effective use of NHS resources based
on the analysis at 2 years. Based on the results of a decision-analytic model to extrapolate trial data over a
longer (5-year) follow-up, there was insufficient evidence to recommend either mesh repair. The results of the
longer-term modelling suggest that the longer-term rate of failure of standard repair would need to increase
substantially relative to synthetic mesh inlay of biological graft inlay before either may be considered
cost-effective.
Strengths and limitations
Pragmatic study
One of the strengths of the PROSPECT Study was its pragmatic reflection of actual practice in a representative
sample of women under the care of UK gynaecologists carrying out prolapse surgery across a large number
of hospital settings. This was reflected in the range of concomitant surgery, and in our ability to differentiate
between women who were having a first or a repeat repair in a particular compartment, defined using the
most up-to-date recommendations for nomenclature.
Validated outcome measures
We used validated, reliable and reproducible instruments to measure outcomes that were relevant and
important to women. Our primary outcome, the POP-SS, comprised seven symptoms that are commonly
reported by women who have prolapse. Our findings were robust whether we used the composite score
or the individual symptoms. The other measures of pelvic floor dysfunction (urinary, sexual, bladder or
bowel) provided similar findings.
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The use of the validated and standardised POP-Q system to objectively measure prolapse provided some
external validity to the trial, in that it is the most commonly reported outcome in the other RCTs that have
examined prolapse surgery.18 We found that although post-surgery measurements were, on average,
better than before, 15% of women who had undergone a primary repair and 10% of women who had a
secondary repair still had a prolapse outside the hymen. This calls into question what can be defined as
‘cure’ of prolapse. We agree with Barber et al.62 – that the important perspective in relation to ‘cure’ is
the woman’s view, encapsulated in her own report of prolapse symptoms, their effect on QoL and her
satisfaction with the overall outcome of surgery, rather than the physical presence of the prolapse.
The mismatch between objective POP-Q and women’s symptoms has been noted by other researchers.3,60
Data from PROSPECT will provide a rich data source for methodological research into which outcomes
matter to women, the relationship between different outcomes, the size of effect, which is important in
clinical terms and hence which outcomes most truly reflects success and failure.
Use of Pelvic Organ Prolapse Quantification and redefinition of ‘failure’
The POP-Q system classes measurements from –1 cm inside the hymen to 1 cm as stage 2.27 We and other
researchers28 have pragmatically used a measurement of > 0 cm to indicate objective failure of treatment,
although recognising that women with worse anatomical findings may not have symptoms and vice versa
(women with objective ‘cure’ may still have prolapse symptoms). This has resulted in a division of Bump et al.’s
stage 2 into 2A (leading edge at the hymen or less, 0 or –1 cm) and 2B (leading edge beyond the hymen,
> 0 cm).27 However, the clinical findings of PROSPECT (in terms of success/failure of treatment) would have
been the same whichever stage of prolapse was chosen as the cut-off.
However, we would encourage the gynaecological community to consider what level of prolapse
constitutes ‘normal vaginal wall laxity’ and which level of prolapse could be considered as clinically
significant. The need for surgery should depend not only on objective findings, but also on the woman’s
clinical symptoms and their effect on QoL, and the chance that surgery is likely to improve them (rather
than improving the anatomical appearance of the prolapse).
Trial design and conduct
We conceived the trial to use primarily a randomised controlled design for maximum scientific reliability.
We designed the study to include CCs of women who were unwilling to be randomised or whose
surgeons were unwilling to randomise them. This provided generalisability but also simplified the process
of recruitment in the centres (in that all women were potentially eligible for one part of the study).
The very high recruitment rate (88% of all eligible women) justified our approach.
We used a secure and unbiased third-party method of randomisation that utilised minimisation to take
account of predictable confounding factors, such as planned concomitant surgery. Allocation was
minimised according to:
l the woman’s age (< 60 years or ≥ 60 years)
l type of prolapse being randomised (anterior, posterior or both)
l need for a concomitant continence procedure (e.g. TVT) or not
l need for a concomitant upper vaginal prolapse procedure (e.g. hysterectomy, cervical amputation,
vault repair) or not
l surgeon.
Web-based randomisation and data entry further simplified the recruitment and follow-up processes.
Our high recruitment rates were matched by high retention rates (withdrawals were rare and non-response
to questionnaires was around 10%). We used evidence-based retention strategies, such as newsletters and
telephone calls, to maintain engagement with our participants.
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Blinding of care providers and participants
It was not possible to blind the surgeon to the randomised procedure. Once in theatre, the surgeon could,
and sometimes did, choose to carry out a different operation to that randomised or that which was
originally planned, if this was clinically indicated. This pragmatic approach reflected real-life practice.
The women, on the other hand, were asked if they would be willing to remain blinded to the surgery to
which they had been randomised, and that which was actually carried out, unless there was a clinical need
to reveal this information. The majority of the women agreed to this. As the primary outcome was their
self-reported prolapse symptoms by questionnaire at intervals after surgery, this would be expected to
reduce the chance that they might report ‘better’ or ‘worse’ symptoms or QoL, depending on their attitude
to the surgery that they actually received.
Blinding of outcome assessors and participants
Data entry from the questionnaires was carried out by staff blinded to randomisation and surgery actually
conducted, using study numbers only to identify participants. The clinical examination at 1 year was carried
out by staff similarly blinded, before looking at the medical notes to find out what had been done. The
women were asked not to disclose any information that they knew about their surgery before they had
been examined. This process was successful in 90% of cases for blinding to randomised allocation, and in
83% of cases for blinding to treatment received.
Generalisability
The inclusion of around 1500 non-randomised women in a CC had a number of advantages. By and large,
the populations in the RCTs and CCs were similar for both the women who were having primary surgery
and those who were having repeat surgery, suggesting that the findings from the randomised women are
generalisable to the larger population of women who are having prolapse surgery in the UK. As the
outcomes in the CCs were similar to those of the comparable randomised women, we conclude that the
findings of the RCTs are generalisable to the whole population of women who are having prolapse surgery
in the UK.
The inclusion of the CCs also increased the power of the study to identify the background rate of adverse
effects in women who are having prolapse surgery. In particular, more women who were having repeat
surgery entered the non-randomised group, sometimes by their own choice to have mesh and sometimes
because their surgeon felt that mesh was indicated. Despite this, their outcomes were broadly similar to
those of the women who were randomised.
Primary compared with secondary (repeat) surgery
When we planned PROSPECT, we found a range of views among gynaecologists about the value of mesh
and its place in women who are having prolapse surgery. In general, those who were less likely to use
mesh thought that it might be of more value in women who had already had a failed previous repair,
as it was known that those women were even more likely to have a failed repeat repair.4 This led to our
decision to run two separate RCTs, according to whether the compartment had previous surgery
(secondary) or not (primary). We did find important demographic differences between these populations of
women (see Chapter 3), justifying our decision to run two trials.
Although we knew that there would be fewer women available for the Secondary trial, the numbers were
further reduced by our strict definition, such that some women who had undergone prolapse surgery in
the past, but in a different compartment, were deemed to be eligible for the Primary trial. In addition, the
women and their surgeons were less open to randomisation, with 61% declining randomisation but being
willing to enter CC2.
For these reasons, we are unable to be conclusive about the findings in the Secondary trial. In particular,
our assumption that these women were more likely to require non-absorbable mesh to provide a stronger
repair cannot be reliably confirmed or denied.
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Analysis by strata
We found that some surgeons were not able to randomise women to all of the three arms in each trial,
for reasons including personal preference, availability of mesh or training in a particular technique.
As a result, the Primary trial consisted of three strata (a three-arm trial and two two-arm trials comparing
standard with synthetic mesh and standard with biological graft). Similarly, the Secondary trial consisted
of three strata (a three-arm trial and two two-arm trials comparing standard with synthetic mesh and
standard with mesh kit). An advantage was that this allowed extra surgeons and centres to participate,
thus boosting the potential population and shortening the trial.
A limitation is that, in order to calculate unbiased estimates of treatment effects, we could use only two
out of three strata in any analysis (strata A + B for comparisons with synthetic mesh, strata A + C for
comparisons with biological graft). However, the power of the analysis was reduced by only a modest
amount because the three-arm stratum A was the largest stratum in both the Primary and Secondary RCTs
and was used in every analysis.
Economic analysis
A full economic evaluation was conducted alongside the Primary and Secondary trials, following best
practice guidelines for economic evaluations. Furthermore, a longer-term decision-analytic model was
developed to extrapolate the trial outcomes over a longer (5-year) time horizon. The decision-analytic
model projects longer-term failure and complications rates for each treatment based on the data observed
in the trial. Although this allows for a longer-term assessment of cost-effectiveness, the data used to
populate the model may not reflect the true longer-term rates of complications and failures. The data
presented from the model are a best estimate of future cost and QALY implications for primary prolapse
repair treatments based on the current data available. Longer-term follow-up data from PROSPECT will be
used to validate the model structure and parameters. These data will inform an updated model, which will
project cost-effectiveness results over a much longer time horizon. This will enable a more comprehensive
assessment of lifetime costs and outcomes of prolapse surgery.
A limitation of the economic analysis is that there were insufficient data to model the longer-term costs
and outcomes specifically relating to secondary prolapse repair. Further information is required to robustly
assess any differences in long-term cost-effectiveness of mesh for women who were having a secondary
prolapse repair.
Need for further research among women requiring treatment for secondary prolapse
As noted, our findings for women who were having repeat surgery were inconclusive because of the small
sample size. Although we expected 3 in 10 of the women to be eligible for the secondary group, the numbers
were lower because our strict definition of ‘repeat surgery’ (according to the most recent classification
this is now defined as ‘in the same compartment’57) and because fewer than expected were willing to be
randomised. Those women have a higher risk of failure than those having their first procedure.4 A further RCT
among women who have already had a previous failure in a particular compartment is therefore needed so
that we can offer them sound evidence-based advice (see also Chapter 11).
Meaning of the study
Comparison with the most recent Cochrane review
PROSPECT has shown that, in the first 2 years after surgery, there is no benefit to women who were
having their first repair either in terms of prolapse symptoms or anatomical cure from the use of synthetic
mesh, biological graft or (less conclusively, because of smaller sample size) mesh kit to reinforce a standard
anterior or posterior repair. This contradicts the conclusions of the most recent Cochrane review in 2013,18
which found both fewer women with prolapse symptoms with synthetic mesh (RR 1.44, 95% CI 1.15
to 1.80; nine RCTs including 930 women) compared with standard repairs and less objective prolapse
(in terms of anatomical measurements: RR 2.45, 95% CI 1.64 to 3.67; 11 RCTs, 1150 women).
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On the other hand, our findings concur with the uncertainty of the 2013 evidence18 for a difference for
biological grafts (RR for number of women with symptoms 1.03, 95% CI 0.61 to 1.75; three RCTs,
400 women; RR for objective failure 1.35, 95% CI 0.74 to 2.46; six RCTs, 560 women) but with
narrower CIs.
Comparison with other randomised controlled trials of no mesh compared
with mesh use in prolapse repair
We have now updated the findings of the 2013 Cochrane review18 by adding information from a further
13 RCTs and two studies, which updated information on already included RCTs. This new systematic
review now includes information from 4232 women, in addition to the current PROSPECT data from
1348 women who were having primary surgery and 154 having repeat surgery (5734 women in total;
see Appendix 7).
The new message from this updated review is that, including additional evidence from the 13 new RCTs
and PROSPECT, the overall result no longer favours synthetic non-absorbable mesh inlay in terms of
the number of women with prolapse symptoms [(36% after standard repair vs. 30% after mesh inlay;
RR at 1 year 1.17, 95% CI 1.00 to 1.37; six RCTs; 1210 women; see Figure 35); (31% compared with
28%; RR at 2 years 1.11, 95% CI 0.94 to 1.33; six RCTs, 1175 women; see Figure 36)]. However, mesh
inlay still seemed to be better than standard repair in that fewer women had objective residual prolapse
[(27% after standard repair vs. 11% with mesh inlay; RR at 1 year 2.79, 95% CI 1.83 to 4.26; 16 RCTs;
2360 women; see Figure 37); (44% vs. 19%; RR at 2 years 2.53, 95% CI 1.52 to 4.22, eight RCTs,
700 women; see Figure 38)]. This difference in objective findings did not translate into a greater number of
women who were having further prolapse surgery by 2 years (5% after standard repair vs. 4% with mesh
inlay; RR 1.23, 95% CI 0.85 to 1.79; 13 RCTs, 2238 women; see Figure 39).
In contrast, findings for mesh kits were conflicting. At 1 year, fewer women had prolapse symptoms after
standard repair (35% vs. 48% after mesh kit; RR 0.73, 95% CI 0.59 to 0.90; three RCTs; 495 women;
see Figure 35), but at 2 years the numbers were small and the difference was not statistically significant
(RR 1.10, 95% CI 0.79 to 1.53; two RCTs; 151 women; see Figure 36). Although fewer women had
symptoms at 1 year, more women had objective prolapse after standard repair (46% vs. 11% after mesh kit,
RR 3.67, 95% CI 2.07 to 6.52; four RCTs, 342 women; see Figure 37) and more women required further
prolapse surgery (5% vs. 1.6% after mesh kit; RR 3.65, 95% CI 1.51 to 8.86; five RCTs, 746 women; see
Figure 39), although the total number of women needing surgery (n = 24) was small. These counterintuitive
results underline the lack of concordance between subjective and objective prolapse outcomes.
There were no new trials testing the effects of biological grafts. The inclusion of data from the PROSPECT
Primary trial (see Chapter 4) has made little difference to the findings. They show either no benefit from
the use of biological grafts or marginally favour the no-graft standard repair (e.g. number of women with
prolapse symptoms at 2 years; 28% vs. 35% with graft; RR 0.78, 95% CI 0.63 to 0.97; three RCTs,
737 women; see Figure 36).
It is difficult to understand why meta-analysis from numerous smaller trials should have previously
demonstrated advantages from synthetic mesh in terms of symptoms and anatomical findings in contrast
with the findings from PROSPECT. It may be that a single large trial that is free from risk of bias is more
powerful than a meta-analysis of many smaller trials of cumulatively equal size (Professor Adrian Grant,
HSRU, November 2014, personal communication) but other factors may play a role.
Women requiring repeat prolapse surgery
The previous RCTs included in the most recent Cochrane review18 rarely reported their outcome data
separately according to the crucial baseline characteristic of repeat surgery. Even when they did, they
identified potentially eligible women as having had ‘any previous prolapse surgery’ rather than our stricter
definition of ‘in the same compartment’. Therefore, it is likely that the data from those RCTs cannot be
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combined with those from the secondary group in PROSPECT because of the heterogeneity in baseline
classification. This is further discussed in Chapter 11.
Long-term follow-up
Given that surgical failures requiring repeat repair occur, on average, 12 years after initial surgery,
longer-term follow-up is required to determine true effectiveness, cost-effectiveness and other sequelae of
mesh or graft insertion. We are funded to follow PROSPECT women in the longer term (for 6 years after
surgery in the first instance) to establish the true incidence of surgical failure and long-term adverse effects.
Adverse effects and mesh complications
Complications from mesh insertion were few and, in general, resolved within the first 2 years. It remains to
be established if there are important long-term adverse effects from the use of mesh or if these may still
be offset by a reduction in the need for repeat prolapse surgery in the long term.
Although there were no differences in outcomes related to pain or dyspareunia (see Tables 22, 23, 29, 57,
58 and 64), the effect of mesh or indeed non-mesh prolapse surgery on long-term pain requires
quantitative and qualitative evaluation. This is hampered by the lack of effective outcome measures for
pain. Ideally, the issue of chronic pain should now be addressed prospectively using standard definitions
and allowing assessment of the degree of pain, as has also been noted in the context of hernia surgery.65
Conclusions
In summary, there is no clear superiority of the synthetic mesh, biological graft or mesh kit over standard
repair in the first 2 years after surgery. Unless there is a significant decrease in the reoperation rates for
failure in the medium or long term in the mesh or graft arms relative to standard repair, it is unlikely that
any type of mesh or graft is going to be cost-effective, given the excess cost over standard repair and the
excess cost of treatment for the adverse effect of mesh exposure or extrusion. Long-term follow-up is
now ongoing.
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Chapter 11 Conclusions and recommendations
The PROSPECT Study includes the largest multicentre RCT evaluating the use of mesh in women who arehaving a first anterior or posterior prolapse repair, and also separately in women who are having repeat
operations. It has comprehensively assessed both the clinical effectiveness and cost-effectiveness of the
use of mesh within the UK NHS, and the results are generalisable to the community of women with these
types of prolapse.
The 1- and 2-year results have demonstrated that there is no extra clinical benefit from mesh in women
who are having their first repair in terms of prolapse symptoms or anatomical resolution of the prolapse.
The incidence of adverse effects (other than mesh exposure) was similar in women who had surgery with
or without mesh or graft. The findings on prolapse symptoms, anatomical prolapse and adverse effects are
not conclusive in women who are having a repeat repair, as a result of the smaller sample size, but are of
the same order.
Equally, however, the short-term result of the prolapse surgery studied for all of the groups was good in
terms of relief of prolapse symptoms and satisfaction rates, achieved in > 80% of women, although 8% in
the primary RCT and 10% in the secondary RCT had a complication that was classified as serious in the
first year (excluding mesh exposure). These benefits were retained to 2 years, but long-term follow-up of
the participants in PROSPECT is essential to identify the need for repeat or further prolapse surgery and the
development of new adverse effects.
Implications for practice
Based on the findings of PROSPECT, there does not appear to be a reason to suggest to women who were
having their first repair that mesh can improve their outcomes in the first 2 years after prolapse surgery.
However, there may be yet unidentified benefits in the medium or longer time span in terms of reduced
need for repeat prolapse surgery. Long-term follow-up is required to identify any potential benefit and,
crucially, late presentation of adverse effects that may affect women’s health and QoL. Assessment of any
longer-term trade-offs between the need for reoperation and longer-term adverse effects will ultimately
inform decision-makers with regard to the most cost-effective treatment strategy.
Because of the risks of any surgery, women should be advised to first explore other effective means to
manage their prolapse symptoms before resorting to surgery. These may include modification of lifestyle
factors, such as obesity and heavy lifting, the use of pessaries, PFMT and other forms of exercise, and, for
postmenopausal women, local oestrogen treatment.
Implications for research
The evidence consistently shows that 30% of women who have surgery for prolapse will require further
prolapse surgery in either the same or a different compartment in the long term. Long-term follow-up
information from PROSPECT will provide detailed prognoses for different clinical groups of women, such as
those who were having a first or repeat repair, who did and did not have combined prolapse surgery in
more than one compartment, and with or without concomitant surgery. The longer-term follow-up data
will provide crucial evidence to more definitively determine the most cost-effective treatment strategy for
primary prolapse repair.
Treatment for women with secondary prolapse
Research is required to determine whether the need for further surgery can be reduced if a first prolapse
operation fails. Those women have a higher risk of failure than those having their first procedure, and had
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a higher symptom score before surgery, indicating worse prolapse symptoms (see Table 8). A further RCT
among women who have already had a previous failure in a particular compartment would therefore be
needed so that we can offer them sound evidence-based advice. However, given the results of PROSPECT
to date, strong doctor/patient preferences and the current political and medico-legal climate, it is unlikely
that any UK surgeons would be willing or able to ‘continue’ the Secondary trial. It may be that in other
countries (such as France) where mesh is still widely used, a new trial would be feasible.
It is also possible that the long-term follow-up of PROSPECT, which includes CC women who were not
randomised, will provide more detailed information on the outcomes of women who have more than one
operation. Previous research has rarely focused on this group of women. Arguably, their higher level of
symptoms and risk of failure might make them more tolerant of a higher risk of adverse effects if their
overall outcomes can be improved.
An alternative approach would be an individual patient data meta-analysis of existing mesh surgery trials,
which would require international co-operation from the triallists and participants who were randomised in
earlier trials. The updated evidence (see Appendix 7) contains information from about 5700 women (of
whom 1500 are from PROSPECT) who were randomised to standard repair compared with a repair plus
mesh or graft. Given that approximately 30% would be having a new repair, data from 1700 women might
be available, giving 850 per arm and sufficient power to detect clinically meaningful differences. However,
only about two-thirds of these were trials of synthetic mesh and it is unlikely that enough triallists would be
able to provide comparable data from sufficient women, given the wide variation in the methods and types
of outcome reporting and how ‘secondary’ prolapse surgery has been defined in the past.
Other prolapse research
New research is required into the reasons for the poor outcomes of surgery, which may suggest specific
ways to improve practice. These might include:
l differences in surgical technique (which has been shown to vary considerably within PROSPECT)
l training of surgeons in the most effective surgical techniques
l better definition of the defects resulting in prolapse, including training in examination techniques, such
as the POP-Q
l better selection of women who may or may not respond well to prolapse surgery (e.g. risk factors such
as younger age, obstetric history)
l timing of that surgery in relation to the natural history of the progression of prolapse symptoms
l the effect of prolapse surgery on concomitant symptoms of pelvic floor dysfunction, such as bladder,
bowel and sexual function
l aspects of postoperative management that may affect success, such as the need for vaginal packing
l the need to treat prolapse in more than one compartment
l the value of and need for concomitant continence surgery
l the value of preoperative and postoperative PFMT
l the value of preoperative and postoperative oestrogen treatment in postmenopausal women, and
l whether or not women who appear to have a genetic predisposition to prolapse have a higher rate of
surgical failure, and whether or not this can be modified.
In addition, research is required into means of prevention of prolapse or slowing down prolapse
progression. The identification of remediable causes of prolapse, or identification of factors related to
poorer outcomes (such as obesity) may suggest alternative or concomitant treatments to help women.
Research should use validated and standardised terminology, and classification of conditions. In particular,
it should use outcome measures that focus on the needs of women by addressing their perception of
prolapse symptoms, the effect on their QoL and avoidance of adverse effects, rather than anatomical
(objective) cure.
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One important outcome is pain, but effective outcome measures for pain need to be developed. Ideally,
the issue of chronic pain should now be addressed prospectively using standard definitions and allowing
assessment of the degree of pain, as has also been noted in the context of hernia surgery.65
Any further research undertaken should include (where feasible and sensible to do so) comprehensive
evaluation of the cost (to both the NHS and to women themselves) and QoL implications of treatment
strategies on the UK NHS. When RCTs are undertaken to address questions of clinical importance, these
should be accompanied by full and comprehensive economic evaluation studies. Such studies should,
ideally, and where data allow, include decision-analytic modelling to explore long-term implications of
treatment decisions.
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The PROSPECT Study is investigating which 
prolapse operations are the safest and most 
effective for women with pelvic organ prolapse  
 
If you are having prolapse surgery you may be 
able to take part 
 
For further information please talk to your 
gynaecologist and/or the 
PROSPECT Recruitment Officer: 
XXXXXXX 
Email  
 
The PROSPECT website is: 
https://www.charttrials.abdn.ac.uk/prospect/ 
 
 
 
 
 
The PROSPECT trial is funded by the NHS National Institute for Health Research 
Evaluation, Trials and Studies Coordinating Centre, Health Technology 
Assessment (NETSCC HTA) Programme.  The Chief Investigator is Prof C 
Glazener and the Trial Office is based within CHaRT (Centre for Healthcare 
Randomised Trials) in the Health Services Research Unit, University of Aberdeen. 
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lth
 S
er
vi
ce
s 
Re
se
ar
ch
 U
ni
t
Un
iv
er
si
ty
 o
f A
be
rd
ee
n
H
ea
lth
 S
ci
en
ce
s 
Bu
ild
in
g
Fo
re
st
er
hi
ll
A
be
rd
ee
n
A
B
25
 2
ZD
Te
l. 
Th
an
k 
yo
u 
fo
r r
ea
di
ng
 th
is
 a
nd
 c
on
si
de
rin
g
ta
ki
ng
 p
ar
t i
n 
th
is
 s
tu
dy
.
PA
TI
EN
T 
IN
FO
RM
AT
IO
N
LE
A
FL
ET
Th
e 
pu
rp
os
e 
of
 th
e 
PR
O
SP
EC
T 
re
se
a
rc
h 
st
ud
y 
is 
to
 c
om
pa
re
th
e 
re
su
lts
 o
f d
iff
er
en
t t
yp
es
 o
f s
ur
ge
ry
 fo
r w
om
en
 w
ith
 v
ag
in
al
w
a
ll p
ro
la
ps
e,
 in
 o
rd
er
 to
 id
en
tif
y 
th
e 
m
os
t e
ffe
ct
ive
 a
nd
 e
ffi
cie
nt
o
pe
ra
tio
n.
Pl
ea
se
 ta
ke
 ti
m
e 
to
 re
ad
 th
is
 in
fo
rm
at
io
n 
le
af
le
t a
nd
 d
is
cu
ss
it 
w
ith
 y
ou
r f
am
ily
, 
fri
en
ds
 o
r G
P 
if 
yo
u 
w
is
h.
D
o 
no
t h
es
ita
te
 to
 c
on
ta
ct
 u
s 
if 
th
er
e 
is
 a
ny
th
in
g 
yo
u 
do
 n
ot
u
n
de
rs
ta
nd
 o
r i
f y
ou
 w
ou
ld
 li
ke
 m
or
e 
in
fo
rm
at
io
n.
Ve
rs
io
n 
3:
 0
1 
Ap
ril
 2
01
0
P
r
o
l
a
p
s
e
S
u
r
g
e
r
y
: 
P
r
a
g
m
a
t
ic
 E
v
a
l
u
a
t
io
n
a
n
d
 r
a
n
d
o
m
is
e
d
 C
o
n
t
r
o
l
l
e
d
 T
r
ia
l
s
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1.
D
es
cr
ip
tio
n 
of
 S
tu
dy
Th
er
e 
ar
e 
m
an
y d
iffe
re
nt
 o
pe
ra
tio
ns
 fo
r p
ro
la
ps
e,
 d
ep
en
di
ng
 o
n 
th
e
ty
pe
 o
f 
pr
ol
ap
se
 w
om
en
 h
av
e 
an
d 
wh
et
he
r 
it 
is 
th
e 
fir
st
 o
r 
a
su
bs
eq
ue
nt
 p
ro
la
ps
e 
op
er
at
io
n.
 T
yp
es
 o
f p
ro
la
ps
e 
in
clu
de
 th
e 
fro
nt
w
al
l o
f t
he
 v
ag
in
a 
[an
 an
ter
ior
 pr
ola
ps
e] 
an
d/o
r a
 pr
ola
ps
e t
o t
he
ba
ck
 w
al
l [a
 po
ste
rio
r p
rol
ap
se
]. T
he
re
 is
 n
ot
 e
no
ug
h 
ev
ide
nc
e 
fro
m
pr
ev
io
us
 re
se
ar
ch
 to
 le
t u
s k
no
w 
wh
ich
 o
pe
ra
tio
ns
 sh
ou
ld
 b
e 
us
ed
. 
2.
W
hy
 h
av
e 
I b
ee
n 
in
vi
te
d 
to
 ta
ke
 p
ar
t?
Yo
u
 a
re
 b
ei
ng
 in
vit
ed
 t
o 
ta
ke
 p
ar
t 
in
 t
he
 P
RO
SP
EC
T 
st
ud
y
be
ca
us
e 
yo
u 
wi
ll b
e 
ha
vin
g 
an
 o
pe
ra
tio
n 
fo
r y
ou
r v
ag
in
al
pr
ol
ap
se
.
Be
fo
re
 y
ou
 d
ec
id
e,
 it
 is
 im
po
rta
nt
 fo
r y
ou
 to
 u
nd
er
st
an
d 
wh
y 
th
e
re
se
a
rc
h 
is
 b
ei
ng
 d
on
e 
an
d 
wh
at
 it
 w
ill 
in
vo
lve
. P
le
as
e 
ta
ke
 ti
m
e
to
 re
ad
 th
e 
fo
llo
wi
ng
 in
fo
rm
at
io
n 
ca
re
fu
lly
.
 
3.
B
ac
kg
ro
un
d
O
ne
 in
 te
n 
wo
m
en
 w
ill 
ne
ed
 a
n 
op
er
at
io
n 
fo
r p
ro
la
ps
e.
 A
ll 
th
e
ty
pe
s o
f p
ro
la
ps
e 
su
rg
er
y t
ha
t y
ou
 m
ig
ht
 u
nd
er
go
 in
 th
is 
st
ud
y a
re
in
 c
om
m
on
 u
se
 in
 th
e 
N
H
S.
 
Th
er
e 
ar
e 
se
ve
ra
l d
iff
e
re
n
t p
ro
la
ps
e 
op
er
at
io
ns
 c
ur
re
nt
ly 
be
in
g
u
se
d 
su
cc
es
sf
ul
ly 
in
 th
e 
NH
S,
 s
om
e 
of
 w
hi
ch
 in
clu
de
 th
e 
us
e 
of
m
e
sh
 o
r g
ra
ft 
m
at
er
ia
ls.
 M
es
h 
is 
th
ou
gh
t t
o 
pr
ov
id
e 
ex
tra
 s
up
po
rt
fo
r t
he
 p
ro
la
ps
e 
wh
ile
 it
 is
 h
ea
lin
g,
 th
us
 p
os
sib
ly 
re
du
cin
g 
th
e
ch
an
ce
 o
f f
ai
lu
re
. O
n 
th
is 
ba
sis
, s
om
e 
do
ct
or
s 
ar
e 
al
re
ad
y 
us
in
g
m
e
sh
 i
n 
th
ei
r 
pr
ol
ap
se
 s
ur
ge
ry
.
 
W
e
 d
o 
no
t 
kn
ow
,
 
ho
w
ev
er
,
w
he
th
er
 th
er
e 
ar
e 
m
or
e 
co
m
pl
ica
tio
ns
 w
ith
 m
es
h 
co
m
pa
re
d 
wi
th
o
pe
ra
tio
ns
 w
ith
ou
t m
es
h.
 W
e
 
n
e
e
d 
to
 b
e 
ab
le
 to
 e
va
lu
at
e 
th
es
e
di
ffe
re
nt
 o
pe
ra
tio
ns
, 
pa
rti
cu
la
rly
 i
n 
th
e 
lo
ng
 t
er
m
, 
an
d 
yo
ur
pa
rti
cip
at
io
n 
in
 th
e 
st
ud
y 
wi
ll h
el
p 
us
 d
o 
so
.
If 
yo
u 
be
ca
m
e 
un
ab
le
 o
r u
nw
illi
ng
 to
 c
on
tin
ue
 in
 P
RO
SP
EC
T,
 
w
e
w
o
u
ld
 
wi
th
dr
aw
 
yo
u 
fro
m
 
th
e 
st
ud
y. 
W
e
 
w
o
u
ld
 
re
ta
in
,
co
n
fid
en
tia
lly
,
 
th
e 
re
le
va
nt
 i
nf
or
m
at
io
n 
th
at
 w
e 
ha
d 
al
re
ad
y
co
lle
ct
ed
 a
bo
ut
 y
ou
 fo
r t
he
 p
ur
po
se
s 
of
 th
e 
st
ud
y 
on
ly.
 
10
.
W
ho
 is
 d
oi
ng
 th
is
 s
tu
dy
?
Th
is 
st
ud
y i
s b
ei
ng
 fu
nd
ed
 b
y t
he
 N
HS
 N
at
io
na
l In
st
itu
te
 fo
r H
ea
lth
R
es
ea
rc
h 
Ev
al
ua
tio
n,
 T
ria
ls
 a
nd
 S
tu
di
es
 C
oo
rd
in
at
in
g 
Ce
nt
re
,
H
ea
lth
 Te
ch
no
lo
gy
 A
ss
es
sm
en
t p
ro
gr
am
m
e 
(N
ET
SC
C 
H
TA
). T
he
re
se
a
rc
h 
is
 b
ei
ng
 c
ar
rie
d 
ou
t b
y 
a 
gr
ou
p 
of
 e
xp
er
ie
nc
ed
 d
oc
to
rs
a
n
d 
re
se
ar
ch
er
s 
fro
m
 th
e 
He
al
th
 S
er
vic
es
 R
es
ea
rc
h 
Un
it 
at
 th
e
Un
ive
rs
ity
 o
f A
be
rd
ee
n 
in
 c
ol
la
bo
ra
tio
n 
wi
th
 th
e 
Br
itis
h 
So
cie
ty
 o
f
Ur
og
yn
ae
co
lo
gi
st
s,
 w
hi
ch
 i
s 
pa
rt 
of
 t
he
 R
oy
al
 C
ol
le
ge
 o
f
O
bs
te
tri
cia
ns
 a
nd
 G
yn
ae
co
lo
gi
st
s.
 
11
.
W
ho
 h
as
 a
pp
ro
ve
d 
th
is
 s
tu
dy
?
Co
m
m
itt
ee
 T
w
o 
of
 th
e 
No
rth
 o
f S
co
tla
nd
 R
es
ea
rc
h 
Et
hi
cs
 S
er
vic
e,
yo
ur
 lo
ca
l h
os
pi
ta
l a
nd
 yo
ur
 g
yn
ae
co
lo
gi
ca
l c
on
su
lta
nt
 h
av
e 
gi
ve
n
a
pp
ro
va
l fo
r t
hi
s s
tu
dy
 to
 b
e 
ca
rri
ed
 o
ut
. A
n 
in
de
pe
nd
en
t S
te
er
in
g
Co
m
m
itt
ee
 a
nd
 a
 D
at
a 
M
on
ito
rin
g 
Co
m
m
itt
ee
 w
ill 
m
on
ito
r s
af
et
y
a
n
d 
en
su
re
 th
at
 th
e 
st
ud
y 
is 
co
nd
uc
te
d 
in
 a
cc
or
da
nc
e 
wi
th
 g
oo
d
re
se
a
rc
h 
pr
ac
tic
e.
 
12
.
H
ow
 d
o 
I g
et
 in
 to
uc
h 
w
ith
 th
e 
re
se
ar
ch
 te
am
 if
 I 
w
an
t a
ny
fu
rth
er
 in
fo
rm
at
io
n 
ab
ou
t t
he
 s
tu
dy
?
If 
yo
u 
ha
ve
 a
ny
 q
ue
st
io
ns
 a
bo
ut
 th
e 
st
ud
y, 
o
r 
a
n
y 
as
pe
ct
 o
f y
ou
r
tre
at
m
en
t o
r h
ea
lth
, p
le
as
e 
sp
ea
k t
o 
yo
ur
 P
RO
SP
EC
T 
re
cr
ui
tm
en
t
o
ffi
ce
r o
r y
ou
r o
wn
 g
yn
ae
co
lo
gy
 c
on
su
lta
nt
 o
r G
P.
 
 
Al
te
rn
at
iv
el
y
yo
u 
ca
n 
co
nt
ac
t t
he
 P
RO
SP
EC
T 
St
ud
y 
O
ffi
ce
 (d
eta
ils
 ov
erl
ea
f).
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8.
H
ow
 w
ill
 th
e 
in
fo
rm
at
io
n 
I p
ro
vi
de
 b
e 
us
ed
?
W
e
 h
op
e 
th
at
 o
ve
r 4
00
0 
wo
m
en
 w
ill 
ta
ke
 p
ar
t i
n 
th
is 
st
ud
y 
du
rin
g
th
e 
ne
xt
 th
re
e 
ye
ar
s i
n 
ce
nt
re
s a
cr
os
s t
he
 U
K.
 G
yn
ae
co
lo
gi
st
s w
ill
be
 in
fo
rm
ed
 o
f t
he
 re
co
m
m
en
da
tio
ns
 
fro
m
 th
e 
st
ud
y, 
so
 th
at
 in
fu
tu
re
 a
ll w
om
en
 c
an
 re
ce
ive
 th
e 
be
st
 a
nd
 s
af
es
t o
pe
ra
tio
ns
. T
he
re
su
lts
 o
f t
he
 s
tu
dy
 w
ill 
be
 p
ub
lis
he
d 
in
 s
cie
nt
ific
 jo
urn
als
 an
d a
sh
or
t v
er
si
on
 w
ill 
al
so
 b
e 
av
ai
la
bl
e 
to
 th
os
e 
wo
m
en
 w
ho
 to
ok
 p
ar
t
in
 th
e 
st
ud
y 
if 
th
ey
 w
ish
. W
o
m
e
n
 w
ill 
no
t b
e 
id
en
tif
ia
bl
e 
in
 a
ny
 o
f
th
e 
st
ud
y 
re
po
rts
. 
9.
W
ha
t i
f t
he
re
 is
 a
 p
ro
bl
em
?
W
e
 d
o 
no
t e
xp
ec
t a
ny
 h
ar
m
 to
 c
om
e 
to
 y
ou
 b
y 
ta
kin
g 
pa
rt 
in
 th
is
st
ud
y. 
Al
l t
he
 m
at
er
ia
ls
 a
nd
 te
ch
ni
qu
es
 a
re
 a
lre
ad
y 
be
in
g 
us
ed
 in
th
e 
N
H
S 
fo
r p
ro
la
ps
e 
su
rg
er
y. 
Yo
u
r 
pa
rti
cip
at
io
n 
in
 th
e 
st
ud
y 
is
th
er
ef
or
e 
on
ly 
to
 h
el
p 
us
 e
va
lu
at
e 
th
es
e 
pr
oc
ed
ur
es
 a
nd
 s
ho
ul
d
n
o
t i
nv
ol
ve
 a
ny
 a
dd
itio
na
l r
isk
 to
 y
ou
. 
If 
yo
u 
ha
ve
 a
 c
on
ce
rn
 a
bo
ut
 a
ny
 a
sp
ec
t o
f t
he
 s
tu
dy
,
 
yo
u 
sh
ou
ld
a
sk
 to
 s
pe
ak
 w
ith
 th
e 
re
se
ar
ch
 te
am
 w
ho
 w
ill 
do
 th
ei
r b
es
t t
o
a
n
sw
e
r 
yo
ur
 q
ue
st
io
ns
 (p
ho
ne
If 
yo
u 
ar
e 
st
ill
co
n
ce
rn
e
d 
an
d 
wi
sh
 to
 c
om
pl
ai
n 
fo
rm
al
ly,
 yo
u 
ca
n 
do
 th
is 
th
ro
ug
h
th
e 
N
H
S 
Co
m
pl
ai
nt
s P
ro
ce
du
re
. D
et
ai
ls 
ca
n 
be
 o
bt
ai
ne
d 
fro
m
 th
e
ho
sp
ita
l.
Ta
ki
ng
 p
ar
t i
n 
th
is 
st
ud
y 
do
es
 n
ot
 a
ffe
ct
 y
ou
r n
or
m
al
 le
ga
l r
ig
ht
s.
W
he
th
er
 o
r n
ot
 y
ou
 d
o 
ta
ke
 p
ar
t, 
yo
u 
wi
ll 
re
ta
in
 th
e 
sa
m
e 
le
ga
l
rig
ht
s a
s a
ny
 o
th
er
 p
at
ie
nt
 in
 th
e 
NH
S 
(w
hic
h i
nc
lud
e p
rof
es
sio
na
l
in
de
m
ni
ty
 in
su
ra
nc
e 
fo
r n
eg
lig
en
ce
). I
f y
ou
 w
ish
 to
 co
mp
lai
n a
bo
ut
yo
ur
 h
ea
lth
 c
ar
e 
or
 a
ny
 a
sp
ec
ts
 o
f t
hi
s 
st
ud
y, 
th
e 
no
rm
al
 N
H
S
m
e
ch
an
is
m
s 
w
ill 
be
 a
va
ila
bl
e 
to
 y
ou
. A
lth
ou
gh
 w
e 
do
 n
ot
 e
xp
ec
t
pa
rti
cip
at
io
n 
to
 a
ffe
ct
 p
riv
at
e 
m
ed
ica
l in
su
ra
nc
e,
 p
le
as
e 
ch
ec
k w
ith
yo
ur
 in
su
re
rs
 b
ef
or
e 
ag
re
ei
ng
 to
 ta
ke
 p
ar
t i
n 
th
e 
st
ud
y. 
 
Yo
u
 w
ill 
no
t h
av
e 
to
 u
nd
er
go
 a
ny
 te
st
s 
or
 p
ro
ce
du
re
s 
th
at
 a
re
 n
ot
pa
rt 
of
 ro
ut
in
e 
ca
re
 fo
r p
ro
la
ps
e.
 
Th
er
e 
m
ay
 b
e 
no
 d
ire
ct
 b
en
ef
it 
to
 y
ou
 if
 y
ou
 d
o 
ta
ke
 p
ar
t, 
bu
t y
ou
w
ill 
be
 h
el
pi
ng
 w
ith
 im
po
rta
nt
 re
se
ar
ch
 e
na
bl
in
g 
do
ct
or
s t
o 
as
se
ss
w
hi
ch
 o
pe
ra
tio
n 
is 
be
st
 a
nd
 s
af
es
t. 
4.
W
ha
t i
s 
th
e 
pu
rp
os
e 
of
 th
e 
st
ud
y?
Th
e 
ai
m
 o
f t
he
 s
tu
dy
 is
 to
 a
ns
we
r t
wo
 m
ai
n 
qu
es
tio
ns
: (1
) w
hic
h
o
f t
he
 o
pe
ra
tio
ns
 g
ive
s 
th
e 
be
st
 re
su
lts
 a
nd
 is
 s
af
es
t, 
an
d 
(2)
w
he
th
er
 o
r 
no
t 
th
e 
us
e 
of
 m
es
h 
im
pr
ov
es
 w
om
en
’s 
pr
ol
ap
se
sy
m
pt
om
s 
wi
th
ou
t c
au
sin
g 
ex
tra
 p
ro
bl
em
s.
 T
he
re
fo
re
, o
nc
e 
we
ha
ve
 th
e 
re
su
lts
 o
f P
RO
SP
EC
T,
 
do
ct
or
s 
in
 th
e 
fu
tu
re
 s
ho
ul
d 
be
a
bl
e 
to
 c
ho
os
e 
th
e 
pr
ol
ap
se
 su
rg
er
y t
ha
t h
as
 th
e 
be
st
 re
su
lts
 w
ith
th
e 
fe
w
es
t p
ro
bl
em
s.
 T
hi
s 
w
ill 
m
ea
n 
fe
w
er
 r
ep
ea
t o
pe
ra
tio
ns
,
be
tte
r h
ea
lth
 a
nd
 q
ua
lity
 o
f l
ife
 fo
r w
om
en
, a
nd
 b
et
te
r u
se
 o
f N
HS
fa
cil
itie
s.
5.
D
o 
I h
av
e 
to
 ta
ke
 p
ar
t?
It 
is 
up
 to
 y
ou
 w
he
th
er
 y
ou
 d
ec
id
e 
to
 ta
ke
 p
ar
t. 
If 
yo
u 
do
 ta
ke
 p
ar
t
yo
u 
wo
ul
d 
be
 fr
ee
 to
 w
ith
dr
aw
 a
t a
ny
 ti
m
e 
wi
th
ou
t g
ivi
ng
 a
ny
re
as
on
. T
hi
s 
wi
ll n
ot
 a
ffe
ct
 yo
ur
 cu
rre
nt
 o
r f
ut
ur
e 
m
ed
ica
l tr
ea
tm
en
t.
Be
fo
re
 y
ou
 d
ec
id
e,
 y
ou
r 
gy
na
ec
ol
og
ist
 o
r 
th
e 
PR
O
SP
EC
T
Re
cr
ui
tm
en
t O
ffic
er
 w
ill 
pr
ov
id
e 
yo
u 
wi
th
 m
or
e 
in
fo
rm
at
io
n 
an
d 
wi
ll
be
 h
ap
py
 to
 d
isc
us
s 
an
y 
qu
es
tio
ns
 y
ou
 m
ay
 h
av
e.
 If
 y
ou
 a
gr
ee
 to
ta
ke
 p
ar
t, 
yo
u 
wi
ll b
e 
as
ke
d 
to
 si
gn
 a
 co
ns
en
t f
or
m
 fo
r t
hi
s r
es
ea
rc
h
st
ud
y. 
Yo
u
r 
gy
na
ec
ol
og
ist
 w
ill 
m
ak
e 
yo
u 
aw
ar
e 
of
 a
ll 
re
le
va
nt
iss
ue
s 
su
rro
un
di
ng
 th
e 
su
rg
er
y i
ts
el
f, 
an
d 
yo
u 
wi
ll s
ig
n 
a 
se
pa
ra
te
NH
S 
in
fo
rm
at
io
n 
an
d 
co
ns
en
t f
or
m
 fo
r y
ou
r o
pe
ra
tio
n.
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6.
W
ha
t w
ill
 p
ar
tic
ip
at
io
n 
in
 th
e 
st
ud
y 
in
vo
lv
e?
As
 d
es
cr
ib
ed
 a
bo
ve
, t
he
re
 a
re
 d
iffe
re
nt
 ty
pe
s o
f o
pe
ra
tio
ns
 th
at
 yo
u
co
ul
d 
ha
ve
. I
f y
ou
r g
yn
ae
co
lo
gi
st
 th
in
ks
 th
at
 a
ll 
of
 th
e 
op
er
at
io
ns
w
ou
ld
 b
e 
eq
ua
lly
 s
ui
ta
bl
e 
fo
r y
ou
, w
ith
 y
ou
r a
gr
ee
m
en
t y
ou
 w
ill 
be
al
lo
ca
te
d 
at
 ra
nd
om
 to
 o
ne
 p
ar
tic
ul
ar
 ty
pe
 o
f o
pe
ra
tio
n.
 T
he
re
fo
re
yo
u 
wo
ul
d 
be
 p
ut
 in
to
 o
ne
 g
ro
up
 b
y 
ch
an
ce
 (r
an
do
ml
y) 
an
d a
ll o
f
th
e 
wo
m
en
 in
 th
at
 g
ro
up
 w
ill 
be
 g
ive
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Surgical information sheet
Surgical Information Sheet for Women having Prolapse Surgery
Generic Information and Consent form for all women having prolapse surgery 
1. Proposed operation:  
Prolapse or Pelvic Floor Repair 
Hysterectomy (full or partial)
Urinary Incontinence operation
2. Why am I having this operation?
You and your gynaecologist have agreed that you need a prolapse operation to cure or improve
your prolapse symptoms, such as a feeling of a bulge in or coming down from your vagina, a
dragging or heavy sensation or problems with your urine control, bowel function or intercourse.  
You should be aware that you are advised not to have any more children after the operation as
another pregnancy may cause the prolapse to come back.  If you have a hysterectomy (removal
of the womb) as well, you will not, of course, be able to have children afterwards.  
3. What will the operation involve?
Prolapse surgery can include replacing the bladder, bowel or uterus in their correct positions,
or removing the uterus (hysterectomy) completely or partially, followed by repair of the weak
vaginal walls.  This can be done using stitches, mesh or graft materials.  If mesh or graft
materials are used, these can be put in place through an incision in the vaginal wall skin (known
as an inlay), or using an ‘introducer’ (known as a ‘mesh kit’).  Mesh materials include man-
made (plastic) materials, some of which dissolve over time while others never dissolve.  Graft
materials are made of natural fibres which may come from animals, humans or plants, and
eventually dissolve.  Your gynaecologist will discuss the exact sort available for you if
necessary.  
Prolapse operations can be done from below through your vagina or through your abdomen or
by using a laparoscope (keyhole surgery).  Even if the surgery is done through the vagina, this
is still a major operation and you should be just as careful as after an abdominal operation.  For
example, you should not do any lifting or strenuous exercise for at least 3 months.
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You and your gynaecologist will decide the exact type of operation that you need.  You should
be aware, however, that whatever is planned before the operation may need to be altered when
you are examined under anaesthetic in theatre.  Sometimes it becomes clear that it is
necessary to perform a different prolapse procedure for clinical reasons.  
After your operation, your gynaecologist may place a catheter in your bladder (from below or
via your abdomen) to help you pass urine at first.  Your gynaecologist may also use a vaginal
pack for the first day after surgery.  You may also be advised to use vaginal oestrogen cream
or tablets for a few weeks after surgery.
4. What type of anaesthesia will I have?
A general anaesthetic (being asleep) or a spinal anaesthetic (or epidural) to numb the lower half
of your body can be used.  The pros and cons of these forms of anaesthetic will be discussed
with you by your gynaecologist and your anaesthetist.  You will be able to choose which type
of anaesthetic you would prefer, provided this is appropriate for your operation. 
5. What extra operations may be carried out at the same time?
If you have stress urinary incontinence, your gynaecologist may recommend having a bladder
support procedure such as placing a sling under the urethra or a colposuspension.  If your
womb is prolapsed, or if you have other problems such as heavy periods, your gynaecologis t
may recommend removing the womb completely (hysterectomy) or only the lower half of the
womb (the cervix) or the upper half of the womb (subtotal hysterectomy).  
Any such extra operations will of course be discussed and agreed with you beforehand.   
6. What extra procedures may become necessary during the operation?
All operations carry a risk of complications such as bleeding, damage to other organs, or
infection. 
If there is a high blood loss, you may require a blood transfusion.  Around 1 in 50 women who
have a vaginal hysterectomy will need a blood transfusion, but it is less likely for other types of
prolapse surgery.  
If blood vessels, bladder or bowel are damaged, these will need to be repaired during the
operation.  This sometimes means having an abdominal operation (laparotomy) to correct the
problem, prevent serious harm to your future health or save your life.  
It must be stressed, however, that such events are rare and unlikely to happen.
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7. What adverse effects or problems may occur after the operation? 
Some problems occur frequently but are not serious, are to be expected in some women, and
can be easily treated.  These include:
• Urinary retention (being unable to pass urine after operation)
• Vaginal bleeding or discharge
• Infections e.g. in the vagina or abdomen.
• Urinary tract infection or passing urine more frequently than normal
• Pain in the abdomen, back or vagina.  
• Mesh erosion through the vaginal walls (this may cause some discharge or bleeding as well
as pain with intercourse).  
Some more serious problems can occur after surgery, are treated as and when they arise, and
include: 
• Damage to blood vessels or excessive bleeding requiring return to theatre or blood transfusion
• Damage to bladder or urinary tract 
• Damage to bowel  
• Blood clots in the legs or lungs (venous thrombosis and embolism)
• Serious infections or pelvic abscess
8. What may I expect in the long term?
Your prolapse surgery is designed to cure your prolapse symptoms, including urine, bowel or
sexual problems.  However, 1 in 3 women will need another prolapse operation at some time
in the future (the average time is 12 years later).  Some women may also develop leakage of
urine for which they will need another operation.  
Your symptoms of prolapse may come back at a lesser level which may not need another
operation.  You may, however, have: 
• Long term effects on your bladder function such as leakage of urine, having to pass urine
frequently or urgently, or being unable to pass urine and needing to use a catheter long
term 
• Bowel symptoms such as leakage, having to rush urgently or constipation 
• Difficulty or pain with intercourse, vaginal scarring or narrowing
• Buttock pain
• The need to remove mesh or graft materials 
• Menopausal symptoms  
In general terms, it is not possible to predict how much you personally will benefit from
surgery or whether you will develop any new problems or need further treatment for
them.  
9. What other prolapse treatments are available?
Women with prolapse may also practise pelvic floor muscle exercises, use oestrogen cream,
or use a ring or other type of plastic pessary.  These treatments may also be used after prolapse
surgery for women who still have symptoms.
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Pictures of Pelvic Organ Prolapses
1. Normal pelvic organs 2. Anterior vaginal wall prolapse
(cystocele)
3. Posterior vaginal wall prolapse 4. Uterine prolapse
(rectocele)
Bladder outlet
supported by
pelvic floor
muscles
Urethra
Vagina
Bladder
Uterus (womb)
Spine
Rectum
AnusPelivc floor
muscles wrap
around the
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bladder, uterus
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support
part of the bladder has
dropped down
(prolapsed) into the
vagina
the uterus has dropped
down (prolapsed) into
the vagina
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into the vagina
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Instructions to gynaecologists
Version 1: 01 January 2010 
 
 
Instructions for gynaecologists when putting women on 
the waiting list for prolapse surgery 
 
1 Explain proposed surgery, using the Prospect Surgical 
Information sheet.  Mention uncertainty about best method of 
performing surgery, that mesh may be used and that this may 
be decided at random.   
 
2 Mention research into prolapse surgery (PROSPECT).  All 
women (whether randomised or not) will be involved in the 
study.  Sign and give woman the PROSPECT Flyer. 
 
3 Complete sticker and attach to POP-Q examination sheet. 
 
4 What happens next?  
The woman will receive more information about PROSPECT 
from a Recruitment Officer or her gynaecologist before her 
surgery 
 
5 In the letter putting her on the waiting list please mention: 
 
 PROSPECT and randomisation has been discussed  
 If the woman is definitely not suitable for randomisation please 
specify why not 
 Describe exactly what previous prolapse surgery has been 
carried out (ie which compartment(s), use of mesh and route of 
hysterectomy) 
 Please specify all the compartments which need to be repaired 
on this occasion and ensure POP-Q is completed 
 If the woman needs a continence operation please mention 
and refer for cystometry if necessary 
 
Any queries please contact: 
Local Researcher: 
Trial Manager:  Suzanne Breeman,
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Ineligible or declined form
ISRCTN 60695184  Version 2: 10 November 2009 
 
Outline data on patients who are ineligible or who decline participation 
 Study number      
   
Q1 Date of attempted recruitment D D / M M / Y Y Y Y 
  
Q2 Year of Birth   Y Y Y Y 
 
Q3 Diagnosis     Q4 Operation planned (tick all that apply) 
 Primary repair?     Anterior?     
         Secondary repair?      Posterior?     
Not Known?  Middle Compartment?     
     Not Known?     
 
 
Q5   Reasons for non-inclusion - tick all that apply 
Missed  
No prolapse  
Operation cancelled – unfit for operation  
Unable to give informed consent  (please go to Q7) 
Unable to complete study questionnaires  (please go to Q7) 
Patient does not want to participate in the study  
Other  
 
Q6 If other, please state:  
  
 
Q7 If unable to give informed consent or complete study questionnaires due to        language problems, please state the language spoken by the participant:  
 
 
Signature:  
 
Print Name:   
PROSPECT INELIGIBLE OR DECLINED FORM 
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Consent form
STUDY CONSENT FORM
PROSPECT: Prolapse Surgery
By signing this form and ticking each box I agree that I have:
• been given the Information Sheet about the study  (Version _  Dated _ _ / _ _ / _ _ )
• had the opportunity to discuss the study
• received satisfactory answers to questions
• been given enough information about the study
I understand that:
• my participation is voluntary and taking part in the study may not benefit my own health
• I am free to withdraw from the study at any time without having to give a reason
• if I withdraw, this will not affect my medical care or legal rights
• I may be contacted in the future for long term follow up
I agree that relevant sections of my medical notes and data collected during the study may be
looked at by individuals from the University of Aberdeen, from regulatory authorities or from the NHS
Trust, where it is relevant to my taking part in this research. Information relevant to the PROSPECT
study may be collected from my hospital and NHS records, including Office of National Statistics
(ONS) and NHS central registers.
I am willing to be asked in the future if I would be willing to take part in other relevant research
I agree that relevant data and my contact details will be held confidentially and securely by the
study office in Aberdeen, and may be subject to audit and monitoring by regulatory authorities, without
breaching data confidentiality
I agree that my family doctor (GP), my hospital consultant and the person I have nominated as my
best contact may be told that I am taking part in this study
I agree to take part in the PROSPECT study
Your signature (participant) ___________________________________________________
Your name in block capitals ___________________________________________________
Date ___________________________________________________
For office use only
I confirm that I have explained to the person named above, the nature and purpose of the PROSPECT study
and the procedures involved.
Signature ___________________________________________________
Date ___________________________________________________
CONSENT TO RANDOMISATION
I confirm that I have discussed the types of surgery suitable for me with my gynaecologist, and I agree
to being randomly allocated to one of them.  
Signature of Participant ___________________________________________________
Date ___________________________________________________
I confirm that I have discussed with my patient the types of surgery suitable for her, and I agree that
she can be randomly allocated to one of them.
Signature of Gynaecologist ___________________________________________________
Date ___________________________________________________
ISRCTN60695184     Version 2: 01.01.10
Prolapse Surgery: Pragmatic Evaluation
and randomised Controlled Trials
Please
tick
ALL
boxes
Participant Study No
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
291

Appendix 2 Participant and general
practitioner letters
Baseline invitation letter
Version 2 10 November 09 
 
 
<< Date >> 
 
Dear <<Title>> <<Surname>>   Prospect STUDY No. << .>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
You are being invited to take part in a research study because you will be having 
surgery for your prolapse in the near future.  We want to give you some information 
about the study now, to give you plenty time to think about it before your operation.  So 
we have enclosed a Participant Information Sheet and a Baseline Questionnaire.   
 
Thank you for taking the trouble to read this information.  We hope that it will be helpful 
in enabling you to decide whether or not you would like to participate in the PROSPECT 
Study.  You will be approached about this when you go to hospital. 
 
If after reading this information you think you would like to take part in this study, 
please complete the baseline questionnaire and bring it along with you to hospital when 
you come in for your pre-assessment or your operation. 
 
Please feel free to discuss this with your family, friends or GP if you wish.  Your own 
gynaecologist or staff at the PROSPECT Study Office will also be happy to answer any 
questions.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
 
 
 
 
 
[Local Gynaecologist]    
 
 
Enclosures Participant Information Sheet 
  Baseline Questionnaire 
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General practitioner letter
ISRCTN: 60695184  Version 1: 01 January 2010   
<< DATE >>         
 
Dr  GPFName   GPSName     Patient Study Number:  
 GPAddress1  
 GPAddress2  
 GPAddress3  
 GPAddress4  
 GPPostCode  
 
Dear Dr  
 
PROSPECT: PROlapse Surgery: Pragmatic Evaluation and randomised 
Controlled Trials. 
 
RE:  Title   FName   SName   DOB   Address1   Address2   Address3   Address4   PostCode  
 
A multicentre UK-wide research study, funded by the NHS National Institute for Health Research Health 
Technology Assessment Programme is investigating which prolapse operations are the safest and most 
clinical and cost-effective for women with anterior and/or posterior vaginal wall prolapse.   CentreHosp is 
one of the participating sites. The trial is needed because there is uncertainty about which type of 
surgery is most effective for these women.  
 
All women who consent will be followed-up and those who are eligible will be randomised to a particular 
type of surgery, depending on whether they are having their first operation or have had previous 
prolapse surgery.  Both women who have had previous prolapse surgery and those having their first 
operation will be included.  We are following up the women after their operations initially for two years, 
but hopefully long- term.  More detailed information about the study is provided overleaf.   
 
Your patient has agreed to join the study.  She will either be followed up as part of the non-randomised 
cohort or may have been randomised to one of the surgery groups as appropriate for her. Her 
gynaecology consultant is ConsFName   ConsSName.   
 
We will carry out postal follow-up (from Aberdeen) by asking participants to complete questionnaires 
after surgery and at 6, 12 and 24 months later.  The questionnaires ask about general health and use of 
the health service as well as specific information about prolapse symptoms.  She will also be reviewed in 
outpatients by an appropriately qualified member of the research team or a gynaecologist 12 months 
following her surgery.   
 
We should not normally need to obtain any information from you.  However, we would be grateful if you 
could contact telephone number                         your patient changes address, is too ill to continue taking 
part, has an adverse effect from prolapse surgery or dies.   
 
If you would like to discuss any aspect of our trial, or require any further details, please do not hesitate to 
contact the PROSPECT Study Office on                        . 
 
Yours sincerely  
 
 
Dr Suzanne Breeman Prof Cathryn Glazener 
PROSPECT Trial Manager PROSPECT Chief Investigator 
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
294
~ PROSPECT GP INFORMATION SHEET 
Title of project 
Clinical and cost-effectiveness of surgical options for the management of anterior and/or 
posterior vaginal wall prolapse   
 
Background  
Around one in ten women will need prolapse surgery at some point in their lives.  It is most 
common in women who have had children, although there has been surprisingly little research 
into its causes and treatment.  A Cochrane review1 and a NICE Interventional Procedures 
review2 have identified that there is insufficient evidence to evaluate the effectiveness, cost-
effectiveness and effect on quality of life of the different types of prolapse surgery, including 
whether mesh should be used.   
 
There are numerous different operations for prolapse, depending on the type of prolapse, 
whether the woman is having her first or a secondary repair and the preference of the 
gynaecological surgeon.  To date, there is a high failure rate after surgery: three in ten women 
who have an operation will have further surgery.  This study will address anterior vaginal wall 
prolapse (cystocele, urethrocele) and posterior vaginal wall prolapse (rectocele, enterocele).  
Some women may need a concomitant procedure if there is uterine or vault prolapse (eg 
vaginal hysterectomy), or if she is incontinent (eg TVT).   
 
Brief outline of the study 
While the women are in hospital, they will have a routine physical examination before surgery 
and they will complete questionnaires both before and after their operation.  Further symptom 
questionnaires will completed 6, 12 and 24 months later.  The women will be examined and 
reviewed in outpatients at 12 months after surgery.  Our main interest is in the cure or 
improvement of prolapse symptoms, as reported by the women themselves.   
 
Ethical approval has been obtained for this study.  The procedures used in the study will be 
standardised and agreed with a team of experienced gynaecologists from the British Society of 
Urogynaecology (RCOG).   
 
The Researchers 
The trial is being co-ordinated by the Centre for Healthcare Randomised Trials (CHaRT, a fully 
registered UK CRN clinical trials unit), at the Health Services Research Unit, University of 
Aberdeen.  Gynaecologists in your local hospital have agreed to allow their patients who are 
having prolapse surgery to be invited to enter the study.  All gynaecologists involved in this 
study will be experienced in each type of surgery to which their patients may be randomised.   
 
If you have any questions about this study or the inclusion of your patient in it, please contact 
the PROSPECT Study Office in Aberdeen on                        .   
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Six-month letter
Version 2 June 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the Prospect Study.   
 
We have enclosed your 6 month review questionnaire. We are keen to find out how 
you have been getting on during the last six months since your prolapse surgery.   
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire fully. However, you are not obliged to answer every question if you 
do not want to.  If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the 
Prospect Study Office on                        . 
 
Please return the questionnaire in the reply-paid envelope provided (no stamp is 
required). 
 
We would like to thank you very much for taking part in the Prospect Study and for 
completing the questionnaire as your views and information about your recovery are very 
important to improving the management of women having prolapse surgery in the future.  
 
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
 
Enclosures Six month Prospect questionnaire 
  Reply-paid envelope 
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Six-month reminder letter 1
Version 2 June 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the Prospect Study to date.   
 
We sent you the enclosed 6 month review questionnaire a few weeks ago.  We are 
keen to find out how you have been getting on during the last six months since your 
prolapse surgery.  Unfortunately we have not yet received your answers. 
 
We appreciate how busy you must be, but believe this to be an important study for 
women's health.  Your reply is very important to us. If your reply is already in the post, I 
would like to thank you for your help and apologise for this reminder.   
 
We are therefore enclosing another copy, and would be most grateful if you could take 
a few minutes of your time to complete it, and return it in the envelope provided (no 
stamp required).  Please note that ALL the information you give will be treated with the 
strictest confidence.   
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire fully.  However, you are not obliged to answer every question if you 
do not want to.  If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the 
Prospect Study Office on                        .
 
We would like to thank you very much for taking part in the Prospect Study and  in 
completing the questionnaire as your views and information about your recovery are 
very important to improving the management of women having prolapse surgery in the 
future.  
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
 
Enclosures 6-month Prospect questionnaire 
  Reply-paid envelope.   
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Six-month reminder letter 2
Version 1 April 09 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect  STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the Prospect Study to date.   
 
We sent you a 6 month review questionnaire a few weeks ago.  We are keen to find out 
how you have been getting on during the last six months since your prolapse surgery.  
Unfortunately we have not yet received your answers.   
 
We appreciate how busy you must be, but your answers to the questionnaire are very 
important to us.  If you cannot answer all the questions don't worry.  Please send it to 
us when you have answered as much as you can, using the envelope provided (no 
stamp required).   
 
If you have any worries or problems in completing the questionnaire, a friend or relative 
may be able to help you.  If still in doubt, do please contact the Prospect Study on 
. Please note that ALL the information you give will be treated with the 
strictest confidence.  If your reply is already in the post, I would like to thank you for 
your help and apologise for this reminder.   
 
We would like to thank you very much for taking part in the Prospect Study and in 
completing the questionnaire as your views and information about your recovery are 
very important to improving the management of women having prolapse surgery in the 
future.  
 
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
 
Enclosures 6 month Prospect questionnaire 
  Reply-paid envelope 
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One-year letter
Version 2 June 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>> PROSPECT STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY : PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the PROSPECT Study – you very kindly agreed 
to help this research project when you had your prolapse surgery.   
 
We are keen to find out how you have been getting on during the last year since your 
operation.  We have enclosed a review questionnaire, and would be very grateful if you 
could fill it in.   
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire fully. However, you are not obliged to answer every question if you 
do not want to.  If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the 
Prospect Study Office on                        .  
 
Please return the questionnaire in the reply-paid envelope provided (no stamp is 
required). 
 
We would like to thank you very much for taking part in the PROSPECT Study and for 
completing the questionnaire as your views and information about your recovery are very 
important to improving the management of women having prolapse surgery in the future.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
Trial Manager 
 
Enclosures One year PROSPECT questionnaire 
  Reply-paid envelope.  
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One-year reminder letter 1
Version 2 June 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the PROSPECT Study.   
 
We sent you a one year review questionnaire a few weeks ago.  We are keen to find 
out how you have been getting on during the last year since your prolapse surgery.  
Unfortunately we have not yet received your reply. 
 
We appreciate how busy you must be, but we believe this to be an important study for 
women's health.  Your reply is very important to us.  
 
We are therefore enclosing a second copy of the questionnaire, and would be most 
grateful if you could give us a little of your time to complete it, and return it in the 
envelope provided (no stamp required).  Please note that ALL the information you give 
will be treated with the strictest confidence.  If your reply is already in the post, we 
would like to thank you for your help and apologise for this reminder. 
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire fully. However, you are not obliged to answer every question if you 
do not want to.  If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the 
Prospect Study Office on                   .
 
We would like to thank you very much for taking part in the PROSPECT Study and for 
completing the questionnaire.  Your views and information about your recovery are 
very important to improving the management of women having prolapse surgery in the 
future.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
 
Enclosures 1 year PROSPECT questionnaire 
Reply-paid envelope.   
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One-year reminder letter 2
Version 1 April 09 
<< Date >> 
 
<<Title>> <<Name>> << Surname>> Prospect STUDY No. << .>>  
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY : PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
 
Thank you very much for taking part in the PROSPECT Study to date.   
 
We sent you a one year review questionnaire a few weeks ago.  We are keen to find 
out how you have been getting on during the last year since your prolapse surgery.  
Unfortunately we have not yet received your answers.   
 
We appreciate how busy you must be, but your answers to the questionnaire are very 
important to us.  If you cannot answer all the questions don't worry.  Please send it to 
us when you have answered as much as you can, using the envelope provided (no 
stamp required).  If your reply is already in the post, we would like to thank you for your  
help and apologise for this reminder.   
 
If you have any worries or problems in completing the questionnaire, a friend or relative 
may be able to help you.  If still in doubt, do please contact the Prospect Study Office 
on                        .  
 
Please note that ALL the information you give will be treated with the strictest 
confidence.   
 
We would like to thank you very much for taking part in the PROSPECT Study and in 
completing the questionnaire as your views and information about your recovery are 
very important to improving the management of women having prolapse surgery in the 
future.  
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
Enclosures One year Prospect questionnaire 
Reply-paid envelope 
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One-year additional letter
Version 1 10 November 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>> PROSPECT STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the PROSPECT Study – you very kindly agreed 
to help this research project when you had your prolapse surgery.   
 
Thank you for returning your one year questionnaire.  Would you be kind enough to 
give us some additional information about your current bladder and bowel function?  
We would be very grateful if you could fill it this additional questionnaire.   
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire as fully as you can. However, you are not obliged to answer any 
question if you do not want to.  If you have any worries or problems in completing the 
questionnaire, a friend or relative may be able to help you.  If still in doubt, do please 
contact the Prospect Study Office on                        .  
 
Please return the questionnaire in the reply-paid envelope provided (no stamp is 
required). 
 
We would like to thank you very much for taking part in the PROSPECT Study and for 
completing the questionnaire.  Your views about your recovery are very important to 
improving the management of women having prolapse surgery in the future.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
Trial Manager 
 
Enclosures One year additional PROSPECT questionnaire 
  Reply-paid envelope.  
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One-year addition reminder letter
Version 1 10 November 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>> PROSPECT STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the PROSPECT Study – you very kindly agreed 
to help this research project when you had your prolapse surgery.   
 
We would be very grateful if you could complete both of the questionnaires enclosed.  
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire as fully as you can. However, you are not obliged to answer any 
question if you do not want to.  If you have any worries or problems in completing the 
questionnaire, a friend or relative may be able to help you.  If still in doubt, do please 
contact the Prospect Study Office on                        .  
 
Please return the questionnaire in the reply-paid envelope provided (no stamp is 
required). 
 
We would like to thank you very much for taking part in the PROSPECT Study and for 
completing the questionnaire.  Your views about your recovery are very important to 
improving the management of women having prolapse surgery in the future.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
Trial Manager 
 
Enclosures One year PROSPECT questionnaire  
One year additional PROSPECT questionnaire 
  Reply-paid envelope.  
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Costs questionnaire letter
PROSPECT is funded by the NIHR Health Technology Assessment Programme 
 
Version 1, 11 November 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and randomised 
Controlled Trials 
 
Thank you very much for taking part in the Prospect Study.  
 
We enclose a questionnaire asking about how much it cost you to use the health service.  We 
wish to know how much money and time were spent by you and any companion when you 
attended appointments and as a result of any hospital admission you may have had.  
 
Although some of the questions may not seem relevant we would like you to complete the 
questionnaire as fully as you can. However, you are not obliged to answer every question if 
you do not want to.  If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the Prospect 
Study Office on                        .  
 
Please return the questionnaire in the reply-paid envelope provided (no stamp is required). 
 
We would like to thank you very much for taking part in the PROSPECT Study and for 
completing the questionnaire.  
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
Trial Manager 
 
Enclosures PROSPECT Participants Costs questionnaire 
  Reply-paid envelope.  
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Costs questionnaire reminder letter
PROSPECT is funded by the NIHR Health Technology Assessment Programme 
 
Version 1, 01 April 2010 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and randomised 
Controlled Trials 
 
Thank you very much for taking part in the Prospect Study to date.   
 
We sent you a participant cost questionnaire a few weeks ago.  We are keen to find out about 
how much it cost you to use the health service.  Unfortunately we have not yet received your 
answers.   
 
We appreciate how busy you must be, but your answers to the questionnaire are very 
important to us.  If you cannot answer all the questions don't worry.  Please send it to us when 
you have answered as much as you can, using the envelope provided (no stamp required).  
 
If you have any worries or problems in completing the questionnaire, a friend or relative may 
be able to help you.  If still in doubt, do please contact the Prospect Study on . 
Please note that ALL the information you give will be treated with the strictest confidence.  If 
your reply is already in the post, I would like to thank you for your help and apologise for this 
reminder.   
 
We would like to thank you very much for taking part in the Prospect Study and for completing 
the questionnaire. 
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
 
 
Trial Manager 
 
Enclosures Participant Cost questionnaire 
  Reply-paid envelope 
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Two-year letter
Version 2 June 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>>  Prospect STUDY No. << .>> 
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY: PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the Prospect Study – you very kindly agreed to 
help this research project when you had your prolapse surgery.   
 
We are keen to find out how you have been getting on during the last two years since 
your operation.  We have enclosed a review questionnaire, and would be very grateful 
if you could fill it in.   
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire fully. However, you are not obliged to answer every question if you 
do not want to. If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the 
Prospect Study Office on                        . 
 
Please return the questionnaire in the reply-paid envelope provided (no stamp is 
required). 
 
We would like to thank you very much for taking part in the Prospect Study and for 
completing the questionnaire as your views and information about your recovery are very 
important to improving the management of women having prolapse surgery in the future.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
 
Trial Manager 
 
Enclosures Two year Prospect questionnaire 
  Reply-paid envelope.   
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Two-year reminder letter 1
Version 2 June 2009 
<< Date >> 
 
<<Title>> <<Name>> << Surname>> Prospect STUDY No. << .>>  
.<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY : PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
 
Thank you very much for taking part in the PROSPECT Study.   
 
We sent you a two year review questionnaire a few weeks ago.  We are keen to find 
out how you have been getting on during the last two years since your prolapse 
surgery.  Unfortunately we have not yet received your reply. 
 
We appreciate how busy you must be, but we believe this to be an important study for 
women's health.  Your reply is very important to us. 
 
We are therefore enclosing a second copy of the questionnaire, and would be most 
grateful if you could give us a little of your time to complete it, and return it in the 
envelope provided (no stamp required).  Please note that ALL the information you give 
will be treated with the strictest confidence.   
 
Although some of the questions may not seem relevant we would like you to complete 
the questionnaire fully. However, you are not obliged to answer every question if you 
do not want to. If you have any worries or problems in completing the questionnaire, a 
friend or relative may be able to help you.  If still in doubt, do please contact the 
Prospect Study Office on .   If your reply is already in the post, we would 
like to thank you for your help and apologise for this reminder.  
 
We would like to thank you very much for taking part in the PROSPECT Study and for 
completing the questionnaire.  Your views and information about your recovery are 
very important to improving the management of women having prolapse surgery in the 
future.   
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
 
Enclosures 2-year PROSPECT questionnaire 
Reply-paid envelope.   
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Two-year reminder letter 2
Version 1 April 09 
<< Date >> 
 
<<Title>> <<Name>> << Surname>> PROSPECT STUDY No 
 <<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>> 
<<Postcode>> 
 
Dear <<Title>> <<Surname>> 
 
The PROSPECT STUDY : PROlapse Surgery: Pragmatic Evaluation and 
randomised Controlled Trials 
 
Thank you very much for taking part in the PROSPECT Study. 
 
We sent you a two year review questionnaire a few weeks ago.  We are keen to find 
out how you have been getting on during the last two years since your prolapse 
surgery.  Unfortunately we have not yet received your answers.   
 
We appreciate how busy you must be, but your answers to the questionnaire are very 
important to us.  If you cannot answer all the questions don't worry.  Please send it to 
us when you have answered as much as you can, using the envelope provided (no 
stamp required).  If your reply is already in the post, we would like to thank you for your  
help and apologise for this reminder.   
 
If you have any worries or problems in completing the questionnaire, a friend or relative 
may be able to help you.  If still in doubt, do please contact the Prospect Study Office 
on                        .  
 
Please note that ALL the information you give will be treated with the strictest 
confidence.   
 
We would like to thank you very much for taking part in the PROSPECT Study and in 
completing the questionnaire as your views and information about your recovery are 
very important to improving the management of women having prolapse surgery in the 
future.  
 
With our very best wishes and thanks for your kind help, 
 
Yours sincerely 
 
 
Trial Manager 
 
Enclosures Two year Prospect questionnaire 
  Reply-paid envelope 
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Best contact form
ISRCTN 60695184  PROSPECT Version 2, 01 July 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date form filled in D D M M Y Y 
 
 
 
 
 
 
BEST CONTACT FORM 
 
We would be very grateful if you could send this form back indicating: 
 
 Any change of address for your relative/friend (question 1) 
 Any issues or comments that may have prevented us from 
contacting your relative/friend (question 2) 
 
 
 
 
    Study Number       
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CONFIDENTIAL 
 
 
1.  PLEASE GIVE DETIALS OF ANY NEW ADDRESS FOR YOUR FRIEND/RELATIVE 
 
House Name                    
 
House Number     
 
Street Name                    
 
District                    
 
Town/City                    
 
County                    
 
Postcode         
 
Telephone No 
(including code) 
              
              
 
 
 
2.  ANY OTHER ISSUES OR COMMENTS  
 
 
 
 
 
 
Thank you very much for filling in this form.  Please return it to the CHaRT 
Study Office, Health Services Research Unit, University of Aberdeen, 
Foresterhill, Aberdeen, AB25 2ZD in the prepaid envelope provided. 
 
Please do not hesitate to telephone the Study Office on  
                        if you have any queries. 
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First letter to best contact
ISRCTN:60695184  PROSPECT Version 2, 01 January 2013  
Study number      
 
<< Date >> 
 
«CurrentTitle» «CurrentFName» «CurrentSName» 
«CurrentAddress1» 
«CurrentAddress2» 
«CurrentAddress3» 
«CurrentAddress4» 
«CurrentPostCode» 
 
Dear «CurrentTitle» «CurrentSName» 
 
We are writing to you because << participant’s name>> of << participant’s address>> has agreed 
to take part in a research study that we are co-ordinating.  
 
She has nominated you as her “best contact”.  We ask people taking part in studies to nominate a 
“best contact”.  A “best contact” is not the same as a person’s “next of kin”, and we prefer to have 
a “best contact” who does not live at same address, though we appreciate that this is not always 
possible.  We only get in touch with the “best contact” when we cannot contact the participant 
themselves, for example if they have moved house or are in hospital.    
 
I hope you are content to act as a “best contact” for the above person.  If you are, we will keep 
your details securely in accordance with the data protection legislation.  We will not give your 
details to anyone outside the study team.  We will only contact you if we cannot contact the 
participant themselves.   
 
If you do not wish to act as a “best contact” for the above person please, get in touch with us and 
we will remove your details from our database. You can do this either by: 
• Returning the attached reply slip to the study office in the enclosed pre-paid envelope; 
• Emailing us at                                     quoting both your name and the study number above; 
• Telephoning us on . If no-one is there to take your call, please leave a 
message quoting both your name and the study number above. It would be helpful if you 
could also leave your telephone number in case we need to get in touch with you. 
 
With very many thanks for your help. 
 
Yours sincerely 
 
 
Trial Manager 
 
«refPatientNo» 
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ISRCTN:60695184  PROSPECT Version 2, 01 January 2013  
REPLY SLIP 
 
Study number      
 
 
 
I, <<insert best contact’s name>> do not wish to act as a “best contact” for <<insert participants 
name>>. 
 
 
 
Signed: .         Date: / ./ . 
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Best contact reminder letter
ISRCTN: 60695184  PROSPECT Version 1, 01 January 2013  
Study number      
 
<< Date >> 
 
«CurrentTitle» «CurrentFName» «CurrentSName» 
«CurrentAddress1» 
«CurrentAddress2» 
«CurrentAddress3» 
«CurrentAddress4» 
«CurrentPostCode» 
 
Dear «CurrentTitle» «CurrentSName» 
 
 
We wrote to you recently and do not appear to have received a response. Please accept our 
apology if this has crossed in the post. 
 
We are writing to you because << participant’s name>> of << participant’s address>> has agreed 
to take part in a research study that we are co-ordinating.  
 
She has nominated you as her “best contact”.  We ask people taking part in studies to nominate a 
“best contact”.  A “best contact” is not the same as a person’s “next of kin”, and we prefer to have 
a “best contact” who does not live at same address, though we appreciate that this is not always 
possible.  We only get in touch with the “best contact” when we cannot contact the participant 
themselves, for example if they have moved house or are in hospital.    
 
I hope you are content to act as a “best contact” for the above person.  If you are, we will keep 
your details securely in accordance with the data protection legislation.  We will not give your 
details to anyone outside the study team.  We will only contact you if we cannot contact the 
participant themselves.   
 
If you do not wish to act as a “best contact” for the above person please, get in touch with us and 
we will remove your details from our database. You can do this either by: 
• Returning the attached reply slip to the study office in the enclosed pre-paid envelope; 
• Emailing us at                                    quoting both your name and the study number above; 
• Telephoning us on             . If no-one is there to take your call, please leave a 
message quoting both your name and the study number above. It would be helpful if you 
could also leave your telephone number in case we need to get in touch with you. 
 
With very many thanks for your help. 
 
Yours sincerely 
 
 
Trial Manager 
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ISRCTN: 60695184  PROSPECT Version 1, 01 January 2013  
REPLY SLIP 
Study number      
 
 
 
I, <<insert best contact’s name>> do not wish to act as a “best contact” for <<insert participants 
name>>. 
 
 
 
 
Signed: .         Date: / ./ . 
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Second letter to best contact
Second letter to Best Contact 
ISRCTN: 60695184  PROSPECT Version 2,  01 July 2011  
 
 
 
Study number      
 
<< Date >> 
 
 
«Merge Record #» 
«Merge Record #» 
«Merge Record #» 
«Merge Record #» 
«Merge Record #» 
 
Dear «Merge Record #» 
 
We wrote to you previously because << participant’s name>> of << participant’s 
address>> had agreed to take part in a research study and had nominated you as 
her ‘best contact’.   
 
The reason why we are contacting you now is that we have been unable to contact 
<< participant’s name>>.  We would therefore be very grateful if you could help us by 
completing the attached ‘best contact form’ and returning it in the envelope provided. 
  
Please do not hesitate to get in touch with us if you have any queries in relation to 
this letter and/or the best contact form.   
 
 
Many thanks for your help. 
 
Yours sincerely 
 
 
 
 
Trial Manager 
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Surgical assessment form
Please return top copy to Local Recruitment Officer in envelope provided and file bottom copy in notes. 
  Version 2 01 November 2011 
 
If pessary is currently in use, use last recorded POP Q or go to A2.   
 
Genital Hiatus Perineal Body Total Vaginal Length  
 cm  cm  cm
                   Cervix present Yes  No   
                   Bladder/empty Yes  No   
                     Bowel/empty Yes  No   
Maximum protrusion seen Yes  No   
 
A1 If ANTERIOR, what type of anterior prolapse does the woman have? 
 
Midfascial  Paravaginal  Both  Unknown  No anterior prolapse   
 
A2 What stage of prolapse does the woman have (0 to 4 in each box)? 
 
                  Anterior (a)           Posterior (p)   
Cervix/uterus (C) OR Vault/cuff (C)
 
A3 Which compartment is going to be repaired? 
 
                  Anterior (a)           Posterior (p)  Suitable for randomisation? YES / NO  
       Cervix/uterus (C)   OR Vault/cuff (C)  Primary?  Secondary?  
 
Height  Weight  BMI  
 cm  kg   
Please attach address label and enter contact telephone number(s) if willing to be contacted by PROSPECT 
researcher (by post and/or telephone) 
 
 
 
 
 
 
 
Surgical Assessment Form (SAF) 
 
Please measure while patient is pushing down. 
 
 
Date of POP-Q D D M M Y Y Consultants Name:____________________________________ 
Woman’s contact telephone number(s) 
1.   
 
2.   
 
Permission to leave message?  YES / NO 
 
 
 
 
 
Place label here (top and bottom copy) 
[Picture of POP-Q here] 
 
 
 
 
External Hymen Internal
cm +6 +5 +4 +3 +2 +1 0 -1 -2 -3 -4 -5 -6 -7 -8 -9 -10
Aa
Ba
C 
D
Bp
Ap
Stage 3 or 4 
(depending on tvl) Stage 2 S1
Stage 0 or 1 
(depending on TVL)
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Recruitment officer case report form
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Section A Contact information from woman and notes
A1 PATIENT DETAILS (Sticker may be used below)
Title Mrs Miss Ms Other
First name
Surname
Date of birth D D M M Y Y
NHS/CHI number Record/Hospital number
Address could use
hospital label
Telephone No Mobile
Email Address
A2 CONSULTANT DETAILS
Title Mr Dr Prof Ms Other
Initials Surname
A3 GP DETAILS
Initials Surname
Address
A4 BEST CONTACT DETAILS
Title Mr Mrs Miss Ms Other
First name
Surname
Address
Telephone No
A5 RELATIONSHIP OF BEST CONTACT TO PARTICIPANT
Please specify
Have you asked the woman to tell this person that she has given us
these details? Yes
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Section D    Baseline information needed for randomisation from woman
and notes
D1 PROSPECT Study consent form signed:
Yes No (If No, stop here and sign)
D2 Surgery-specific leaflet received by woman:
Yes No (If No, give Surgical Information Sheet)
D3 Centre (named, already known from Study ID no)
D4 Date of birth D D M M Y Y
D4a Age (Auto-calculated from DoB):
<60 yrs ≥60 yrs
D5 Type of prolapse for planned repair
Yes No
Anterior
Posterior
D6 Concomitant upper vaginal prolapse surgery planned
Yes No
Hysterectomy (vaginal)
Hysterectomy (abdominal)
Cervical amputation
Vault repair eg sacrospinous mesh suspension, sacrocolpopexy
(YES to any one of these is taken as a concomitant middle compartment procedure)
(If YES to a concomitant middle compartment procedure but NO to both anterior and posterior
repair, then eligible for comprehensive cohort only)
D7 Concomitant incontinence surgery planned (e.g. TVT, colposuspension) 
Yes No
Study Number Recruitment Officer CRF
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D8 Has the woman had a previous prolapse repair?
Yes No If no, go to D9
What was the previous repair compartment?
D8a Anterior only: Number of repairs Mesh used: Yes No
D8b Posterior only: Number of repairs Mesh used: Yes No
D8c Compartment unknown
D8d Previous hysterectomy Yes No
D8e Previous cervical amputation Yes No
D8f Previous vault procedure Yes No
D9 (calculated by database from response to D5 and D8)
Therefore, type of prolapse surgery planned is: Primary Secondary
D10 Is woman eligible for randomisation AND is consent to randomisation signed?
(A) BY WOMAN Yes No
(B) BY GYNAECOLOGIST Yes No
(If No to either, woman is eligible for Comprehensive Cohort only)
D11 If No, reason for not randomising:
Patient declined Reason
Gynaecologist declined Reason
D12 Types of mesh available for randomisation: Yes
Synthetic non-absorbable
Biological
Mesh kit
D13 (After entry of above details to Prospect DB) Randomised allocation is:
Primary: Standard midline Secondary: Standard midline
Synthetic mesh inlay Synthetic mesh inlay
Biological mesh inlay Mesh Kit
(or if not randomised) COMPREHENSIVE COHORT
D14 Theatre informed / arrangements made to implement allocated procedure
Yes No
(assume that the woman
is having a primary repair)
(if without A or P, we assume that the
woman is having a primary repair)
(if without A or P, we assume that the
woman is having a primary repair)
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Section E Intra-operative (theatre) information from notes or
gynaecologist
E1 Date of admission D D M M Y Y
E2 Date of operation D D M M Y Y
E3 Grade of Operating Gynaecologist
Consultant Specialty doctor
Registrar /junior Supervised by consultant Yes No
E4 Grade of Anaesthetist
Consultant Specialty doctor
Registrar /junior Supervised by consultant Yes No
E5 Operation time
Please specify time of (using 24 hour clock):
Entry into anaesthetic room: H H : M M
Time of leaving operating room: H H : M M
E6 Which type of anaesthetic was used? (Tick all relevant boxes)
General Spinal / epidural
Local Other (please give details)
If Other anaesthetic, please give details:
E7 Was a prophylactic antibiotic used for the operation? Yes No
E8 Type of vaginal prolapse surgery carried out:
Anterior Type of mesh used: No mesh
Synthetic non-absorbable inlay
Biological inlay
Mesh kit
Posterior Type of mesh used: No mesh
Synthetic non-absorbable inlay
Biological inlay
Mesh kit
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E9 Did the woman receive the randomised allocation?
Yes No Comprehensive Cohort (N/A)
(If No, go to E9a)
E9a If NO - Please give reason:
E10 Concomitant upper compartment prolapse surgery:
VAGINAL ABDOMINAL
Cervical amputation Abdominal hysterectomy
Vaginal hysterectomy *Abdominal vault fixation
* Vaginal vault suspension / fixation *Abdominal uterine suspension
* Vaginal uterine suspension
* E10a If Vault or Uterine Suspension procedure, please give details of mesh used:
No mesh Biological
Synthetic non-absorbable Mesh kit
If any other prolapse surgery, enter details in E12
E11 Concomitant incontinence surgery:
Continence procedure (vaginal) Continence procedure (abdominal)
E11a Please give details of mesh used for continence surgery:
No mesh
Synthetic non-absorbable
Biological
E12 If any other surgery, please give details:
E13 What was the estimated blood loss? mls  (add to E17)
E14 Was a catheter inserted in theatre? Yes No Don’t know
E15 If Yes, what type of catheter was used?
Suprapubi oth
Urethral None
Don’t know
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E16 Was a vaginal pack inserted in theatre? Yes No Don’t know
E17 Intra-or post operative complications before discharge (If none tick:)
Ureteric injury Yes No If YES, complete Adverse Events Form
Bladder injury Yes No If YES, complete Adverse Events Form
Bowel injury Yes No If YES, complete Adverse Events Form
Vascular injury Yes No If YES, complete Adverse Events Form
Neurological injury Yes No If YES, complete Adverse Events Form
Blood loss > 500 ml Yes No If YES, complete Adverse Events Form
Peri or postoperative Yes No If YES, complete Adverse Events Form
blood transfusion
Peri or post-operative Yes No If YES, complete Adverse Events Form
thromboembolism
Death Yes No If YES, complete Adverse Events Form
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Section F Postoperative information from notes or nursing cardex
POSTOPERATIVE DATA
F1 Return to theatre for procedure Yes No Details
related event within 72 hours
F2 Catheterisation required for Yes No Details
more than 10 days post op
F3 Pain relief Oral Yes No
Parenteral Yes No
F4 Laxatives Yes No
F5 Infection Yes No
If Yes: F5a UTI Yes No
F5b Wound Infection Yes No
F5c Pelvic sepsis/ Yes No If Yes, complete Adverse 
abscess/ Events Form
septicaemia
F6 Treatment for infection
Antibiotics Yes No
F7 Haematoma Yes No
F8 Other adverse events Yes No
postoperatively
If YES, give details and contact study office
F9 Date of discharge D D M M Y Y
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Serious adverse event/death report form
ISRCTN: 60695184                                   Version 4: 01 July 2013 
  
 
 
 To be completed for any Serious Adverse Event (SAE) that is: 
• related (resulted from administration of any of the research procedures) and 
• expected or unexpected (expected events are listed in section 8.4.2 of the protocol) 
ALL deaths must be recorded using this Report Form 
 PROSPECT Study No 
       
 
Day          Month   Year 
 Report Date   /   /     
 
 Patient Details:  
 
 Patient’s Name   
    
  
 Date of Birth Hospital Number 
            Day                 Month                    Year 
   /   /       
  
 
Q1 Type of event (cross all appropriate to adverse event – if any boxes are crossed the 
adverse event is “serious”)    
 Patient died  
 Hospitalisation  
 Prolongation of existing hospitalisation  
 Persistent or significant disability or incapacity  
 Life threatening  
 Considered medically significant by the investigator  
 
Q2 If the Serious Adverse Event was expected, please cross all that apply 
 
Intraoperative occurrences associated with surgery 
 Injury to organs  
 Excess blood loss  
 Blood transfusion  
 Anaesthetic complications  
 Death  
Postoperative occurrences associated with surgery 
 Thrombosis  
 Infection (UTI, sepsis, abscess)  
 Pain  
 Urinary retention  
 Bowel obstruction  
 
Serious Adverse 
Event/Death Report Form 
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  Constipation  
 Mesh erosion  
 Excess blood loss  
 Vaginal adhesions  
 Haematoma  
 Skin tag  
 Granulation tissue  
 New or persistent urinary tract symptoms  
 Death  
 
Q3 Date of event 
           Day                 Month                    Year 
   /   /     
 
 
Q4 Location  
 
  
 
 
 
 
Q5 Describe the circumstances of the event 
 
   
 
 
 
 
 
Q6 Details of any intervention required  
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 Assessment of whether the event was caused by trial participation:  
 
Q7 Is it reasonably likely that the adverse event was caused by taking part in PROSPECT? 
 
Yes  No   
 
Q7a Why? 
 
   
 
 
 
Q8 If event likely to have been caused by taking part in PROSPECT, describe any 
implications for the safety of study participants and how will these be addressed? 
 
   
 
 
 
 
 
Q9a Name and position of person making this judgment 
 
   
 
 
 
Q9b Date of assessment 
 
          Day               Month                    Year 
   /   /     
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Withdrawal/change of status form
ISRCTN60695184 Version 2: 01 March 2011 
 
 
 
 
 
  To be completed on withdrawal/change of status from study 
 
 
Study No 
       
 
                        Day               Month                   Year  
Q1 Date of withdrawal   /   /     
 
 
   Reason for withdrawal 
 
Q2 Participant decided to withdraw? (state reason)  
  
 
 
 
 
Q3 Any medical reason for withdrawal? (please state reason)  
  
 
 
 
 
What is participant withdrawing from? 
 
Q4 Randomisation? 
 
Yes  No   
 
Q5  Follow-up clinic visits? 
 
Yes  No   
 
Q6  Completing questionnaires? 
 
Yes  No   
 
 Q7  Relevant outcome data being collected (via hospital and GP records)? 
 
Yes  No   
 
WITHDRAWAL/ 
CHANGE OF STATUS 
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Surgical standardisation form
Version 7, 01 August 2011
 
Standardisation of Surgical Procedures in PROSPECT 
 
Please complete last column to indicate your own practice when performing prolapse 
surgery (circle or amend).  If you vary your technique, please tell us about the one you use 
most often.   
 
Name .. 
 
Centre . 
 
1.  Standard anterior repair 
 
Date:  
 
/ /20 .. 
Procedures  Local practice (variations) 
Please circle or amend 
   
 Midline skin incision through fascial 
layer and dissection of bladder off 
cervix / vault 
Midline incision 
 
Other (details) .. 
 
. 
 
 +/- hydrodissection with 1 in 
200,000 adrenaline 
 
Yes  No 
 
Volume:  ..ml 
 
 
Anterior Repair  
Type 1 
 
Dissect fascia off vaginal epithelium   
 
Blunt dissection? 
 
Sharp dissection? 
 
Anterior Repair  
Type 2 
Leave fascia on vaginal skin 
 
Dissection laterally (but not all the 
way to the ‘white line’) and sutures 
placed into fascia in this area 
Blunt dissection? 
 
Sharp dissection? 
 
 
Closure Fascia and skin closed separately 
(2-layer closure) 
 
Plicate fascia in midline if midline 
defect?  Yes  No 
 
Separate closure of other fascial 
defects?  Yes  No 
 
Paravaginal repair?    Yes  No 
 
Skin closed 
 
FASCIA 
PDS or Vicryl? 
Fascial sutures:  
• continuous locking 
• continuous non-locking 
• interrupted? 
 
SKIN 
PDS or Vicryl? 
Skin sutures:  
• continuous locking 
• continuous non-locking 
• interrupted? 
 
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
335
Version 7, 01 August 2011
2.  Standard Posterior repair 
Date:  
 
/ /20 .. 
Procedures  Local practice (variations) 
Please circle or amend 
   
 Midline skin incision through fascial 
layer 
Midline incision 
 
Other (details) .. 
 
. 
 
 +/- hydrodissection with 1 in 
200,000 adrenaline 
 
Yes  No 
 
Volume:  ..ml 
 
 
Posterior Repair  
Type 1 
 
Dissect fascia off vaginal epithelium  
 
 
 
Blunt dissection? 
 
Sharp dissection? 
 
 
Posterior Repair  
Type 2 
Leave fascia on vaginal skin 
 
Dissection laterally (but not all the 
way to the sacrospinous ligament) 
and sutures placed into fascia in 
this area 
Blunt dissection? 
 
Sharp dissection? 
 
 
 
Rectal plication Optional Yes    No 
 
Closure Fascia and skin closed separately  
(2-layer closure) 
 
Plicate fascia over rectum in midline 
if midline defect?   Yes  No 
 
Separate closure of other fascial 
defects?    Yes  No 
 
 
Skin closed  
FASCIA 
PDS or Vicryl? 
Fascial sutures:  
• continuous locking 
• continuous non-locking 
• interrupted? 
 
SKIN 
PDS or Vicryl? 
Skin sutures:  
• continuous locking 
• continuous non-locking 
• interrupted? 
 
 
Levator plication 
in midline 
NOT to be done as causes 
dyspareunia 
 
 
Rectal 
examination 
PR examination during dissection or 
after operation to ensure sutures do 
not penetrate rectal wall 
Yes  No 
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3.  Mesh / graft inlay 
Date:  
 
/ /20 .. 
Procedures  Local practice (variations) 
Please circle or amend 
   
  
Nonabsorbable mesh 
 
Biological graft 
 
Mesh Kit 
 
Type: . 
 
Type: . 
 
Type: . 
 
 How many kit procedures have you 
performed? <10;  10-20;  20-49;  > 50 
 
Lateral dissection 
of pubocervical 
fascia from 
vaginal wall 
Separate bladder / rectum from 
fascia using blunt / sharp dissection  
 
+/- hydrodissection with 1 in 
200,000 adrenaline 
Dissect fascia off vaginal epithelium 
[Optional] Dissect out to pelvic side 
wall (white line or sacrospinous 
ligament) 
Blunt dissection? 
Sharp dissection? 
 
Hydrodissection with 1 in 
200,000 adrenaline? 
 
Lateral dissection to white line or 
sacrospinous ligament? 
 
Graft / mesh inlay Cut material to size and lay below 
fascia (inlay, recommended):  
OR 
above fascial layer:  
 
 
Size of mesh/graft: 
 
 
[Optional] soak mesh in Rifampicin? 
OR 
Other fluid? 
 
ATTACHING THE MESH 
Fix at least 2 PDS/Vicryl sutures or 
2 non-absorbable sutures to pelvic 
side wall / coccygeus muscle on 
each side  
 
 
OR 
Attach to white line or sacrospinous 
ligament 
 
 
 
+/- Capio suturing device 
Below fascial layer (INLAY),  
 
OR 
above fascial layer (OVERLAY) 
 
 
Size of mesh patch: cm2 
 
 
Rifampicin?  
OR 
Other fluid?.......................... 
 
 
PDS to attach mesh? 
 
Vicryl to attach mesh? 
 
Non-absorbable suture? 
 
 
Attach to white line (ant)?  
 
Attach to sacrospinous ligament 
(post)? 
 
Capio suturing device?  
Yes  No 
 
 
 (for anterior repair):   
Mesh should also be secured to 
vault or cervix with a suture(s) 
Yes  No 
 
 
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
337
Version 7, 01 August 2011
3.  Mesh / graft inlay (continued) 
 
Closure Two-layer closure (PDS or Vicryl):  
 
1.  Fascial sutures inserted back 
from skin edge over mesh/graft 
(INLAY) 
 
2.  Skin closed as second layer 
(OVERLAY) 
FASCIA 
PDS or Vicryl? 
Fascial sutures:  
• continuous locking 
• continuous non-locking 
• interrupted? 
 
SKIN 
PDS or Vicryl? 
Skin sutures:  
• continuous locking 
• continuous non-locking 
• interrupted? 
 
 
 
 
4.  Vaginal packs and lubricants 
Date:  
 
/ /20 .. 
Procedures  Local practice (variations) 
Please circle or amend 
   
  
Vaginal pack used for  up to 24 
hours 
 
 
Yes  No 
 (If yes) Lubricated? Oestrogen Proflavine 
 
Betadine Dalacin 
 
Hibitane Obstetric cream 
 
Saline  Savlon 
 
Aquagel Dry pack 
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5.  POP-Q standardisation  
Date:  
 
/ /20 .. 
Recommended 
 
Local practice (variations) 
Please circle or amend 
method used most often 
   
Position Lithotomy / in leg rests 
 
Lithotomy / in leg rests 
On back on flat bed or table 
On side 
Standing up 
In theatre / under anaesthetic 
 
Sims speculum 
Plastic speculum (halved) 
Other 
 
Conditions Bladder status not specified but 
recorded 
 
 
 
 
Bowel loading recorded 
 
 
Full extent of prolapse seen? 
 
 
During Valsalva / pushing down 
 
 
 
Ruler / measuring stick 
 
 
Full bladder 
Empty bladder 
Not specified but recorded 
Bladder status not assessed 
 
 
Bowel loading recorded 
Bowel loading not recorded 
 
Full extent recorded 
Full extent not recorded 
 
At rest 
During Valsalva / pushing down 
During cough 
 
Ruler / measuring stick 
Finger measure 
Estimate by eye 
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Appendix 4 Postal questionnaires
Baseline questionnaire
CONFIDENTIAL Participant Study No
BASELINE QUESTIONNAIRE
We are interested in how having prolapse surgery affects your health and everyday life in
any way. We would be very grateful if you could complete and return this questionnaire.
If you would like any further information or have any queries about the study,
please contact:
PROSPECT Study Office
Centre for Healthcare Randomised Trials (CHaRT)
Health Services Research Unit
University of Aberdeen
Health Sciences Building
Aberdeen
AB25 2ZD
Tel: 
E-mail: 
Thank you for taking time to help us with our research.
Funded by the National Institute for Health Research
Health Technology Assessment programme (NIHR HTA)
ISRCTN No: 60695184 Version 3: 05 November 09
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and randomised Controlled Trials
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How often during the last four weeks Occasion- Some- Most of All of
have you had the following symptoms: Never ally times the time the time
A9 use your fingers to push up the
prolapse to ease discomfort or pain?
A10 take extra measures to ensure the
prolapse does not cause personal
hygiene problems?
A11 which of the actions above (questions A9 Not
to A10) causes you the most bother? applicable
Please enter either 9 to 10 in the box, or tick ‘Not applicable’
A12 How long have you been aware
that you have a prolapse?
A13 How long have you been having Not
bothersome symptoms from applicable
your prolapse?
A14 Overall, how much do your prolapse symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
0 1 2 3 4 5 6 7 8 9 10
not at a great
all deal
Years Months
Years Months
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Section B General health (EQ 5D) TODAY
The next section is about your health in general.  By placing a tick in one box in each group below, please
indicate which statements best describe your own health state today.
B1 Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
B2 Self-care
I have no problems with self-care
I have some problems washing myself or dressing myself
I am unable to wash or dress myself
B3 Usual activities (such as work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
B4 Pain/discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
B5 Anxiety/depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
Study Number  Baseline Questionnaire
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Section C Urine symptoms
Many people experience urinary symptoms some of the time. We are trying to find out how many women
with prolapse experience urinary symptoms or leak urine, and how much these bother them.  We would
be grateful if you could answer the following questions, thinking about how you have been, on average, over
the LAST FOUR WEEKS.
C1 During the night, how many times do you have to get up to urinate none
(pass water), on average?
one
two
three
four or more
C2 Do you have a sudden need to rush to the toilet to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
C3 Do you have pain in your bladder? never
occasionally
sometimes
most of the time
all of the time
C4 How often do you pass urine during the day? 1 to 6 times
7 to 8 times
9 to 10 times
11 to 12 times
13 or more times
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
346
C5 Is there a delay before you can start to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
C6 Do you have to strain to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
C7 Do you stop and start more than once while you urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
C8 Do you have to use your fingers to push up the prolapse to help never
empty your bladder (pass water)?
occasionally
sometimes
most of the time
all of the time
C9 Overall, how much do urinary symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
0 1 2 3 4 5 6 7 8 9 10
not at a great
all deal
Not applicable
Study Number Baseline Questionnaire
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C10 Does urine leak before you can get to the toilet (if never, go to section D)? never
occasionally
sometimes
most of the time
all of the time
C11 How often do you leak urine? never
about once a week or less often
two or three times a week
about once a day
several times a day
all the time
C12 We would like to know how much urine you think leaks. none
How much urine do you usually leak (whether you wear
protection or not)? a small amount
a moderate amount
a large amount
C13 Does urine leak when you are physically active, exert yourself, never
cough or sneeze?
occasionally
sometimes
most of the time
all of the time
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C14 Do you ever leak urine for no obvious reason and without never
feeling that you want to go?
occasionally
sometimes
most of the time
all of the time
C15 Do you leak urine when you are asleep? never
occasionally
sometimes
most of the time
all of the time
C16 Do you leak urine when you have sexual intercourse? not at all
a little
somewhat
a lot
C17 Overall, how much does leaking urine interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
0 1 2 3 4 5 6 7 8 9 10
not at a great
all deal
Not applicable
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Section D Bowel symptoms
Many people experience bowel symptoms some of the time.  We are trying to find out how many women
with prolapse experience bowel symptoms, and how much they bother them.  We would be grateful if you
could answer the following questions, thinking about how you have been, on average, over the PAST
FOUR WEEKS.
D1 On average how many times do you open four or more times a day
(move) your bowels?
about one to three times a day
about once a day
once every two or three days (two or three times per week)
once a week or less
D2 Are your stools (faeces, motions) usually… watery
sloppy
soft and formed
hard
D3 Do you have to strain to open (move) your bowels? never
occasionally
sometimes
most of the time
all of the time
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D4 Do you have to insert a finger into your back passage to help empty stool never
(faeces, motion) from your bowel?
occasionally
sometimes
most of the time
all of the time
D5 Do you have to rush to the toilet when you need to open (move) your bowels? never
occasionally
sometimes
most of the time
all of the time
D6 Do stool (faeces, motion) leak at an inappropriate time or place, or before never
you can get to the toilet?
occasionally
sometimes
most of the time
all of the time
D7 Overall, how much do bowel symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
0 1 2 3 4 5 6 7 8 9 10
not at a great
all deal
Not applicable
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Section E Vaginal and sexual symptoms
Many people experience vaginal or sexual symptoms some of the time. We are trying to find out how many
women with prolapse experience vaginal or sexual symptoms, and how much they bother them. We would
be grateful if you could answer the following questions, thinking about how you have been, on average, over
the PAST FOUR WEEKS.
E1 Are you aware of a dragging pain in your lower abdomen (tummy)? never
occasionally
sometimes
most of the time
all of the time
E2 Are you aware of soreness in your vagina? never
occasionally
sometimes
most of the time
all of the time
E3 Do you feel that you have reduced sensation or feeling in or around
your vagina? not at all
a little
somewhat
a lot
E4 Do you feel that your vagina is too loose or lax? not at all
a little
somewhat
a lot
E5 Are you aware of a lump or bulge coming down in your vagina? never
occasionally
sometimes
most of the time
all of the time
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
352
E6 Do you feel a lump or bulge come out of your vagina, so that you can feel
it on the outside or see it on the outside? never
occasionally
sometimes
most of the time
all of the time
E7 Do you feel that your vagina is too dry? never
occasionally
sometimes
most of the time
all of the time
E8 Do you have to insert a finger into your vagina to help empty your bowels? never
occasionally
sometimes
most of the time
all of the time
E9 Do you feel that your vagina is too tight? never
occasionally
sometimes
most of the time
all of the time
E10 Overall, how much do vaginal symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
0 1 2 3 4 5 6 7 8 9 10
not at a great
all deal
Not applicable
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E11 Do you have a sex life at present?
Yes If yes, go to E13 No If no, go to E12
E12 (If you do not have a sex life at present) is it for any of these reasons?
No, because I do not have a partner
No, because of my vaginal symptoms
No, because of my prolapse symptoms
No, because of other reasons (please specify below)
E13 Do you have pain when you have sexual intercourse? not at all
a little
somewhat
a lot
E14 Do worries about your vagina interfere with your sex life? not at all
a little
somewhat
a lot
E15 Do you feel that your relationship with your partner is affected
by vaginal symptoms? not at all
a little
somewhat
a lot
E16 Overall, how much do you feel that your sex life has been spoilt by vaginal symptoms?
Please tick a number between 0 (not at all) and 10 (a great deal)
0 1 2 3 4 5 6 7 8 9 10
not at a great
all deal
Not applicable
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Finally,
Date questionnaire filled in D D M M Y Y Y Y
Your date of birth D D M M Y Y Y Y
THANK YOU.
Thank you very much for answering these questions.
We intend to use the information you have given us for
research to help women like yourself with prolapse.
If you would like any further information or have any queries about the study, please contact:
PROSPECT Study Office
Tel: 
E-mail: 
Thank you again for taking time to help us with our research.
PLEASE BRING THE QUESTIONNAIRE WITH YOU TO HOSPITAL
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Six-month questionnaire
CONFIDENTIAL Participant Study No
6 MONTH QUESTIONNAIRE
We are interested in how your health and everyday life is affected in any way by having
prolapse surgery.  We would be very grateful if you could complete and return this
questionnaire.
If you would like any further information or have any queries about the study,
please contact:
PROSPECT Study Office
Centre for Healthcare Randomised Trials (CHaRT)
Health Services Research Unit
University of Aberdeen
Health Sciences Building
Aberdeen
AB25 2ZD
Tel: 
E-mail: 
Thank you for taking time to help us with our research.
Funded by the National Institute for Health Research
Health Technology Assessment programme (NIHR HTA)
ISRCTN No: 60695184 Version 3: 05 November 09
Prolapse Surgery: Pragmatic Evaluation
and randomised Controlled Trials
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Section B General health (EQ 5D) TODAY
The next section is about your health in general.  By placing a tick in one box in each group below, please
indicate which statements best describe your own health state today.
B1 Mobility I have no problems in walking about
I have some problems in walking about
I am confined to bed
B2 Self-care I have no problems with self-care
I have some problems washing myself or dressing myself
I am unable to wash or dress myself
B3 Usual activities (such as work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
B4 Pain/discomfort I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
B5 Anxiety/depression I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
358
Section C Treatments for symptoms
C1 Were you re-admitted to hospital, in relation to your Ye oprolapse surgery, in the last six months?
If yes to question C1 how many nights were you readmitted for in total?
(If you were admitted only as a day case, write 0 in the box provided)
C2 If yes, when and why were you re-admitted? (Please give details of all re-admissions):
Finally,
Date questionnaire filled in D D M M Y Y Y Y
Your date of birth D D M M Y Y Y Y
THANK YOU
Thank you very much for being part of the PROSPECT study and for
your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us 
to advise women and doctors about prolapse surgery in the future.  
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen 
in the envelope provided.
We hope to contact you again in the future to check on how your health is 
after your prolapse surgery
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One-year questionnaire
CONFIDENTIAL Participant Study No
ONE YEAR QUESTIONNAIRE
We are interested in how having prolapse surgery affects your health and everyday life in
any way.  We would be very grateful if you could complete and return this questionnaire.
If you would like any further information or have any queries about the study,
please contact:
PROSPECT Study Office
Centre for Healthcare Randomised Trials (CHaRT)
Health Services Research Unit
University of Aberdeen
Health Sciences Building
Aberdeen
AB25 2ZD
Tel: 
E-mail: 
Thank you for taking time to help us with our research.
Funded by the National Institute for Health Research
Health Technology Assessment programme (NIHR HTA)
ISRCTN No:60695184 Version 3: 06 November 09 
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Section B General health (EQ 5D) TODAY
The next section is about your health in general.  By placing a tick in one box in each group below, please
indicate which statements best describe your own health state today.
B1 Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
B2 Self-care
I have no problems with self-care
I have some problems washing myself or dressing myself
I am unable to wash or dress myself
B3 Usual activities (such as work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
B4 Pain/discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
B5 Anxiety/depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
363
Section C Treatments since your prolapse operation
C1 Have you had a new prolapse operation since your operation Yes No
one year ago?
If yes, please give details, eg what operation and when?
C2 Have you had a new operation for leaking urine since your Yes No
prolapse operation one year ago?
If yes, please give details, eg what operation and when?
C3 Have you had any stitches removed from the site of your prolapse operation one year ago?
Yes No Don’t know
C4 Have you had any mesh removed from the site of your prolapse operation one year ago?
Yes No Don’t know
C5 In the last six months were you re-admitted to hospital for any other Yes No
reason, in relation to your prolapse surgery one year ago?
If yes to question C5 how many nights were you readmitted for in total?
If you were admitted only as a day case, write 0 in the box:
C6 If yes, when and why were you re-admitted? (Please give details):
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C7 Are you using absorbent pads for leakage of urine? Yes No
C8 Are you using a permanent catheter (inside your bladder) Yes Noto collect urine?
C9 Do you ever use a disposable or reusable (intermittent) Yes No
catheter to help you to empty your bladder?
C10 Were you prescribed any medicines by a doctor or nurse, in Yes No
relation to your prolapse symptoms, in the last year?
C11 Have you had any other treatment for prolapse or leaking urine?
If yes to question C10 or 11, please tick all treatments you have had Yes No
in question C12
C12 Please tick all prescribed medicines or other treatments for prolapse or leaking urine
that you have had since your operation
Oestrogen treatment (eg vaginal cream, HRT)
Drug treatment for bladder problems or leaking urine (please give details)
A ring pessary inserted
A shelf pessary inserted 
Any other treatment for prolapse or another gynae problem (please give details)
Details:
C13 If you are in paid employment, how many days off sick have you had in
the last year? (If you are not in paid employment, please ignore this question)
C14 Have you seen your GP, in relation to your prolapse, in the last year? Yes No
If yes to question C14, how many times did you see your GP?
C15 Have you seen a practice nurse in relation to your prolapse in the Yes Nolast year?
If yes to question C15, how many times did you see the nurse?
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C16  Have you visited hospital outpatients to see a doctor, in relation Yes Noto your prolapse, in the last year?
If yes to question C16, how many times did you visit outpatients?
C17  Have you seen a physiotherapist, in relation to your prolapse, Yes Noin the last six months?
If yes to question C17, how many times did you see the physiotherapist?
C18  Have you visited any other health care professional, in relation Yes Noto your prolapse, in the last year?
If yes to question C18, specify whom you have seen and the number of
times you have seen them in the boxes provided:
Other (please  specify): Times
C19 Did you buy any medicines over the counter to treat your prolapse Yes No
symptoms in the last year?
C20 If yes to C19 above, how much in total did you spend? £ .
C21 Did you pay to see any private health care professional, in relation Yes Noto your prolapse, in the last year?
C22 Have you paid for any other healthcare, in relation to your prolapse, Yes Noin the last year?
C23 If yes to C21 or C22 above, how much did you spend? £ .
THANK YOU
Thank you very much for being part of the PROSPECT study and 
your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us 
to advise women and doctors about prolapse surgery in the future.  
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen 
in the envelope provided.
We hope to contact you again in the future to check on how your health is 
after your prolapse surgery. 
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One-year additional questionnaire
CONFIDENTIAL Participant Study No
ONE YEAR ADDITIONAL
QUESTIONNAIRE
We are interested in how having prolapse surgery affects your health and everyday life in
any way. We would be very grateful if you could complete and return this questionnaire.
If you would like any further information or have any queries about the study,
please contact:
PROSPECT Study Office
Tel: 
E-mail: 
Thank you for taking time to help us with our research.
Funded by the National Institute for Health Research
Health Technology Assessment programme (NIHR HTA)
ISRCTN No: 60695184 Version 3: 05 November 09
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Please start here:
Date questionnaire filled in D D M M Y Y Y Y
Your date of birth D D M M Y Y Y Y
Section A Urine symptoms
Many people experience urinary symptoms some of the time. We are trying to find out how many women
with prolapse experience urinary symptoms or leak urine, and how much these bother them.  We would
be grateful if you could answer the following questions, thinking about how you have been, on average, over
the LAST FOUR WEEKS.
A1 During the night, how many times do you have to get up to urinate none
(pass water), on average?
one
two
three
four or more
A2 Do you have a sudden need to rush to the toilet to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
A3 Do you have pain in your bladder? never
occasionally
sometimes
most of the time
all of the time
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Study Number One Year Additional Questionnaire
A4 How often do you pass urine during the day? 1 to 6 times
7 to 8 times
9 to 10 times
11 to 12 times
13 or more times
A5 Is there a delay before you can start to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
A6 Do you have to strain to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
A7 Do you stop and start more than once while you urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
A8 Do you have to use your fingers to push up the prolapse never
to help empty your bladder (pass water)?
occasionally
sometimes
most of the time
all of the time
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A9 Overall, how much do urinary symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
A10 Does urine leak before you can get to the toilet (if never, go to section B)? never
occasionally
sometimes
most of the time
all of the time
A11 How often do you leak urine? never
about once a week or less often
two or three times a week
about once a day
several times a day
all the time
A12 We would like to know how much urine you think leaks. none
How much urine do you usually leak (whether you wear 
protection or not)? a small amount
a moderate amount
a large amount
A13 Does urine leak when you are physically active, exert yourself, never
cough or sneeze?
occasionally
sometimes
most of the time
all of the time
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A14 Do you ever leak urine for no obvious reason and without never
feeling that you want to go?
occasionally
sometimes
most of the time
all of the time
A15 Do you leak urine when you are asleep? never
occasionally
sometimes
most of the time
all of the time
A16 Do you leak urine when you have sexual intercourse? not at all
a little
somewhat
a lot
A17 Overall, how much does leaking urine interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
Study Number One Year Additional Questionnaire
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Section B Bowel symptoms
Many people experience bowel symptoms some of the time.  We are trying to find out how many women
with prolapse experience bowel symptoms, and how much they bother them.  We would be grateful if you
could answer the following questions, thinking about how you have been, on average, over the PAST
FOUR WEEKS.
B1 On average how many times do you open four or more times a day
(move) your bowels?
about one to three times a day
about once a day
once every two or three days (two or three times per week)
once a week or less
B2 Are your stools (faeces, motions) usually… watery
sloppy
soft and formed
hard
B3 Do you have to strain to open (move) your bowels? never
occasionally
sometimes
most of the time
all of the time
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B4 Do you have to insert a finger into your back passage to help empty stool never
(faeces, motion) from your bowel?
occasionally
sometimes
most of the time
all of the time
B5 Do you have to rush to the toilet when you need to open (move) your bowels? never
occasionally
sometimes
most of the time
all of the time
B6 Do stool (faeces, motion) leak at an inappropriate time or place, or before never
you can get to the toilet?
occasionally
sometimes
most of the time
all of the time
B7 Overall, how much do bowel symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
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Section C Vaginal and sexual symptoms
Many people experience vaginal or sexual symptoms some of the time. We are trying to find out how many
women with prolapse experience vaginal or sexual symptoms, and how much they bother them. We would
be grateful if you could answer the following questions, thinking about how you have been, on average, over
the PAST FOUR WEEKS.
C1 Do you have to insert a finger into your vagina to push up the prolapse to never
ease discomfort or pain?
occasionally
sometimes
most of the time
all of the time
C2 Do you have to take extra measures to ensure the prolapse does not never
cause personal hygiene problems?
occasionally
sometimes
most of the time
all of the time
C3 Are you aware of a dragging pain in your lower abdomen (tummy)? never
occasionally
sometimes
most of the time
all of the time
C4 Are you aware of soreness in your vagina? never
occasionally
sometimes
most of the time
all of the time
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C5 Do you feel that you have reduced sensation or feeling in or around not at all
your vagina?
a little
somewhat
a lot
C6 Do you feel that your vagina is too loose or lax? not at all
a little
somewhat
a lot
C7 Are you aware of a lump or bulge coming down in your vagina? never
occasionally
sometimes
most of the time
all of the time
C8 Do you feel a lump or bulge come out of your vagina, so that you never
can feel it on the outside or see it on the outside?
occasionally
sometimes
most of the time
all of the time
C9 Do you feel that your vagina is too dry? never
occasionally
sometimes
most of the time
all of the time
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C10 Do you have to insert a finger into your vagina to help empty your bowels? never
occasionally
sometimes
most of the time
all of the time
C11 Do you feel that your vagina is too tight? never
occasionally
sometimes
most of the time
all of the time
C12 Overall, how much do vaginal symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
C13 Do you have a sex life at present?
Yes If yes, go to C15 No If no, go to C14
C14 (If you do not have a sex life at present) is it for any of these reasons?
No, because I do not have a partner
No, because of my vaginal symptoms
No, because of my prolapse symptoms
No, because of other reasons (please specify below)
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C15 Do you have pain when you have sexual intercourse? not at all
a little
somewhat
a lot
C16 Do worries about your vagina interfere with your sex life? not at all
a little
somewhat
a lot
C17 Do you feel that your relationship with your partner is affected
by vaginal symptoms? not at all
a little
somewhat
a lot
C18 Overall, how much do you feel that your sex life has been spoilt by vaginal symptoms?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
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Section D General information
D1 After your prolapse surgery a year ago, how long was it before you were able to get back to
your normal daily activities?
Enter number of months
D2 Please describe how your prolapse is now, compared with very much better
how it was before you had surgery one year ago:
much better
a little better
no change
a little worse
much worse
very much worse
D3 Overall how satisfied are you with the results of the operation completely satisfied
fairly satisfied
fairly dissatisfied
very dissatisfied
not sure
D4 Would you recommend this operation to a friend? Yes No
THANK YOU
Thank you very much for being part of the PROSPECT study and 
your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us 
to advise women and doctors about prolapse surgery in the future.  
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen 
in the envelope provided.
We hope to contact you again in the future to check on how your health is 
after your prolapse surgery. 
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Patient costs questionnaire
CONFIDENTIAL Participant Study No
PARTICIPANT COSTS
QUESTIONNAIRE
Thank you for helping us with our research into prolapse surgery.
We would be very grateful if you could complete and return this
questionnaire.
Thank you for taking the time to help us with our research.
ISRCTN60695184 Version 2   01 July 2011
Prolapse Surgery: Pragmatic Evaluation
and randomised Controlled Trials
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This questionnaire will help us to find out how much it costs you to use health
services.  We wish to ask about your most recent admission to hospital, your most
recent outpatient appointment and your most recent appointment with a GP.  We
wish to know how much money and time were spent by you and any companion in
attending these appointments and as a result of any hospital admission you may
have had. 
It may have been a long time ago and we understand that you are unlikely to
remember the exact details.  Please just give us your best guess.
If you have a problem in answering any question please telephone the PROSPECT
Study Office on             .  Please return the questionnaire in the enclosed
pre-paid envelope. 
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Section A Your most recent admission to hospital
If in the last 12 months you were not admitted to hospital please go to Section B
1. Please circle the number that best describes how you travelled.  If you used more than one form of
transport please indicate the way you travelled for the main (longest in terms of distance) part of
your journey.
Walked...................................................1 Taxi ................................................................5
Cycled ...................................................2 Hospital car....................................................6
Bus ........................................................3 Ambulance.....................................................7
Train ......................................................4 Private car......................................................8
Other (please specify) 9
2. If you travelled by bus, train or taxi to hospital what was the total cost of the (one-way) journey?
Please write the cost in the box below.  Please put zero if you did not travel by bus, train or taxi at
all or if you did not pay a fare. If you purchased a return ticket, please put half the cost of your
ticket.
Cost of (one-way) fare (£) - pence
3. If you travelled by private car about how many miles did you travel one-way?  Please write the
number of miles in the box below.  Please put zero if you did not travel by private car at all.
Number of miles one-way 
4. If you travelled by private car and you or your companion had to pay a parking fee how much did
this cost?  Please write the cost in the box below.  Please put zero if you did not pay a parking fee.
Expenditure on parking fee (£) - Pence
5. When you were admitted to the hospital, how long did you spend there?  Please write the number
of days in the box below. 
Number of days
6. What would you otherwise have been doing as your main activity if you had not had to be
admitted to hospital? Please circle the number that best applies to you. 
Housework ............................................1 Paid work .......................................................5
Childcare ...............................................2 Voluntary work ...............................................6
Caring for a relative or friend.................3 Leisure activities ............................................7
Unemployed ..........................................4
Other (please specify) 8
Study Number Participant Costs Questionnaire
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7. When you were admitted to hospital, did anyone come with you?  Please circle the appropriate
response.
Yes (continue with question 8)...............1 No (go to section B) .......................................2
8. Who accompanied you to the hospital?  Please circle the number that best describes the main
person who accompanied you to the hospital. 
Partner/spouse ......................................1 Paid caregiver................................................3
Other relative.........................................2 Friend.............................................................4
Other (please specify) 5
9. Please circle the number that best describes what your main companion would otherwise have
been doing as their main activity if they had not gone with you to the hospital.
Housework ............................................1 Paid work .......................................................5
Childcare ...............................................2 Voluntary work ...............................................6
Caring for a relative or friend.................3 Leisure activities ............................................7
Unemployed ..........................................4
Other (please specify) 8
10. Did your main companion take time off from paid work (or business activity if self-employed)?
Please circle the appropriate response.
Yes (continue with question 11).............1 No (go to section B) .......................................2
11. Please write the number of hours your companion took off from paid work (or business activity if
self-employed) in the box below.  Please put zero if your main companion did not take time off
from paid work (or business activity if self-employed) to accompany you to the hospital.
Number of hours
12. Whilst you were in hospital, approximately how many times did your main companion come to visit
you?
Number of times
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Section B     Your most recent outpatient visit
If in the last 12 months you did not have an outpatients appointment please go to Section C
1. Please circle the number that best describes how you travelled.  If you used more than one form of
transport please indicate the way you travelled for the main (longest in terms of distance) part of
your journey.
Walked...................................................1 Taxi ................................................................5
Cycled ...................................................2 Hospital car....................................................6
Bus ........................................................3 Ambulance.....................................................7
Train ......................................................4 Private car......................................................8
Other (please specify) 9
2. If you travelled by bus, taxi or train to hospital what was the total cost of the (one-way) journey?
Please write the cost in the box below.  Please put zero if you did not travel by bus, train or taxi at
all or if you did not pay a fare. If you purchased a return ticket, please put half the cost of the return
ticket.
Cost of (one-way) fare (£) - pence
3. If you travelled by private car about how many miles did you travel one-way?  Please write the
number of miles in the box below.  Please put zero if you did not travel by private car at all.
Number of miles one-way
4. If you travelled by private car and you or your companion had to pay a parking fee how much did
this cost?  Please write the cost in the box below.  Please put zero if you did not pay a parking fee.
Expenditure on parking fee (£) - Pence
5. When you visited outpatients, how long did it take to travel there?  Please write the number of
hours and minutes in the box below.
Number of hours - minutes
6. When you visited outpatients, how long did you spend there?  Please write the number of hours
and minutes in the box below. 
Number of hours - minutes
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7. Please circle the number that best describes what you otherwise would have been doing as your
main activity if you had not been visiting outpatients?
Housework ............................................1 Paid work .......................................................5
Childcare ...............................................2 Voluntary work ...............................................6
Caring for a relative or friend.................3 Leisure activities ............................................7
Unemployed ..........................................4
Other (please specify) 8
8. When you visited outpatients did anyone come with you?  Please circle the appropriate response.
Yes (continue with question 9)...............1 No (go to section C).......................................2
9. Please circle the number that best describes the main person who accompanied you to
outpatients.
Partner/spouse ......................................1 Paid caregiver................................................3
Other relative ........................................2 Friend.............................................................4
Other (please specify) 5
10. If your main companion travelled with you by bus or train approximately how much did they pay
(one-way) in fares?  Please write the approximate cost in the box below.  Please put zero if your
main companion did not travel by bus or train at all.  If they purchased a return ticket, please put
half the cost of the return ticket.
Cost of (one-way) fare (£) - pence
11. Please circle the number that best describes what your main companion would otherwise have
been doing as their main activity if they had not gone with you to outpatients.
Housework ............................................1 Paid work .......................................................5
Childcare ...............................................2 Voluntary work ...............................................6
Caring for a relative or friend ................3 Leisure activities ............................................7
Unemployed ..........................................4
Other (please specify) 8
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Section C     Your most recent GP appointment
1. Please circle the number that best describes how you travelled to your GP appointment.  If you
used more than one form of transport please indicate the way you travelled for the main (longest
in terms of distance) part of your journey.
Walked...................................................1 Taxi ................................................................5
Cycled ...................................................2 Hospital car....................................................6
Bus ........................................................3 Ambulance.....................................................7
Train ......................................................4 Private car......................................................8
Other (please specify) 9
2. If you travelled by bus, train or taxi, what was the cost of the (one-way) fare?  Please write the cost
in the box below.  Please put zero if you did not travel by bus, train or taxi or if you did not pay the
fare. If you purchased a return ticket, please put half the cost of the return ticket.
Cost of (one-way) fare (£) - pence
3. If you travelled by private car about how many miles did you travel one-way?  Please write the
number of miles in the box below.  Please put zero if you did not travel by private car at all.
Number of miles one-way 
4. If you travelled by private car and you or a companion had to pay a parking fee how much did this
cost?  Please write the cost in the box below.  Please put zero if you did not pay for parking.
Expenditure on parking fee (£) - Pence
5. When you visited the GP, how long did it take to travel there?  Please write the number of minutes
in the box below.
Number of minutes
6. When you visited the GP, how long did you spend there?  Please write the number of minutes in
the box below.  Please include in your answer the time spent waiting and also the time spent with
the doctors and nurses  
Number of minutes
DOI: 10.3310/hta20950 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 95
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
385
7. Please circle the number that best describes what you otherwise would have been doing as your
main activity if you had not visited the GP.
Housework ............................................1 Paid work .......................................................5
Childcare ...............................................2 Voluntary work ...............................................6
Caring for a relative or friend.................3 Leisure activities ............................................7
Unemployed ..........................................4
Other (please specify) 8
8. When you visited the GP did anyone come with you?  Please circle the appropriate response.
Yes (continue with question 9)...............1 No (go to the end)..........................................2
9. Please circle the number(s) that best describe the person(s) who accompanied you to the GP’s
surgery.  You may circle more than one response if appropriate.
Partner/spouse ......................................1 Paid caregiver ...............................................3
Other relative.........................................2 Friend.............................................................4
Other (please specify) 5
10. If your main companion travelled with you by bus or train how much approximately did they pay
(one-way) in fares (if anything)?  Please write the cost in the box below.  Please put zero if your
main companion did not travel by bus or train at all. If they purchased a return ticket, please put
half the cost of the return ticket.
Cost of (one-way) fare (£) - pence
11. Please circle the number that best describes what your main companion would otherwise have
been doing as their main activity if they had not gone with you to the GP’s surgery.
Housework ............................................1 Paid work .......................................................5
Childcare ...............................................2 Voluntary work ...............................................6
Caring for a relative or friend.................3 Leisure activities ............................................7
Unemployed ..........................................4
Other (please specify) 5
If you wish to provide any further information please do so below.
Thank you for filling in this questionnaire, please post it back to us in the envelope provided
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Two-year questionnaire
CONFIDENTIAL Participant Study No
TWO YEAR QUESTIONNAIRE
We are interested in how having prolapse surgery affects your health and everyday life in
any way. We would be very grateful if you could complete and return this questionnaire.
If you would like any further information or have any queries about the study,
please contact:
PROSPECT Study Office
Tel: 
E-mail: 
Thank you for taking time to help us with our research.
Funded by the National Institute for Health Research
Health Technology Assessment programme (NIHR HTA)
ISRCTN No: 60695184 Version 3: 09 November 09
TW
O
 Y
EA
R 
QU
ES
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ON
NA
IR
E
Prolapse Surgery: Pragmatic Evaluation
and randomised Controlled Trials
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Section B General health (EQ 5D) TODAY
The next section is about your health in general.  By placing a tick in one box in each group below, please
indicate which statements best describe your own health state today.
B1 Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
B2 Self-care
I have no problems with self-care
I have some problems washing myself or dressing myself
I am unable to wash or dress myself
B3 Usual activities (such as work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
B4 Pain/discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
B5 Anxiety/depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
Study Number Two Year Questionnaire
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Section C Treatments for symptoms
C1 In the last year, have you had a new prolapse operation? Yes No
If yes, please give details, eg what operation and when?
C2 Are you now on the waiting list for a new prolapse operation? Yes No
C3 In the last year, have you had a new operation for leaking urine? Yes No
If yes, please give details, eg what operation and when?
C4 Are you now on the waiting list for a new operation for leaking urine? Yes No
C5 In the last year, have you had any stitches removed from the site of your prolapse operation?
Yes No Don’t know
C6 In the last year, have you had any mesh removed from the site of your prolapse operation?
Yes No Don’t know
C7 In the last year, were you re-admitted to hospital for any other Yes No
reason, in relation to your prolapse surgery two years ago?
If yes to question C7 how many nights were you readmitted for in total?
(If you were admitted only as a day case, write 0 in the box provided)
C8 If yes, why were you re-admitted? (Please give details of all re-admissions):
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Study Number Two Year Questionnaire
C9 Are you using absorbent pads for leakage of urine? Yes No
C10 Are you using a permanent catheter (inside your bladder) Yes Noto collect urine?
C11 Do you ever use a disposable or reusable (intermittent) Yes No
catheter to help you to empty your bladder?
C12 Were you prescribed any medicines by a doctor or nurse, in Yes No
relation to your prolapse symptoms, in the last year?
C13 Have you had any other treatment for prolapse or leaking urine? Yes No
If yes to question C12 or 13, please tick all treatments you have had in question C14
C14 Please tick all prescribed medicines or other treatments for prolapse or leaking urine
that you have had since your operation
Oestrogen treatment (eg vaginal cream, HRT)
Drug treatment for bladder problems or leaking urine (please give details)
A ring pessary inserted
A shelf pessary inserted 
Any other treatment for prolapse or another gynae problem (please give details)
Details:
C15 If you are in paid employment, how many days off sick have you had in
the last year? (If you are not in paid employment, please ignore this question)
C16 Have you seen your GP, in relation to your prolapse, in the last year? Yes No
If yes to question C16, how many times did you see your GP?
C17 Have you seen a practice nurse in relation to your prolapse in the Yes Nolast year?
If yes to question C17, how many times did you see the nurse?
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C18  Have you visited hospital outpatients to see a doctor, in relation Yes Noto your prolapse, in the last year?
If yes to question C18, how many times did you visit outpatients?
C19  Have you seen a physiotherapist, in relation to your prolapse, Yes Noin the last year?
If yes to question C19, how many times did you see the physiotherapist?
C20  Have you visited any other health care professional, in relation Yes Noto your prolapse, in the last year?
If yes to question C20, specify whom you have seen and the number of
times you have seen them in the boxes provided:
Other (please  specify): Times
C21 Did you buy any medicines over the counter to treat your prolapse Yes No
symptoms in the last year?
C22 If yes to C21 above, how much in total did you spend? £ .
C23 Did you pay to see any private health care professional, in relation Yes No
to your prolapse, in the last year?
C24 Have you paid for any other healthcare, in relation to your prolapse, Yes No
in the last year?
C25 If yes to C23 or C24 above, how much did you spend? £ .
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Section D Urine symptoms
Many people experience urinary symptoms some of the time. We are trying to find out how many women
with prolapse experience urinary symptoms or leak urine, and how much these bother them.  We would
be grateful if you could answer the following questions, thinking about how you have been, on average, over
the LAST FOUR WEEKS.
D1 During the night, how many times do you have to get up to urinate none
(pass water), on average?
one
two
three
four or more
D2 Do you have a sudden need to rush to the toilet to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
D3 Do you have pain in your bladder? never
occasionally
sometimes
most of the time
all of the time
D4 How often do you pass urine during the day? 1 to 6 times
7 to 8 times
9 to 10 times
11 to 12 times
13 or more times
Study Number Two Year Questionnaire
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D5 Is there a delay before you can start to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
D6 Do you have to strain to urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
D7 Do you stop and start more than once while you urinate (pass water)? never
occasionally
sometimes
most of the time
all of the time
D8 Do you have to use your fingers to push up the prolapse never
to help empty your bladder (pass water)?
occasionally
sometimes
most of the time
all of the time
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D9 Overall, how much do urinary symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
D10 Does urine leak before you can get to the toilet (if never, go to section E)? never
occasionally
sometimes
most of the time
all of the time
D11 How often do you leak urine? never
about once a week or less often
two or three times a week
about once a day
several times a day
all the time
D12 We would like to know how much urine you think leaks. none
How much urine do you usually leak (whether you wear
protection or not)? a small amount
a moderate amount
a large amount
D13 Does urine leak when you are physically active, exert yourself, never
cough or sneeze?
occasionally
sometimes
most of the time
all of the time
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D14 Do you ever leak urine for no obvious reason and without never
feeling that you want to go?
occasionally
sometimes
most of the time
all of the time
D15 Do you leak urine when you are asleep? never
occasionally
sometimes
most of the time
all of the time
D16 Do you leak urine when you have sexual intercourse? not at all
a little
somewhat
a lot
D17 Overall, how much does leaking urine interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
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Section E Bowel symptoms
Many people experience bowel symptoms some of the time.  We are trying to find out how many women
with prolapse experience bowel symptoms, and how much they bother them.  We would be grateful if you
could answer the following questions, thinking about how you have been, on average, over the PAST
FOUR WEEKS.
E1 On average how many times do you open four or more times a day
(move) your bowels?
about one to three times a day
about once a day
once every two or three days (two or three times per week)
once a week or less
E2 Are your stools (faeces, motions) usually… watery
sloppy
soft and formed
hard
E3 Do you have to strain to open (move) your bowels? never
occasionally
sometimes
most of the time
all of the time
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E4 Do you have to insert a finger into your back passage to help empty stool never
(faeces, motion) from your bowel?
occasionally
sometimes
most of the time
all of the time
E5 Do you have to rush to the toilet when you need to open (move) your bowels? never
occasionally
sometimes
most of the time
all of the time
E6 Do stool (faeces, motion) leak at an inappropriate time or place, or before never
you can get to the toilet?
occasionally
sometimes
most of the time
all of the time
E7 Overall, how much do bowel symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
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Section F Vaginal and sexual symptoms
Many people experience vaginal or sexual symptoms some of the time. We are trying to find out how many
women with prolapse experience vaginal or sexual symptoms, and how much they bother them. We would
be grateful if you could answer the following questions, thinking about how you have been, on average, over
the PAST FOUR WEEKS.
F1 Do you have to insert a finger into your vagina to push up the prolapse to never
ease discomfort or pain?
occasionally
sometimes
most of the time
all of the time
F2 Do you have to take extra measures to ensure the prolapse does not never
cause personal hygiene problems?
occasionally
sometimes
most of the time
all of the time
F3 Are you aware of a dragging pain in your lower abdomen (tummy)? never
occasionally
sometimes
most of the time
all of the time
F4 Are you aware of soreness in your vagina? never
occasionally
sometimes
most of the time
all of the time
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F5 Do you feel that you have reduced sensation or feeling in or around not at all
your vagina?
a little
somewhat
a lot
F6 Do you feel that your vagina is too loose or lax? not at all
a little
somewhat
a lot
F7 Are you aware of a lump or bulge coming down in your vagina? never
occasionally
sometimes
most of the time
all of the time
F8 Do you feel a lump or bulge come out of your vagina, so that you never
can feel it on the outside or see it on the outside?
occasionally
sometimes
most of the time
all of the time
F9 Do you feel that your vagina is too dry? never
occasionally
sometimes
most of the time
all of the time
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F10 Do you have to insert a finger into your vagina to help empty your bowels? never
occasionally
sometimes
most of the time
all of the time
F11 Do you feel that your vagina is too tight? never
occasionally
sometimes
most of the time
all of the time
F12 Overall, how much do vaginal symptoms interfere with your everyday life?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
F13 Do you have a sex life at present?
Yes If yes, go to F15 No If no, go to F14
F14 (If you do not have a sex life at present) is it for any of these reasons?
No, because I do not have a partner
No, because of my vaginal symptoms
No, because of my prolapse symptoms
No, because of other reasons (please specify below)
Now go to Section G
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F15 Do you have pain when you have sexual intercourse? not at all
a little
somewhat
a lot
F16 Do worries about your vagina interfere with your sex life? not at all
a little
somewhat
a lot
F17 Do you feel that your relationship with your partner is affected
by vaginal symptoms? not at all
a little
somewhat
a lot
F18 Overall, how much do you feel that your sex life has been spoilt by vaginal symptoms?
Please tick a number between 0 (not at all) and 10 (a great deal)
not at 0 1 2 3 4 5 6 7 8 9 10 a great
all deal
Not applicable
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Section G General information
G1 Please describe how your prolapse is now, compared with very much better
how it was before you had surgery two years ago:
much better
a little better
no change
a little worse
much worse
very much worse
G2 Overall how satisfied are you with the results of the operation completely satisfied
fairly satisfied
fairly dissatisfied
very dissatisfied
not sure
G3 Would you recommend this operation to a friend? Yes No
THANK YOU
Thank you very much for being part of the PROSPECT study and 
your time and patience in filling in this questionnaire.
The information you have given us will be extremely useful in helping us 
to advise women and doctors about prolapse surgery in the future.  
It will be treated with the strictest confidence and kept securely.
Please send the questionnaire back to us in Aberdeen 
in the envelope provided.
We hope to contact you again in the future to check on how your health is 
after your prolapse surgery. 
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Appendix 5 Statistical analysis plan
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Study Design 
PROSPECT is a multi-centred randomised control trial with a parallel-cohort 
design.  The aim of the study is to investigate the safety, effectiveness and 
cost-effectiveness of operations for women with pelvic organ prolapse.  The 
study includes two RCTs within a Comprehensive Cohort Study, with the 
following principle objectives: 
In women having a primary prolapse repair, the effects of a standard repair 
versus the following:   
1)   Standard repair using a biological graft inlay 
2)   Standard repair using a non-absorbable or combined mesh inlay 
 
In women having a secondary prolapse repair, the effects of a standard repair 
versus the following: 
3)   Standard repair using a non-absorbable or combined mesh inlay 
4)   Mesh kit procedure 
Treatment allocation is minimised by age (>60/60+), type of planned prolapse 
surgery (anterior/posterior/both), concomitant continence procedure and 
concomitant prolapse procedure.  Treatment allocations are summarised in 
Figure 1. 
 
 
Figure 1. Treatment allocation in PROSPECT RCTs 
Since recruitment began, additional randomisation menu options have been 
made available, partly as a result of some mesh types being unavailable on 
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certain days. It is possible in RCT1 to randomise just between standard repair 
and non-absorbable mesh (RCT1B), or between standard repair and 
biological mesh (RCT1C).  In the secondary trial, an additional menu option of 
randomising between standard repair and mesh kit has been added (RCT2D). 
At close of recruitment (August 2013), there were 36 participating centres 
throughout the UK.  The centres are listed in Table 1. 
Table 11– PROSPECT participating centres 
 
Outcome Measures 
All outcome measures are recorded at baseline, 12 months and 24 months. 
Primary Outcomes 
The primary patient-reported outcomes are symptoms of prolapse, measured 
as: 
• the number and frequency of prolapse symptoms on the Pelvic Organ 
Prolapse Symptom Scale (POP-SS)1 at one year after surgery  
• a quality of life outcome measured as the overall effect of prolapse 
symptoms on everyday life.  
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The POP-SS is a composite outcome measure comprising seven patient 
recorded items each relating to a different symptom.  Each item has an 
ordinal response schedule with five levels of response based on frequency of 
the symptom (“never”, “occasionally”, sometimes”, “most of the time” and “all 
of the time”) and is scored from 0 to 4 respectively.  The overall POP-SS 
score is the sum of each item score and can range from zero to 28.   
 
For the primary analysis, individual items that are missing will be assumed to 
have a value of zero.  However, this assumption will be tested in sensitivity 
analyses.  If all seven questions are unanswered, then the POP-SS score will 
be treated as missing. 
 
The primary economic outcome measure of cost effectiveness is incremental 
cost per QALY (QALYs based on the EQ-5D2).  The cost effectiveness 
analysis is set out separately in the economic analysis plan. 
Secondary Outcomes 
General  
• immediate and late post-operative morbidity (injury to organs, excess 
blood loss, blood transfusion, infection (UTI, sepsis, abscess), pain, 
urinary retention, constipation) 
• other adverse effects or complications including mesh erosion or 
removal 
• operating time 
• blood loss 
• number of nights in hospital 
• time until resumption of usual activities 
 
Prolapse outcomes  
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• subjective recurrence of prolapse 
• subjective continuation / recurrence of prolapse symptoms 
• objective residual prolapse stage (POP-Q) at original site 
• development of new (de novo) prolapse at another site 
• need for other conservative prolapse treatment (e.g. PFMT, 
mechanical device) 
• need for further surgery for prolapse and/or for urinary incontinence 
• time to further surgery 
• satisfaction with surgery 
 
Urinary outcomes  
• Urinary incontinence (persistent or de novo, and types of incontinence) 
• Need for alternative management for incontinence (e.g. PFMT, 
mechanical devices, pads, surgery, drugs, intermittent catheterisation) 
 
Bowel outcomes  
• Constipation (persistent or de novo) 
• Bowel urgency (persistent or de novo) 
• Faecal incontinence (persistent or de novo) 
 
Vaginal symptoms and sexual function outcomes  
• Vaginal symptoms 
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• Dyspareunia / apareunia / difficulty with intercourse (persistent or de 
novo) 
 
Quality of life outcome measures  
• Condition-specific quality of life measures (urinary, bowel, vaginal, 
sexual) 
• General health measure (EQ-5D2)  
 
Missing data 
Loss to follow-up 
Complete loss to follow-up is defined as a participant who has no information 
on outcomes at any follow-up timepoint, but has not withdrawn consent. Such 
patients will not contribute data to any of the assessed outcomes. 
Partial loss to follow-up is defined as a participant contributing some follow-up 
data, but no further information is known on other follow-up outcomes. Such 
participants will contribute to the outcomes for which there are data. 
Withdrawals 
If a participant prospectively withdraws consent, no further data are captured 
or retained on or after the date of withdrawal of consent. Depending on when 
the consent is withdrawn, the above rules on loss to follow-up apply.  
Post-randomisation exclusions 
If a participant is excluded from the trial, then their data will be excluded from 
analyses and will not contribute to any of the assessed outcomes. 
Imputation 
Imputation of missing baseline data (collected prior to randomisation) will be 
undertaken in order to reduce bias.  Although no imputation of missing 
participant-level outcome data will be carried out in the main analysis of the 
primary outcome, imputation of instruments (e.g. POP-SS) will be undertaken 
at item-level according to the rules of the specific instrument. 
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Sensitivity analyses 
It is recommended that sensitivity analyses are carried out where there are 
missing outcome data3.  For the primary outcome POP-SS at data 12 months 
we will explore the explore the impact of missing data on the complete-case 
treatment estimates and confidence intervals by using multiple imputation and 
pattern mixture modelling methods depending on level and  patterns of 
missing data.  
Statistical Methods 
General Methods 
The statistical analysis of the RCTs will be based on all women as 
randomised, irrespective of subsequent compliance with the treatment 
allocated (intention to treat). The principal comparisons will be:  
• In women having a primary prolapse repair,  
o a standard anterior and/or posterior repair will be compared with 
a standard repair using a biological graft inlay; and  
o a standard anterior and/or posterior repair will be compared with 
a standard repair using a non-absorbable or combined mesh 
inlay.  
• In women having a secondary prolapse repair,  
o a standard anterior and/or posterior repair will be compared with 
a standard repair using a non-absorbable or combined mesh 
inlay; and  
o a standard anterior and/or posterior repair will be compared with 
a mesh kit procedure using an introducer device.  
The two trials are being considered independently because different surgical 
options are considered to be appropriate for clinical reasons.   Women who 
are not randomised but who are in the Comprehensive Cohort group will be 
analysed according to the operation actually carried out.  
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Descriptive statistics will be tabulated by treatment allocation for all outcomes 
(mean and SD for continuous data, proportions for binary data).  Treatment 
effects will be estimated with 95% confidence intervals for all outcomes (mean 
differences for continuous data, odds ratios for binary data).  Statistical 
significance will be at the 5% level and corresponding confidence intervals will 
be derived. Analyses will be conducted using SAS v9.3. 
Primary/Secondary Outcomes 
Outcomes at 12 months will be analysed using a generalised linear model 
which will adjust for minimisation and baseline covariates. The development 
of treatment effects over time will be explored using repeated measures 
mixed effects models that make use of available outcome data at each time 
point, e.g. 6, 12 and 24 months for the POP-SS (this assumes outcome data 
missing at random conditional on the observed covariates).     
 
Furthermore, it is anticipated that many women may be asymptomatic one 
year after surgery and their POP-SS will be zero.  A composite binary/linear 
model will be used to analyse the primary outcome (POP-SS at 12 months) so 
that a distribution of POP-SS with a high proportion of zero values is taken 
into account.  The binary element will be based on a POP-SS=0, and the 
linear element will treat the POP-SS score as a continuous measure with 
possible values ranging from 0 to 28. 
 
The menu design of the trials will be taken into account in the analyses of all 
outcomes.  Both RCTs have 3 strata, as shown in Table 2 and Table 3. 
 
Table 2: Number of participants randomised to each stratum in the 
primary RCT 
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Table 3: Number of participants randomised to each stratum in the 
secondary RCT 
 
In the primary RCT, RCT1 will be analysed on its own and treatment effects 
for treatments B and C (compared with A) will be estimated.  In addition, the 
RCT1 and RCT1B strata will be combined (using just data in arms A and B) in 
a separate model to create a further estimate of the treatment effect between 
A and B.  Similarly, the RCT1 and RCT1C strata will be combined (using just 
data in arms A and C) in a separate model to create a further estimate of the 
treatment effect between A and C.  Where strata are combined, the stratum 
variable will be fitted as a fixed effect in the model.  The secondary trial will be 
similarly analysed, although RCT2 will not be combined with RCT2D due to 
the small number randomised to RCT2D. 
 
Secondary outcomes will be analysed in a similar fashion to the primary 
outcome using appropriate link functions.    
Subgroup analyses 
Subgroup analyses (separately for the two populations) will explore the effect 
on prolapse symptoms at 12 months after surgery of:  
• mesh kit versus other procedures in those that could have been 
randomised to mesh kits 
• concomitant continence procedure or not 
• concomitant hysterectomy/cervical amputation/vault procedure or not 
• age (<60 or >=60 years) 
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• parity 
• between those having one type of prolapse repair alone (anterior or 
posterior) versus both 
 
Heterogeneity of treatment effects amongst subgroups will be tested for using 
the appropriate subgroup by treatment group interactions. Stricter levels of 
statistical significance (2P<0.01) will be sought, reflecting the exploratory 
nature of these analyses.  
Non-compliance will allocated treatment  
The primary analysis strategy of the trial will follow the intention-to-treat 
principle, i.e. participants will analysed as randomised, regardless of the 
intervention received. However, secondary analyses may be undertaken to 
investigate issues relating to compliance (e.g. mesh inlays being misidentified 
as mesh kits). Depending on levels and patterns of non-compliance analyses 
methods other than intention-to-treat may be used, for example per-protocol 
analyses or estimation of complier average treatment effects. 
Methodological analyses  
The responses from women and their objective clinical findings will provide a 
rich data source for exploration of the correlation between patient-reported 
and clinician-observed outcomes, and between prolapse symptoms and their 
effect on quality of life. This methodological research is intended to advance 
the controversial field. 
1.1. Timing of analyses 
An analysis of 12 month outcomes (including the primary outcome) will be 
performed and published one year after recruitment closes.  A final analysis of 
all outcomes will be conducted at the end of the trial when all follow-up has 
been completed (up to 24 months).  
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Sample Size and Power Calculation 
In an average population of women having prolapse surgery, about 70% will 
be having a primary procedure. Two comparisons will be made:  
• a standard repair versus a standard repair using a biological graft inlay; 
and  
• a standard repair versus a standard repair using a non-absorbable or 
combined mesh inlay.  
Pilot data have shown that a conservative estimate of the standard deviation 
of the primary patient-reported outcome POP-SS is 8 units. A difference in 
means of 2 units would represent an improvement in the response to a POP-
SS question, for example, a feeling of something coming down or in the 
vagina, from ‘Most of the Time’ to ‘Occasionally’. To detect a standardised 
difference of 0.25 with 90% power and alpha equal to 0.025 (to maintain the 
nominal p value at 0.05 with two tests being used), we would need to 
randomise 400 women to each arm of the study. Best efforts using evidence 
based techniques will be employed to maximise the response rate at follow 
up. Nevertheless, we feel it prudent to inflate the estimated sample size for 
15% dropout at one year requiring approximately 1450 women having primary 
surgery to be recruited to the trial. Adjusting for baseline covariates and 
minimising the loss to follow up will potentially improve this power. A trial of 
this size would also be adequately powered to detect important differences in 
the economic and secondary outcomes.  
 
It is estimated that the other 30% of women requiring anterior and/or posterior 
repair will receive a secondary or subsequent repair. Therefore, during the 
proposed time period required for recruiting 1450 women to the primary repair 
RCT above, it is anticipated approximately 620 women having secondary 
surgery will be eligible and will be willing to be randomised.  Within the 
secondary RCT two comparisons will be made:  
• a standard repair versus a standard repair using a non-absorbable or 
combined mesh inlay; and  
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• a standard repair versus a mesh kit procedure.  
 
It would be possible to detect with 90% power and alpha equal to 0.025 a 
standardised effect size of 0.38 which equates to 3 points on the POP-SS 
scale (this estimated effect detectable has been calculated adjusting for 
potential 15% dropout at one year). The pilot data from IMPRESS indicated 
that women having secondary repairs have a higher level of symptoms at 
baseline. Therefore it is biologically plausible that these women may show a 
larger benefit from the options available.  
 
Thus 2070 women will be randomised in total. Based on data from the 
feasibility study, we expect that in a typical centre, 200 women a year will be 
eligible, of whom 50% will be willing to be randomised. Of these women, 70% 
will be having primary surgery, 30% will have both anterior and posterior 
surgery, 15% may have a concomitant continence procedure and 30% a 
concomitant upper vaginal procedure (e.g. cervical amputation or vaginal 
hysterectomy). More than 15 centres are willing to take part.  
If we conservatively assume 50% of the women will agree to be randomised, 
we calculate we will need the equivalent of 18 months full time recruitment to 
randomise 2070 women and will follow up 4140 women in total including 
those in the Comprehensive Cohort. Allowing for about another 10% who will 
not wish to be studied in any way, we will need to approach around 4500 
women.  
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Appendix 6 Health economics
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Costs for a ring pessary
Product Price (£) for 1
Bioteque America (San Jose, CA, USA) 20.00
GBUK Healthcare (Selby, UK) 19.00
Milex (Mediplus, High Wycombe, UK) 20.94
Average 19.98
Costs for a shelf pessary (assume Gellhorn pessary)
Product Price (£) for 1
Bioteque America 21.50
GBUK 20.49
Milex 22.55
Average 21.51
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Appendix 7 Evidence synthesis
Meta-analyses: prolapse surgery with no mesh compared with
prolapse surgery with mesh (Fiona Stewart, Lynda Constable,
Moira Cruickshank, Clare Robertson)
This appendix contains the results of meta-analyses of RCTs comparing prolapse surgery with and without
mesh, updated with new RCTs published since the last Cochrane review in 201318 and with the new data
from PROSPECT.
Meta-analyses have been undertaken for outcomes measured up to 1 year after surgery and for the same
outcomes measured beyond the first postoperative year (usually for 2 years, with some trials following up
participants for 3 years).
Within 1 year of surgery, the risk of having persistent prolapse symptoms is significantly greater for women
who are undergoing surgery with mesh kit than for those without mesh (RR 0.73, 95% CI 0.59 to 0.90).
There is no evidence of a difference between surgery without mesh and surgery with absorbable,
biological graft or non-absorbable mesh (Figure 35). PROSPECT has contributed over half of the evidence
for the graft and mesh inlay outcomes.
References
No mesh compared with absorbable mesh
Allahdin S, Glazener C, Bain C. A randomised controlled trial evaluating the use of polyglactin mesh,
polydioxanone and polyglactin sutures for pelvic organ prolapse surgery. J Obstet Gynaecol
2008;28:427–31.66
Robert M, Girard I, Brennand E, Tang S, Birch C, Murphy M, et al. Absorbable mesh augmentation
compared with no mesh for anterior prolapse: a randomized controlled trial. Obstet Gynecol
2014;123:288–94.67
No mesh compared with biological graft
Gandhi S, Goldberg RP, Kwon C, Koduri S, Beaumont JL, Abramov Y, et al. A prospective randomized trial
using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse.
Am J Obstet Gynecol 2005;192:1649–54.68
Glazener 2016, Primary and Secondary – reference is to the current monograph.
Hviid U, Hviid TV, Rudnicki M. Porcine skin collagen implants for anterior vaginal wall prolapse:
a randomised prospective controlled study. Int Urogynecol J 2010;21:529–34.69
Meschia M, Pifarotti P, Bernasconi F, Magatti F, Riva D, Kocjancic E. Porcine skin collagen implants to
prevent anterior vaginal wall prolapse recurrence: a multicenter, randomized study. J Urol
2007;177:192–5.70
Sung VW, Rardin CR, Raker CA, Lasala CA, Myers DL. Porcine subintestinal submucosal graft
augmentation for rectocele repair: a randomized controlled trial. Obstet Gynecol 2012;119:125–33.71
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No mesh compared with non-absorbable mesh
Carey M, Higgs P, Goh J, Lim J, Leong A, Krause H, et al. Vaginal repair with mesh versus colporrhaphy for
prolapse: a randomised controlled trial. BJOG 2009;116:1380–6.72
De Tayrac R, Cornille A, Eglin G, Guilbaud O, Mansoor A, Alonso S, et al. Comparison between
trans-obturator trans-vaginal meshand traditional anterior colporrhaphy in the treatmentof anterior
vaginal wall prolapse: results of a French RCT. Int Urogynecol J 2013;24:1651–61.73
El-Nazer MA, Gomaa IA, Ismail Madkour WA, Swidan KH, El-Etriby MA. Anterior colporrhaphy versus
repair with mesh for anterior vaginal wall prolapse: a comparative clinical study. Arch Gynecol Obstet
2012;286:965–72.74
Glazener 2016, Primary and Secondary – reference is to the current monograph.
Turgal M, Sivaslioglu A, Yildiz A, Dolen I. Anatomical and functional assessment of anterior colporrhaphy
versus polypropylene mesh surgery in cystocele treatment. Eur J Obstet Gynecol Reproduct Biol
2013;170:555–8.75
No mesh compared with mesh kit
Altman D, Väyrynen T, Engh ME, Axelsen S, Falconer C. Anterior colporrhaphy versus transvaginal mesh
for pelvic-organ prolapse. N Engl J Med 2011;364:1826–36.76
Delroy CA, Castro RDA, Dias MM, Feldner PC, Jr, Bortolini MAT, Girao MJBC, et al. The use of transvaginal
synthetic mesh for anterior vaginal wall prolapse repair: a randomized controlled trial. Int Urogynecol J
2013;24:1899–907.77
Glazener 2016, Primary and Secondary – reference is to the current monograph.
Beyond the first postoperative year, the risk of persistent prolapse symptoms is greater with biological graft
than surgery without mesh (RR 0.78, 95% CI 0.63 to 0.97). There is no evidence of a difference between
surgery without mesh and surgery with absorbable or non-absorbable mesh or mesh kit (Figure 36).
PROSPECT has contributed over half the evidence for the graft and mesh inlay outcomes.
References
No mesh compared with absorbable mesh
Allahdin S, Glazener C, Bain C. A randomised controlled trial evaluating the use of polyglactin mesh,
polydioxanone and polyglactin sutures for pelvic organ prolapse surgery. J Obstet Gynaecol
2008;28:427–31.66
Chmielewski L, Walters MD, Weber AM, Barber MD. Reanalysis of a randomized trial of 3 techniques of
anterior colporrhaphy using clinically relevant definitions of success. Am J Obstet Gynecol
2011;205:69.e1–8.78
Minassian VA, Parekh M, Poplawsky D, Gorman J, Litzy L. Randomized controlled trial comparing two
procedures for anterior vaginal wall prolapse. Neurourol Urodyn 2014;33:72–7.79
No mesh compared with biological graft
Dahlgren E, Kjolhede P, RPOP-PELVICOL Study Group. Long-term outcome of porcine skin graft in surgical
treatment of recurrent pelvic organ prolapse. An open randomized controlled multicenter study.
Acta Obstet Gynecol Scand 2011;90:1393–401.80
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Type of repair Primary: 1126 Secondary: 244 Uterine/vault: 215
Stratum/comparison Comprehensive cohort: 1585
Treatment arm CC1: 1126 CC2: 244 CC3: 215 Uterine: 69 Vault: 146
Received surgery 1104 (98%) 240 (98%) 212 (99%) 68 (99%) 144 (99%)
Standard repair 931 (84%) 128 (53%) 17 (8%) 12 (18%) 5 (3%)
Synthetic mesh 44 (4%) 52 (22%) 3 (1%) 0 (0%) 3 (2%)
Biological graft 45 (4%) 17 (7%) 0 (0%) 0 (0%) 0 (0%)
Mesh kit 17 (2%) 25 (10%) 1 (0%) 0 (0%) 1 (1%)
Other surgery 67 (6%) 18 (8%) 191 (90%) 56 (82%) 135 (94%)
No surgery 22 (2%) 4 (2%) 3 (1%) 1 (1%) 2 (1%)
Baseline questionnaire 997 (89%) 221 (91%) 202 (94%) 65 (94%) 137 (94%)
6-month questionnaire 966 (88%) 214 (89%) 175 (83%) 54 (79%) 121 (84%)
Withdrawals within 6 months 5 (0%) 0 (0%) 1 (0%) 0 (0%) 1 (1%)
Deaths within 6 months 1 (0%) 0 (0%) 1 (0%) 0 (0%) 1 (1%)
12-month short questionnaire 972 (88%) 216 (90%) 173 (82%) 57 (84%) 116 (81%)
12-month long questionnaire 893 (81%) 191 (80%) 158 (75%) 46 (68%) 112 (78%)
12-month clinic assessment 11 (1%) 8 (3%) 0 (0%) 0 (0%) 0 (0%)
Withdrawals within 12 months 14 (1%) 0 (0%) 5 (2%) 1 (1%) 4 (3%)
Deaths within 12 months 3 (0%) 0 (0%) 1 (0%) 0 (0%) 1 (1%)
24-month questionnaire 848 (77%) 191 (80%) 152 (72%) 48 (71%) 104 (72%)
Withdrawals within 24 months 32 (3%) 6 (3%) 11 (5%) 3 (4%) 8 (6%)
Deaths within 24 months 3 (0%) 1 (0%) 4 (2%) 2 (3%) 2 (1%)
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